<!DOCTYPE html><html  lang="en" data-capo=""><head><meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Frontiers | Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases</title>
<link rel="stylesheet" href="/ap-2024/_nuxt/entry.CWBB-NGm.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/vue-core.B-WA3Vg5.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/explainer.CMppEa5M.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleDetails.B93eTAmx.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleLayoutHeader.CKWUz2Al.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/AnnouncementCard.Db7nmstV.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/FloatingButtons.xuP8gC33.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleEvent.D0PaxIW7.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/SimilarArticles.BMee4Fk4.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleTemplateBanner.CXmOJ7NH.css">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/v1IBIWh4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/B674Mi_H.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BXedFy5e.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/eQMj-Fph.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Y8NTh2i4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUyL5Z_3.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/m8mdd2tc.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DHv8pTSw.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BHPWSuhB.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/x5HZk7Le.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CNJXQ6ZR.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dss5ciUI.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Do5q9QoL.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BhVAcJSK.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/y69VltF1.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Bw-bWKkJ.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/sQBxgu5L.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/D5YKKJGW.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CSLdjdGS.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUN89Jk2.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CCeQzihV.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DVDwh0-U.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dw4ta0fP.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CYv-CzHi.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/U-mJlaMn.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/NhyIC1F3.js">
<link rel="prefetch" as="style" crossorigin href="/ap-2024/_nuxt/ArticleHubLayout.q6CU8_bN.css">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/CKQJuUlk.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/D3plh7Cs.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/GWtHKqLR.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/DS3EY-DL.js">
<meta name="theme-color" content="#0C4DED">
<meta name="mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-capable" content="yes">
<script type="text/javascript" data-hid="4cd079c">window.NREUM||(NREUM={});NREUM.info = {"agent":"","beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"598a124f17","applicationID":"586843029","agentToken":null,"applicationTime":3.665315,"transactionName":"MQcDMkECCkNSW0YMWghNLwlBDgVcWkJXAWAUC04MXBYWXlJUQUpaCAEOClwEHR9SSkYMVgoHEkkZTAJfXVscVwVUUU9XAlJVAQoJHQNACg4=","queueTime":0,"ttGuid":"f8605b482bab50b7"}; (window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]},feature_flags:["soft_nav"],distributed_tracing:{enabled:true}};(window.NREUM||(NREUM={})).loader_config={agentID:"594460232",accountID:"230385",trustKey:"230385",xpid:"VgUHUl5WGwYIUllWBAEFXw==",licenseKey:"598a124f17",applicationID:"586843029",browserID:"594460232"};;/*! For license information please see nr-loader-spa-1.303.0.min.js.LICENSE.txt */
(()=>{var e,t,r={384:(e,t,r)=>{"use strict";r.d(t,{NT:()=>s,US:()=>d,Zm:()=>a,bQ:()=>u,dV:()=>c,pV:()=>l});var n=r(6154),i=r(1863),o=r(1910);const s={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return n.gm.NREUM||(n.gm.NREUM={}),void 0===n.gm.newrelic&&(n.gm.newrelic=n.gm.NREUM),n.gm.NREUM}function c(){let e=a();return e.o||(e.o={ST:n.gm.setTimeout,SI:n.gm.setImmediate||n.gm.setInterval,CT:n.gm.clearTimeout,XHR:n.gm.XMLHttpRequest,REQ:n.gm.Request,EV:n.gm.Event,PR:n.gm.Promise,MO:n.gm.MutationObserver,FETCH:n.gm.fetch,WS:n.gm.WebSocket},(0,o.i)(...Object.values(e.o))),e}function u(e,t){let r=a();r.initializedAgents??={},t.initializedAt={ms:(0,i.t)(),date:new Date},r.initializedAgents[e]=t}function d(e,t){a()[e]=t}function l(){return function(){let e=a();const t=e.info||{};e.info={beacon:s.beacon,errorBeacon:s.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),c(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},782:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewTiming},860:(e,t,r)=>{"use strict";r.d(t,{$J:()=>d,K7:()=>c,P3:()=>u,XX:()=>i,Yy:()=>a,df:()=>o,qY:()=>n,v4:()=>s});const n="events",i="jserrors",o="browser/blobs",s="rum",a="browser/logs",c={ajax:"ajax",genericEvents:"generic_events",jserrors:i,logging:"logging",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",softNav:"soft_navigations",spa:"spa"},u={[c.pageViewEvent]:1,[c.pageViewTiming]:2,[c.metrics]:3,[c.jserrors]:4,[c.spa]:5,[c.ajax]:6,[c.sessionTrace]:7,[c.softNav]:8,[c.sessionReplay]:9,[c.logging]:10,[c.genericEvents]:11},d={[c.pageViewEvent]:s,[c.pageViewTiming]:n,[c.ajax]:n,[c.spa]:n,[c.softNav]:n,[c.metrics]:i,[c.jserrors]:i,[c.sessionTrace]:o,[c.sessionReplay]:o,[c.logging]:a,[c.genericEvents]:"ins"}},944:(e,t,r)=>{"use strict";r.d(t,{R:()=>i});var n=r(3241);function i(e,t){"function"==typeof console.debug&&(console.debug("New Relic Warning: https://github.com/newrelic/newrelic-browser-agent/blob/main/docs/warning-codes.md#".concat(e),t),(0,n.W)({agentIdentifier:null,drained:null,type:"data",name:"warn",feature:"warn",data:{code:e,secondary:t}}))}},993:(e,t,r)=>{"use strict";r.d(t,{A$:()=>o,ET:()=>s,TZ:()=>a,p_:()=>i});var n=r(860);const i={ERROR:"ERROR",WARN:"WARN",INFO:"INFO",DEBUG:"DEBUG",TRACE:"TRACE"},o={OFF:0,ERROR:1,WARN:2,INFO:3,DEBUG:4,TRACE:5},s="log",a=n.K7.logging},1687:(e,t,r)=>{"use strict";r.d(t,{Ak:()=>u,Ze:()=>f,x3:()=>d});var n=r(3241),i=r(7836),o=r(3606),s=r(860),a=r(2646);const c={};function u(e,t){const r={staged:!1,priority:s.P3[t]||0};l(e),c[e].get(t)||c[e].set(t,r)}function d(e,t){e&&c[e]&&(c[e].get(t)&&c[e].delete(t),p(e,t,!1),c[e].size&&h(e))}function l(e){if(!e)throw new Error("agentIdentifier required");c[e]||(c[e]=new Map)}function f(e="",t="feature",r=!1){if(l(e),!e||!c[e].get(t)||r)return p(e,t);c[e].get(t).staged=!0,h(e)}function h(e){const t=Array.from(c[e]);t.every(([e,t])=>t.staged)&&(t.sort((e,t)=>e[1].priority-t[1].priority),t.forEach(([t])=>{c[e].delete(t),p(e,t)}))}function p(e,t,r=!0){const s=e?i.ee.get(e):i.ee,c=o.i.handlers;if(!s.aborted&&s.backlog&&c){if((0,n.W)({agentIdentifier:e,type:"lifecycle",name:"drain",feature:t}),r){const e=s.backlog[t],r=c[t];if(r){for(let t=0;e&&t<e.length;++t)g(e[t],r);Object.entries(r).forEach(([e,t])=>{Object.values(t||{}).forEach(t=>{t[0]?.on&&t[0]?.context()instanceof a.y&&t[0].on(e,t[1])})})}}s.isolatedBacklog||delete c[t],s.backlog[t]=null,s.emit("drain-"+t,[])}}function g(e,t){var r=e[1];Object.values(t[r]||{}).forEach(t=>{var r=e[0];if(t[0]===r){var n=t[1],i=e[3],o=e[2];n.apply(i,o)}})}},1741:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(944),i=r(4261);class o{#e(e,...t){if(this[e]!==o.prototype[e])return this[e](...t);(0,n.R)(35,e)}addPageAction(e,t){return this.#e(i.hG,e,t)}register(e){return this.#e(i.eY,e)}recordCustomEvent(e,t){return this.#e(i.fF,e,t)}setPageViewName(e,t){return this.#e(i.Fw,e,t)}setCustomAttribute(e,t,r){return this.#e(i.cD,e,t,r)}noticeError(e,t){return this.#e(i.o5,e,t)}setUserId(e){return this.#e(i.Dl,e)}setApplicationVersion(e){return this.#e(i.nb,e)}setErrorHandler(e){return this.#e(i.bt,e)}addRelease(e,t){return this.#e(i.k6,e,t)}log(e,t){return this.#e(i.$9,e,t)}start(){return this.#e(i.d3)}finished(e){return this.#e(i.BL,e)}recordReplay(){return this.#e(i.CH)}pauseReplay(){return this.#e(i.Tb)}addToTrace(e){return this.#e(i.U2,e)}setCurrentRouteName(e){return this.#e(i.PA,e)}interaction(e){return this.#e(i.dT,e)}wrapLogger(e,t,r){return this.#e(i.Wb,e,t,r)}measure(e,t){return this.#e(i.V1,e,t)}consent(e){return this.#e(i.Pv,e)}}},1863:(e,t,r)=>{"use strict";function n(){return Math.floor(performance.now())}r.d(t,{t:()=>n})},1910:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(944);const i=new Map;function o(...e){return e.every(e=>{if(i.has(e))return i.get(e);const t="function"==typeof e&&e.toString().includes("[native code]");return t||(0,n.R)(64,e?.name||e?.toString()),i.set(e,t),t})}},2555:(e,t,r)=>{"use strict";r.d(t,{D:()=>a,f:()=>s});var n=r(384),i=r(8122);const o={beacon:n.NT.beacon,errorBeacon:n.NT.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0};function s(e){try{return!!e.licenseKey&&!!e.errorBeacon&&!!e.applicationID}catch(e){return!1}}const a=e=>(0,i.a)(e,o)},2614:(e,t,r)=>{"use strict";r.d(t,{BB:()=>s,H3:()=>n,g:()=>u,iL:()=>c,tS:()=>a,uh:()=>i,wk:()=>o});const n="NRBA",i="SESSION",o=144e5,s=18e5,a={STARTED:"session-started",PAUSE:"session-pause",RESET:"session-reset",RESUME:"session-resume",UPDATE:"session-update"},c={SAME_TAB:"same-tab",CROSS_TAB:"cross-tab"},u={OFF:0,FULL:1,ERROR:2}},2646:(e,t,r)=>{"use strict";r.d(t,{y:()=>n});class n{constructor(e){this.contextId=e}}},2843:(e,t,r)=>{"use strict";r.d(t,{u:()=>i});var n=r(3878);function i(e,t=!1,r,i){(0,n.DD)("visibilitychange",function(){if(t)return void("hidden"===document.visibilityState&&e());e(document.visibilityState)},r,i)}},3241:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(6154);const i="newrelic";function o(e={}){try{n.gm.dispatchEvent(new CustomEvent(i,{detail:e}))}catch(e){}}},3304:(e,t,r)=>{"use strict";r.d(t,{A:()=>o});var n=r(7836);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())??""}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}return""}}},3333:(e,t,r)=>{"use strict";r.d(t,{$v:()=>d,TZ:()=>n,Xh:()=>c,Zp:()=>i,kd:()=>u,mq:()=>a,nf:()=>s,qN:()=>o});const n=r(860).K7.genericEvents,i=["auxclick","click","copy","keydown","paste","scrollend"],o=["focus","blur"],s=4,a=1e3,c=2e3,u=["PageAction","UserAction","BrowserPerformance"],d={RESOURCES:"experimental.resources",REGISTER:"register"}},3434:(e,t,r)=>{"use strict";r.d(t,{Jt:()=>o,YM:()=>u});var n=r(7836),i=r(5607);const o="nr@original:".concat(i.W),s=50;var a=Object.prototype.hasOwnProperty,c=!1;function u(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");const s="-"===n.charAt(0);for(let a=0;a<t.length;a++){const c=t[a],u=e[c];l(u)||(e[c]=r(u,s?c+n:n,i,c,o))}},r.flag=o,r;function r(t,r,n,c,u){return l(t)?t:(r||(r=""),nrWrapper[o]=t,function(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach(function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})}),t}catch(e){d([e],r)}for(var n in e)a.call(e,n)&&(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var o,a,l,f;let h;try{a=this,o=[...arguments],l="function"==typeof n?n(o,a):n||{}}catch(t){d([t,"",[o,a,c],l],e)}i(r+"start",[o,a,c],l,u);const p=performance.now();let g;try{return f=t.apply(a,o),g=performance.now(),f}catch(e){throw g=performance.now(),i(r+"err",[o,a,e],l,u),h=e,h}finally{const e=g-p,t={start:p,end:g,duration:e,isLongTask:e>=s,methodName:c,thrownError:h};t.isLongTask&&i("long-task",[t,a],l,u),i(r+"end",[o,a,f],l,u)}}}function i(r,n,i,o){if(!c||t){var s=c;c=!0;try{e.emit(r,n,i,t,o)}catch(t){d([t,r,n,i],e)}c=s}}}function d(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function l(e){return!(e&&"function"==typeof e&&e.apply&&!e[o])}},3606:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(9908);o.on=s;var i=o.handlers={};function o(e,t,r,o){s(o||n.d,i,e,t,r)}function s(e,t,r,i,o){o||(o="feature"),e||(e=n.d);var s=t[o]=t[o]||{};(s[r]=s[r]||[]).push([e,i])}},3738:(e,t,r)=>{"use strict";r.d(t,{He:()=>i,Kp:()=>a,Lc:()=>u,Rz:()=>d,TZ:()=>n,bD:()=>o,d3:()=>s,jx:()=>l,sl:()=>f,uP:()=>c});const n=r(860).K7.sessionTrace,i="bstResource",o="resource",s="-start",a="-end",c="fn"+s,u="fn"+a,d="pushState",l=1e3,f=3e4},3785:(e,t,r)=>{"use strict";r.d(t,{R:()=>c,b:()=>u});var n=r(9908),i=r(1863),o=r(860),s=r(8154),a=r(993);function c(e,t,r={},c=a.p_.INFO,u,d=(0,i.t)()){(0,n.p)(s.xV,["API/logging/".concat(c.toLowerCase(),"/called")],void 0,o.K7.metrics,e),(0,n.p)(a.ET,[d,t,r,c,u],void 0,o.K7.logging,e)}function u(e){return"string"==typeof e&&Object.values(a.p_).some(t=>t===e.toUpperCase().trim())}},3878:(e,t,r)=>{"use strict";function n(e,t){return{capture:e,passive:!1,signal:t}}function i(e,t,r=!1,i){window.addEventListener(e,t,n(r,i))}function o(e,t,r=!1,i){document.addEventListener(e,t,n(r,i))}r.d(t,{DD:()=>o,jT:()=>n,sp:()=>i})},3962:(e,t,r)=>{"use strict";r.d(t,{AM:()=>s,O2:()=>l,OV:()=>o,Qu:()=>f,TZ:()=>c,ih:()=>h,pP:()=>a,t1:()=>d,tC:()=>i,wD:()=>u});var n=r(860);const i=["click","keydown","submit"],o="popstate",s="api",a="initialPageLoad",c=n.K7.softNav,u=5e3,d=500,l={INITIAL_PAGE_LOAD:"",ROUTE_CHANGE:1,UNSPECIFIED:2},f={INTERACTION:1,AJAX:2,CUSTOM_END:3,CUSTOM_TRACER:4},h={IP:"in progress",PF:"pending finish",FIN:"finished",CAN:"cancelled"}},4234:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(7836),i=r(1687);class o{constructor(e,t){this.agentIdentifier=e,this.ee=n.ee.get(e),this.featureName=t,this.blocked=!1}deregisterDrain(){(0,i.x3)(this.agentIdentifier,this.featureName)}}},4261:(e,t,r)=>{"use strict";r.d(t,{$9:()=>d,BL:()=>c,CH:()=>p,Dl:()=>R,Fw:()=>w,PA:()=>v,Pl:()=>n,Pv:()=>A,Tb:()=>f,U2:()=>s,V1:()=>E,Wb:()=>T,bt:()=>y,cD:()=>b,d3:()=>x,dT:()=>u,eY:()=>g,fF:()=>h,hG:()=>o,hw:()=>i,k6:()=>a,nb:()=>m,o5:()=>l});const n="api-",i=n+"ixn-",o="addPageAction",s="addToTrace",a="addRelease",c="finished",u="interaction",d="log",l="noticeError",f="pauseReplay",h="recordCustomEvent",p="recordReplay",g="register",m="setApplicationVersion",v="setCurrentRouteName",b="setCustomAttribute",y="setErrorHandler",w="setPageViewName",R="setUserId",x="start",T="wrapLogger",E="measure",A="consent"},4387:(e,t,r)=>{"use strict";function n(e={}){return!(!e.id||!e.name)}function i(e){return"string"==typeof e&&e.trim().length<501||"number"==typeof e}function o(e,t){if(2!==t?.harvestEndpointVersion)return{};const r=t.agentRef.runtime.appMetadata.agents[0].entityGuid;return n(e)?{"mfe.id":e.id,"mfe.name":e.name,eventSource:e.eventSource,"parent.id":e.parent?.id||r}:{"entity.guid":r,appId:t.agentRef.info.applicationID}}r.d(t,{Ux:()=>o,c7:()=>n,yo:()=>i})},5205:(e,t,r)=>{"use strict";r.d(t,{j:()=>_});var n=r(384),i=r(1741);var o=r(2555),s=r(3333);const a=e=>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var c=r(2614),u=r(944),d=r(8122);const l="[data-nr-mask]",f=e=>(0,d.a)(e,(()=>{const e={feature_flags:[],experimental:{allow_registered_children:!1,resources:!1},mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{ajax:{deny_list:void 0,block_internal:!0,enabled:!0,autoStart:!0},api:{get allow_registered_children(){return e.feature_flags.includes(s.$v.REGISTER)||e.experimental.allow_registered_children},set allow_registered_children(t){e.experimental.allow_registered_children=t},duplicate_registered_data:!1},browser_consent_mode:{enabled:!1},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},get feature_flags(){return e.feature_flags},set feature_flags(t){e.feature_flags=t},generic_events:{enabled:!0,autoStart:!0},harvest:{interval:30},jserrors:{enabled:!0,autoStart:!0},logging:{enabled:!0,autoStart:!0},metrics:{enabled:!0,autoStart:!0},obfuscate:void 0,page_action:{enabled:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,autoStart:!0},performance:{capture_marks:!1,capture_measures:!1,capture_detail:!0,resources:{get enabled(){return e.feature_flags.includes(s.$v.RESOURCES)||e.experimental.resources},set enabled(t){e.experimental.resources=t},asset_types:[],first_party_domains:[],ignore_newrelic:!0}},privacy:{cookies_enabled:!0},proxy:{assets:void 0,beacon:void 0},session:{expiresMs:c.wk,inactiveMs:c.BB},session_replay:{autoStart:!0,enabled:!1,preload:!1,sampling_rate:10,error_sampling_rate:100,collect_fonts:!1,inline_images:!1,fix_stylesheets:!0,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){a(t)?e.mask_selector="".concat(t,",").concat(l):""===t||null===t?e.mask_selector=l:(0,u.R)(5,t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){a(t)?e.block_selector+=",".concat(t):""!==t&&(0,u.R)(6,t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&&"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,u.R)(7,t)}},session_trace:{enabled:!0,autoStart:!0},soft_navigations:{enabled:!0,autoStart:!0},spa:{enabled:!0,autoStart:!0},ssl:void 0,user_actions:{enabled:!0,elementAttributes:["id","className","tagName","type"]}}})());var h=r(6154),p=r(9324);let g=0;const m={buildEnv:p.F3,distMethod:p.Xs,version:p.xv,originTime:h.WN},v={consented:!1},b={appMetadata:{},get consented(){return this.session?.state?.consent||v.consented},set consented(e){v.consented=e},customTransaction:void 0,denyList:void 0,disabled:!1,harvester:void 0,isolatedBacklog:!1,isRecording:!1,loaderType:void 0,maxBytes:3e4,obfuscator:void 0,onerror:void 0,ptid:void 0,releaseIds:{},session:void 0,timeKeeper:void 0,registeredEntities:[],jsAttributesMetadata:{bytes:0},get harvestCount(){return++g}},y=e=>{const t=(0,d.a)(e,b),r=Object.keys(m).reduce((e,t)=>(e[t]={value:m[t],writable:!1,configurable:!0,enumerable:!0},e),{});return Object.defineProperties(t,r)};var w=r(5701);const R=e=>{const t=e.startsWith("http");e+="/",r.p=t?e:"https://"+e};var x=r(7836),T=r(3241);const E={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},A=e=>(0,d.a)(e,E),S=new Set;function _(e,t={},r,s){let{init:a,info:c,loader_config:u,runtime:d={},exposed:l=!0}=t;if(!c){const e=(0,n.pV)();a=e.init,c=e.info,u=e.loader_config}e.init=f(a||{}),e.loader_config=A(u||{}),c.jsAttributes??={},h.bv&&(c.jsAttributes.isWorker=!0),e.info=(0,o.D)(c);const p=e.init,g=[c.beacon,c.errorBeacon];S.has(e.agentIdentifier)||(p.proxy.assets&&(R(p.proxy.assets),g.push(p.proxy.assets)),p.proxy.beacon&&g.push(p.proxy.beacon),e.beacons=[...g],function(e){const t=(0,n.pV)();Object.getOwnPropertyNames(i.W.prototype).forEach(r=>{const n=i.W.prototype[r];if("function"!=typeof n||"constructor"===n)return;let o=t[r];e[r]&&!1!==e.exposed&&"micro-agent"!==e.runtime?.loaderType&&(t[r]=(...t)=>{const n=e[r](...t);return o?o(...t):n})})}(e),(0,n.US)("activatedFeatures",w.B),e.runSoftNavOverSpa&&=!0===p.soft_navigations.enabled&&p.feature_flags.includes("soft_nav")),d.denyList=[...p.ajax.deny_list||[],...p.ajax.block_internal?g:[]],d.ptid=e.agentIdentifier,d.loaderType=r,e.runtime=y(d),S.has(e.agentIdentifier)||(e.ee=x.ee.get(e.agentIdentifier),e.exposed=l,(0,T.W)({agentIdentifier:e.agentIdentifier,drained:!!w.B?.[e.agentIdentifier],type:"lifecycle",name:"initialize",feature:void 0,data:e.config})),S.add(e.agentIdentifier)}},5270:(e,t,r)=>{"use strict";r.d(t,{Aw:()=>s,SR:()=>o,rF:()=>a});var n=r(384),i=r(7767);function o(e){return!!(0,n.dV)().o.MO&&(0,i.V)(e)&&!0===e?.session_trace.enabled}function s(e){return!0===e?.session_replay.preload&&o(e)}function a(e,t){try{if("string"==typeof t?.type){if("password"===t.type.toLowerCase())return"*".repeat(e?.length||0);if(void 0!==t?.dataset?.nrUnmask||t?.classList?.contains("nr-unmask"))return e}}catch(e){}return"string"==typeof e?e.replace(/[\S]/g,"*"):"*".repeat(e?.length||0)}},5289:(e,t,r)=>{"use strict";r.d(t,{GG:()=>o,Qr:()=>a,sB:()=>s});var n=r(3878);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.sp)("load",e,t)}function s(e){if(i())return e();(0,n.DD)("DOMContentLoaded",e)}function a(e){if(i())return e();(0,n.sp)("popstate",e)}},5607:(e,t,r)=>{"use strict";r.d(t,{W:()=>n});const n=(0,r(9566).bz)()},5701:(e,t,r)=>{"use strict";r.d(t,{B:()=>o,t:()=>s});var n=r(3241);const i=new Set,o={};function s(e,t){const r=t.agentIdentifier;o[r]??={},e&&"object"==typeof e&&(i.has(r)||(t.ee.emit("rumresp",[e]),o[r]=e,i.add(r),(0,n.W)({agentIdentifier:r,loaded:!0,drained:!0,type:"lifecycle",name:"load",feature:void 0,data:e})))}},6154:(e,t,r)=>{"use strict";r.d(t,{A4:()=>a,OF:()=>d,RI:()=>i,WN:()=>h,bv:()=>o,gm:()=>s,lR:()=>f,m:()=>u,mw:()=>c,sb:()=>l});var n=r(1863);const i="undefined"!=typeof window&&!!window.document,o="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),s=i?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a="complete"===s?.document?.readyState,c=Boolean("hidden"===s?.document?.visibilityState),u=""+s?.location,d=/iPad|iPhone|iPod/.test(s.navigator?.userAgent),l=d&&"undefined"==typeof SharedWorker,f=(()=>{const e=s.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),h=Date.now()-(0,n.t)()},6344:(e,t,r)=>{"use strict";r.d(t,{BB:()=>d,Qb:()=>l,TZ:()=>i,Ug:()=>s,Vh:()=>o,_s:()=>a,bc:()=>u,yP:()=>c});var n=r(2614);const i=r(860).K7.sessionReplay,o="errorDuringReplay",s=.12,a={DomContentLoaded:0,Load:1,FullSnapshot:2,IncrementalSnapshot:3,Meta:4,Custom:5},c={[n.g.ERROR]:15e3,[n.g.FULL]:3e5,[n.g.OFF]:0},u={RESET:{message:"Session was reset",sm:"Reset"},IMPORT:{message:"Recorder failed to import",sm:"Import"},TOO_MANY:{message:"429: Too Many Requests",sm:"Too-Many"},TOO_BIG:{message:"Payload was too large",sm:"Too-Big"},CROSS_TAB:{message:"Session Entity was set to OFF on another tab",sm:"Cross-Tab"},ENTITLEMENTS:{message:"Session Replay is not allowed and will not be started",sm:"Entitlement"}},d=5e3,l={API:"api",RESUME:"resume",SWITCH_TO_FULL:"switchToFull",INITIALIZE:"initialize",PRELOAD:"preload"}},6389:(e,t,r)=>{"use strict";function n(e,t=500,r={}){const n=r?.leading||!1;let i;return(...r)=>{n&&void 0===i&&(e.apply(this,r),i=setTimeout(()=>{i=clearTimeout(i)},t)),n||(clearTimeout(i),i=setTimeout(()=>{e.apply(this,r)},t))}}function i(e){let t=!1;return(...r)=>{t||(t=!0,e.apply(this,r))}}r.d(t,{J:()=>i,s:()=>n})},6630:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewEvent},6774:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.jserrors},7295:(e,t,r)=>{"use strict";r.d(t,{Xv:()=>s,gX:()=>i,iW:()=>o});var n=[];function i(e){if(!e||o(e))return!1;if(0===n.length)return!0;for(var t=0;t<n.length;t++){var r=n[t];if("*"===r.hostname)return!1;if(a(r.hostname,e.hostname)&&c(r.pathname,e.pathname))return!1}return!0}function o(e){return void 0===e.hostname}function s(e){if(n=[],e&&e.length)for(var t=0;t<e.length;t++){let r=e[t];if(!r)continue;0===r.indexOf("http://")?r=r.substring(7):0===r.indexOf("https://")&&(r=r.substring(8));const i=r.indexOf("/");let o,s;i>0?(o=r.substring(0,i),s=r.substring(i)):(o=r,s="");let[a]=o.split(":");n.push({hostname:a,pathname:s})}}function a(e,t){return!(e.length>t.length)&&t.indexOf(e)===t.length-e.length}function c(e,t){return 0===e.indexOf("/")&&(e=e.substring(1)),0===t.indexOf("/")&&(t=t.substring(1)),""===e||e===t}},7378:(e,t,r)=>{"use strict";r.d(t,{$p:()=>x,BR:()=>b,Kp:()=>R,L3:()=>y,Lc:()=>c,NC:()=>o,SG:()=>d,TZ:()=>i,U6:()=>p,UT:()=>m,d3:()=>w,dT:()=>f,e5:()=>E,gx:()=>v,l9:()=>l,oW:()=>h,op:()=>g,rw:()=>u,tH:()=>A,uP:()=>a,wW:()=>T,xq:()=>s});var n=r(384);const i=r(860).K7.spa,o=["click","submit","keypress","keydown","keyup","change"],s=999,a="fn-start",c="fn-end",u="cb-start",d="api-ixn-",l="remaining",f="interaction",h="spaNode",p="jsonpNode",g="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=(0,n.dV)().o.ST,w="-start",R="-end",x="-body",T="cb"+R,E="jsTime",A="fetch"},7485:(e,t,r)=>{"use strict";r.d(t,{D:()=>i});var n=r(6154);function i(e){if(0===(e||"").indexOf("data:"))return{protocol:"data"};try{const t=new URL(e,location.href),r={port:t.port,hostname:t.hostname,pathname:t.pathname,search:t.search,protocol:t.protocol.slice(0,t.protocol.indexOf(":")),sameOrigin:t.protocol===n.gm?.location?.protocol&&t.host===n.gm?.location?.host};return r.port&&""!==r.port||("http:"===t.protocol&&(r.port="80"),"https:"===t.protocol&&(r.port="443")),r.pathname&&""!==r.pathname?r.pathname.startsWith("/")||(r.pathname="/".concat(r.pathname)):r.pathname="/",r}catch(e){return{}}}},7699:(e,t,r)=>{"use strict";r.d(t,{It:()=>o,KC:()=>a,No:()=>i,qh:()=>s});var n=r(860);const i=16e3,o=1e6,s="SESSION_ERROR",a={[n.K7.logging]:!0,[n.K7.genericEvents]:!1,[n.K7.jserrors]:!1,[n.K7.ajax]:!1}},7767:(e,t,r)=>{"use strict";r.d(t,{V:()=>i});var n=r(6154);const i=e=>n.RI&&!0===e?.privacy.cookies_enabled},7836:(e,t,r)=>{"use strict";r.d(t,{P:()=>a,ee:()=>c});var n=r(384),i=r(8990),o=r(2646),s=r(5607);const a="nr@context:".concat(s.W),c=function e(t,r){var n={},s={},d={},l=!1;try{l=16===r.length&&u.initializedAgents?.[r]?.runtime.isolatedBacklog}catch(e){}var f={on:p,addEventListener:p,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)},emit:function(e,r,n,i,o){!1!==o&&(o=!0);if(c.aborted&&!i)return;t&&o&&t.emit(e,r,n);var a=h(n);g(e).forEach(e=>{e.apply(a,r)});var u=v()[s[e]];u&&u.push([f,e,r,a]);return a},get:m,listeners:g,context:h,buffer:function(e,t){const r=v();if(t=t||"feature",f.aborted)return;Object.entries(e||{}).forEach(([e,n])=>{s[n]=t,t in r||(r[t]=[])})},abort:function(){f._aborted=!0,Object.keys(f.backlog).forEach(e=>{delete f.backlog[e]})},isBuffering:function(e){return!!v()[s[e]]},debugId:r,backlog:l?{}:t&&"object"==typeof t.backlog?t.backlog:{},isolatedBacklog:l};return Object.defineProperty(f,"aborted",{get:()=>{let e=f._aborted||!1;return e||(t&&(e=t.aborted),e)}}),f;function h(e){return e&&e instanceof o.y?e:e?(0,i.I)(e,a,()=>new o.y(a)):new o.y(a)}function p(e,t){n[e]=g(e).concat(t)}function g(e){return n[e]||[]}function m(t){return d[t]=d[t]||e(f,t)}function v(){return f.backlog}}(void 0,"globalEE"),u=(0,n.Zm)();u.ee||(u.ee=c)},8122:(e,t,r)=>{"use strict";r.d(t,{a:()=>i});var n=r(944);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.R)(3);if(!t||"object"!=typeof t)return(0,n.R)(4);const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let s in o)if(void 0!==e[s])try{if(null===e[s]){r[s]=null;continue}Array.isArray(e[s])&&Array.isArray(t[s])?r[s]=Array.from(new Set([...e[s],...t[s]])):"object"==typeof e[s]&&"object"==typeof t[s]?r[s]=i(e[s],t[s]):r[s]=e[s]}catch(e){r[s]||(0,n.R)(1,e)}return r}catch(e){(0,n.R)(2,e)}}},8139:(e,t,r)=>{"use strict";r.d(t,{u:()=>f});var n=r(7836),i=r(3434),o=r(8990),s=r(6154);const a={},c=s.gm.XMLHttpRequest,u="addEventListener",d="removeEventListener",l="nr@wrapped:".concat(n.P);function f(e){var t=function(e){return(e||n.ee).get("events")}(e);if(a[t.debugId]++)return t;a[t.debugId]=1;var r=(0,i.YM)(t,!0);function f(e){r.inPlace(e,[u,d],"-",p)}function p(e,t){return e[1]}return"getPrototypeOf"in Object&&(s.RI&&h(document,f),c&&h(c.prototype,f),h(s.gm,f)),t.on(u+"-start",function(e,t){var n=e[1];if(null!==n&&("function"==typeof n||"object"==typeof n)&&"newrelic"!==e[0]){var i=(0,o.I)(n,l,function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=e[1]=i}}),t.on(d+"-start",function(e){e[1]=this.wrapped||e[1]}),t}function h(e,t,...r){let n=e;for(;"object"==typeof n&&!Object.prototype.hasOwnProperty.call(n,u);)n=Object.getPrototypeOf(n);n&&t(n,...r)}},8154:(e,t,r)=>{"use strict";r.d(t,{z_:()=>o,XG:()=>a,TZ:()=>n,rs:()=>i,xV:()=>s});r(6154),r(9566),r(384);const n=r(860).K7.metrics,i="sm",o="cm",s="storeSupportabilityMetrics",a="storeEventMetrics"},8374:(e,t,r)=>{r.nc=(()=>{try{return document?.currentScript?.nonce}catch(e){}return""})()},8990:(e,t,r)=>{"use strict";r.d(t,{I:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},9300:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.ajax},9324:(e,t,r)=>{"use strict";r.d(t,{AJ:()=>s,F3:()=>i,Xs:()=>o,Yq:()=>a,xv:()=>n});const n="1.303.0",i="PROD",o="CDN",s="@newrelic/rrweb",a="1.0.1"},9566:(e,t,r)=>{"use strict";r.d(t,{LA:()=>a,ZF:()=>c,bz:()=>s,el:()=>u});var n=r(6154);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function s(){const e=n.gm?.crypto||n.gm?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(30))),i.split("").map(e=>"x"===e?o(t,r++).toString(16):"y"===e?(3&o()|8).toString(16):e).join("")}function a(e){const t=n.gm?.crypto||n.gm?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(e)));const s=[];for(var a=0;a<e;a++)s.push(o(r,i++).toString(16));return s.join("")}function c(){return a(16)}function u(){return a(32)}},9908:(e,t,r)=>{"use strict";r.d(t,{d:()=>n,p:()=>i});var n=r(7836).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce((t,r)=>(i.f[r](e,t),t),[])),i.u=e=>({212:"nr-spa-compressor",249:"nr-spa-recorder",478:"nr-spa"}[e]+"-1.303.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.303.0.PROD:",i.l=(r,n,o,s)=>{if(e[r])e[r].push(n);else{var a,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d<u.length;d++){var l=u[d];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+o){a=l;break}}if(!a){c=!0;var f={478:"sha512-Q1pLqcoiNmLHv0rtq3wFkJBA3kofBdRJl0ExDl0mTuAoCBd0qe/1J0XWrDlQKuNlUryL6aZfVkAMPLmoikWIoQ==",249:"sha512-695ZzudsxlMtHKnpDNvkMlJd3tdMtY03IQKVCw9SX12tjUC+f7Nrx5tnWO72Vg9RFf6DSY6wVmM3cEkRM12kkQ==",212:"sha512-18Gx1wIBsppcn0AnKFhwgw4IciNgFxiw3J74W393Ape+wtg4hlg7t6SBKsIE/Dk/tfl2yltgcgBFvYRs283AFg=="};(a=document.createElement("script")).charset="utf-8",i.nc&&a.setAttribute("nonce",i.nc),a.setAttribute("data-webpack",t+o),a.src=r,0!==a.src.indexOf(window.location.origin+"/")&&(a.crossOrigin="anonymous"),f[s]&&(a.integrity=f[s])}e[r]=[n];var h=(t,n)=>{a.onerror=a.onload=null,clearTimeout(p);var i=e[r];if(delete e[r],a.parentNode&&a.parentNode.removeChild(a),i&&i.forEach(e=>e(n)),t)return t(n)},p=setTimeout(h.bind(null,void 0,{type:"timeout",target:a}),12e4);a.onerror=h.bind(null,a.onerror),a.onload=h.bind(null,a.onload),c&&document.head.appendChild(a)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=>{var e={38:0,788:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise((r,i)=>n=e[t]=[r,i]);r.push(n[2]=o);var s=i.p+i.u(t),a=new Error;i.l(s,r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),s=r&&r.target&&r.target.src;a.message="Loading chunk "+t+" failed.\n("+o+": "+s+")",a.name="ChunkLoadError",a.type=o,a.request=s,n[1](a)}},"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[s,a,c]=r,u=0;if(s.some(t=>0!==e[t])){for(n in a)i.o(a,n)&&(i.m[n]=a[n]);if(c)c(i)}for(t&&t(r);u<s.length;u++)o=s[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=self["webpackChunk:NRBA-1.303.0.PROD"]=self["webpackChunk:NRBA-1.303.0.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=>{"use strict";i(8374);var e=i(9566),t=i(1741);class r extends t.W{agentIdentifier=(0,e.LA)(16)}var n=i(860);const o=Object.values(n.K7);var s=i(5205);var a=i(9908),c=i(1863),u=i(4261),d=i(3241),l=i(944),f=i(5701),h=i(8154);function p(e,t,i,o){const s=o||i;!s||s[e]&&s[e]!==r.prototype[e]||(s[e]=function(){(0,a.p)(h.xV,["API/"+e+"/called"],void 0,n.K7.metrics,i.ee),(0,d.W)({agentIdentifier:i.agentIdentifier,drained:!!f.B?.[i.agentIdentifier],type:"data",name:"api",feature:u.Pl+e,data:{}});try{return t.apply(this,arguments)}catch(e){(0,l.R)(23,e)}})}function g(e,t,r,n,i){const o=e.info;null===r?delete o.jsAttributes[t]:o.jsAttributes[t]=r,(i||null===r)&&(0,a.p)(u.Pl+n,[(0,c.t)(),t,r],void 0,"session",e.ee)}var m=i(1687),v=i(4234),b=i(5289),y=i(6154),w=i(5270),R=i(7767),x=i(6389),T=i(7699);class E extends v.W{constructor(e,t){super(e.agentIdentifier,t),this.agentRef=e,this.abortHandler=void 0,this.featAggregate=void 0,this.loadedSuccessfully=void 0,this.onAggregateImported=new Promise(e=>{this.loadedSuccessfully=e}),this.deferred=Promise.resolve(),!1===e.init[this.featureName].autoStart?this.deferred=new Promise((t,r)=>{this.ee.on("manual-start-all",(0,x.J)(()=>{(0,m.Ak)(e.agentIdentifier,this.featureName),t()}))}):(0,m.Ak)(e.agentIdentifier,t)}importAggregator(e,t,r={}){if(this.featAggregate)return;const n=async()=>{let n;await this.deferred;try{if((0,R.V)(e.init)){const{setupAgentSession:t}=await i.e(478).then(i.bind(i,8766));n=t(e)}}catch(e){(0,l.R)(20,e),this.ee.emit("internal-error",[e]),(0,a.p)(T.qh,[e],void 0,this.featureName,this.ee)}try{if(!this.#t(this.featureName,n,e.init))return(0,m.Ze)(this.agentIdentifier,this.featureName),void this.loadedSuccessfully(!1);const{Aggregate:i}=await t();this.featAggregate=new i(e,r),e.runtime.harvester.initializedAggregates.push(this.featAggregate),this.loadedSuccessfully(!0)}catch(e){(0,l.R)(34,e),this.abortHandler?.(),(0,m.Ze)(this.agentIdentifier,this.featureName,!0),this.loadedSuccessfully(!1),this.ee&&this.ee.abort()}};y.RI?(0,b.GG)(()=>n(),!0):n()}#t(e,t,r){if(this.blocked)return!1;switch(e){case n.K7.sessionReplay:return(0,w.SR)(r)&&!!t;case n.K7.sessionTrace:return!!t;default:return!0}}}var A=i(6630),S=i(2614);class _ extends E{static featureName=A.T;constructor(e){var t;super(e,A.T),this.setupInspectionEvents(e.agentIdentifier),t=e,p(u.Fw,function(e,r){"string"==typeof e&&("/"!==e.charAt(0)&&(e="/"+e),t.runtime.customTransaction=(r||"http://custom.transaction")+e,(0,a.p)(u.Pl+u.Fw,[(0,c.t)()],void 0,void 0,t.ee))},t),this.importAggregator(e,()=>i.e(478).then(i.bind(i,1983)))}setupInspectionEvents(e){const t=(t,r)=>{t&&(0,d.W)({agentIdentifier:e,timeStamp:t.timeStamp,loaded:"complete"===t.target.readyState,type:"window",name:r,data:t.target.location+""})};(0,b.sB)(e=>{t(e,"DOMContentLoaded")}),(0,b.GG)(e=>{t(e,"load")}),(0,b.Qr)(e=>{t(e,"navigate")}),this.ee.on(S.tS.UPDATE,(t,r)=>{(0,d.W)({agentIdentifier:e,type:"lifecycle",name:"session",data:r})})}}var O=i(384);var N=i(2843),I=i(3878),P=i(782);class j extends E{static featureName=P.T;constructor(e){super(e,P.T),y.RI&&((0,N.u)(()=>(0,a.p)("docHidden",[(0,c.t)()],void 0,P.T,this.ee),!0),(0,I.sp)("pagehide",()=>(0,a.p)("winPagehide",[(0,c.t)()],void 0,P.T,this.ee)),this.importAggregator(e,()=>i.e(478).then(i.bind(i,9917))))}}class k extends E{static featureName=h.TZ;constructor(e){super(e,h.TZ),y.RI&&document.addEventListener("securitypolicyviolation",e=>{(0,a.p)(h.xV,["Generic/CSPViolation/Detected"],void 0,this.featureName,this.ee)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,6555)))}}var C=i(6774),L=i(3304);class H{constructor(e,t,r,n,i){this.name="UncaughtError",this.message="string"==typeof e?e:(0,L.A)(e),this.sourceURL=t,this.line=r,this.column=n,this.__newrelic=i}}function M(e){return U(e)?e:new H(void 0!==e?.message?e.message:e,e?.filename||e?.sourceURL,e?.lineno||e?.line,e?.colno||e?.col,e?.__newrelic,e?.cause)}function K(e){const t="Unhandled Promise Rejection: ";if(!e?.reason)return;if(U(e.reason)){try{e.reason.message.startsWith(t)||(e.reason.message=t+e.reason.message)}catch(e){}return M(e.reason)}const r=M(e.reason);return(r.message||"").startsWith(t)||(r.message=t+r.message),r}function D(e){if(e.error instanceof SyntaxError&&!/:\d+$/.test(e.error.stack?.trim())){const t=new H(e.message,e.filename,e.lineno,e.colno,e.error.__newrelic,e.cause);return t.name=SyntaxError.name,t}return U(e.error)?e.error:M(e)}function U(e){return e instanceof Error&&!!e.stack}function F(e,t,r,i,o=(0,c.t)()){"string"==typeof e&&(e=new Error(e)),(0,a.p)("err",[e,o,!1,t,r.runtime.isRecording,void 0,i],void 0,n.K7.jserrors,r.ee),(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,r.ee)}var W=i(4387),B=i(993),V=i(3785);function G(e,{customAttributes:t={},level:r=B.p_.INFO}={},n,i,o=(0,c.t)()){(0,V.R)(n.ee,e,t,r,i,o)}function z(e,t,r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.hG,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function Z(e,t,r,i,o=(0,c.t)()){const{start:s,end:d,customAttributes:f}=t||{},h={customAttributes:f||{}};if("object"!=typeof h.customAttributes||"string"!=typeof e||0===e.length)return void(0,l.R)(57);const p=(e,t)=>null==e?t:"number"==typeof e?e:e instanceof PerformanceMark?e.startTime:Number.NaN;if(h.start=p(s,0),h.end=p(d,o),Number.isNaN(h.start)||Number.isNaN(h.end))(0,l.R)(57);else{if(h.duration=h.end-h.start,!(h.duration<0))return(0,a.p)(u.Pl+u.V1,[h,e,i],void 0,n.K7.genericEvents,r.ee),h;(0,l.R)(58)}}function q(e,t={},r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.fF,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function X(e){p(u.eY,function(t){return Y(e,t)},e)}function Y(e,t,r){const i={};(0,l.R)(54,"newrelic.register"),t||={},t.eventSource="MicroFrontendBrowserAgent",t.licenseKey||=e.info.licenseKey,t.blocked=!1,t.parent=r||{};let o=()=>{};const s=e.runtime.registeredEntities,u=s.find(({metadata:{target:{id:e,name:r}}})=>e===t.id);if(u)return u.metadata.target.name!==t.name&&(u.metadata.target.name=t.name),u;const d=e=>{t.blocked=!0,o=e};e.init.api.allow_registered_children||d((0,x.J)(()=>(0,l.R)(55))),(0,W.c7)(t)||d((0,x.J)(()=>(0,l.R)(48,t))),(0,W.yo)(t.id)&&(0,W.yo)(t.name)||d((0,x.J)(()=>(0,l.R)(48,t)));const f={addPageAction:(r,n={})=>m(z,[r,{...i,...n},e],t),log:(r,n={})=>m(G,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),measure:(r,n={})=>m(Z,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),noticeError:(r,n={})=>m(F,[r,{...i,...n},e],t),register:(t={})=>m(Y,[e,t],f.metadata.target),recordCustomEvent:(r,n={})=>m(q,[r,{...i,...n},e],t),setApplicationVersion:e=>g("application.version",e),setCustomAttribute:(e,t)=>g(e,t),setUserId:e=>g("enduser.id",e),metadata:{customAttributes:i,target:t}},p=()=>(t.blocked&&o(),t.blocked);p()||s.push(f);const g=(e,t)=>{p()||(i[e]=t)},m=(t,r,i)=>{if(p())return;const o=(0,c.t)();(0,a.p)(h.xV,["API/register/".concat(t.name,"/called")],void 0,n.K7.metrics,e.ee);try{return e.init.api.duplicate_registered_data&&"register"!==t.name&&t(...r,void 0,o),t(...r,i,o)}catch(e){(0,l.R)(50,e)}};return f}class J extends E{static featureName=C.T;constructor(e){var t;super(e,C.T),t=e,p(u.o5,(e,r)=>F(e,r,t),t),function(e){p(u.bt,function(t){e.runtime.onerror=t},e)}(e),function(e){let t=0;p(u.k6,function(e,r){++t>10||(this.runtime.releaseIds[e.slice(-200)]=(""+r).slice(-200))},e)}(e),X(e);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("internal-error",(t,r)=>{this.abortHandler&&(0,a.p)("ierr",[M(t),(0,c.t)(),!0,{},e.runtime.isRecording,r],void 0,this.featureName,this.ee)}),y.gm.addEventListener("unhandledrejection",t=>{this.abortHandler&&(0,a.p)("err",[K(t),(0,c.t)(),!1,{unhandledPromiseRejection:1},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),y.gm.addEventListener("error",t=>{this.abortHandler&&(0,a.p)("err",[D(t),(0,c.t)(),!1,{},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,2176)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var Q=i(8990);let ee=1;function te(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===y.gm?0:(0,Q.I)(e,"nr@id",function(){return ee++})}function re(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,L.A)(e).length}catch(e){return}}}var ne=i(8139),ie=i(7836),oe=i(3434);const se={},ae=["open","send"];function ce(e){var t=e||ie.ee;const r=function(e){return(e||ie.ee).get("xhr")}(t);if(void 0===y.gm.XMLHttpRequest)return r;if(se[r.debugId]++)return r;se[r.debugId]=1,(0,ne.u)(t);var n=(0,oe.YM)(r),i=y.gm.XMLHttpRequest,o=y.gm.MutationObserver,s=y.gm.Promise,a=y.gm.setInterval,c="readystatechange",u=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],d=[],f=y.gm.XMLHttpRequest=function(e){const t=new i(e),o=r.context(t);try{r.emit("new-xhr",[t],o),t.addEventListener(c,(s=o,function(){var e=this;e.readyState>3&&!s.resolved&&(s.resolved=!0,r.emit("xhr-resolved",[],e)),n.inPlace(e,u,"fn-",b)}),(0,I.jT)(!1))}catch(e){(0,l.R)(15,e);try{r.emit("internal-error",[e])}catch(e){}}var s;return t};function h(e,t){n.inPlace(t,["onreadystatechange"],"fn-",b)}if(function(e,t){for(var r in e)t[r]=e[r]}(i,f),f.prototype=i.prototype,n.inPlace(f.prototype,ae,"-xhr-",b),r.on("send-xhr-start",function(e,t){h(e,t),function(e){d.push(e),o&&(p?p.then(v):a?a(v):(g=-g,m.data=g))}(t)}),r.on("open-xhr-start",h),o){var p=s&&s.resolve();if(!a&&!s){var g=1,m=document.createTextNode(g);new o(v).observe(m,{characterData:!0})}}else t.on("fn-end",function(e){e[0]&&e[0].type===c||v()});function v(){for(var e=0;e<d.length;e++)h(0,d[e]);d.length&&(d=[])}function b(e,t){return t}return r}var ue="fetch-",de=ue+"body-",le=["arrayBuffer","blob","json","text","formData"],fe=y.gm.Request,he=y.gm.Response,pe="prototype";const ge={};function me(e){const t=function(e){return(e||ie.ee).get("fetch")}(e);if(!(fe&&he&&y.gm.fetch))return t;if(ge[t.debugId]++)return t;function r(e,r,n){var i=e[r];"function"==typeof i&&(e[r]=function(){var e,r=[...arguments],o={};t.emit(n+"before-start",[r],o),o[ie.P]&&o[ie.P].dt&&(e=o[ie.P].dt);var s=i.apply(this,r);return t.emit(n+"start",[r,e],s),s.then(function(e){return t.emit(n+"end",[null,e],s),e},function(e){throw t.emit(n+"end",[e],s),e})})}return ge[t.debugId]=1,le.forEach(e=>{r(fe[pe],e,de),r(he[pe],e,de)}),r(y.gm,"fetch",ue),t.on(ue+"end",function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(ue+"done",[null,r],n)}else t.emit(ue+"done",[e],n)}),t}var ve=i(7485);class be{constructor(e){this.agentRef=e}generateTracePayload(t){const r=this.agentRef.loader_config;if(!this.shouldGenerateTrace(t)||!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var s=(0,e.ZF)(),a=(0,e.el)(),c=Date.now(),u={spanId:s,traceId:a,timestamp:c};return(t.sameOrigin||this.isAllowedOrigin(t)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(s,a),u.traceContextStateHeader=this.generateTraceContextStateHeader(s,c,n,i,o)),(t.sameOrigin&&!this.excludeNewrelicHeader()||!t.sameOrigin&&this.isAllowedOrigin(t)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(s,a,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof y.gm?.btoa))return null;var s={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(s.d.tk=o),btoa((0,L.A)(s))}shouldGenerateTrace(e){return this.agentRef.init?.distributed_tracing?.enabled&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1;const r=this.agentRef.init?.distributed_tracing;if(e.sameOrigin)t=!0;else if(r?.allowed_origins instanceof Array)for(var n=0;n<r.allowed_origins.length;n++){var i=(0,ve.D)(r.allowed_origins[n]);if(e.hostname===i.hostname&&e.protocol===i.protocol&&e.port===i.port){t=!0;break}}return t}excludeNewrelicHeader(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.cors_use_tracecontext_headers}}var ye=i(9300),we=i(7295);function Re(e){return"string"==typeof e?e:e instanceof(0,O.dV)().o.REQ?e.url:y.gm?.URL&&e instanceof URL?e.href:void 0}var xe=["load","error","abort","timeout"],Te=xe.length,Ee=(0,O.dV)().o.REQ,Ae=(0,O.dV)().o.XHR;const Se="X-NewRelic-App-Data";class _e extends E{static featureName=ye.T;constructor(e){super(e,ye.T),this.dt=new be(e),this.handler=(e,t,r,n)=>(0,a.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};y.gm?.performance?.getEntriesByType("resource").forEach(t=>{if(t.initiatorType in e&&0!==t.responseStatus){const r={status:t.responseStatus},i={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};Oe(r,t.name),this.handler("xhr",[r,i,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,n.K7.ajax)}})}catch(e){}me(this.ee),ce(this.ee),function(e,t,r,i){function o(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},t.latestLongtaskEnd=0,e.addEventListener("load",function(r){A(t,e)},(0,I.jT)(!1)),y.lR||e.addEventListener("progress",function(e){t.lastSize=e.loaded},(0,I.jT)(!1))}function s(e){this.params={method:e[0]},Oe(this,e[1]),this.metrics={}}function u(t,r){e.loader_config.xpid&&this.sameOrigin&&r.setRequestHeader("X-NewRelic-ID",e.loader_config.xpid);var n=i.generateTracePayload(this.parsedOrigin);if(n){var o=!1;n.newrelicHeader&&(r.setRequestHeader("newrelic",n.newrelicHeader),o=!0),n.traceContextParentHeader&&(r.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&r.setRequestHeader("tracestate",n.traceContextStateHeader),o=!0),o&&(this.dt=n)}}function d(e,r){var n=this.metrics,i=e[0],o=this;if(n&&i){var s=re(i);s&&(n.txSize=s)}this.startTime=(0,c.t)(),this.body=i,this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof r.onload)&&"function"==typeof o.end)&&o.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var a=0;a<Te;a++)r.addEventListener(xe[a],this.listener,(0,I.jT)(!1))}function l(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function f(e,t){var r=""+te(e)+!!t;this.xhrGuids&&!this.xhrGuids[r]&&(this.xhrGuids[r]=!0,this.totalCbs+=1)}function p(e,t){var r=""+te(e)+!!t;this.xhrGuids&&this.xhrGuids[r]&&(delete this.xhrGuids[r],this.totalCbs-=1)}function g(){this.endTime=(0,c.t)()}function m(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-added",[e[1],e[2]],r)}function v(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-removed",[e[1],e[2]],r)}function b(e,t,r){t instanceof Ae&&("onload"===r&&(this.onload=!0),("load"===(e[0]&&e[0].type)||this.onload)&&(this.xhrCbStart=(0,c.t)()))}function w(e,r){this.xhrCbStart&&t.emit("xhr-cb-time",[(0,c.t)()-this.xhrCbStart,this.onload,r],r)}function R(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&&y.RI&&(t=""+y.gm.location.href):e[0]&&e[0].url?t=e[0].url:y.gm?.URL&&e[0]&&e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&&(t=e[0].toString()),"string"==typeof t&&0!==t.length){t&&(this.parsedOrigin=(0,ve.D)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var n=i.generateTracePayload(this.parsedOrigin);if(n&&(n.newrelicHeader||n.traceContextParentHeader))if(e[0]&&e[0].headers)a(e[0].headers,n)&&(this.dt=n);else{var o={};for(var s in r)o[s]=r[s];o.headers=new Headers(r.headers||{}),a(o.headers,n)&&(this.dt=n),e.length>1?e[1]=o:e.push(o)}}function a(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,c.t)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r=this.opts||{},n=this.target;Oe(this,Re(n));var i=(""+(n&&n instanceof Ee&&n.method||r.method||"GET")).toUpperCase();this.params.method=i,this.body=r.body,this.txSize=re(r.body)||0}function T(e,t){if(this.endTime=(0,c.t)(),this.params||(this.params={}),(0,we.iW)(this.params))return;let i;this.params.status=t?t.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(i=+this.rxSize);const o={txSize:this.txSize,rxSize:i,duration:(0,c.t)()-this.startTime};r("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,n.K7.ajax)}function E(e){const t=this.params,i=this.metrics;if(!this.ended){this.ended=!0;for(let t=0;t<Te;t++)e.removeEventListener(xe[t],this.listener,!1);t.aborted||(0,we.iW)(t)||(i.duration=(0,c.t)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&&(t.status=0):A(this,e),i.cbTime=this.cbTime,r("xhr",[t,i,this.startTime,this.endTime,"xhr"],this,n.K7.ajax))}}function A(e,r){e.params.status=r.status;var i=function(e,t){var r=e.responseType;return"json"===r&&null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?re(e.response):"text"===r||""===r||void 0===r?re(e.responseText):void 0}(r,e.lastSize);if(i&&(e.metrics.rxSize=i),e.sameOrigin&&r.getAllResponseHeaders().indexOf(Se)>=0){var o=r.getResponseHeader(Se);o&&((0,a.p)(h.rs,["Ajax/CrossApplicationTracing/Header/Seen"],void 0,n.K7.metrics,t),e.params.cat=o.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",o),t.on("open-xhr-start",s),t.on("open-xhr-end",u),t.on("send-xhr-start",d),t.on("xhr-cb-time",l),t.on("xhr-load-added",f),t.on("xhr-load-removed",p),t.on("xhr-resolved",g),t.on("addEventListener-end",m),t.on("removeEventListener-end",v),t.on("fn-end",w),t.on("fetch-before-start",R),t.on("fetch-start",x),t.on("fn-start",b),t.on("fetch-done",T)}(e,this.ee,this.handler,this.dt),this.importAggregator(e,()=>i.e(478).then(i.bind(i,3845)))}}function Oe(e,t){var r=(0,ve.D)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}const Ne={},Ie=["pushState","replaceState"];function Pe(e){const t=function(e){return(e||ie.ee).get("history")}(e);return!y.RI||Ne[t.debugId]++||(Ne[t.debugId]=1,(0,oe.YM)(t).inPlace(window.history,Ie,"-")),t}var je=i(3738);function ke(e){p(u.BL,function(t=Date.now()){const r=t-y.WN;r<0&&(0,l.R)(62,t),(0,a.p)(h.XG,[u.BL,{time:r}],void 0,n.K7.metrics,e.ee),e.addToTrace({name:u.BL,start:t,origin:"nr"}),(0,a.p)(u.Pl+u.hG,[r,u.BL],void 0,n.K7.genericEvents,e.ee)},e)}const{He:Ce,bD:Le,d3:He,Kp:Me,TZ:Ke,Lc:De,uP:Ue,Rz:Fe}=je;class We extends E{static featureName=Ke;constructor(e){var t;super(e,Ke),t=e,p(u.U2,function(e){if(!(e&&"object"==typeof e&&e.name&&e.start))return;const r={n:e.name,s:e.start-y.WN,e:(e.end||e.start)-y.WN,o:e.origin||"",t:"api"};r.s<0||r.e<0||r.e<r.s?(0,l.R)(61,{start:r.s,end:r.e}):(0,a.p)("bstApi",[r],void 0,n.K7.sessionTrace,t.ee)},t),ke(e);if(!(0,R.V)(e.init))return void this.deregisterDrain();const r=this.ee;let o;Pe(r),this.eventsEE=(0,ne.u)(r),this.eventsEE.on(Ue,function(e,t){this.bstStart=(0,c.t)()}),this.eventsEE.on(De,function(e,t){(0,a.p)("bst",[e[0],t,this.bstStart,(0,c.t)()],void 0,n.K7.sessionTrace,r)}),r.on(Fe+He,function(e){this.time=(0,c.t)(),this.startPath=location.pathname+location.hash}),r.on(Fe+Me,function(e){(0,a.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,n.K7.sessionTrace,r)});try{o=new PerformanceObserver(e=>{const t=e.getEntries();(0,a.p)(Ce,[t],void 0,n.K7.sessionTrace,r)}),o.observe({type:Le,buffered:!0})}catch(e){}this.importAggregator(e,()=>i.e(478).then(i.bind(i,6974)),{resourceObserver:o})}}var Be=i(6344);class Ve extends E{static featureName=Be.TZ;#n;recorder;constructor(e){var t;let r;super(e,Be.TZ),t=e,p(u.CH,function(){(0,a.p)(u.CH,[],void 0,n.K7.sessionReplay,t.ee)},t),function(e){p(u.Tb,function(){(0,a.p)(u.Tb,[],void 0,n.K7.sessionReplay,e.ee)},e)}(e);try{r=JSON.parse(localStorage.getItem("".concat(S.H3,"_").concat(S.uh)))}catch(e){}(0,w.SR)(e.init)&&this.ee.on(u.CH,()=>this.#i()),this.#o(r)&&this.importRecorder().then(e=>{e.startRecording(Be.Qb.PRELOAD,r?.sessionReplayMode)}),this.importAggregator(this.agentRef,()=>i.e(478).then(i.bind(i,6167)),this),this.ee.on("err",e=>{this.blocked||this.agentRef.runtime.isRecording&&(this.errorNoticed=!0,(0,a.p)(Be.Vh,[e],void 0,this.featureName,this.ee))})}#o(e){return e&&(e.sessionReplayMode===S.g.FULL||e.sessionReplayMode===S.g.ERROR)||(0,w.Aw)(this.agentRef.init)}importRecorder(){return this.recorder?Promise.resolve(this.recorder):(this.#n??=Promise.all([i.e(478),i.e(249)]).then(i.bind(i,4866)).then(({Recorder:e})=>(this.recorder=new e(this),this.recorder)).catch(e=>{throw this.ee.emit("internal-error",[e]),this.blocked=!0,e}),this.#n)}#i(){this.blocked||(this.featAggregate?this.featAggregate.mode!==S.g.FULL&&this.featAggregate.initializeRecording(S.g.FULL,!0,Be.Qb.API):this.importRecorder().then(()=>{this.recorder.startRecording(Be.Qb.API,S.g.FULL)}))}}var Ge=i(3962);function ze(e){const t=e.ee.get("tracer");function r(){}p(u.dT,function(e){return(new r).get("object"==typeof e?e:{})},e);const i=r.prototype={createTracer:function(r,i){var o={},s=this,d="function"==typeof i;return(0,a.p)(h.xV,["API/createTracer/called"],void 0,n.K7.metrics,e.ee),e.runSoftNavOverSpa||(0,a.p)(u.hw+"tracer",[(0,c.t)(),r,o],s,n.K7.spa,e.ee),function(){if(t.emit((d?"":"no-")+"fn-start",[(0,c.t)(),s,d],o),d)try{return i.apply(this,arguments)}catch(e){const r="string"==typeof e?new Error(e):e;throw t.emit("fn-err",[arguments,this,r],o),r}finally{t.emit("fn-end",[(0,c.t)()],o)}}}};["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach(t=>{p.apply(this,[t,function(){return(0,a.p)(u.hw+t,[(0,c.t)(),...arguments],this,e.runSoftNavOverSpa?n.K7.softNav:n.K7.spa,e.ee),this},e,i])}),p(u.PA,function(){e.runSoftNavOverSpa?(0,a.p)(u.hw+"routeName",[performance.now(),...arguments],void 0,n.K7.softNav,e.ee):(0,a.p)(u.Pl+"routeName",[(0,c.t)(),...arguments],this,n.K7.spa,e.ee)},e)}class Ze extends E{static featureName=Ge.TZ;constructor(e){if(super(e,Ge.TZ),ze(e),!y.RI||!(0,O.dV)().o.MO)return;const t=Pe(this.ee);try{this.removeOnAbort=new AbortController}catch(e){}Ge.tC.forEach(e=>{(0,I.sp)(e,e=>{s(e)},!0,this.removeOnAbort?.signal)});const r=()=>(0,a.p)("newURL",[(0,c.t)(),""+window.location],void 0,this.featureName,this.ee);t.on("pushState-end",r),t.on("replaceState-end",r),(0,I.sp)(Ge.OV,e=>{s(e),(0,a.p)("newURL",[e.timeStamp,""+window.location],void 0,this.featureName,this.ee)},!0,this.removeOnAbort?.signal);let n=!1;const o=new((0,O.dV)().o.MO)((e,t)=>{n||(n=!0,requestAnimationFrame(()=>{(0,a.p)("newDom",[(0,c.t)()],void 0,this.featureName,this.ee),n=!1}))}),s=(0,x.s)(e=>{(0,a.p)("newUIEvent",[e],void 0,this.featureName,this.ee),o.observe(document.body,{attributes:!0,childList:!0,subtree:!0,characterData:!0})},100,{leading:!0});this.abortHandler=function(){this.removeOnAbort?.abort(),o.disconnect(),this.abortHandler=void 0},this.importAggregator(e,()=>i.e(478).then(i.bind(i,4393)),{domObserver:o})}}var qe=i(7378);const Xe={},Ye=["appendChild","insertBefore","replaceChild"];function Je(e){const t=function(e){return(e||ie.ee).get("jsonp")}(e);if(!y.RI||Xe[t.debugId])return t;Xe[t.debugId]=!0;var r=(0,oe.YM)(t),n=/[?&](?:callback|cb)=([^&#]+)/,i=/(.*)\.([^.]+)/,o=/^(\w+)(\.|$)(.*)$/;function s(e,t){if(!e)return t;const r=e.match(o),n=r[1];return s(r[3],t[n])}return r.inPlace(Node.prototype,Ye,"dom-"),t.on("dom-start",function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var o=(a=e.src,c=a.match(n),c?c[1]:null);var a,c;if(!o)return;var u=function(e){var t=e.match(i);if(t&&t.length>=3)return{key:t[2],parent:s(t[1],window)};return{key:e,parent:window}}(o);if("function"!=typeof u.parent[u.key])return;var d={};function l(){t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}function f(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",l,(0,I.jT)(!1)),e.addEventListener("error",f,(0,I.jT)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])}),t}const $e={};function Qe(e){const t=function(e){return(e||ie.ee).get("promise")}(e);if($e[t.debugId])return t;$e[t.debugId]=!0;var r=t.context,n=(0,oe.YM)(t),i=y.gm.Promise;return i&&function(){function e(r){var o=t.context(),s=n(r,"executor-",o,null,!1);const a=Reflect.construct(i,[s],e);return t.context(a).getCtx=function(){return o},a}y.gm.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return i.toString()},Object.setPrototypeOf(e,i),["all","race"].forEach(function(r){const n=i[r];e[r]=function(e){let i=!1;[...e||[]].forEach(e=>{this.resolve(e).then(s("all"===r),s(!1))});const o=n.apply(this,arguments);return o;function s(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}}),["resolve","reject"].forEach(function(r){const n=i[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}}),e.prototype=i.prototype;const o=i.prototype.then;i.prototype.then=function(...e){var i=this,s=r(i);s.promise=i,e[0]=n(e[0],"cb-",s,null,!1),e[1]=n(e[1],"cb-",s,null,!1);const a=o.apply(this,e);return s.nextPromise=a,t.emit("propagate",[i,!0],a,!1,!1),a},i.prototype.then[oe.Jt]=o,t.on("executor-start",function(e){e[0]=n(e[0],"resolve-",this,null,!1),e[1]=n(e[1],"resolve-",this,null,!1)}),t.on("executor-err",function(e,t,r){e[1](r)}),t.on("cb-end",function(e,r,n){t.emit("propagate",[n,!0],this.nextPromise,!1,!1)}),t.on("propagate",function(e,r,n){if(!this.getCtx||r){const r=this,n=e instanceof Promise?t.context(e):null;let i;this.getCtx=function(){return i||(i=n&&n!==r?"function"==typeof n.getCtx?n.getCtx():n:r,i)}}})}(),t}const et={},tt="setTimeout",rt="setInterval",nt="clearTimeout",it="-start",ot=[tt,"setImmediate",rt,nt,"clearImmediate"];function st(e){const t=function(e){return(e||ie.ee).get("timer")}(e);if(et[t.debugId]++)return t;et[t.debugId]=1;var r=(0,oe.YM)(t);return r.inPlace(y.gm,ot.slice(0,2),tt+"-"),r.inPlace(y.gm,ot.slice(2,3),rt+"-"),r.inPlace(y.gm,ot.slice(3),nt+"-"),t.on(rt+it,function(e,t,n){e[0]=r(e[0],"fn-",null,n)}),t.on(tt+it,function(e,t,n){this.method=n,this.timerDuration=isNaN(e[1])?0:+e[1],e[0]=r(e[0],"fn-",this,n)}),t}const at={};function ct(e){const t=function(e){return(e||ie.ee).get("mutation")}(e);if(!y.RI||at[t.debugId])return t;at[t.debugId]=!0;var r=(0,oe.YM)(t),n=y.gm.MutationObserver;return n&&(window.MutationObserver=function(e){return this instanceof n?new n(r(e,"fn-")):n.apply(this,arguments)},MutationObserver.prototype=n.prototype),t}const{TZ:ut,d3:dt,Kp:lt,$p:ft,wW:ht,e5:pt,tH:gt,uP:mt,rw:vt,Lc:bt}=qe;class yt extends E{static featureName=ut;constructor(e){if(super(e,ut),ze(e),!y.RI)return;try{this.removeOnAbort=new AbortController}catch(e){}let t,r=0;const n=this.ee.get("tracer"),o=Je(this.ee),s=Qe(this.ee),u=st(this.ee),d=ce(this.ee),l=this.ee.get("events"),f=me(this.ee),h=Pe(this.ee),p=ct(this.ee);function g(e,t){h.emit("newURL",[""+window.location,t])}function m(){r++,t=window.location.hash,this[mt]=(0,c.t)()}function v(){r--,window.location.hash!==t&&g(0,!0);var e=(0,c.t)();this[pt]=~~this[pt]+e-this[mt],this[bt]=e}function b(e,t){e.on(t,function(){this[t]=(0,c.t)()})}this.ee.on(mt,m),s.on(vt,m),o.on(vt,m),this.ee.on(bt,v),s.on(ht,v),o.on(ht,v),this.ee.on("fn-err",(...t)=>{t[2]?.__newrelic?.[e.agentIdentifier]||(0,a.p)("function-err",[...t],void 0,this.featureName,this.ee)}),this.ee.buffer([mt,bt,"xhr-resolved"],this.featureName),l.buffer([mt],this.featureName),u.buffer(["setTimeout"+lt,"clearTimeout"+dt,mt],this.featureName),d.buffer([mt,"new-xhr","send-xhr"+dt],this.featureName),f.buffer([gt+dt,gt+"-done",gt+ft+dt,gt+ft+lt],this.featureName),h.buffer(["newURL"],this.featureName),p.buffer([mt],this.featureName),s.buffer(["propagate",vt,ht,"executor-err","resolve"+dt],this.featureName),n.buffer([mt,"no-"+mt],this.featureName),o.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),b(f,gt+dt),b(f,gt+"-done"),b(o,"new-jsonp"),b(o,"jsonp-end"),b(o,"cb-start"),h.on("pushState-end",g),h.on("replaceState-end",g),window.addEventListener("hashchange",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",function(){g(0,r>1)},(0,I.jT)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,5592)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var wt=i(3333);class Rt extends E{static featureName=wt.TZ;constructor(e){super(e,wt.TZ);const t=[e.init.page_action.enabled,e.init.performance.capture_marks,e.init.performance.capture_measures,e.init.user_actions.enabled,e.init.performance.resources.enabled];var r;r=e,p(u.hG,(e,t)=>z(e,t,r),r),function(e){p(u.fF,(t,r)=>q(t,r,e),e)}(e),ke(e),X(e),function(e){p(u.V1,(t,r)=>Z(t,r,e),e)}(e);const o=e.init.feature_flags.includes("user_frustrations");let s;if(y.RI&&o&&(me(this.ee),ce(this.ee),s=Pe(this.ee)),y.RI){if(e.init.user_actions.enabled&&(wt.Zp.forEach(e=>(0,I.sp)(e,e=>(0,a.p)("ua",[e],void 0,this.featureName,this.ee),!0)),wt.qN.forEach(e=>{const t=(0,x.s)(e=>{(0,a.p)("ua",[e],void 0,this.featureName,this.ee)},500,{leading:!0});(0,I.sp)(e,t)}),o)){function c(t){const r=(0,ve.D)(t);return e.beacons.includes(r.hostname+":"+r.port)}function d(){s.emit("navChange")}y.gm.addEventListener("error",()=>{(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.ee.on("open-xhr-start",(e,t)=>{c(e[1])||t.addEventListener("readystatechange",()=>{2===t.readyState&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)})}),this.ee.on("fetch-start",e=>{e.length>=1&&!c(Re(e[0]))&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)}),s.on("pushState-end",d),s.on("replaceState-end",d),window.addEventListener("hashchange",d,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",d,(0,I.jT)(!0,this.removeOnAbort?.signal))}if(e.init.performance.resources.enabled&&y.gm.PerformanceObserver?.supportedEntryTypes.includes("resource")){new PerformanceObserver(e=>{e.getEntries().forEach(e=>{(0,a.p)("browserPerformance.resource",[e],void 0,this.featureName,this.ee)})}).observe({type:"resource",buffered:!0})}}try{this.removeOnAbort=new AbortController}catch(l){}this.abortHandler=()=>{this.removeOnAbort?.abort(),this.abortHandler=void 0},t.some(e=>e)?this.importAggregator(e,()=>i.e(478).then(i.bind(i,8019))):this.deregisterDrain()}}var xt=i(2646);const Tt=new Map;function Et(e,t,r,n){if("object"!=typeof t||!t||"string"!=typeof r||!r||"function"!=typeof t[r])return(0,l.R)(29);const i=function(e){return(e||ie.ee).get("logger")}(e),o=(0,oe.YM)(i),s=new xt.y(ie.P);s.level=n.level,s.customAttributes=n.customAttributes;const a=t[r]?.[oe.Jt]||t[r];return Tt.set(a,s),o.inPlace(t,[r],"wrap-logger-",()=>Tt.get(a)),i}var At=i(1910);class St extends E{static featureName=B.TZ;constructor(e){var t;super(e,B.TZ),t=e,p(u.$9,(e,r)=>G(e,r,t),t),function(e){p(u.Wb,(t,r,{customAttributes:n={},level:i=B.p_.INFO}={})=>{Et(e.ee,t,r,{customAttributes:n,level:i})},e)}(e),X(e);const r=this.ee;["log","error","warn","info","debug","trace"].forEach(e=>{(0,At.i)(y.gm.console[e]),Et(r,y.gm.console,e,{level:"log"===e?"info":e})}),this.ee.on("wrap-logger-end",function([e]){const{level:t,customAttributes:n}=this;(0,V.R)(r,e,n,t)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,5288)))}}new class extends r{constructor(e){var t;(super(),y.gm)?(this.features={},(0,O.bQ)(this.agentIdentifier,this),this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(_),this.runSoftNavOverSpa=[...this.desiredFeatures].some(e=>e.featureName===n.K7.softNav),(0,s.j)(this,e,e.loaderType||"agent"),t=this,p(u.cD,function(e,r,n=!1){if("string"==typeof e){if(["string","number","boolean"].includes(typeof r)||null===r)return g(t,e,r,u.cD,n);(0,l.R)(40,typeof r)}else(0,l.R)(39,typeof e)},t),function(e){p(u.Dl,function(t){if("string"==typeof t||null===t)return g(e,"enduser.id",t,u.Dl,!0);(0,l.R)(41,typeof t)},e)}(this),function(e){p(u.nb,function(t){if("string"==typeof t||null===t)return g(e,"application.version",t,u.nb,!1);(0,l.R)(42,typeof t)},e)}(this),function(e){p(u.d3,function(){e.ee.emit("manual-start-all")},e)}(this),function(e){p(u.Pv,function(t=!0){if("boolean"==typeof t){if((0,a.p)(u.Pl+u.Pv,[t],void 0,"session",e.ee),e.runtime.consented=t,t){const t=e.features.page_view_event;t.onAggregateImported.then(e=>{const r=t.featAggregate;e&&!r.sentRum&&r.sendRum()})}}else(0,l.R)(65,typeof t)},e)}(this),this.run()):(0,l.R)(21)}get config(){return{info:this.info,init:this.init,loader_config:this.loader_config,runtime:this.runtime}}get api(){return this}run(){try{const e=function(e){const t={};return o.forEach(r=>{t[r]=!!e[r]?.enabled}),t}(this.init),t=[...this.desiredFeatures];t.sort((e,t)=>n.P3[e.featureName]-n.P3[t.featureName]),t.forEach(t=>{if(!e[t.featureName]&&t.featureName!==n.K7.pageViewEvent)return;if(this.runSoftNavOverSpa&&t.featureName===n.K7.spa)return;if(!this.runSoftNavOverSpa&&t.featureName===n.K7.softNav)return;const r=function(e){switch(e){case n.K7.ajax:return[n.K7.jserrors];case n.K7.sessionTrace:return[n.K7.ajax,n.K7.pageViewEvent];case n.K7.sessionReplay:return[n.K7.sessionTrace];case n.K7.pageViewTiming:return[n.K7.pageViewEvent];default:return[]}}(t.featureName).filter(e=>!(e in this.features));r.length>0&&(0,l.R)(36,{targetFeature:t.featureName,missingDependencies:r}),this.features[t.featureName]=new t(this)})}catch(e){(0,l.R)(22,e);for(const e in this.features)this.features[e].abortHandler?.();const t=(0,O.Zm)();delete t.initializedAgents[this.agentIdentifier]?.features,delete this.sharedAggregator;return t.ee.get(this.agentIdentifier).abort(),!1}}}({features:[_e,_,j,We,Ve,k,J,Rt,St,Ze,yt],loaderType:"spa"})})()})();</script>
<link rel="icon" type="image/png" sizes="16x16" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png">
<meta name="apple-mobile-web-app-title" content="Frontiers | Articles">
<link rel="manifest" href="/manifest.json">
<link rel="canonical" href="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/full">
<meta property="description" name="description" content="Not all familial ovarian cancer (OC) cases are explained by pathogenic germline variants in known risk genes. A candidate gene approach involving DNA repair ...">
<meta property="og:title" name="title" content="Frontiers | Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases">
<meta property="og:description" name="description" content="Not all familial ovarian cancer (OC) cases are explained by pathogenic germline variants in known risk genes. A candidate gene approach involving DNA repair ...">
<meta name="keywords" content="Germline variants,Familial ovarian cancer,Cancer predisposing genes,whole exome sequencing,DNA repair pathways,single-stranded DNA repair genes,double-stranded DNA repair genes">
<meta property="og:site_name" name="site_name" content="Frontiers">
<meta property="og:image" name="image" content="https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g001.jpg">
<meta property="og:type" name="type" content="article">
<meta property="og:url" name="url" content="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/full">
<meta name="twitter:card" content="summary_large_image">
<meta name="citation_volume" content="13">
<meta name="citation_journal_title" content="Frontiers in Oncology">
<meta name="citation_publisher" content="Frontiers">
<meta name="citation_journal_abbrev" content="Front. Oncol.">
<meta name="citation_issn" content="2234-943X">
<meta name="citation_doi" content="10.3389/fonc.2023.1111191">
<meta name="citation_firstpage" content="1111191">
<meta name="citation_language" content="English">
<meta name="citation_title" content="Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases">
<meta name="citation_keywords" content="Germline variants; Familial ovarian cancer; Cancer predisposing genes; whole exome sequencing; DNA repair pathways; single-stranded DNA repair genes; double-stranded DNA repair genes">
<meta name="citation_abstract" content="Not all familial ovarian cancer (OC) cases are explained by pathogenic germline variants in known risk genes. A candidate gene approach involving DNA repair pathway genes was applied to identify rare recurring pathogenic variants in familial OC cases not associated with known OC risk genes from a population exhibiting genetic drift. Whole exome sequencing (WES) data of 15 OC cases from 13 families tested negative for pathogenic variants in known OC risk genes were investigated for candidate variants in 468 DNA repair pathway genes. Filtering and prioritization criteria were applied to WES data to select top candidates for further analyses. Candidates were genotyped in ancestry defined study groups of 214 familial and 998 sporadic OC or breast cancer (BC) cases and 1025 population-matched controls and screened for additional carriers in 605 population-matched OC cases. The candidate genes were also analyzed in WES data from 937 familial or sporadic OC cases of diverse ancestries. Top candidate variants in ERCC5, EXO1, FANCC, NEIL1 and NTHL1 were identified in 5/13 (39%) OC families. Collectively, candidate variants were identified in 7/435 (1.6%) sporadic OC cases and 1/566 (0.2%) sporadic BC cases versus 1/1025 (0.1%) controls. Additional carriers were identified in 6/605 (0.9%) OC cases. Tumour DNA from ERCC5, NEIL1 and NTHL1 variant carriers exhibited loss of the wild-type allele. Carriers of various candidate variants in these genes were identified in 31/937 (3.3%) OC cases of diverse ancestries versus 0-0.004% in cancer-free controls. The strategy of applying a candidate gene approach in a population exhibiting genetic drift identified new candidate OC predisposition variants in DNA repair pathway genes.">
<meta name="citation_article_type" content="Original Research">
<meta name="citation_pdf_url" content="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/pdf">
<meta name="citation_xml_url" content="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/xml">
<meta name="citation_fulltext_world_readable" content="yes">
<meta name="citation_online_date" content="2023/02/06">
<meta name="citation_publication_date" content="2023/03/08">
<meta name="citation_author" content="Alenezi, Wejdan M. ">
<meta name="citation_author_institution" content="Department of Human Genetics, McGill University, Canada">
<meta name="citation_author" content="Fierheller, Caitlin T. ">
<meta name="citation_author_institution" content="Department of Human Genetics, McGill University, Canada">
<meta name="citation_author" content="Serruya, Corinne ">
<meta name="citation_author_institution" content="Cancer Research Program, Centre for Translational Biology, The Research Institute of McGill University Health Centre, Canada">
<meta name="citation_author" content="Revil, Timothe ">
<meta name="citation_author_institution" content="Department of Human Genetics, McGill University, Canada">
<meta name="citation_author" content="Oros, Kathleen K. ">
<meta name="citation_author_institution" content="Lady Davis Institute for Medical Research of the Jewish General Hospital, Canada">
<meta name="citation_author" content="Subramanian, Deepak N. ">
<meta name="citation_author_institution" content="Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Australia">
<meta name="citation_author" content="Bruce, Jeffrey ">
<meta name="citation_author_institution" content="Princess Margaret Cancer Centre, University Health Network, Canada">
<meta name="citation_author" content="Spiegelman, Dan ">
<meta name="citation_author_institution" content="Department of Human Genetics, McGill University, Canada">
<meta name="citation_author" content="Pugh, Trevor ">
<meta name="citation_author_institution" content="Princess Margaret Cancer Centre, University Health Network, Canada">
<meta name="citation_author" content="Campbell, Ian G. ">
<meta name="citation_author_institution" content="Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Australia">
<meta name="citation_author" content="Mes-Masson, Anne-Marie ">
<meta name="citation_author_institution" content="Centre de recherche du Centre hospitalier de lUniversit de Montral and Institut du cancer de Montral, Canada">
<meta name="citation_author" content="Provencher, Diane ">
<meta name="citation_author_institution" content="Centre de recherche du Centre hospitalier de lUniversit de Montral and Institut du cancer de Montral, Canada">
<meta name="citation_author" content="Foulkes, William D. ">
<meta name="citation_author_institution" content="Department of Human Genetics, McGill University, Canada">
<meta name="citation_author" content="Haffaf, Zaki El ">
<meta name="citation_author_institution" content="Centre de recherche du Centre hospitalier de lUniversit de Montral and Institut du cancer de Montral, Canada">
<meta name="citation_author" content="Rouleau, Guy ">
<meta name="citation_author_institution" content="Department of Human Genetics, McGill University, Canada">
<meta name="citation_author" content="Bouchard, Luigi ">
<meta name="citation_author_institution" content="Department of Biochemistry and Functional Genomics, Universit de Sherbrooke, Canada">
<meta name="citation_author" content="Greenwood, Celia M. T. ">
<meta name="citation_author_institution" content="Department of Human Genetics, McGill University, Canada">
<meta name="citation_author" content="Ragoussis, Jiannis ">
<meta name="citation_author_institution" content="Department of Human Genetics, McGill University, Canada">
<meta name="citation_author" content="Tonin, Patricia N. ">
<meta name="citation_author_institution" content="Department of Human Genetics, McGill University, Canada">
<meta name="dc.identifier" content="doi:10.3389/fonc.2023.1111191">
<script type="application/ld+json">{"@context":"https://schema.org","@type":"ScholarlyArticle","headline":"Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases","author":[{"@type":"Person","name":"Wejdan M. Alenezi","affiliation":["Department of Human Genetics, McGill University, Canada","Cancer Research Program, Centre for Translational Biology, The Research Institute of McGill University Health Centre, Canada","Department of Medical Laboratory Technology, Taibah University, Saudi Arabia"]},{"@type":"Person","name":"Caitlin T. Fierheller","affiliation":["Department of Human Genetics, McGill University, Canada","Cancer Research Program, Centre for Translational Biology, The Research Institute of McGill University Health Centre, Canada"]},{"@type":"Person","name":"Corinne Serruya","affiliation":["Cancer Research Program, Centre for Translational Biology, The Research Institute of McGill University Health Centre, Canada"]},{"@type":"Person","name":"Timothe Revil","affiliation":["Department of Human Genetics, McGill University, Canada","McGill Genome Centre, McGill University, Canada"]},{"@type":"Person","name":"Kathleen K. Oros","affiliation":["Lady Davis Institute for Medical Research of the Jewish General Hospital, Canada"]},{"@type":"Person","name":"Deepak N. Subramanian","affiliation":["Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Australia"]},{"@type":"Person","name":"Jeffrey Bruce","affiliation":["Princess Margaret Cancer Centre, University Health Network, Canada"]},{"@type":"Person","name":"Dan Spiegelman","affiliation":["Department of Human Genetics, McGill University, Canada","Montreal Neurological Institute, McGill University, Canada"]},{"@type":"Person","name":"Trevor Pugh","affiliation":["Princess Margaret Cancer Centre, University Health Network, Canada","Department of Medical Biophysics, University of Toronto, Canada","Ontario Institute for Cancer Research, Canada"]},{"@type":"Person","name":"Ian G. Campbell","affiliation":["Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Australia","Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia"]},{"@type":"Person","name":"Anne-Marie Mes-Masson","affiliation":["Centre de recherche du Centre hospitalier de lUniversit de Montral and Institut du cancer de Montral, Canada","Departement of Medicine, Universit de Montral, Canada"]},{"@type":"Person","name":"Diane Provencher","affiliation":["Centre de recherche du Centre hospitalier de lUniversit de Montral and Institut du cancer de Montral, Canada","Division of Gynecologic Oncology, Universit de Montral, Canada"]},{"@type":"Person","name":"William D. Foulkes","affiliation":["Department of Human Genetics, McGill University, Canada","Cancer Research Program, Centre for Translational Biology, The Research Institute of McGill University Health Centre, Canada","Lady Davis Institute for Medical Research of the Jewish General Hospital, Canada","Department of Medical Genetics, McGill University Health Centre, Canada","Department of Medicine, McGill University, Canada","Gerald Bronfman Department of Oncology, McGill University, Canada"]},{"@type":"Person","name":"Zaki El Haffaf","affiliation":["Centre de recherche du Centre hospitalier de lUniversit de Montral and Institut du cancer de Montral, Canada","Service de Mdecine Gnique, Centre Hospitalier de lUniversit de Montral, Canada"]},{"@type":"Person","name":"Guy Rouleau","affiliation":["Department of Human Genetics, McGill University, Canada","Montreal Neurological Institute, McGill University, Canada"]},{"@type":"Person","name":"Luigi Bouchard","affiliation":["Department of Biochemistry and Functional Genomics, Universit de Sherbrooke, Canada","Department of Medical Biology, Centres intgrs universitaires de sant et de services sociaux du Saguenay-Lac-Saint-Jean hpital Universitaire de Chicoutimi, Canada","Centre de Recherche du Centre hospitalier lUniversit de Sherbrooke, Canada"]},{"@type":"Person","name":"Celia M. T. Greenwood","affiliation":["Department of Human Genetics, McGill University, Canada","Lady Davis Institute for Medical Research of the Jewish General Hospital, Canada","Gerald Bronfman Department of Oncology, McGill University, Canada","Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Canada"]},{"@type":"Person","name":"Jiannis Ragoussis","affiliation":["Department of Human Genetics, McGill University, Canada","McGill Genome Centre, McGill University, Canada"]},{"@type":"Person","name":"Patricia N. Tonin","affiliation":["Department of Human Genetics, McGill University, Canada","Cancer Research Program, Centre for Translational Biology, The Research Institute of McGill University Health Centre, Canada","Department of Medicine, McGill University, Canada"]}],"datePublished":"2023-03-08","dateModified":"2025-11-25","publisher":{"@type":"Organization","name":"Frontiers"},"isPartOf":{"@type":"PublicationIssue","datePublished":"2023","isPartOf":{"@type":"PublicationVolume","volumeNumber":"13","isPartOf":{"@type":"Periodical","name":"Frontiers in Oncology"}}},"citation":["https://doi.org/10.3389/fonc.2023.1111191"],"inLanguage":"en"}</script>
<script type="module" src="/ap-2024/_nuxt/v1IBIWh4.js" crossorigin></script>
<script id="unhead:payload" type="application/json">{"title":"Frontiers | Articles"}</script></head><body  class="body--v3"><div id="__nuxt"><!--[--><!----><div theme="purple"><nav class="Ibar"><div class="Ibar__main"><div class="Ibar__wrapper"><button class="Ibar__burger" aria-label="Open Menu" data-event="iBar-btn-openMenu"></button><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/oncology" class="Ibar__journalName" data-event="iBar-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div class="Ibar__dropdown--aboutUs" parent-data-event="iBar"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=57&amp;specialtyid=0&amp;entitytype=2&amp;entityid=451" data-event="iBar-a-submit">Submit your research</a><div class="Ibar__spacer"></div><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><div><div class="Ibar__menu Ibar__menu--journal"><div class="Ibar__menu__header"><div class="Ibar__logo"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div></div><button class="Ibar__close" aria-label="Close Menu" data-event="iBarMenu-btn-closeMenu"></button></div><div class="Ibar__menu__wrapper"><div class="Ibar__menu__journal"><a href="//www.frontiersin.org/journals/oncology" data-event="iBarMenu-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/breast-cancer" data-event="iBarJournal-sections-a_id_500">Breast Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-cell-signaling" data-event="iBarJournal-sections-a_id_2606">Cancer Cell Signaling</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_513">Cancer Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-genetics" data-event="iBarJournal-sections-a_id_506">Cancer Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-imaging-and-image-directed-interventions" data-event="iBarJournal-sections-a_id_515">Cancer Imaging and Image-directed Interventions</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-immunity-and-immunotherapy" data-event="iBarJournal-sections-a_id_527">Cancer Immunity and Immunotherapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-metabolism" data-event="iBarJournal-sections-a_id_1510">Cancer Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-molecular-targets-and-therapeutics" data-event="iBarJournal-sections-a_id_507">Cancer Molecular Targets and Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-colorectal-cancer" data-event="iBarJournal-sections-a_id_2413">Gastrointestinal Cancers: Colorectal Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-gastric-and-esophageal-cancers" data-event="iBarJournal-sections-a_id_2415">Gastrointestinal Cancers: Gastric and Esophageal Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-hepato-pancreatic-biliary-cancers" data-event="iBarJournal-sections-a_id_2414">Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/genitourinary-oncology" data-event="iBarJournal-sections-a_id_503">Genitourinary Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gynecological-oncology" data-event="iBarJournal-sections-a_id_2079">Gynecological Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/head-and-neck-cancer" data-event="iBarJournal-sections-a_id_517">Head and Neck Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/hematologic-malignancies" data-event="iBarJournal-sections-a_id_505">Hematologic Malignancies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/molecular-and-cellular-oncology" data-event="iBarJournal-sections-a_id_508">Molecular and Cellular Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pediatric-oncology" data-event="iBarJournal-sections-a_id_509">Pediatric Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/radiation-oncology" data-event="iBarJournal-sections-a_id_511">Radiation Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/skin-cancer" data-event="iBarJournal-sections-a_id_1630">Skin Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/surgical-oncology" data-event="iBarJournal-sections-a_id_512">Surgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/thoracic-oncology" data-event="iBarJournal-sections-a_id_502">Thoracic Oncology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div></div><div class="Ibar__dropdown--aboutUs" parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><!----><!----><!----><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=57&amp;specialtyid=0&amp;entitytype=2&amp;entityid=451" data-event="iBarMenu-a-submit">Submit your research</a></div></div></div><!--[--><div class="Ibar__journal Ibar__journal--main"><div class="Ibar__wrapper Ibar__wrapper--journal"><a href="//www.frontiersin.org/journals/oncology" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/breast-cancer" data-event="iBarJournal-sections-a_id_500">Breast Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-cell-signaling" data-event="iBarJournal-sections-a_id_2606">Cancer Cell Signaling</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_513">Cancer Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-genetics" data-event="iBarJournal-sections-a_id_506">Cancer Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-imaging-and-image-directed-interventions" data-event="iBarJournal-sections-a_id_515">Cancer Imaging and Image-directed Interventions</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-immunity-and-immunotherapy" data-event="iBarJournal-sections-a_id_527">Cancer Immunity and Immunotherapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-metabolism" data-event="iBarJournal-sections-a_id_1510">Cancer Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-molecular-targets-and-therapeutics" data-event="iBarJournal-sections-a_id_507">Cancer Molecular Targets and Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-colorectal-cancer" data-event="iBarJournal-sections-a_id_2413">Gastrointestinal Cancers: Colorectal Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-gastric-and-esophageal-cancers" data-event="iBarJournal-sections-a_id_2415">Gastrointestinal Cancers: Gastric and Esophageal Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-hepato-pancreatic-biliary-cancers" data-event="iBarJournal-sections-a_id_2414">Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/genitourinary-oncology" data-event="iBarJournal-sections-a_id_503">Genitourinary Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gynecological-oncology" data-event="iBarJournal-sections-a_id_2079">Gynecological Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/head-and-neck-cancer" data-event="iBarJournal-sections-a_id_517">Head and Neck Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/hematologic-malignancies" data-event="iBarJournal-sections-a_id_505">Hematologic Malignancies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/molecular-and-cellular-oncology" data-event="iBarJournal-sections-a_id_508">Molecular and Cellular Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pediatric-oncology" data-event="iBarJournal-sections-a_id_509">Pediatric Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/radiation-oncology" data-event="iBarJournal-sections-a_id_511">Radiation Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/skin-cancer" data-event="iBarJournal-sections-a_id_1630">Skin Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/surgical-oncology" data-event="iBarJournal-sections-a_id_512">Surgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/thoracic-oncology" data-event="iBarJournal-sections-a_id_502">Thoracic Oncology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div></div></div><div class="Ibar__journal Ibar__journal--mix"><div class="Ibar__wrapper Ibar__wrapper--journal"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/oncology" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div class="Ibar__spacer"></div><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/breast-cancer" data-event="iBarJournal-sections-a_id_500">Breast Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-cell-signaling" data-event="iBarJournal-sections-a_id_2606">Cancer Cell Signaling</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_513">Cancer Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-genetics" data-event="iBarJournal-sections-a_id_506">Cancer Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-imaging-and-image-directed-interventions" data-event="iBarJournal-sections-a_id_515">Cancer Imaging and Image-directed Interventions</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-immunity-and-immunotherapy" data-event="iBarJournal-sections-a_id_527">Cancer Immunity and Immunotherapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-metabolism" data-event="iBarJournal-sections-a_id_1510">Cancer Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-molecular-targets-and-therapeutics" data-event="iBarJournal-sections-a_id_507">Cancer Molecular Targets and Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-colorectal-cancer" data-event="iBarJournal-sections-a_id_2413">Gastrointestinal Cancers: Colorectal Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-gastric-and-esophageal-cancers" data-event="iBarJournal-sections-a_id_2415">Gastrointestinal Cancers: Gastric and Esophageal Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-hepato-pancreatic-biliary-cancers" data-event="iBarJournal-sections-a_id_2414">Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/genitourinary-oncology" data-event="iBarJournal-sections-a_id_503">Genitourinary Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gynecological-oncology" data-event="iBarJournal-sections-a_id_2079">Gynecological Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/head-and-neck-cancer" data-event="iBarJournal-sections-a_id_517">Head and Neck Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/hematologic-malignancies" data-event="iBarJournal-sections-a_id_505">Hematologic Malignancies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/molecular-and-cellular-oncology" data-event="iBarJournal-sections-a_id_508">Molecular and Cellular Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pediatric-oncology" data-event="iBarJournal-sections-a_id_509">Pediatric Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/radiation-oncology" data-event="iBarJournal-sections-a_id_511">Radiation Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/skin-cancer" data-event="iBarJournal-sections-a_id_1630">Skin Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/surgical-oncology" data-event="iBarJournal-sections-a_id_512">Surgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/thoracic-oncology" data-event="iBarJournal-sections-a_id_502">Thoracic Oncology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=57&amp;specialtyid=0&amp;entitytype=2&amp;entityid=451" data-event="iBarJournal-a-submit"><span>Submit</span><span>your research</span></a><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><!--]--></nav><div class="ArticlePage"><!--[--><div class="Layout Layout--withAside Layout--withIbarMix"><div class="Alert Alert--info Alert--noInfo ArticleTemplateBanner"><div class="Alert__icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" class="FeedbackIcon"><path fill="#fff" d="M10 10h28v28H10z"></path><path fill="var(--blue50)" d="M24 2.88a21.12 21.12 0 1 0 0 42.24 21.12 21.12 0 0 0 0-42.24ZM22.08 13.4a.96.96 0 0 1 .96-.96h1.92a.96.96 0 0 1 .96.96v1.92a.96.96 0 0 1-.96.96h-1.92a.96.96 0 0 1-.96-.96V13.4Zm5.76 21.2a.96.96 0 0 1-.96.97h-5.76a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h.96v-7.68h-.96a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h3.84a.96.96 0 0 1 .96.96v10.56h.96a.96.96 0 0 1 .96.96v1.92Z"></path></svg></div><div class="Alert__main"><p class="Alert__message">Your new experience awaits. Try the new design now and help us make it even better</p><!--[--><button type="button" class="Button Button--outline Button--grey80 Button--small ArticleTemplateBanner__switchButton" data-event="btn-action"><span>Switch to the new experience</span></button><!--]--><!----></div><ol class="Alert__info"><!--[--><!--]--></ol></div><!----><main class="Layout__main"><!----><div class="ArticleDetails"><div class="ArticleLayoutHeader"><div class="ArticleLayoutHeader__info"><p class="ArticleLayoutHeader__info__title">ORIGINAL RESEARCH article</p><p class="ArticleLayoutHeader__info__journalDate"><span>Front. Oncol.</span><span>, 08 March 2023</span></p><p class="ArticleLayoutHeader__info__journalDate"> Sec. Cancer Genetics</p><p class="ArticleLayoutHeader__info__doiVolume"><span>Volume 13 - 2023 | </span><a class="ArticleLayoutHeader__info__doi" href="https://doi.org/10.3389/fonc.2023.1111191">https://doi.org/10.3389/fonc.2023.1111191</a></p><!----></div><!----><p class="ArticleLayoutHeader__isPartOfRT"><span class="ArticleLayoutHeader__isPartOfRT__label">This article is part of the Research Topic</span><span class="ArticleLayoutHeader__isPartOfRT__title">Bioinformatics and computational approaches for precision medicine implementation</span><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View all 5 articles" href="https://www.frontiersin.org/research-topics/49571/bioinformatics-and-computational-approaches-for-precision-medicine-implementation/magazine" target="_self" data-event="customLink-linkType-a_viewAll5Articles"><span>View all 5 articles</span></a></span></p></div><div class="ArticleDetails__main__content"><div class="ArticleDetails__main__content__main ArticleDetails__main__content__main--fullArticle"><div class="JournalAbstract"><div class="JournalAbstract__titleWrapper"><h1>Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases</h1><!----></div><!----></div><div class="JournalFullText"><div class="JournalAbstract"><a id="h1" name="h1"></a><div class="authors"><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Wejdan M. Alenezi,," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Wejdan M. Alenezi<sup>1,2,3</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Caitlin T. Fierheller," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Caitlin T. Fierheller<sup>1,2</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Corinne Serruya" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Corinne Serruya<sup>2</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/608170" class="user-id-608170"><img class="pr5" src="https://loop.frontiersin.org/images/profile/608170/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Timoth&#xe;e Revil,">Timoth&#xe9;e Revil</a><sup>1,4</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/341820" class="user-id-341820"><img class="pr5" src="https://loop.frontiersin.org/images/profile/341820/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Kathleen K. Oros">Kathleen K. Oros</a><sup>5</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Deepak N. Subramanian" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Deepak N. Subramanian<sup>6</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Jeffrey Bruce" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Jeffrey Bruce<sup>7</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Dan Spiegelman," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Dan Spiegelman<sup>1,8</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Trevor Pugh,," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Trevor Pugh<sup>7,9,10</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/43010" class="user-id-43010"><img class="pr5" src="https://loop.frontiersin.org/images/profile/43010/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Ian G. Campbell,">Ian G. Campbell</a><sup>6,11</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/866336" class="user-id-866336"><img class="pr5" src="https://loop.frontiersin.org/images/profile/866336/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Anne-Marie Mes-Masson,">Anne-Marie Mes-Masson</a><sup>12,13</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Diane Provencher," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Diane Provencher<sup>12,14</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1785849" class="user-id-1785849"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1785849/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="William D. Foulkes,,,,,">William D. Foulkes</a><sup>1,2,5,15,16,17</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Zaki El Haffaf," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Zaki El Haffaf<sup>12,18</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/530157" class="user-id-530157"><img class="pr5" src="https://loop.frontiersin.org/images/profile/530157/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Guy Rouleau,">Guy Rouleau</a><sup>1,8</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/48062" class="user-id-48062"><img class="pr5" src="https://loop.frontiersin.org/images/profile/48062/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Luigi Bouchard,,">Luigi Bouchard</a><sup>19,20,21</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/29786" class="user-id-29786"><img class="pr5" src="https://loop.frontiersin.org/images/profile/29786/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Celia M. T. Greenwood,,,">Celia M. T. Greenwood</a><sup>1,5,17,22</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/350612" class="user-id-350612"><img class="pr5" src="https://loop.frontiersin.org/images/profile/350612/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Jiannis Ragoussis,">Jiannis Ragoussis</a><sup>1,4</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/363949" class="user-id-363949"><img class="pr5" src="https://loop.frontiersin.org/images/profile/363949/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Patricia N. Tonin,,*">Patricia N. Tonin</a><sup>1,2,16*</sup></span></div><ul class="notes"><li><span><sup>1</sup></span>Department of Human Genetics, McGill University, Montreal, QC, Canada</li><li><span><sup>2</sup></span>Cancer Research Program, Centre for Translational Biology, The Research Institute of McGill University Health Centre, Montreal, QC, Canada</li><li><span><sup>3</sup></span>Department of Medical Laboratory Technology, Taibah University, Medina, Saudi Arabia</li><li><span><sup>4</sup></span>McGill Genome Centre, McGill University, Montreal, QC, Canada</li><li><span><sup>5</sup></span>Lady Davis Institute for Medical Research of the Jewish General Hospital, Montreal, QC, Canada</li><li><span><sup>6</sup></span>Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia</li><li><span><sup>7</sup></span>Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada</li><li><span><sup>8</sup></span>Montreal Neurological Institute, McGill University, Montreal, QC, Canada</li><li><span><sup>9</sup></span>Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada</li><li><span><sup>10</sup></span>Ontario Institute for Cancer Research, Toronto, ON, Canada</li><li><span><sup>11</sup></span>Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia</li><li><span><sup>12</sup></span>Centre de recherche du Centre hospitalier de l&#x2019;Universit&#xe9; de Montr&#xe9;al and Institut du cancer de Montr&#xe9;al, Montreal, QC, Canada</li><li><span><sup>13</sup></span>Departement of Medicine, Universit&#xe9; de Montr&#xe9;al, Montreal, QC, Canada</li><li><span><sup>14</sup></span>Division of Gynecologic Oncology, Universit&#xe9; de Montr&#xe9;al, Montreal, QC, Canada</li><li><span><sup>15</sup></span>Department of Medical Genetics, McGill University Health Centre, Montreal, QC, Canada</li><li><span><sup>16</sup></span>Department of Medicine, McGill University, Montreal, QC, Canada</li><li><span><sup>17</sup></span>Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada</li><li><span><sup>18</sup></span>Service de M&#xe9;decine G&#xe9;nique, Centre Hospitalier de l&#x2019;Universit&#xe9; de Montr&#xe9;al, Montreal, QC, Canada</li><li><span><sup>19</sup></span>Department of Biochemistry and Functional Genomics, Universit&#xe9; de Sherbrooke, Sherbrooke, QC, Canada</li><li><span><sup>20</sup></span>Department of Medical Biology, Centres int&#xe9;gr&#xe9;s universitaires de sant&#xe9; et de services sociaux du Saguenay-Lac-Saint-Jean h&#xf4;pital Universitaire de Chicoutimi, Saguenay, QC, Canada</li><li><span><sup>21</sup></span>Centre de Recherche du Centre hospitalier l&#x2019;Universit&#xe9; de Sherbrooke, Sherbrooke, QC, Canada</li><li><span><sup>22</sup></span>Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada</li></ul><p>Not all familial ovarian cancer (OC) cases are explained by pathogenic germline variants in known risk genes. A candidate gene approach involving DNA repair pathway genes was applied to identify rare recurring pathogenic variants in familial OC cases not associated with known OC risk genes from a population exhibiting genetic drift. Whole exome sequencing (WES) data of 15 OC cases from 13 families tested negative for pathogenic variants in known OC risk genes were investigated for candidate variants in 468 DNA repair pathway genes. Filtering and prioritization criteria were applied to WES data to select top candidates for further analyses. Candidates were genotyped in ancestry defined study groups of 214 familial and 998 sporadic OC or breast cancer (BC) cases and 1025 population-matched controls and screened for additional carriers in 605 population-matched OC cases. The candidate genes were also analyzed in WES data from 937 familial or sporadic OC cases of diverse ancestries. Top candidate variants in <i>ERCC5</i>, <i>EXO1</i>, <i>FANCC, NEIL1</i> and <i>NTHL1</i> were identified in 5/13 (39%) OC families. Collectively, candidate variants were identified in 7/435 (1.6%) sporadic OC cases and 1/566 (0.2%) sporadic BC cases versus 1/1025 (0.1%) controls. Additional carriers were identified in 6/605 (0.9%) OC cases. Tumour DNA from <i>ERCC5, NEIL1</i> and <i>NTHL1</i> variant carriers exhibited loss of the wild-type allele. Carriers of various candidate variants in these genes were identified in 31/937 (3.3%) OC cases of diverse ancestries versus 0-0.004% in cancer-free controls. The strategy of applying a candidate gene approach in a population exhibiting genetic drift identified new candidate OC predisposition variants in DNA repair pathway genes.</p><div class="clear"></div></div><div class="JournalFullText"><a id="h2" name="h2"></a><h2>Introduction</h2><p class="mb15">Since the identification of <i>BRCA1</i> (<a href="#B1">1</a>) and <i>BRCA2</i> (<a href="#B2">2</a>) as breast cancer (BC) and ovarian cancer (OC) predisposing genes, which are involved in the homologous recombination (HR) DNA repair pathway (<a href="#B3">3</a>), no other major high risk gene has been reported to account for the remaining familial cancer cases found to be negative for germline pathogenic variants (PVs) in these genes (<a href="#B4">4</a>). Carriers of PVs in <i>MLH1, MSH2</i>, <i>MSH6</i> or <i>PMS2</i>, genes involved in the mismatch repair (MMR) pathway (<a href="#B3">3</a>), have also been shown to have a significantly increased lifetime risk of developing OC (<a href="#B5">5</a>, <a href="#B6">6</a>) often associated with hereditary non-polyposis colorectal cancer syndrome families (<a href="#B7">7</a>). However, carriers of PVs in MMR genes are very rare accounting for fewer than 1% of sporadic OC cases, which is significantly lower than the 5-15% carrier frequency of PVs in <i>BRCA1</i> and <i>BRCA2</i>, depending on the population studied (<a href="#B8">8</a>). Carriers of PVs in relatively new OC predisposing genes have been reported such as <i>RAD51C</i> (<a href="#B9">9</a>), <i>RAD51D</i> (<a href="#B10">10</a>) and <i>BRIP1</i> (<a href="#B11">11</a>), genes also involved in the HR DNA repair pathway (<a href="#B3">3</a>). The carrier frequency of PVs in each of these genes combined is estimated to be less than 2% of sporadic OC cases (<a href="#B8">8</a>, <a href="#B12">12</a>&#x2013;<a href="#B14">14</a>). PVs in other DNA repair genes such as <i>PALB2</i> (<a href="#B15">15</a>&#x2013;<a href="#B19">19</a>), <i>CHEK2</i> (<a href="#B16">16</a>, <a href="#B20">20</a>) and <i>ATM</i> (<a href="#B16">16</a>, <a href="#B17">17</a>), all associated with BC risk, were recently associated with OC, though risk has yet to be established. Other genes also playing a role in various DNA repair pathways have been proposed as candidate OC risk genes such as <i>FANCM</i> (<a href="#B15">15</a>, <a href="#B21">21</a>), <i>POLE</i> (<a href="#B22">22</a>), <i>MRE11</i> (<a href="#B17">17</a>, <a href="#B23">23</a>), <i>RAD1</i> (<a href="#B17">17</a>) and <i>FANCI</i> (<a href="#B24">24</a>), and collectively, the frequency of carriers of PVs in these genes are also low relative to <i>BRCA1</i> and <i>BRCA2</i> carriers. Thus, research has consistently shown that a candidate gene approach investigating DNA pathway genes has successfully identified new and candidate OC predisposing genes (<a href="#B25">25</a>, <a href="#B26">26</a>), though it is expected that the carrier frequency is significantly lower relative to carriers harbouring PVs in <i>BRCA1</i> and <i>BRCA2</i>.</p><p class="mb15">Defining the contribution of moderate- to high-risk genes in OC remains a challenge as it is not clear that all monogenic cancer predisposing genes have been identified for this genetically heterogeneous disease (<a href="#B4">4</a>). Based on the family history of cancer and the population investigated, the proportion of OC families known to be negative for <i>BRCA1</i> or <i>BRCA2</i> PVs has a wide range of approximately 15-65% (<a href="#B8">8</a>, <a href="#B27">27</a>). Indeed, a recent whole exome sequencing (WES) study of familial and sporadic OC cases revealed significant heterogeneity of candidate OC risk genes, representing diverse functional pathways with relatively few involved in the approximately 200 investigated DNA repair genes (<a href="#B17">17</a>). However, this study focused only on investigating rare, protein-coding loss-of-function (LoF) variants (<a href="#B17">17</a>). As there are at least 400 known or putative genes that are directly or indirectly involved in repairing DNA (<a href="#B3">3</a>, <a href="#B28">28</a>&#x2013;<a href="#B32">32</a>), it is plausible that PVs (LoF or missense) in genes not previously investigated in OC could be associated with OC risk that have yet to be identified. As carriers of new candidate variants are likely to be rare, identifying them will be challenging.</p><p class="mb15">We have proposed a strategy for identifying candidate variants in new cancer predisposing genes that involves the investigation of cancer families from populations exhibiting genetic drift (<a href="#B33">33</a>). Over time, rare PVs in such populations could attain disproportionally high carrier frequencies of rare risk variants relative to the general population (<a href="#B34">34</a>, <a href="#B35">35</a>). For example, <i>PALB2</i> (<a href="#B36">36</a>) and <i>BRIP1</i> (<a href="#B11">11</a>) were discovered as BC and OC predisposing genes by investigating cancer families and cases from the Finnish and Icelandic populations, respectively, both populations exhibiting genetic drift. Our research of French Canadians (FC) from the Quebec population of Canada, identified <i>RECQL</i> (<a href="#B37">37</a>) and <i>FANCI</i> (<a href="#B24">24</a>) as new candidate BC or OC predisposing genes, respectively. Genetic drift in the FCs of Quebec has been attributed to common ancestors as a result of the geographic isolation and multiple waves of expansion of European settlers from France since 1608 (<a href="#B33">33</a>&#x2013;<a href="#B35">35</a>, <a href="#B38">38</a>, <a href="#B39">39</a>). Investigating these populations facilitates the characterization of deleterious variants in known or candidate cancer predisposing genes as all types of variants could be investigated and not only LoF variants (<a href="#B33">33</a>). A small number of PVs in <i>BRCA1</i> and <i>BRCA2</i> (<a href="#B40">40</a>, <a href="#B41">41</a>) and one in each of <i>PALB2</i> (<a href="#B42">42</a>), <i>RAD51C</i> (<a href="#B43">43</a>) and <i>RAD51D</i> (<a href="#B43">43</a>, <a href="#B44">44</a>) have been shown to be frequently occurring in FC OC and/or BC cases versus population-matched controls. Specific PVs in <i>MLH1</i> (<a href="#B45">45</a>)<i>, MSH2</i> (<a href="#B45">45</a>) and <i>MSH6</i> (<a href="#B46">46</a>) have also been reported in FCs in the context of hereditary non-polyposis colorectal cancer.</p><p class="mb0">We recently reported that not all remaining <i>BRCA1</i> and <i>BRCA2</i> negative families with at least two close relatives with OC from the FC population of Quebec by WES analysis were due to PVs in <i>RAD51C</i>, <i>RAD51D</i> or <i>BRIP1</i> approximating that 40% of such cases are unaccounted for by known or emerging OC predisposing genes (<a href="#B33">33</a>, <a href="#B43">43</a>, <a href="#B47">47</a>). Also, we reported that likely pathogenic variants (LPV) in <i>FANCI</i>, a proposed new OC predisposing gene from the Fanconi anemia (FA) pathway, were rarely implicated in familial and sporadic OC cases in this population (<a href="#B24">24</a>). We posit that DNA repair pathways genes have not been fully explored as candidate OC risk genes. In this study, we report the identification of candidate LPVs in DNA repair pathway genes that were identified by applying a candidate gene approach focusing on an extensive list of 468 DNA repair pathway genes in available WES data derived from the germline of FC familial OC cases. Candidate variants prioritized based on our bioinformatic analyses were selected for targeted genotyping in larger groups of defined FC cases to determine carrier frequencies in 1212 FC and 937 non-FC familial and sporadic OC cases and 1025 population-matched controls. Available tumour DNA from our FC carriers also was investigated for loss of the wild-type allele of candidate loci.</p><a id="h3" name="h3"></a><h2>Materials and methods</h2><h3>Study participants</h3><p class="mb0">FC cancer cases and controls are described in <a href="#f1">Figure&#xa0;1</a> and <a href="#h10">Table S1</a>. For clarity, cases diagnosed with primary fallopian tubes or peritoneal cancers were included as cases in recognition of common aetiology with OC, which are associated with hereditary cancer risk factors (<a href="#B48">48</a>, <a href="#B49">49</a>). For the discovery of new candidate OC risk variants (study phase I; <a href="#f1">Figure&#xa0;1A</a>), WES data from peripheral blood lymphocytes (PBL) DNA was available from 15 OC cases from 13 families, each family having at least two first-, second- or third-degree relatives with OC. These cases were confirmed negative for PVs in the known OC risk genes: <i>BRCA1</i>, <i>BRCA2, BRIP1, RAD51C</i> or <i>RAD51D</i> as previously reported (<a href="#B47">47</a>, <a href="#B43">43</a>). This group includes three index cases harbouring a LPV in <i>FANCI</i> c.1813C&gt;T; p.Leu605Phe (<a href="#B24">24</a>). As <i>FANCI</i> remains a candidate OC predisposing gene requiring further independent studies, we did not exclude <i>FANCI</i> variant carriers from any of our study groups for our investigation.</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE&#xa0;1</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g001.jpg" name="" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g001.jpg" alt="www.frontiersin.org" id="f1" loading="lazy">
  </picture>
</a><p><b>Figure&#xa0;1</b> Scheme describing different phases of this study in identifying and evaluating candidate variants in genes involved in various DNA repair pathways. The diagram illustrates: <b>(A)</b> study phase I for identifying candidate variants by applying a candidate gene approach of known or putative DNA repair genes (see <a href="#h10">Table S2</a>) on peripheral blood lymphocytes (PBL) DNA from familial ovarian cancer (OC) cases of French Canadians (FC) of Quebec by whole exome sequencing (WES) and bioinformatic analyses (see <a href="#h10">Table S1</a>); <b>(B)</b> study phase II for determining the carrier frequencies of the topprioritized candidate variants in FC familial and sporadic OC and BC cases, including hereditary breast and ovarian cancer (HBOC) syndrome and hereditary breast cancer (HBC) syndrome families, and population-matched controls by targeted genetic analyses (see <a href="#h10">Table S1</a>); <b>(C)</b> study phase III for identifying additional carriers in FC OC cases by targeted genetic analyses (see <a href="#h10">Table S1</a>); and <b>(D)</b> study phase IV for identifying candidate variants in the identified candidate DNA repair genes from phase I in non-FC OC cases, mainly of European origin, by targeted genetic analyses: (MIX, mixed ethnicity; AUS, Australian; and TCGA, The Cancer Genome Atlas) (see <a href="#h10">Table S1</a>). Teal ribbon signifies women with OC and pink ribbon signifies women with BC, and diagrams contain the provincial flag of Quebec, Canada denoting the geographic ascertainment of cases and controls. MAF, Minor allele frequency; and VAF, Variant allele frequency.</p></div><div class="DottedLine"></div><p class="mb15 w100pc float_left mt15">Targeted analyses of the candidate variants was performed to determine their carrier frequencies (study phase II; <a href="#f1">Figure&#xa0;1B</a>) on the PBL DNA from FC OC cases, regardless of their carrier status for <i>BRCA1</i> and <i>BRCA2</i> PVs, from 42 hereditary breast and ovarian cancer (HBOC) syndrome families having one OC and at least two BC cases in the same familial branch and 435 sporadic OC cases not selected for age at diagnosis with the disease or for family history of any cancers. Genetic data was available from 1025 population-matched controls provided by three independent biobanks as previously described (<a href="#B43">43</a>). As known OC predisposing genes are also involved in BC risk (nccn.org/guidelines/category_2), targeted analyses of the candidate variants was also performed on the PBL DNA from FC BC cases, regardless of their <i>BRCA1</i> and <i>BRCA2</i> PV carrier status, from 33 HBOC families, 139 hereditary breast cancer (HBC) syndrome families having at least three close relatives with BC within first-, second- or third-degree of relationship from the same familial branch and 563 sporadic BC cases not selected for age at diagnosis with the disease or for family history of any cancers.</p><p class="mb15">Targeted analyses of PBL DNA from additional OC cases was performed to identify more OC carriers of our candidate variants (study phase III; <a href="#f1">Figure&#xa0;1C</a>). These groups were comprised of: 52 sporadic early-onset cases diagnosed with high-grade serous ovarian carcinoma (HGSC) before the age of 50 years who tested negative for PVs in <i>BRCA1</i> or <i>BRCA2</i>; and 553 OC cases, regardless of their <i>BRCA1</i> and <i>BRCA2</i> PV carrier status and not defined by any criteria as previously described in this study (<a href="#B43">43</a>).</p><p class="mb15">The majority of FC cancer cases self-reported FC ancestry of Quebec as described previously (<a href="#B24">24</a>, <a href="#B40">40</a>, <a href="#B41">41</a>, <a href="#B43">43</a>, <a href="#B47">47</a>, <a href="#B50">50</a>&#x2013;<a href="#B56">56</a>). FC controls from Universit&#xe9; de Sherbrooke-The Genetics of Glucose Regulation in Gestation and Growth (Gen3G) (<a href="#B57">57</a>) and McGill University-Montreal Neurological Institute (MNI) (<a href="#B58">58</a>) biobanks self-reported FC ancestry as described previously (<a href="#B43">43</a>). FC controls from CARTaGENE biobank (cartagene.qc.ca) were born in the province of Quebec, reported being FC ancestry, having parents and all four grandparents born in Canada and French as first language learned as described previously (<a href="#B43">43</a>, <a href="#B59">59</a>).</p><p class="mb15">The cancer cases and controls not selected for being of FC ancestry of Quebec, mainly of European ancestry are referred to as non-FC groups in this study, were available from different resources. Genetic analyses to determine the spectrum and prevalence of candidate variants in genes that were identified in the study phase I were performed (study phase IV; <a href="#f1">Figure&#xa0;1D</a>) on available genetic data derived from PBL DNA from three independent groups with OC: 9 OC cases from 7 families with at least two close relatives with OC (MIX familial OC cases) (<a href="#B47">47</a>); 516 OC familial or sporadic cases from the Australian population (AUS OC cases) (<a href="#B17">17</a>) and 412 OC cases as part of The Cancer Genome Atlas (TCGA) Pan-Cancer Atlas project (not selected for ethnicity) (<a href="#B60">60</a>) and cancer-free controls as part of the Genome Aggregation Database (gnomAD) v2.1.1. (<a href="#B61">61</a>). The gnomAD v2.1.1. controls were also used to filter common variants as part of study phase I (<a href="#f1">Figure&#xa0;1A</a> and <a href="#h10">Table S1</a>) which is described in the following section.</p><p class="mb0">All biological samples, clinico-pathological, pedigree and relevant medical genetic information from the cancer cases and control groups that were investigated in this study are from biobanks where participants had been recruited in accordance with ethical guidelines of the biobanks respective Institutions Research Ethics Boards as described in <a href="#h10">Table S1</a>. Where applicable, samples were anonymized at source by the providers and were assigned a unique identifier (PT followed by four digits) to further protect their identity. This project was conducted with approval and in accordance with the guidelines of The McGill University Health Centre Research Ethics Board (MP-37-2019-4783).</p><h3>Identifying and selecting for top candidate variants in FC cancer cases</h3><p class="mb15">For phase I of the study (<a href="#f1">Figure&#xa0;1A</a>), WES data was available from PBL DNA from 15 OC index cases from 13 cancer families that had at least one first-, second- or third-degree relative from the same familial branch with OC, and were confirmed being negative for PVs in <i>BRCA1</i>, <i>BRCA2, BRIP1, RAD51C</i> or <i>RAD51D</i> by WES analyses (<a href="#B43">43</a>, <a href="#B47">47</a>). WES had been subjected to a customized bioinformatics pipeline for germline variant calling at the McGill Genome Center as previously reported by our group (<a href="#B24">24</a>, <a href="#B43">43</a>). In brief, NimbleGen SeqCap<sup>&#xae;</sup> EZ Exome v3.0 library kit (Roche, US), followed by paired-end sequencing on different Illumina HiSeq platforms was performed. Reads were aligned to the human reference genome assembly GRCh37/hg19 using Burrows-Wheeler aligner v0.7.17, followed by PCR deduplication using Picard v2.9.0. Realignment around small insertions and deletions was performed, and germline variants were called using HaplotypeCaller using Genome Analysis Toolkit (GATK) v3.5. Variants were then filtered for base sequencing quality score &#x2265;30 and annotated using Ensembl Variant Effect Predictor (VEP) and GEMINI v0.19.1.</p><p class="mb15">Using a candidate gene approach, a curated list of 468 known or putative DNA repair genes (<a href="#B28">28</a>&#x2013;<a href="#B32">32</a>) (ebi.ac.uk/QuickGO/term/GO:0006281) (<a href="#h10">Table S2</a>) were investigated for candidate PVs in WES data from selected index OC cases (<a href="#f1">Figure&#xa0;1A</a>). Variants identified in these DNA repair genes were extracted from the annotated variant call format (VCF) files from the index OC cases (<a href="#f1">Figure&#xa0;1A</a><b>)</b>. Variants with minor allele frequency (MAF) &gt;0.005 in gnomAD v2.1.1. (<a href="#B61">61</a>, <a href="#B62">62</a>), with total low coverage &lt;10 reads and/or those with variant allele frequency (VAF) &lt;0.2 and &gt;0.8 were filtered out and retained variants were subjected for further prioritization and selection. These thresholds have been tested previously under the assumption that new variants follow an autosomal dominant mode of inheritance (<a href="#B63">63</a>). These variants were then verified by manual inspection in the aligned sequences in compressed binary alignment map (BAM) files by Integrative Genomics Viewer (IGV) v2.4.10. (<a href="#B64">64</a>).</p><p class="mb15">Top candidate variants were selected from this master list of variants for further analyses based on various prioritization criteria as shown in <a href="#f1">Figure&#xa0;1A</a>. First, we prioritized LoF variants (nonsense, frameshift and alternative splicing variants), inframe, missense and intronic variants, which were predicted to be conserved and damaging at the RNA or protein level by 15 selected in silico tools: (1) by at least one out of three prediction tools for conservation Genomic Evolutionary Rate Profiling v1.0 (GERP++ [score&#x2265;2.0]) (<a href="#B65">65</a>), Phylogenetic P value of 100 vertebrates v4.2 (PhyloP 100 way [score &#x2265;0.2]) (<a href="#B66">66</a>) and PHAST Conservation of 100 vertebrates v4.2 (PhastCons 100 way [score &#x2265;0.9]) (<a href="#B67">67</a>); (2) by at least one out of four prediction tools for splicing Maximum Entropy Estimates of Splice Junction v2.0 (MaxEntScan) (<a href="#B68">68</a>), two different Database Splicing Consensus Single Nucleotide Variant (dbscSNV) in silico tools: AdaBoost v4.0 (ADA [score &#x2265;0.4]) and Random Forest v4.0 (RF [score&#x2265;0.4]) (<a href="#B69">69</a>) and SpliceAI (score &#x2265;0.4) (<a href="#B70">70</a>); and (3) at least six out of eight prediction tools for damaging of protein function based on their best performance (<a href="#B71">71</a>&#x2013;<a href="#B74">74</a>): Combined Annotation Dependent Depletion v1.4 (CADD [Phred score &#x2265;20]) (<a href="#B75">75</a>), Eigen (score &#x2265;0.0) (<a href="#B76">76</a>), Meta-analytic Logistic Regression v4.2 (MetaLR [score &#x2265;0.5]) (<a href="#B77">77</a>), Meta-analytic support Vector Machine v4.2 (MetaSVM [score &#x2265;0.0]) (<a href="#B77">77</a>), MetaRNN 4.2 (score &#x2265;0.5) (<a href="#B78">78</a>), Rare Exome Variant Ensemble Learner v4.2 (REVEL [score &#x2265;0.5)) (<a href="#B79">79</a>), Variant Effect Scoring Test v4.2 (VEST [score &#x2265;0.5]) (<a href="#B80">80</a>) and Protein Variation Effect Analyzer v4.0 (PROVEAN v4.0 [score &#x2264;&#x2212;2.5]) (<a href="#B81">81</a>). Then, the variants having a clinical classification as benign or likely benign in the context of hereditary cancer syndromes in ClinVar (<a href="#B82">82</a>, <a href="#B83">83</a>) and/or American College of Medical Genetics and Genomics (ACMG) guidelines (<a href="#B84">84</a>, <a href="#B85">85</a>) were given a lower priority for further investigation.</p><p class="mb15">The remaining prioritized variants were then subjected to further prioritization. Variants were surveyed in available genetic data generated from the germline of three FC study groups (<a href="#h10">Table S1</a>): (1) WES data from the germline of 52 sporadic early-onset OC cases negative for PVs in <i>BRCA1</i> and <i>BRCA2</i> (<a href="#B43">43</a>, <a href="#B47">47</a>); and (2) sequencing-based (WES or whole genome sequencing [WGS]) data and/or genotyping-based data from 1025 FC controls (<a href="#B43">43</a>). Then, the variants were subjected for further selection and characterization for genetic analyses.</p><p class="mb0">Selected top candidate variants were verified in the PBL DNA by bidirectional Sanger sequencing using customized primers (available upon request) performed at the McGill Genome Center as described previously (<a href="#B86">86</a>, <a href="#B43">43</a>, <a href="#B47">47</a>; <a href="#B24">24</a>, <a href="#B33">33</a>). Sequencing chromatograms were visually inspected for variant heterozygosity using 4Peaks v1.8. (nucleobytes.com/4peaks/) (The Netherlands Cancer institute, Amsterdam, The Netherlands).</p><h3>Determining carrier frequencies of selected candidate variants in FC cancer cases and controls</h3><p class="mb15">Selected top candidate variants were investigated for carrier frequencies in defined FC study groups (study phase II) comprised of 42 index OC and 33 index BC cases from 75 HBOC families, 139 index BC cases from 139 HBC families, 435 sporadic OC cases and 563 sporadic BC cases (<a href="#f1">Figure&#xa0;1B</a> and <a href="#h10">Table S1</a>). PBL DNA from index cases were genotyped using customized TaqMan<sup>&#xae;</sup> (<a href="#B87">87</a>), Sequenom iPLEX<sup>&#xae;</sup> Gold (<a href="#B88">88</a>) or Fluidigm<sup>&#xae;</sup> SNP Type<sup>&#x2122;</sup>(<a href="#B89">89</a>) genotyping assays (primers available upon request) as described previously (<a href="#B24">24</a>, <a href="#B43">43</a>, <a href="#B90">90</a>). Tumour DNA samples from the index case were genotyped where PBL DNA was no longer available from the biobank. Carriers of candidate variants were verified by bidirectional Sanger sequencing of PBL DNA as described above. Selected candidate variants were also investigated for carrier frequency in population-matched controls by surveying 1025 available sequencing-based data sets (<a href="#h10">Table S1</a>) and/or 8493 single nucleotide polymorphism (SNP) genotyping-based data sets as previously described (<a href="#B43">43</a>). For probes of variants not presented on the SNP array, pre-phasing and imputation were performed as described previously (<a href="#B24">24</a>, <a href="#B43">43</a>).</p><p class="mb0">Pair-wise comparisons were performed of carrier frequencies of candidate variants in different FC cancer groups versus sequencing-based controls. Two-tailed Fisher&#x2019;s exact test was used to compare carrier frequencies in the cancer versus control groups where un-adjusted <i>P</i> values &lt;0.05 for multiple testing was considered significant.</p><h3>Targeted genetic analyses of selected candidate variants or genes in FC cancer cases</h3><p class="mb0">To further characterize our candidate variants and genes in a population exhibiting genetic drift, we investigated carrier status in additional OC cases from the FC population. Selected top candidate variants were investigated (study phase III) in 52 sporadic early-onset FC HGSC cases and in an additional 553 FC OC cases by surveying available genetic data or targeted genotyping of PBL DNA (<a href="#f1">Figure&#xa0;1C</a> and <a href="#h10">Table S1</a>). We also investigated other variants in our gene candidates that met our filtering and prioritizing criteria in the available WES data from the sporadic early-onset OC cases (<a href="#f1">Figure&#xa0;1C</a>).</p><h3>Loss of heterozygosity analyses of candidate genes loci in OC tumour DNA from FC candidate variant carriers</h3><p class="mb0">To investigate evidence for inactivation of candidate genes in cancer cells, we performed loss of heterozygosity (LOH) analysis of tumour DNA from variant carriers. Bi-directional Sanger sequencing of available tumour DNA was performed using customized primers (available upon request) as described above. Extracted DNA from fresh-frozen (FF) or histopathological sections from formalin-fixed paraffin-embedded (FFPE) tumour tissues were provided by the RRCancer biobank for DNA extraction and LOH analysis (Promega, Canada). Sequencing chromatograms were inspected for loss of the wild-type allele using 4Peaks v1.8. (nucleobytes.com/4peaks/) (The Netherlands Cancer Institute, Amsterdam, The Netherlands).</p><h3>Genetic analyses of candidate genes in non-FC cancer cases and controls</h3><p class="mb0">To further characterize the candidate variants and genes identified in our FC cancer cases, we investigated available genetic data from other populations that were not specifically selected for FC ancestry. The spectrum and prevalence of our candidate variants were investigated in genetic data from non-FC OC cases being predominantly of European ancestry and cancer-free controls were investigated for new variants in our candidate genes that met our filtering and prioritizing criteria (<a href="#f1">Figure&#xa0;1D</a> and <a href="#h10">Table S1</a>). Variants were extracted from the annotated VCF files generated by WES data from the germline of: (1) 9 MIX familial OC cases; (2) 516 AUS OC cases; and (3) 412 OC cases from the Pan-Cancer TCGA project. Variants were extracted from the comma separated value (CSV) files downloaded directly from (<a href="https://gnomad.broadinstitute.org">https://gnomad.broadinstitute.org</a>). All variants were annotated and subjected to our filtering and prioritizing criteria to identify candidate variants as described above (see <a href="#f1">Figure&#xa0;1A</a>).</p><h3>Genetic analyses for co-occurring rare pathogenic variants in known OC risk genes in FC and non-FC candidate variant carriers</h3><p class="mb0">We investigated available WES data from OC cases, to determine whether the identified carriers of candidate variants (regardless of the ethnicity and study phase in which they were identified) also harbour rare PVs or LPVs in known OC risk genes (n=11): <i>BRCA1</i> (NM_007294.4), <i>BRCA2</i> (NM_000059.4), <i>MLH1</i> (NM_000249.4), <i>MSH2</i> (NM_000251.3), <i>MSH6</i> (NM_000179.3), <i>PMS2</i> (NM_000535.7), <i>BRIP1</i> (NM_032043.3), <i>RAD51C</i> (NM_058216.3), <i>RAD51D</i> (NM_001142571.2), <i>PALB2</i> (NM_024675.4) and <i>ATM</i> (NM_000051.4) based on the National Comprehensive Cancer Network (NCCN) Clinical Practice in Oncology Guidelines 2022 (Version 2.2022) &#x2014;Genetic/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic (nccn.org/guidelines/category_2). Variants were extracted from the annotated VCF files from carriers and subjected to our filtering and prioritizing criteria as previously described (<a href="#B47">47</a>).</p><a id="h4" name="h4"></a><h2>Results</h2><h3>Prioritization and selection of candidate variants: Phase I</h3><p class="mb0">We first extracted variants identified in a curated list of 468 DNA repair genes (<a href="#h10">Table S2</a>) from VCF files generated from WES data from the 15 index FC OC cases from 13 families. In these index cases, we identified a total of 3,557 variants in 426 of 468 DNA repair genes (<a href="#f1">Figure&#xa0;1</a>). Based on their rarity and variant quality, we retained a total of 201 variants in 137 of 426 DNA repair genes where each index case harboured 3 to 25 (median=15) variants. From this list of 201 variants, we prioritized candidates that were predicted to be conserved or damaging at the level of RNA or protein using our selected in silico tools; and those classified benign or likely benign in the context of hereditary cancers using ClinVar and/or ACMG guidelines were not pursued further. Using these criteria, we retained a total of 15 of the 201 variants, each of which was found in a different gene: 3 nonsense variants, 1 canonical alternative splicing variant, 1 inframe and 10 missense variants (<a href="#h10">Table S3</a>). These variants were identified in 10 of the 15 index cases from 8 out of the 13 OC families (<a href="#f2">Figures&#xa0;2</a>,  <a href="#h10">S1</a>). One of these variants was identified in two OC cases from the same family, two variants were identified in two OC cases from the same family and the remaining 12 variants were identified in one index case from independent OC families (<a href="#h10">Table S3</a>). Two cases harboured either three or four variants, while the remaining nine cases harboured one to two variants.</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE&#xa0;2</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g002.jpg" name="" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g002.jpg" alt="www.frontiersin.org" id="f2" loading="lazy">
  </picture>
</a><p><b>Figure&#xa0;2</b> Pedigrees of index ovarian cancer cases harbouring candidate variants in DNA repair genes identified in phase I of the study. Selected top candidate variants were identified in 5 of 13 families having at least two or more OC cases. Anonymized pedigrees indicate carrier status of tested index case (arrow) and available family members denoted by plus (carrier) or minus (not a carrier) signs. All Index cases (arrow) were subjected to whole exome sequencing analyses (WES). All carriers were found in a heterozygous state. Age in years is shown at cancer diagnosis and death where applicable. Superscript C denotes histological subtypes that were confirmed by pathology reports or death certificates.</p></div><div class="DottedLine"></div><p class="mb0">To select our top candidates for further analyses, we reviewed the individual context wherein the 15 variants were identified as shown in <a href="#h10">Table S3</a> and <a href="#f2">Figures&#xa0;2</a>, <a href="#h10">S1</a>. We estimated the allele frequencies of the 15 candidate variants in population-matched FC controls. Thereby, we did not pursue <i>ALKBH3</i> c.677A&gt;G; p.Asn226Ser, which was identified in an index case (PT0136) from family F1506, as it has a MAF &#x2265;0.01 in FC controls. We also excluded the missense variant in <i>DNA2</i> c.836C&gt;T; p.Thr279Ile for further analyses as it was identified in the index case (PT0128) and four unaffected members of the family F694, and was not inherited from the affected mother with the family history of OC and other cancers (<a href="#h10">Figure S1</a>). We did not pursue <i>RBBP8</i> c.1941T&gt;G; p.Asp647Glu as it was not harboured by the other index OC case (PT0056) from the same family F1528 (<a href="#h10">Figure S1</a>). Additional variants that were excluded for further analyses included: (1) <i>RHNO1</i> c.250C&gt;T; p.Arg84Ter in the index OC case (PT0158) from family F1288; (2) <i>ATRX</i> c.4377_4379del; p.Glu1464del in one of the index OC case (PT0057) from family F1528 as they were classified as benign in ClinVar and by ACMG guidelines, and the latter as not being harboured by the other index OC case of the same family F1528 (<a href="#h10">Figure S1</a>); (3) <i>SMARCA2</i> c.3265C&gt;T in the index OC case (PT0128) from family F694; p.Arg1089Trp; and (4) <i>KMT2C</i> c.6916C&gt;T; p.Pro2306Ser in the index OC case (PT0047) from family F1490 as variants in these genes are associated with non-cancer related syndromes (<a href="#h10">Figure S1</a>). Heterozygous germline variants in <i>SMARCA2</i> are linked with Nicolaides-Baraitser syndrome (MIM: 601358), which is characterized by intellectual disability, seizures, limited to absence of speech ability, short stature, dysmorphic facial features and sparse hair (<a href="#B91">91</a>, <a href="#B92">92</a>; <a href="#B93">93</a>&#x2013;<a href="#B97">97</a>); and heterozygous germline variants in <i>KMT2C</i> are linked with Kleefstra syndrome, type 2 (MIM: 617768), which is characterized by delayed psychomotor development, variable intellectual disability and mild dysmorphic features (<a href="#B98">98</a>&#x2013;<a href="#B101">101</a>). A genotype-phenotype of heterozygous variants located within exon 15-25 of <i>SMARCA2</i>, which encodes the ATPase domain, have been recently reported that over 80% of these variants were <i>de novo</i> based on WES analyses of 80 cases in trios with Nicolaides-Baraitser syndrome that have been documented worldwide so far (<a href="#B92">92</a>, <a href="#B95">95</a>, <a href="#B97">97</a>). Our <i>SMARCA2</i> c.3265C&gt;T; p.Arg1089Trp has never been reported in the literature, but it is located in exon 23 that encodes the ATPase domain (<a href="#B97">97</a>). Whereas, <i>KMT2C</i> c.6916C&gt;T; p.Pro2306Ser was reported in the context of Kleefstra syndrome (<a href="#B100">100</a>). Finally, we did not pursue: <i>RECQL5</i> c.918G&gt;A; p.Met306Ile, <i>ASCC3</i> c.3808C&gt;T; p.Arg1270Ter and <i>UBB</i> c.569C&gt;A; p.Pro190His as all were harboured by the same index case (PT0139) from family F1606 that also harbouring <i>FANCC</i> c.897G&gt;T; p.Arg299Ser as this variant is a plausible and intriguing candidate where <i>FANCC</i> has been reported as a candidate BC predisposing gene (<a href="#B102">102</a>). Thus, <i>FANCC</i> c.897G&gt;T; p.Arg299Ser and the remaining variants identified in <i>ERCC5</i> c.2556A&gt;G; p.Ile852Met<i>, EXO1</i> c.1268-1G&gt;T<i>, NEIL1</i> c.248G&gt;T; p.Gly83Asp and <i>NTHL1</i> c.244C&gt;T; p.Gln82Ter from our list of most promising variants were selected for further analyses as candidates.</p><h3>Characterization of the selected top candidate variants: Phase I</h3><p class="mb0">We selected five variants each identified in an OC family for further characterization and analyses (<a href="#T1">Table&#xa0;1</a> and <a href="#f2">Figure&#xa0;2</a>): a nonsense variant <i>NTHL1</i> c.244C&gt;T; p.Gln82Ter, a canonical splicing variant <i>EXO1</i> c.1268-1G&gt;T, an exonic splicing variant <i>FANCC</i> c.897G&gt;T; p.Arg299Ser and two missense variants <i>ERCC5</i> c.2556A&gt;G; p.Ile852Met and <i>NEIL1</i> c.248G&gt;T; p.Gly83Asp. Both missense variants were predicted to affect amino acid residues that are located in catalytic domains of their respective proteins that are critical to the biological function of ERCC5 (<a href="#B108">108</a>) and NEIL1 (<a href="#B109">109</a>) in the HR, nucleotide excision repair (NER) and base excision repair (BER) pathways.</p><div class="DottedLine"></div><div class="Imageheaders">TABLE&#xa0;1</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t001.jpg" name="table&#xa0;1" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t001.jpg" alt="www.frontiersin.org" id="T1" loading="lazy">
  </picture>
</a><p><b>Table&#xa0;1</b> Characteristics of top-prioritized candidate variants identified in familial French Canadian cases with ovarian cancer.</p></div><div class="DottedLine"></div><p class="mb15 w100pc float_left mt15">Except for <i>EXO1</i> c.1268-1G&gt;T, which was not found in the gnomAD v2.1.1. database, all other candidate variants were found to have MAFs between 0.002 and 0.00001 in the non-cancer non-Finnish European populations with variation in these frequencies across populations of different ancestry groups (<a href="#h10">Table S4</a>). The loci of all five candidate variants were predicted to be conserved by at least one of the selected in silico tools. The variants in <i>EXO1</i> and <i>FANCC</i> were predicted to affect splicing by all four selected in silico tools. The missense variants in <i>ERCC5</i> and <i>NEIL1</i> were predicted to be damaging by at least six selected in silico tools, including REVEL and VEST, which are two of the recently validated as top performing prediction in silico tools (<a href="#B73">73</a>) (<a href="#h10">Table S3</a>). Only <i>NTHL1</i> c.244C&gt;T; p.Gln82Ter is classified as PV in ClinVar and by ACMG guidelines in the context of hereditary multi-cancer syndrome in an autosomal recessive mode of inheritance, and has recently been associated with BC risk in an autosomal dominant mode of inheritance (<a href="#B110">110</a>, <a href="#B111">111</a>). Whereas, <i>FANCC</i> c.897G&gt;T; p.Arg299Ser was classified as being of uncertain significance (VUS) in ClinVar in the context of FA, an autosomal recessive disorder (MIM: 227645) and as LPV by ACMG guidelines. As noted above, <i>FANCC</i> has been associated with BC predisposition in an autosomal dominant mode of inheritance (<a href="#B102">102</a>). The remaining candidate variants have not been reported in ClinVar, but classified by ACMG guidelines as LPV for <i>EXO1</i> c.1268-1G&gt;T, VUS for <i>ERCC5</i> c.2556A&gt;G; p.Ile852Met and likely benign for <i>NEIL1</i> c.248G&gt;T; p.Gly83Asp.</p><p class="mb0">We genotyped PBL DNA samples from family members of the index carriers where possible to determine if the candidate allele segregated with disease (<a href="#f2">Figure&#xa0;2</a>). For family F1085, both the unaffected mother (PT0178) and sister (PT0177) of the index carrier cases did not carry <i>NTHL1</i> c.244C&gt;T; p.Gln82Ter, suggesting that the variant allele may have been transmitted paternally. This observation is interesting as the paternal side of the family had numerous cancer cases including BC, OC, colorectal and pancreatic cancers. In family F1288, though the mother of the index <i>EXO1</i> c.1268-1G&gt;T carrier case (PT0158) with BC and melanoma also carried the <i>EXO1</i> variant, her sibling (PT0180) and maternal female cousin (PT0181) both with BC were not carriers of the <i>EXO1</i> variant. These observations are interesting given the number of different types of cancer cases on the maternal side of the family. In family F1506, the index carrier harbouring <i>ERCC5</i> c.2556 A&gt;G also had a remarkable family history of diverse cancer types, whereas the index carrier of <i>NEIL1</i> c.248G&gt;T; c.1268-1G&gt;T from family F1601 had a cancer family history consistent with HBOC syndrome. The index carrier of <i>FANCC</i> c.897G&gt;T; p.Arg299Ser from family F1606 reported a mother with OC and a father with lung cancer.</p><h3>Identification of carriers of selected candidate variants in defined FC cancer study groups: Phase II</h3><p class="mb15">We genotyped or surveyed available genetic data of our candidate variants: <i>NTHL1</i> c.244C&gt;T; p.Gln82Ter, <i>EXO1</i> c.1268-1G&gt;T<i>, FANCC</i> c.897G&gt;T; p.Arg299Ser, <i>ERCC5</i> c.2556A&gt;G; p.Ile852Met and <i>NEIL1</i> c.248G&gt;T; p.Gly83Asp in different FC OC and BC study groups and population-matched controls, regardless of their carrier status for <i>BRCA1</i> and <i>BRCA2</i> PVs (<a href="#f1">Figure&#xa0;1B</a> and <a href="#h10">Table S1</a>). Carriers were identified in the sporadic OC study group with frequencies of 0.2% (1/435) for <i>EXO1</i> variant carriers and 0.5% (2/435) for carriers of each <i>NTHL1</i>, <i>ERCC5</i> or <i>NEIL1</i> variants, and one <i>NTHL1</i> carrier among sporadic BC cases (0.2%, 1/563). Carriers were not identified among index cases from HBOC and HBC families. <i>FANCC</i> variant carriers were not identified in any of these FC cancer study groups.</p><p class="mb0">Carriers of all candidate variants in the FC controls are likely very rare as indicated by the observation that only one carrier was identified among 1025 FC sequencing-based controls (<a href="#T2">Table&#xa0;2</a>). Identifying a carrier of <i>NTHL1</i> c.224C&gt;T; p.Gln82Ter was not surprising given the frequency of carriers of this variant = 0.002 in the non-cancer non-Finnish European population in gnomAD v2.1.1 (<a href="#h10">Table S4</a>). Overall, the carrier frequencies of our candidates are higher in cancer groups relative to our population-matched controls though the results were not significant (<a href="#T2">Table&#xa0;2</a>).</p><div class="DottedLine"></div><div class="Imageheaders">TABLE&#xa0;2</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t002.jpg" name="table&#xa0;2" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t002.jpg" alt="www.frontiersin.org" id="T2" loading="lazy">
  </picture>
</a><p><b>Table&#xa0;2</b> Carrier frequency of candidate variants in French Canadian cancer cases and controls.</p></div><div class="DottedLine"></div><p class="mb0">We investigated our variants in 8493 non-cancer SNP array genotyping-based controls from cancer-free FC population (see <a href="#h10">Table S1</a>). None of the probes for variants in <i>EXO1, FANCC</i> and <i>ERCC5</i> were represented on any of the SNP arrays, nor was imputation possible as they were not represented in the Haplotype Reference Consortium (HRC.r1) release panel (<a href="#B43">43</a>). However, we were able to determine the carrier frequency of the <i>NTHL1</i> (0.2%, 19/8493) and <i>NEIL1</i> (0.3%, 24/8493) variants (<a href="#h10">Table S5</a>). The frequencies of these variants are consistent with those in the non-cancer non-Finnish European population in gnomAD v2.1.1. (<a href="#h10">Table S4</a>), though we did not identify any carriers among the FC controls harbouring both <i>NTHL1</i> and <i>NEIL1</i> candidate variants.</p><h3>Genetic analyses of other FC OC cases identified additional carriers of candidate variants: Phase III</h3><p class="mb0">Given genetic drift exhibited by the FC population that may result in higher frequency of candidate variant carriers with OC (<a href="#B34">34</a>, <a href="#B35">35</a>, <a href="#B43">43</a>), we genotyped the germline of PBL DNA from additional 553 FC OC cases, which were recruited to the biobank but did not meet our criteria for the abovementioned defined OC study groups, and surveyed WES data available from 52 early-onset OC cases (<a href="#f1">Figure&#xa0;1C</a> and <a href="#h10">Table S1</a>). We identified a total of six OC cases harbouring <i>NTHL1</i> c.244C&gt;T (n=1), <i>EXO1</i> c.1268-1G&gt;T (n=1), <i>FANCC</i> c.897G&gt;T (n=1) and <i>NEIL1</i> c.248G&gt;A (n=3) (<a href="#h10">Table S6</a>).</p><h3>Genetic analyses of sporadic early-onset FC OC cases identified other variants in our candidate genes: Phase III</h3><p class="mb0">Given the genetic heterogeneity observed in the FC population for rare PVs identified in <i>BRCA1, BRCA2</i>, <i>RAD51C</i> and <i>RAD51D</i> (<a href="#B33">33</a>, <a href="#B43">43</a>, <a href="#B44">44</a>), we surveyed WES data available from 52 early-onset FC OC cases diagnosed at less than 50 years of age (<a href="#f1">Figure&#xa0;1C</a> and <a href="#h10">Table S1</a>). The rationale for investigating this group is based on the plausibility that carriers of some of the known OC predisposing genes are more likely to develop OC before age of 60 as it is the median age of diagnosis of this disease in the general population with OC (<a href="#B112">112</a>, <a href="#B113">113</a>). We identified a carrier of a rare variant in <i>NEIL1</i> c.569C&gt;A; p.Pro276His that met our filtering and prioritizing criteria (<a href="#h10">Table S6</a>). We genotyped this variant in our defined FC cancer study groups and controls, and we did not identify any other carriers of this <i>NEIL1</i> variant or in any of the additional 553 FC OC cases. We could not determine the variant carrier frequency in the 8493 genotyping-based FC cancer-free controls as it was not represented on the SNP array, and we could not impute this variant as it was not available in the HRC.r1 haplotype reference panel.</p><h3>Evidence of loss of the wild-type allele in tumour DNA from carriers of candidate variants</h3><p class="mb0">As known OC risk genes behave as tumour suppressors where there is loss of the gene function in tumours is be expected (<a href="#B114">114</a>), we performed LOH analyses to investigate one of the classical mechanisms of inactivation of the loci of our candidate genes: <i>ERCC5</i>, <i>EXO1</i>, <i>FANCC</i>, <i>NEIL1</i> or <i>NTHL1</i>. We were able to perform LOH analyses on OC tumour DNA from our FC carriers of the candidate variants where possible due to availability from the RRCancer biobank as follows: <i>NTHL1</i> c.244C&gt;T; p.Gln82Ter (n=4), <i>FANCC</i> c.897G&gt;T; p.Arg299Ser (n=1), <i>ERCC5</i> c.2556A&gt;G; p.Ile852Met (n=2) and <i>NEIL1</i> c.248G&gt;T; p.Gly83Asp (n=3) (<a href="#h10">Table S7</a>). Chromatograms of bidirectional Sanger sequencing of OC tumour DNA and case matched normal were inspected for allelic content. We observed partial or complete loss of the wild-type alleles in the tumour DNA from two <i>NEIL1</i> variant carriers, two <i>NTHL1</i> variant carriers and one <i>ERCC5</i> variant carrier (<a href="#h10">Table S7</a>); chromatogram of one example is shown in <a href="#f3">Figure&#xa0;3</a>. Moreover, we observed partial or complete loss of the wild-type alleles in the tumour DNA from the left and the right ovaries from both <i>NTHL1</i> variant carriers having bilateral OC. There was no clear evidence for loss of the wild-type allele in the remaining samples from tumour DNA from carriers of <i>FANCC</i> or <i>EXO1</i>. However, loss of the variant allele was observed in the tumour DNA from <i>FANCC</i> and <i>EXO1</i> variant carriers (<a href="#h10">Table S7</a>).</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE&#xa0;3</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g003.jpg" name="" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g003.jpg" alt="www.frontiersin.org" id="f3" loading="lazy">
  </picture>
</a><p><b>Figure&#xa0;3</b> Loss of heterozygosity analyses of candidate genes loci. Sanger sequencing chromatograms showing loss of heterozygosity (LOH) analyses of the candidate variants (see <a href="#h10">Table S7</a>), in genomic peripheral blood lymphocyte (PBL) DNA, ovarian tumour tissue DNA from carriers of <b>(A)</b> <i>NEIL1</i> c.248G&gt;T; p.Gly83Asp (PT0171); <b>(B)</b> <i>NTHL1</i> c.244C&gt;T; p.Gln82Ter (PT0160); and <b>(C)</b> <i>ERCC5</i> c.2556A&gt;G; p.Ile852Met (PT0136). Each variant is indicated by an arrow. One example of such genetic event per candidate variant carrier is shown.</p></div><div class="DottedLine"></div><h3>Genetic analyses of non-FC cases identified other candidate variants in our gene candidates: Phase IV</h3><p class="mb0">To determine the relevance of our candidate genes to OC in non-FC populations, we investigated the spectrum and prevalence of rare variants in our candidate genes in genetic data from three defined non-FC study groups (<a href="#f1">Figure&#xa0;1D</a> and <a href="#h10">Table S1</a>). We applied our filtering and prioritizing criteria to WES data that was available from the germline of PBL DNA from: (1) 9 index OC cases from MIX familial OC cases; (2) 516 index AUS OC cases from HBOC and sporadic disease; and (3) 412 OC cases from Pan-Cancer &#x2013; TCGA. In these study groups, we identified: one of the 9 MIX familial OC cases (11.1%) harbouring a <i>NTHL1</i> variant; 17 of 516 AUS OC cases (3.3%) harbouring 11 variants in <i>NTHL1</i> (n=6), <i>NEIL1</i> (n=3), <i>ERCC5</i> (n=1) and <i>EXO1</i> (n=1); 12 of 412 Pan-Cancer &#x2013; TCGA OC cases (2.9%) harbouring 10 variants in <i>NEIL1</i> (n=4), <i>EXO1</i> (n=2), <i>FANCC</i> (n=2), <i>NTHL1</i> (n=1) and <i>ERCC5</i> (n=1) (<a href="#h10">Table S6</a> and <a href="#f4">Figure&#xa0;4</a>). Noteworthy, the frequency of all LoF rare (MAF &#x2264;0.005) variants in these genes in the cancer-free gnomAD v2.1.1 controls as follows: 112/1,563 (0.07) in <i>ERCC5</i>; 105/1,207 (0.09) in <i>EXO1</i>; 87/943 (0.09) in <i>FANCC</i>; 85/811 (0.1) in <i>NEIL1</i> and 47/629 (0.07) in <i>NTHL1</i>. Collectively, candidate variants we identified in cancer cases are comprised of three nonsense, four frameshift, three alternative splicing and nine missense variants. Variants in and <i>NEIL1</i> (n=3), <i>EXO1</i> (n=2), <i>NTHL1</i> (n=2), <i>ERCC5</i> (n=1) and <i>FANCC</i> (n=1) were LoF variants and classified as PVs or LPVs in ClinVar and/or by ACMG guidelines. The remaining variants were missense predicted to be PV or LPVs by our set of in silico tools. Some of these variants were those already identified in our FC study groups: three of 516 (0.6%) AUS OC cases and two of 412 (0.5%) Pan-Cancer &#x2013; TCGA OC cases carried <i>NTHL1</i> c.244C&gt;T; p.Gln82Ter, while one each of 516 (0.2%) AUS OC cases and 412 (0.2%) Pan-Cancer &#x2013; TCGA OC cases carried <i>NEIL1</i> c.248G&gt;A; p.Gly83Asp.</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE&#xa0;4</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g004.jpg" name="" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g004.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g004.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g004.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g004.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g004.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g004.jpg" alt="www.frontiersin.org" id="f4" loading="lazy">
  </picture>
</a><p><b>Figure&#xa0;4</b> Location of candidate variants in <i>NTHL1</i>, <i>EXO1</i>, <i>FANCC</i>, <i>ERCC5</i> and <i>NEIL1</i> identified in all study groups. The coding regions and protein domains of candidate genes <i>NTHL1</i> (NM_002528.7), <i>EXO1</i> (NM_130398.4), <i>FANCC</i> (NM_000136.3), <i>ERCC5</i> (NM_000123.4) and <i>NEIL1</i> (NM_024608.4), based on NCBI RefSeq transcripts (tark.ensembl.org/web/manelist/) (<a href="#B103">103</a>), were annotated for the location of candidate variants. Variants classified as PV or LPV are bolded and those identified in French Canadian ovarian cancer cases each are indicated with an arrow.</p></div><div class="DottedLine"></div><p class="mb0">We identified one Pan-Cancer &#x2013; TCGA OC carrier of a synonymous variant in <i>NEIL1</i> c.159C&gt;T; p.Gly53Gly that was predicted to affect splicing using SpliceAI (<a href="#B115">115</a>) that may result in gain of a new donor splice site.</p><h3>Most candidate variant carriers do not harbour co-occurring pathogenic variants in known OC predisposing genes</h3><p class="mb15">We investigated whether OC carriers harbouring any of our candidate variants may also harbour PVs in known OC predisposing genes (n=11) (nccn.org/guidelines/category_2) (<a href="#h10">Tables S8</a>, <a href="#h10">S9</a>). Only one of the 15 FC OC carriers investigated carried both <i>NEIL1</i> c.248G&gt;A; p.Gly83Asp (PT0175) and <i>BRCA1</i> c.5102_5103del; p.Leu1701GlnfsTer14. This <i>BRCA1</i> variant is one of the most frequently occurring PVs in OC and BC cases from the FC population (<a href="#B33">33</a>, <a href="#B40">40</a>, <a href="#B41">41</a>, <a href="#B116">116</a>).</p><p class="mb0">Regarding non-FC OC carriers, one of the 17 OC AUS carriers of <i>NEIL1</i> c.248G&gt;A; p.Gly83Asp (PT0314) also harboured a variant in a known OC risk gene <i>RAD51C</i> c.145+1_145+2insC, which was classified as PV by ACMG guidelines (<a href="#h10">Table S9</a>) and was reported previously in an investigation of this study group (<a href="#B17">17</a>). Two of the 13 carriers of our candidate variants from OC Pan-Cancer &#x2013; TCGA project cases, harboured variants in known OC risk genes: a carrier of <i>NTHL1</i> c.244C&gt;T; p.Gln82Ter (PT0261) also harboured <i>BRCA2</i> c.5065_5066insA; p.Ala1689AspfsTer6 and a carrier of <i>EXO1</i> c.2152C&gt;T; p.Gln718Ter (PT0263) also harboured <i>BRCA2</i> c.1029del; p.Lys343AsnfsTer6. Both <i>BRCA2</i> variants have been classified as PVs in the ClinVar database and by ACMG guidelines.</p><a id="h5" name="h5"></a><h2>Discussion</h2><p class="mb15">Our investigation of potentially deleterious variants in 468 genes that play a direct or associated role in various DNA repair pathways in the FC population exhibiting genetic drift identified LoF and potentially deleterious missense variants as candidates for OC predisposition in <i>ERCC5</i>, <i>EXO1</i>, <i>FANCC</i>, <i>NEIL1</i> or <i>NTHL1</i>. Genotyping analyses of independently ascertained FC cancer study groups identified multiple carriers with OC harbouring the same variant, which is likely due to common ancestors within the FC population of Quebec (<a href="#B33">33</a>&#x2013;<a href="#B35">35</a>). Overall, carriers of each variant are rare, each accounting for &lt;1%, but collectively 9.6% of 52 familial OC cases with at least two or more OC cases and 1.6% of all 435 sporadic OC cases versus 0.1% of the population-matched controls. It is notable that none of the variants were found in known OC predisposing genes (nccn.org/guidelines/category_2), confirming prior findings from either clinical testing or our WES analyses of this group of cases (<a href="#B24">24</a>, <a href="#B43">43</a>, <a href="#B47">47</a>).</p><p class="mb15">Our candidate variants were identified by investigating a curated list of 468 known or putative genes involved in different DNA repair pathways. <i>ERCC5</i> is known to be involved in the NER pathway as an endonuclease, but it has been shown that this gene is also involved in the BER (<a href="#B117">117</a>) and HR (<a href="#B108">108</a>) pathways. <i>EXO1</i> is involved in the HR and MMR pathways as an exonuclease (<a href="#B118">118</a>, <a href="#B119">119</a>). <i>FANCC</i> plays a role in the FA pathway as a member of the core complex (<a href="#B120">120</a>). <i>NTHL1</i> and <i>NEIL1</i> are DNA glycosylases in the BER pathway (<a href="#B121">121</a>). Although the role of these genes in conferring risk to hereditary OC requires further investigation with larger cohorts, a recent Australian study of familial and sporadic OC cases reported that there was a statistically significant difference in the frequency of germline LoF variants in the single-stranded DNA repair pathway genes involved in BER, NER and MMR in OC cases versus non-cancer controls (<a href="#B17">17</a>). On the other hand, homozygous or compound heterozygous PVs in <i>NTHL1</i> have been linked to Familial adenomatous polyposis - 3 (MIM: 616415) (<a href="#B122">122</a>) and most recently a multi-tumour phenotype (<a href="#B123">123</a>). Homozygous or compound heterozygous PVs in <i>FANCC</i> and <i>ERCC5</i> are known to be linked to autosomal recessive disorders, Fanconi anemia complementation group C (MIM: 227645) and Xeroderma pigmentosum complementation group G (MIM: 278780), respectively, known to exhibit increased risk to cancer.</p><p class="mb15">Three of our top candidate variants were predicted to be LoF: <i>NTHL1</i> c.244C&gt;T; p.Gln82Ter, <i>EXO1</i> c.1268-1G&gt;T and <i>FANCC</i> c.897G&gt;T; p.Arg299Ser. <i>NTHL1</i> c.244C&gt;T; p.Gln82Ter has been independently reported in the literature due to its frequency, while <i>FANCC</i> c.897G&gt;T; p.Arg299Ser has been reported only in ClinVar database. The introduction of a termination codon in <i>NTHL1</i> p.Gln82Ter is predicted to affect NTHL1 protein production, eliciting its classification as PV in ClinVar and by ACMG guidelines. <i>EXO1</i> c.1268-1G&gt;T and <i>FANCC</i> c.897G&gt;T; p.Arg299Ser were predicted to affect splicing by all of our selected in silico tools. As RNA was not available from carriers of these variants, we were unable to investigate their effect on the gene transcripts. We applied a stringent criteria for prioritizing missense variants using a selected set of high performance in silico prediction tools (<a href="#B71">71</a>&#x2013;<a href="#B74">74</a>). <i>ERCC5</i> c.2556A&gt;G; p.Ile852Met and <i>NEIL1</i> c.248G&gt;T; p.Gly83Asp, which have been independently reported in the literature due to their frequencies, were among our top prioritized missense variants. A recent study assessed the performance of 44 in silico tools with 70 tool-threshold combinations in predicting missense variants using a curated dataset of over 9,000 missense variants in five OC and/or BC risk genes that were classified as deleterious or tolerated based on different functional assays (<a href="#B73">73</a>). Two of the in silico tools that were selected in our analysis, REVEL with a threshold of &gt;0.7 and VEST with a threshold of &#x2265;0.5 prediction scores of a missense variant being deleterious, were shown to have the best performance of 79% and 74%, respectively (<a href="#B73">73</a>). Moreover, a combination of both tools with these prediction score thresholds boosts the prediction performance up to 81% (<a href="#B73">73</a>). <i>NEIL1</i> c.248G&gt;A; p.Gly83Asp had REVEL and VEST scores of &gt;0.7, while <i>ERCC5</i> c.2556A&gt;G; p.Ile852Met had a REVEL score at the threshold of 0.7 and VEST score of 0.9. The biological impact of ERCC5 p.Ile852Met is unknown, though the variant alters a codon in the highly conserved I-Nuclease domain (see <a href="#f4">Figure&#xa0;4</a>), which may impact ERCC5 endonuclease activity. Whereas, cells expressing NEIL1 p.Gly83Asp have been shown to increase levels of stalled replication forks and double-strand breaks as compared to wild-type NEIL1 (<a href="#B109">109</a>). For the missense variants identified in the non-FC cases, eight of the nine missense variants were predicted to be deleterious by REVEL (&gt;0.7) and/or VEST (&#x2265;0.5). One variant, <i>NTHL1</i> c.349C&gt;T; p.Pro117Ser, was found to have a REVEL score of 0.6 and VEST score of 0.5, which is within the intermediate window of prediction scores (REVEL &lt;0.7-&gt;0.4; VEST&lt;0.5) where the threshold of predicting missense variants being tolerated is &lt;0.4 (<a href="#B73">73</a>). It is evident that in silico tools are being developed with increasing improvement in their performance and are useful alternatives to biological modelling of variants for selecting and prioritizing missense candidates for further characterization (<a href="#B73">73</a>, <a href="#B124">124</a>).</p><p class="mb15">We applied stringent criteria to select top candidates for further analyses as it was not feasible to perform WES on all our FC OC study cases. Though selecting for rare variants with MAF &#x2264;0.005 aligns with our hypothesis for identifying candidate moderate- to high-risk variants with the assumption that new candidate genes are transmitted <i>via</i> an autosomal dominant mode of inheritance (<a href="#B63">63</a>, <a href="#B114">114</a>, <a href="#B125">125</a>, <a href="#B126">126</a>), we filtered out our recently reported, LPV <i>FANCI</i> c.1813C&gt;T; p.Leu605Phe (<a href="#B24">24</a>). Notable is that the one family harbouring this <i>FANCI</i> variant among the 13 familial cases investigated in this study, did not harbour any of our top candidates. As our strategy selected but not eliminated top candidates, further research is required to determine their relevance to OC risk. Moreover, as we have shown in our studies of predicted missense identified in <i>RAD51C</i> and <i>RAD51D</i> (<a href="#B43">43</a>) and <i>FANCI</i> (<a href="#B24">24</a>) in OC cases from the FC population, modeling variants by in cellulo assays would provide further evidence for their relevance in OC biology.</p><p class="mb15">Some of our candidate variants or others in these genes that met our selection criteria were identified in 3.3% of 937 non-FC familial or sporadic OC cases of mostly European ancestry 0-0.004% in gnomAD controls, suggesting that our gene candidates may be relevant in other populations. Though this observation was not unexpected, given that approximately 55% of our non-FC OC cases were from the same Australian study group (<a href="#B17">17</a>), they are also consistent with our analysis of the Pan-Cancer TCGA OC cases. During the course of this study, a recent report investigated a set of DNA repair genes in 33 different cancers from Pan-Cancer TCGA, and they found that missense variants predicted damaging are statistically enriched in OC cases (<a href="#B127">127</a>). Moreover, carriers of LoF variants in some of our candidate genes have been reported in HBOC families such as <i>ERCC5</i> (<a href="#B128">128</a>, <a href="#B129">129</a>)<i>, FANCC</i> (<a href="#B130">130</a>&#x2013;<a href="#B133">133</a>) or <i>NTHL1</i> (<a href="#B111">111</a>, <a href="#B134">134</a>, <a href="#B135">135</a>) from different populations. Interestingly, LoF variants in <i>ERCC5</i> (<a href="#B110">110</a>), <i>FANCC</i> (<a href="#B102">102</a>) or <i>NTHL1</i> (<a href="#B111">111</a>, <a href="#B110">110</a>) have been associated with hereditary BC cases in the context of HBOC families. On the other hand, our literature search did not identify reports of germline PVs in <i>EXO1</i> or <i>NEIL1</i> in OC, although variants in these genes have been reported in the context of other hereditary cancers such as colorectal cancer (<a href="#B136">136</a>&#x2013;<a href="#B138">138</a>). However, common variants (MAF&gt;1%) in <i>EXO1</i> have been associated with OC risk (<a href="#B139">139</a>).</p><p class="mb15">Although we are limited by sample size, we did not observe any striking clinical characteristics regarding age at diagnosis or histopathology of OC disease in carriers of our candidate variants. The average age at diagnosis with OC in FC variant carriers (average=58; median=60 years) is comparable to that of AUS variant carriers as well as Pan-Cancer &#x2013; TCGA variant carriers (average=59; median=59 years), which in turn is comparable with that of carriers of <i>BRCA2</i> PVs (average=58 years) (<a href="#B41">41</a>) and the general population (median=63 years) (<a href="#B112">112</a>, <a href="#B113">113</a>). The majority of OC cases harbouring the candidate variants had HGSC (91.1%, 41/45), which is the most common subtype of OC reported in epithelial ovarian cancer (<a href="#B49">49</a>) and thus is overrepresented in our study groups (<a href="#B56">56</a>). We did observe three carriers of <i>EXO1</i> c.1268-1G&gt;T, <i>NEIL1</i> c.248G&gt;A; p.Gly83Asp and <i>NTHL1</i> c.244C&gt;T; p.Gln82Ter with mixed histology (serous mixed with endometrioid or unspecified cell type; and endometrioid mixed with mucinous) (see <a href="#h10">Table S8</a>). Interestingly, a survey of our candidate variants in the Ovarian Cancer Association Consortium (OCAC) database (ocac.ccge.medschl.cam.ac.uk/data-projects/, accessed on 15 June 2020), showed that <i>NEIL1</i> c.248G&gt;T; p.Gly83Asp was significantly associated with OC overall (odds ratio [OR] = 1.5; p = 0.038), and this association was stronger with the endometrioid subtype (OR = 3.75; p= 0.00008) (see <a href="#h10">Table S10</a>). <i>NTHL1</i> c.244C&gt;T; p.Gln82Ter showed a higher OR = 1.5 in clear cell subtype but was not statistically significant (p = 0.36) (see <a href="#h10">Table S10</a>). These observations are interesting as <i>NTHL1</i> and <i>NEIL1</i> are involved in repairing single stranded-DNA breaks <i>via</i> BER pathway. MMR genes as also involved in repairing single stranded-DNA breaks <i>via</i> MMR pathway that are associated with conferring an increased risk to the endometrioid and clear cell histological subtypes of OC (<a href="#B7">7</a>). We could not investigate the other candidate variants <i>ERCC5</i> c.2556A&gt;G; p.Ile852Met, <i>EXO1</i> c.1268-1G&gt;T and <i>FANCC</i> c.897G&gt;T; p.Arg299Ser from this genotyping-based database as they were not represented in the SNP arrays, which could be due to their rarity in the general population.</p><p class="mb15">The role of our candidate genes in the etiology of OC is unknown, though LOH analyses suggest that loss of function of some of our candidate genes in tumour cells may be important in tumourigenesis of OC as has been demonstrated for known OC risk genes (<a href="#B114">114</a>). We showed loss of the wild-type allele in tumours from carriers of <i>ERCC5</i> c.2556A&gt;G, <i>NEIL1</i> c.248G&gt;T; p.Gly83Asp or <i>NTHL1</i> c.244C&gt;T; p.Gln82Ter. We also showed loss of the wild-type allele in the tumour DNA from the left and the right ovaries from two <i>NTHL1</i> c.244C&gt;T carriers with bilateral OC. This suggests the possibility that loss of wild-type allele occurred at an early stage in tumourigenesis (<a href="#B140">140</a>). However, we observed no LOH in tumour DNA from one carrier each of <i>ERCC5</i> or <i>NEIL1</i> variants and two carriers of <i>NTHL1</i> variant (see <a href="#h10">Table S7</a>). In previous studies we have also demonstrated complete or partial loss of wild-type alleles in tumour DNA from FC carriers of <i>RAD51C</i> c.705G&gt;T; p.Lys235Asn (<a href="#B43">43</a>), <i>RAD51D</i> c.620C&gt;T; p.Ser207Leu (<a href="#B43">43</a>, <a href="#B44">44</a>) and <i>FANCI</i> c.1813C&gt;T; p.Leu605Phe (<a href="#B24">24</a>) also from the analyses of RRCancer biobank materials. We also observed no LOH in some of the tumour DNA from OC carriers of our <i>RAD51C</i> c.705G&gt;T; p.Lys235AsnAs and <i>RAD51D</i> c.620C&gt;T; p.Ser207Leu, as the DNA was extracted post-chemotherapy treatment, suggesting the possibility of stromal cell contamination (<a href="#B43">43</a>, <a href="#B44">44</a>). Indeed, all of the DNA tumours from the four cases analysed in this study were confirmed to be extracted after chemotherapy. Interestingly, our LOH analyses in this study provided evidence for loss of variant allele from other candidate variants <i>EXO1</i> c.1268-1G&gt;T and <i>FANCC</i> c.897G&gt;T carriers. It is not clear if this is due to contaminating normal tissues as our analyses were not performed on selected tumour cells as HGSC samples are often enriched in tumour cells (<a href="#B24">24</a>). Srinivasan et&#xa0;al. (<a href="#B141">141</a>) recently reported that approximately 20% of the 55 investigated cancers, including OC, showed a retention of the wild-type alleles in the high-penetrant genes such as <i>BRCA1</i> and <i>BRCA2</i> (<a href="#B141">141</a>). A retention of the <i>RAD51D</i> c.620C&gt;T; p.Ser207Leu was also observed in tumour DNA from an OC carrier (<a href="#B44">44</a>). It is not clear if such cases reflect a reversion of variant to wild type allele as has been shown with <i>BRCA1</i> or <i>BRCA2</i> carriers in the context of developing resistance to cisplatin or the targeted therapy poly (ADP-ribose) polymerase (PARP) inhibitors (<a href="#B142">142</a>, <a href="#B143">143</a>). Further research is required at the tumour cell level to determine biological impact of variants in the context of wild-type alleles in carriers.</p><p class="mb15">There are several limitations in this original study that should be acknowledged. This study was limited in the sample size of the FC OC families, sporadic cases and cancer-free controls (study phase I and II). The small sample size in our cases and controls did not allow us to estimate the associated risk with OC of any of the candidate variants to support their candidacy as OC predisposing variants/genes (<a href="#B144">144</a>) as such risk assessment requires thousands of cases and controls (<a href="#B12">12</a>, <a href="#B13">13</a>, 1, <a href="#B19">19</a>). However, our highly selected OC families regardless of their status of PVs in <i>BRCA1</i> and <i>BRCA2</i> are very rare. The proportion of families with two first-degree relatives with OC is estimated to be less than 5%, and less than 1% for those with more than two first-degree relatives with OC (<a href="#B145">145</a>&#x2013;<a href="#B147">147</a>). This study was also limited in lacking of biological samples that were required to confirm the predicted effect on RNA splicing of two of the candidate variants <i>EXO1</i> c.1268-1G&gt;T and <i>FANCC</i> c.897G&gt;T; p.Arg299Ser. Likewise, we were not able to perform LOH analysis on all OC carriers of the candidate variants as well as genotyping PBL DNA of the other family members to further support the candidacy of our variants. This was due to the fact that the extracted DNA from only PBL and/or tumour specimens were biobanked for almost all of the OC cases. Moreover, histopathological blocks for DNA and/or RNA extraction of these carriers were not available from the respective biobanks as some of the cancer families and cases date back to the early 2000s (see <a href="#h10">Table S1</a>).</p><p class="mb0">In conclusion, our WES and genetic analyses of 468 genes directly or associated with DNA repair pathways in study groups from a genetically defined population identified candidate variants in <i>ERCC5</i>, <i>EXO1</i>, <i>FANCC</i>, <i>NEIL1</i> or <i>NTHL1</i>. The genetic analyses of these variants and genes in non-FC OC study groups implicate these genes in other populations. Genetic epidemiology of variant carriers and functional assays to assess the biological impact of variant proteins could elucidate the effect of candidate variants to OC risk.</p><a id="h6" name="h6"></a><h2>Data availability statement</h2><p class="mb0">The datasets presented in this article are not readily available because sequencing data for familial and sporadic ovarian cancer (OC) cases, CARTaGENE, McGill University-Montreal Neurological Institute (MNI) and Universit&#xe9; de Sherbrooke-The Genetics of Glucose Regulation in Gestation and Growth (Gen3G) will be returned to their respective biobanks at the conclusion of our study of OC predisposing genes which is still ongoing. For more information concerning these data contact Patricia N. Tonin at <a id="encmail">cGF0cmljaWEudG9uaW5AbWNnaWxsLmNh</a>. The data from the analyses of investigation of The Ovarian Cancer Association Consortium (OCAC) and The Genome Aggregation Database (gnomAD) are available from each of these data resource banks.</p><a id="h7" name="h7"></a><h2>Ethics statement</h2><p class="mb0">This project has received approval from The McGill University Health Centre (MUHC) REB (MP-37-2019-4783). The patients/participants provided their written informed consent to participate in this study.</p><a id="h8" name="h8"></a><h2>Author contributions</h2><p class="mb15">WA and PT conceived and designed the study. WA performed whole exome sequencing and bioinformatics analyses, conducted, and interpreted the genotyping and Sanger sequencing and wrote the initial drafts of this manuscript. TR performed the bioinformatics pipelines. CF aided in bioinformatics analysis. CS aided in collecting and reviewing all clinical pedigrees with associated information. KO performed imputation and provided required information from CARTaGENE genotyping-based data. DS and IC provided required information from in-house sequencing-based Australian ovarian cancer cases. JB and TP provided required information from The Cancer Genomic Atlas (TCGA) sequencing-based breast and ovarian cancer cases. DS, GR and LB provided required information from in-house sequencing-based control data. A-MM-M, DP, WF and ZH provided the study samples and clinical information. CG oversaw the statistical analyses. JR oversaw the WES analysis and bioinformatics pipeline. PT designed and oversaw all aspects of the study. All authors contributed to the article and approved the submitted version.</p><a id="h9" name="h9"></a><h2>Funding</h2><p class="mb15">The work was supported in part by the Department of Medicine, McGill University to PT; Saudi Arabian Cultural Bureau to PT and WA; The Canadian Institute for Health Research (CIHR) operating grants (PCC-156736 to PT, CG and JR) and (PJT-156124 to PT and JR); Cancer Research Society and Ovarian Cancer Canada partnership grant (21123 to PT); Department of Medicine, McGill University Grant to PT; the Fond de la recherche du Qu&#xe9;bec en sant&#xe9; (FRQS) and Quebec Breast Cancer Foundation network grants to PT; Compute Canada resource allocation project wst-164 and Genome Canada Genome Technology Platform award to JR; Institut du cancer de Montr&#xe9;al Fonds D&#xe9;fi Spyder and Anne-Marie Chagnon which covers funds from platform to DP and A-MM-M; Gen3G has been supported over the time by FRQS grant (20697 to Marie-France Hivert); CIHR grant (MOP-115071 to Dr. Marie-France Hivert) and (PJT-152989 to LB); American Diabetes Association (ADA) accelerator award (1-15-ACE-26 to Marie-France Hivert). LB is a senior research scholar from FRQS. The sequencing of the Gen3G offspring has been sponsored by Fonds de recherche du Qu&#xe9;bec, McGill University and Universit&#xe9; de Sherbrooke. Ovarian tumour banking was supported by the Banque de tissus et de donn&#xe9;es of the R&#xe9;seau de recherche sur le cancer of the FRQS affiliated with the Canadian Tumour Repository Network (CTRNet). WA was supported by a Scholarship Award by Ministry of Education in Saudi Arabia and CF was supported in part by RI-MUHC Scholarship Award and James O and Maria Meadows Award.</p><a id="h10" name="h10"></a><h2>Acknowledgments</h2><p class="mb0">We acknowledge the Banque de tissus et de donn&#xe9;es of the RRCancer of the Fonds recherche Qu&#xe9;bec - Sant&#xe9; (FRQS), which is affiliated with the Canadian Tissue Repository Network (CTRNet) for providing the DNA samples from cancer families. We also acknowledge CARTaGENE biobank; and Drs. Patrice Peron, Luigi Bouchard, and Marie-France Hivert who established the Gen3G cohort and sequencing. Pierre-&#xc9;tienne Jacques and Simon Gravel contributed to the generation and analysis of sequencing data in Gen3G. The authors acknowledge Manon De Ladurantaye and Lise Portelance for providing all clinical data and DNA from the RRCancer biobank; Liliane Meunier for providing the sections from histopathological blocks; Supriya Behl, Nancy Hamel and Celine Domecq for providing genetic data for sporadic breast cancer cases; and Suzanna Arcand for organizing samples for whole exome sequencing (WES). The authors acknowledge Mary Fujiwara for reviewing the final draft of the manuscript.</p><a id="h11" name="h11"></a><h2>Conflict of interest</h2><p class="mb0">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p><a id="h12" name="h12"></a><h2>Publisher&#x2019;s note</h2><p class="mb0">All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p><a id="h13" name="h13"></a><h2>Supplementary material</h2><p class="mb15">The Supplementary Material for this article can be found online at: <a href="https://www.frontiersin.org/articles/10.3389/fonc.2023.1111191/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fonc.2023.1111191/full#supplementary-material</a></p><a id="h14" name="h14"></a><h2>References</h2><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B1" id="B1"></a> 1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. <i>Science</i> (1994) 266(5182):66&#x2013;71. doi:&#xa0;10.1126/science.7545954</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/7545954/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1126/science.7545954" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=Y+Miki&amp;author=J+Swensen&amp;author=D+Shattuck-Eidens&amp;author=PA+Futreal&amp;author=K+Harshman&amp;author=S+Tavtigian&amp;publication_year=1994&amp;title=A%20strong%20candidate%20for%20the%20breast%20and%20ovarian%20cancer%20susceptibility%20gene%20BRCA1&amp;journal=Science&amp;volume=266&amp;pages=66-71" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B2" id="B2"></a> 2. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. <i>Nature</i> (1995) 378(6559):789&#x2013;92. doi:&#xa0;10.1038/378789a0</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/8524414/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/378789a0" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R+Wooster&amp;author=G+Bignell&amp;author=J+Lancaster&amp;author=S+Swift&amp;author=S+Seal&amp;author=J+Mangion&amp;publication_year=1995&amp;title=Identification%20of%20the%20breast%20cancer%20susceptibility%20gene%20BRCA2&amp;journal=Nature&amp;volume=378&amp;pages=789-92" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B3" id="B3"></a> 3. Nielsen FC, van Overeem Hansen T, S&#xf8;rensen CS. Hereditary breast and ovarian cancer: new genes in confined pathways. <i>Nat Rev Cancer 2016 16:9</i> (2016) 16:599&#x2013;612. doi:&#xa0;10.1038/nrc.2016.72</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1038/nrc.2016.72" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=FC+Nielsen&amp;author=T+van%20Overeem%20Hansen&amp;author=CS+S%C3%B8rensen&amp;publication_year=2016&amp;title=Hereditary%20breast%20and%20ovarian%20cancer%3A%20new%20genes%20in%20confined%20pathways&amp;journal=Nat+Rev+Cancer+2016+16:9&amp;volume=16&amp;pages=599" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B4" id="B4"></a> 4. Turnbull C, Sud A, Houlston RS. Cancer genetics, precision prevention and a call to action. <i>Nat Genet</i> (2018) 50(9):1212&#x2013;8. doi:&#xa0;10.1038/s41588-018-0202-0</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/30158684/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41588-018-0202-0" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C+Turnbull&amp;author=A+Sud&amp;author=RS+Houlston&amp;publication_year=2018&amp;title=Cancer%20genetics%2C%20precision%20prevention%20and%20a%20call%20to%20action&amp;journal=Nat+Genet&amp;volume=50&amp;pages=1212-8" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B5" id="B5"></a> 5. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, De A, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. <i>Wiley Online Library</i> (1999) 81:214&#x2013;8. doi: 10.1002/(SICI)1097-0215(19990412)81:2&lt;214::AID-IJC8&gt;3.0.CO;2-L</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1002/(SICI)1097-0215(19990412)81:2&lt;214::AID-IJC8&gt;3.0.CO;2-L" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Aarnio&amp;author=R+Sankila&amp;author=E+Pukkala&amp;author=R+Salovaara&amp;author=LA+Aaltonen&amp;author=A+De&amp;publication_year=1999&amp;title=Cancer%20risk%20in%20mutation%20carriers%20of%20DNA-mismatch-repair%20genes&amp;journal=Wiley+Online+Library&amp;volume=81&amp;pages=214-8" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B6" id="B6"></a> 6. Stoll J, Rosenthal E, Cummings S, Willmott J, Bernhisel R, Kupferl SS. No evidence of increased risk of breast cancer in women with lynch syndrome identified by multigene panel testing. <i>JCO Precis Oncol</i> (2020) 4:51&#x2013;60. doi:&#xa0;10.1200/PO.19.00271</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/35050728/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1200/PO.19.00271" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Stoll&amp;author=E+Rosenthal&amp;author=S+Cummings&amp;author=J+Willmott&amp;author=R+Bernhisel&amp;author=SS+Kupferl&amp;publication_year=2020&amp;title=No%20evidence%20of%20increased%20risk%20of%20breast%20cancer%20in%20women%20with%20lynch%20syndrome%20identified%20by%20multigene%20panel%20testing&amp;journal=JCO+Precis+Oncol&amp;volume=4&amp;pages=51" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B7" id="B7"></a> 7. Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M, et al. Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management. <i>Mol Oncol</i> (2009) 3(2):97&#x2013;137. doi:&#xa0;10.1016/j.molonc.2009.02.004</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/19383374/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.molonc.2009.02.004" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=HT+Lynch&amp;author=MJ+Casey&amp;author=CL+Snyder&amp;author=C+Bewtra&amp;author=JF+Lynch&amp;author=M+Butts&amp;publication_year=2009&amp;title=Hereditary%20ovarian%20carcinoma%3A%20Heterogeneity%2C%20molecular%20genetics%2C%20pathology%2C%20and%20management&amp;journal=Mol+Oncol&amp;volume=3&amp;pages=97-137" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B8" id="B8"></a> 8. Pavanello M, Chan IH, Ariff A, Pharoah PD, Gayther SA, Ramus SJ. Rare germline genetic variants and the risks of epithelial ovarian cancer. <i>Cancers 2020 Vol. 12 Page 3046</i> (2020) 12:3046. doi:&#xa0;10.3390/CANCERS12103046</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.3390/CANCERS12103046" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Pavanello&amp;author=IH+Chan&amp;author=A+Ariff&amp;author=PD+Pharoah&amp;author=SA+Gayther&amp;author=SJ+Ramus&amp;publication_year=2020&amp;title=Rare%20germline%20genetic%20variants%20and%20the%20risks%20of%20epithelial%20ovarian%20cancer&amp;journal=Cancers+2020+Vol.+12+Page+3046&amp;volume=12&amp;pages=3046" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B9" id="B9"></a> 9. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. <i>Nat Genet</i> (2010) 42(5):410&#x2013;4. doi:&#xa0;10.1038/ng.569</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/20400964/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/ng.569" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Meindl&amp;author=H+Hellebrand&amp;author=C+Wiek&amp;author=V+Erven&amp;author=B+Wappenschmidt&amp;author=D+Niederacher&amp;publication_year=2010&amp;title=Germline%20mutations%20in%20breast%20and%20ovarian%20cancer%20pedigrees%20establish%20RAD51C%20as%20a%20human%20cancer%20susceptibility%20gene&amp;journal=Nat+Genet&amp;volume=42&amp;pages=410-4" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B10" id="B10"></a> 10. Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. <i>Nat Genet</i> (2011) 43(9):879&#x2013;82. doi:&#xa0;10.1038/ng.893</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/21822267/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/ng.893" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C+Loveday&amp;author=C+Turnbull&amp;author=E+Ramsay&amp;author=D+Hughes&amp;author=E+Ruark&amp;author=JR+Frankum&amp;publication_year=2011&amp;title=Germline%20mutations%20in%20RAD51D%20confer%20susceptibility%20to%20ovarian%20cancer&amp;journal=Nat+Genet&amp;volume=43&amp;pages=879-82" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B11" id="B11"></a> 11. Rafnar T, Gudbjartsson DF, Sulem P, Jonasdottir A, Sigurdsson A, Jonasdottir A, et al. Mutations in BRIP1 confer high risk of ovarian cancer. <i>Nat Genet</i> (2011) 43(11):1104&#x2013;7. doi:&#xa0;10.1038/ng.955</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/21964575/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/ng.955" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=T+Rafnar&amp;author=DF+Gudbjartsson&amp;author=P+Sulem&amp;author=A+Jonasdottir&amp;author=A+Sigurdsson&amp;author=A+Jonasdottir&amp;publication_year=2011&amp;title=Mutations%20in%20BRIP1%20confer%20high%20risk%20of%20ovarian%20cancer&amp;journal=Nat+Genet&amp;volume=43&amp;pages=1104-7" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B12" id="B12"></a> 12. Ramus SJ, Song H, Dicks E, Tyrer JP, Rosenthal AN, Intermaggio MP, et al. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. <i>J Natl Cancer Institute</i> (2015) 107(11):djv214. doi:&#xa0;10.1093/jnci/djv214</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1093/jnci/djv214" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SJ+Ramus&amp;author=H+Song&amp;author=E+Dicks&amp;author=JP+Tyrer&amp;author=AN+Rosenthal&amp;author=MP+Intermaggio&amp;publication_year=2015&amp;title=Germline%20mutations%20in%20the%20BRIP1%2C%20BARD1%2C%20PALB2%2C%20and%20NBN%20genes%20in%20women%20with%20ovarian%20cancer&amp;journal=J+Natl+Cancer+Institute&amp;volume=107&amp;pages=djv214" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B13" id="B13"></a> 13. Song H, Dicks E, Ramus SJ, Tyrer JP, Intermaggio MP, Hayward J, et al. Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. <i>J Clin Oncol</i> (2015) 33:2901&#x2013;7. doi:&#xa0;10.1200/JCO.2015.61.2408</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/26261251/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1200/JCO.2015.61.2408" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H+Song&amp;author=E+Dicks&amp;author=SJ+Ramus&amp;author=JP+Tyrer&amp;author=MP+Intermaggio&amp;author=J+Hayward&amp;publication_year=2015&amp;title=Contribution%20of%20germline%20mutations%20in%20the%20RAD51B%2C%20RAD51C%2C%20and%20RAD51D%20genes%20to%20ovarian%20cancer%20in%20the%20population&amp;journal=J+Clin+Oncol&amp;volume=33&amp;pages=2901-7" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B14" id="B14"></a> 14. Suszynska M, Ratajska M, Kozlowski P. BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: Mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases. <i>J Ovarian Res</i> (2020) 13(1):50. doi:&#xa0;10.1186/s13048-020-00654-3</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/32359370/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s13048-020-00654-3" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Suszynska&amp;author=M+Ratajska&amp;author=P+Kozlowski&amp;publication_year=2020&amp;title=BRIP1%2C%20RAD51C%2C%20and%20RAD51D%20mutations%20are%20associated%20with%20high%20susceptibility%20to%20ovarian%20cancer%3A%20Mutation%20prevalence%20and%20precise%20risk%20estimates%20based%20on%20a%20pooled%20analysis%20of%20~30%2C000%20cases&amp;journal=J+Ovarian+Res&amp;volume=13&amp;pages=50" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B15" id="B15"></a> 15. Kanchi KL, Johnson KJ, Lu C, McLellan MD, Leiserson MDM, Wendl MC, et al. Integrated analysis of germline and somatic variants in ovarian cancer. <i>Nat Commun</i> (2014) 5:3156. doi:&#xa0;10.1038/ncomms4156</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/24448499/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/ncomms4156" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=KL+Kanchi&amp;author=KJ+Johnson&amp;author=C+Lu&amp;author=MD+McLellan&amp;author=MDM+Leiserson&amp;author=MC+Wendl&amp;publication_year=2014&amp;title=Integrated%20analysis%20of%20germline%20and%20somatic%20variants%20in%20ovarian%20cancer&amp;journal=Nat+Commun&amp;volume=5&amp;pages=3156" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B16" id="B16"></a> 16. Lu HM, Li S, Black MH, Lee S, Hoiness R, Wu S, et al. Association of breast and ovarian cancers with predisposition genes identified by Large-scale sequencing. <i>JAMA Oncol</i> (2019) 5:51&#x2013;7. doi:&#xa0;10.1001/JAMAONCOL.2018.2956</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/30128536/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1001/JAMAONCOL.2018.2956" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=HM+Lu&amp;author=S+Li&amp;author=MH+Black&amp;author=S+Lee&amp;author=R+Hoiness&amp;author=S+Wu&amp;publication_year=2019&amp;title=Association%20of%20breast%20and%20ovarian%20cancers%20with%20predisposition%20genes%20identified%20by%20Large-scale%20sequencing&amp;journal=JAMA+Oncol&amp;volume=5&amp;pages=51-7" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B17" id="B17"></a> 17. Subramanian DN, Zethoven M, McInerny S, Morgan JA, Rowley SM, Lee JEA, et al. Exome sequencing of familial high-grade serous ovarian carcinoma reveals heterogeneity for rare candidate susceptibility genes. <i>Nat Commun</i> (2020) 11:1&#x2013;11. doi:&#xa0;10.1038/s41467-020-15461-z</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/31911652/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41467-020-15461-z" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=DN+Subramanian&amp;author=M+Zethoven&amp;author=S+McInerny&amp;author=JA+Morgan&amp;author=SM+Rowley&amp;author=JEA+Lee&amp;publication_year=2020&amp;title=Exome%20sequencing%20of%20familial%20high-grade%20serous%20ovarian%20carcinoma%20reveals%20heterogeneity%20for%20rare%20candidate%20susceptibility%20genes&amp;journal=Nat+Commun&amp;volume=11&amp;pages=1" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B18" id="B18"></a> 18. Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, et al. Cancer risks associated with germline PALB2 pathogenic variants: An international study of 524 families. <i>J Clin Oncol</i> (2020) 38:674&#x2013;85. doi:&#xa0;10.1200/JCO.19.01907</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/31841383/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1200/JCO.19.01907" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=X+Yang&amp;author=G+Leslie&amp;author=A+Doroszuk&amp;author=S+Schneider&amp;author=J+Allen&amp;author=B+Decker&amp;publication_year=2020&amp;title=Cancer%20risks%20associated%20with%20germline%20PALB2%20pathogenic%20variants%3A%20An%20international%20study%20of%20524%20families&amp;journal=J+Clin+Oncol&amp;volume=38&amp;pages=674-85" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B19" id="B19"></a> 19. Song H, Dicks EM, Tyrer J, Intermaggio M, Chenevix-Trench G, Bowtell DD, et al. Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer. <i>J Med Genet</i> (2021) 58:305&#x2013;13. doi:&#xa0;10.1136/JMEDGENET-2019-106739</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/32546565/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1136/JMEDGENET-2019-106739" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H+Song&amp;author=EM+Dicks&amp;author=J+Tyrer&amp;author=M+Intermaggio&amp;author=G+Chenevix-Trench&amp;author=DD+Bowtell&amp;publication_year=2021&amp;title=Population-based%20targeted%20sequencing%20of%2054%20candidate%20genes%20identifies%20PALB2%20as%20a%20susceptibility%20gene%20for%20high-grade%20serous%20ovarian%20cancer&amp;journal=J+Med+Genet&amp;volume=58&amp;pages=305-13" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B20" id="B20"></a> 20. Szymanska-Pasternak J, Szymanska A, Medrek K, Imyanitov EN, Cybulski C, Gorski B, et al. CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors. <i>Gynecologic Oncol</i> (2006) 102:429&#x2013;31. doi:&#xa0;10.1016/J.YGYNO.2006.05.040</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1016/J.YGYNO.2006.05.040" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Szymanska-Pasternak&amp;author=A+Szymanska&amp;author=K+Medrek&amp;author=EN+Imyanitov&amp;author=C+Cybulski&amp;author=B+Gorski&amp;publication_year=2006&amp;title=CHEK2%20variants%20predispose%20to%20benign%2C%20borderline%20and%20low-grade%20invasive%20ovarian%20tumors&amp;journal=Gynecologic+Oncol&amp;volume=102&amp;pages=429-31" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B21" id="B21"></a> 21. Dicks E, Song H, Ramus SJ, Van Oudenhove E, Tyrer JP, Intermaggio MP, et al. Germline whole exome sequencing and large-scale replication identifies &amp;lt;i&lt;FANCM&amp;lt;/i&lt; as a likely high grade serous ovarian cancer susceptibility gene. <i>Oncotarget</i> (2017) 8(31):50930&#x2013;40. doi:&#xa0;10.18632/oncotarget.15871</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/28881617/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.18632/oncotarget.15871" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=E+Dicks&amp;author=H+Song&amp;author=SJ+Ramus&amp;author=E+Van%20Oudenhove&amp;author=JP+Tyrer&amp;author=MP+Intermaggio&amp;publication_year=2017&amp;title=Germline%20whole%20exome%20sequencing%20and%20large-scale%20replication%20identifies%20%26lt%3Bi%3CFANCM%26lt%3B%2Fi%3C%20as%20a%20likely%20high%20grade%20serous%20ovarian%20cancer%20susceptibility%20gene&amp;journal=Oncotarget&amp;volume=8&amp;pages=50930-40" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B22" id="B22"></a> 22. Zhu Q, Zhang J, Chen Y, Hu Q, Shen H, Huang RY, et al. Whole-exome sequencing of ovarian cancer families uncovers putative predisposition genes. <i>Int J Cancer</i> (2019) 146(8):2147&#x2013;55. doi:&#xa0;10.1002/ijc.32545</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/31265121/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/ijc.32545" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=Q+Zhu&amp;author=J+Zhang&amp;author=Y+Chen&amp;author=Q+Hu&amp;author=H+Shen&amp;author=RY+Huang&amp;publication_year=2019&amp;title=Whole-exome%20sequencing%20of%20ovarian%20cancer%20families%20uncovers%20putative%20predisposition%20genes&amp;journal=Int+J+Cancer&amp;volume=146&amp;pages=2147-55" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B23" id="B23"></a> 23. Heikkinen K, Karppinen SM, Soini Y, M&#xe4;kinen M, Winqvist R. Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility. <i>J Med Genet</i> (2003) 40(12):e131. doi:&#xa0;10.1136/JMG.40.12.E131</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/14684699/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1136/JMG.40.12.E131" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=K+Heikkinen&amp;author=SM+Karppinen&amp;author=Y+Soini&amp;author=M+M%C3%A4kinen&amp;author=R+Winqvist&amp;publication_year=2003&amp;title=Mutation%20screening%20of%20Mre11%20complex%20genes%3A%20indication%20of%20RAD50%20involvement%20in%20breast%20and%20ovarian%20cancer%20susceptibility&amp;journal=J+Med+Genet&amp;volume=40&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B24" id="B24"></a> 24. Fierheller CT, Guitton-Sert L, Alenezi WM, Revil T, Oros KK, Gao Y, et al. A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene. <i>Genome Med</i> (2021) 13(1):186. doi:&#xa0;10.1186/S13073-021-00998-5</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/34861889/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/S13073-021-00998-5" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=CT+Fierheller&amp;author=L+Guitton-Sert&amp;author=WM+Alenezi&amp;author=T+Revil&amp;author=KK+Oros&amp;author=Y+Gao&amp;publication_year=2021&amp;title=A%20functionally%20impaired%20missense%20variant%20identified%20in%20French%20Canadian%20families%20implicates%20FANCI%20as%20a%20candidate%20ovarian%20cancer-predisposing%20gene&amp;journal=Genome+Med&amp;volume=13&amp;pages=186" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B25" id="B25"></a> 25. Pharoah PDP, Dunning AM, Ponder BAJ, Easton DF. Association studies for finding cancer-susceptibility genetic variants. <i>Nat Rev Cancer</i> (2004) 4:850&#x2013;60. doi:&#xa0;10.1038/nrc1476</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/15516958/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nrc1476" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=PDP+Pharoah&amp;author=AM+Dunning&amp;author=BAJ+Ponder&amp;author=DF+Easton&amp;publication_year=2004&amp;title=Association%20studies%20for%20finding%20cancer-susceptibility%20genetic%20variants&amp;journal=Nat+Rev+Cancer&amp;volume=4&amp;pages=850-60" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B26" id="B26"></a> 26. Rahman N. Realizing the promise of cancer predisposition genes. <i>Nature</i> (2014) 505(7483):302&#x2013;8. doi:&#xa0;10.1038/nature12981</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/24429628/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nature12981" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=N+Rahman&amp;publication_year=2014&amp;title=Realizing%20the%20promise%20of%20cancer%20predisposition%20genes&amp;journal=Nature&amp;volume=505&amp;pages=302-8" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B27" id="B27"></a> 27. Ramus SJ, Gayther SA. The contribution of BRCA1 and BRCA2 to ovarian cancer. <i>Mol Oncol</i> (2009) 3(2):138&#x2013;50. doi:&#xa0;10.1016/j.molonc.2009.02.001</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/19383375/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.molonc.2009.02.001" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SJ+Ramus&amp;author=SA+Gayther&amp;publication_year=2009&amp;title=The%20contribution%20of%20BRCA1%20and%20BRCA2%20to%20ovarian%20cancer&amp;journal=Mol+Oncol&amp;volume=3&amp;pages=138-50" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B28" id="B28"></a> 28. Milanowska K, Krwawicz J, Papaj G, Kosi&#x144;ski J, Poleszak K, Lesiak J, et al. REPAIRtoire&#x2013;a database of DNA repair pathways. <i>Nucleic Acids Res</i> (2011) 39(Database issue):D788&#x2013;92. doi:&#xa0;10.1093/NAR/GKQ1087</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/21051355/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/NAR/GKQ1087" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=K+Milanowska&amp;author=J+Krwawicz&amp;author=G+Papaj&amp;author=J+Kosi%C5%84ski&amp;author=K+Poleszak&amp;author=J+Lesiak&amp;publication_year=2011&amp;title=REPAIRtoire%E2%80%93a%20database%20of%20DNA%20repair%20pathways&amp;journal=Nucleic+Acids+Res&amp;volume=39&amp;pages=D788-92" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B29" id="B29"></a> 29. Chae YK, Anker JF, Carneiro BA, Chandra S, Kaplan J, Kalyan A, et al. Genomic landscape of DNA repair genes in cancer. <i>Oncotarget</i> (2016). doi:&#xa0;10.18632/oncotarget.8196</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.18632/oncotarget.8196" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=YK+Chae&amp;author=JF+Anker&amp;author=BA+Carneiro&amp;author=S+Chandra&amp;author=J+Kaplan&amp;author=A+Kalyan&amp;publication_year=2016&amp;title=Genomic%20landscape%20of%20DNA%20repair%20genes%20in%20cancer&amp;journal=Oncotarget&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B30" id="B30"></a> 30. Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, et al. Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas. <i>Cell Rep</i> (2018) 23(1):239&#x2013;254.e6. doi:&#xa0;10.1016/j.celrep.2018.03.076</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/29617664/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.celrep.2018.03.076" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=TA+Knijnenburg&amp;author=L+Wang&amp;author=MT+Zimmermann&amp;author=N+Chambwe&amp;author=GF+Gao&amp;author=AD+Cherniack&amp;publication_year=2018&amp;title=Genomic%20and%20molecular%20landscape%20of%20DNA%20damage%20repair%20deficiency%20across%20the%20cancer%20genome%20atlas&amp;journal=Cell+Rep&amp;volume=23&amp;pages=239-254.e6" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B31" id="B31"></a> 31. Glentis S, Dimopoulos AC, Rouskas K, Ntritsos G, Evangelou E, Narod SA, et al. Exome sequencing in BRCA1- and BRCA2-negative Greek families identifies MDM1 and NBEAL1 as candidate risk genes for hereditary breast cancer. <i>Front Genet</i> (2019) 10:1005. doi:&#xa0;10.3389/FGENE.2019.01005</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/31681433/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3389/FGENE.2019.01005" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Glentis&amp;author=AC+Dimopoulos&amp;author=K+Rouskas&amp;author=G+Ntritsos&amp;author=E+Evangelou&amp;author=SA+Narod&amp;publication_year=2019&amp;title=Exome%20sequencing%20in%20BRCA1-%20and%20BRCA2-negative%20Greek%20families%20identifies%20MDM1%20and%20NBEAL1%20as%20candidate%20risk%20genes%20for%20hereditary%20breast%20cancer&amp;journal=Front+Genet&amp;volume=10&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B32" id="B32"></a> 32. Sherill-Rofe D, Rahat D, Findlay S, Mellul A, Guberman I, Braun M, et al. Mapping global and local coevolution across 600 species to identify novel homologous recombination repair genes. <i>Genome Res</i> (2019) 29:439&#x2013;48. doi:&#xa0;10.1101/gr.241414.118</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/30718334/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1101/gr.241414.118" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=D+Sherill-Rofe&amp;author=D+Rahat&amp;author=S+Findlay&amp;author=A+Mellul&amp;author=I+Guberman&amp;author=M+Braun&amp;publication_year=2019&amp;title=Mapping%20global%20and%20local%20coevolution%20across%20600%20species%20to%20identify%20novel%20homologous%20recombination%20repair%20genes&amp;journal=Genome+Res&amp;volume=29&amp;pages=439-48" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B33" id="B33"></a> 33. Fierheller CT, Alenezi WM, Tonin PN. The genetic analyses of French canadians of Quebec facilitate the characterization of new cancer predisposing genes implicated in hereditary breast and/or ovarian cancer syndrome families. <i>Cancers</i> (2021) 13(14):3406. doi:&#xa0;10.3390/CANCERS13143406</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/34298626/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3390/CANCERS13143406" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=CT+Fierheller&amp;author=WM+Alenezi&amp;author=PN+Tonin&amp;publication_year=2021&amp;title=The%20genetic%20analyses%20of%20French%20canadians%20of%20Quebec%20facilitate%20the%20characterization%20of%20new%20cancer%20predisposing%20genes%20implicated%20in%20hereditary%20breast%20and%2For%20ovarian%20cancer%20syndrome%20families&amp;journal=Cancers&amp;volume=13&amp;pages=3406" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B34" id="B34"></a> 34. Scriver CR. Human genetics: lessons from Quebec populations. <i>Annual review of genomics and human genetics</i>. <i>Annu Rev Genomics Hum Genet</i> (2001) 2:69&#x2013;101. doi:&#xa0;10.1146/annurev.genom.6.080604.162340</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/11701644/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1146/annurev.genom.6.080604.162340" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=CR+Scriver&amp;publication_year=2001&amp;title=Human%20genetics%3A%20lessons%20from%20Quebec%20populations.%20Annual%20review%20of%20genomics%20and%20human%20genetics&amp;journal=Annu+Rev+Genomics+Hum+Genet&amp;volume=2&amp;pages=69-101" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B35" id="B35"></a> 35. Laberge AM, Michaud J, Richter A, Lemyre E, Lambert M, Brais B, et al. Population history and its impact on medical genetics in Quebec. <i>Clin Genet</i> (2005) 68(4):287&#x2013;301. doi:&#xa0;10.1111/j.1399-0004.2005.00497.x</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/16143014/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/j.1399-0004.2005.00497.x" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=AM+Laberge&amp;author=J+Michaud&amp;author=A+Richter&amp;author=E+Lemyre&amp;author=M+Lambert&amp;author=B+Brais&amp;publication_year=2005&amp;title=Population%20history%20and%20its%20impact%20on%20medical%20genetics%20in%20Quebec&amp;journal=Clin+Genet&amp;volume=68&amp;pages=287-301" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B36" id="B36"></a> 36. Erkko H, Xia B, Nikkil&#xe4; J, Schleutker J, Syrj&#xe4;koski K, Mannermaa A, et al. LETTERS a recurrent mutation in PALB2 in Finnish cancer families. <i>Nature</i> (2007) 446(7133):316&#x2013;9. doi:&#xa0;10.1038/nature05609</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/17287723/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nature05609" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H+Erkko&amp;author=B+Xia&amp;author=J+Nikkil%C3%A4&amp;author=J+Schleutker&amp;author=K+Syrj%C3%A4koski&amp;author=A+Mannermaa&amp;publication_year=2007&amp;title=LETTERS%20a%20recurrent%20mutation%20in%20PALB2%20in%20Finnish%20cancer%20families&amp;journal=Nature&amp;volume=446&amp;pages=316-9" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B37" id="B37"></a> 37. Cybulski C, Carrot-Zhang J, Klulniak W, Rivera B, Kashyap A, Wokolorczyk D, et al. Germline RECQL mutations are associated with breast cancer susceptibility. <i>Nat Genet</i> (2015) 47:643&#x2013;6. doi:&#xa0;10.1038/NG.3284</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25915596/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/NG.3284" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C+Cybulski&amp;author=J+Carrot-Zhang&amp;author=W+Klulniak&amp;author=B+Rivera&amp;author=A+Kashyap&amp;author=D+Wokolorczyk&amp;publication_year=2015&amp;title=Germline%20RECQL%20mutations%20are%20associated%20with%20breast%20cancer%20susceptibility&amp;journal=Nat+Genet&amp;volume=47&amp;pages=643-6" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B38" id="B38"></a> 38. Charbonneau H, Desjardins B, L&#xe9;gar&#xe9; J, Denis H. &#x201c;The population of the st. Lawrence Valley 1608-1760 | bibliographie sur l&#x2019;histoire de montr&#xe9;al,&#x201d;. In: Haines MR, Steckel RH, editors. <i>A population history of north America</i>. Cambridge University Press (2000). p. 99&#x2013;142.</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="http://scholar.google.com/scholar_lookup?author=H+Charbonneau&amp;author=B+Desjardins&amp;author=J+L%C3%A9gar%C3%A9&amp;author=H+Denis&amp;publication_year=2000&amp;title=%E2%80%9CThe%20population%20of%20the%20st.%20Lawrence%20Valley%201608-1760%20%7C%20bibliographie%20sur%20l%E2%80%99histoire%20de%20montr%C3%A9al%2C%E2%80%9D&amp;book=A+population+history+of+north+America&amp;pages=99" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B39" id="B39"></a> 39. Gagnon A, Heyer E. Fragmentation of the qu&#xe9;bec population genetic pool (Canada): Evidence from the genetic contribution of founders per region in the 17th and 18th centuries. <i>Am J Phys Anthropology</i> (2001) 114:30&#x2013;41. doi:&#xa0;10.1002/1096-8644(200101)114:1&lt;30::AID-AJPA1003&gt;3.0.CO;2-L</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1002/1096-8644(200101)114:1&lt;30::AID-AJPA1003&gt;3.0.CO;2-L" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Gagnon&amp;author=E+Heyer&amp;publication_year=2001&amp;title=Fragmentation%20of%20the%20qu%C3%A9bec%20population%20genetic%20pool%20%28Canada%29%3A%20Evidence%20from%20the%20genetic%20contribution%20of%20founders%20per%20region%20in%20the%2017th%20and%2018th%20centuries&amp;journal=Am+J+Phys+Anthropology&amp;volume=114&amp;pages=30" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B40" id="B40"></a> 40. Tonin PN, Mes-Masson A-M, Futreal PA, Morgan K, Mahon M, Foulkes WD, et al. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. <i>Am J Hum Genet</i> (1998) 63(5):1341&#x2013;51. doi:&#xa0;10.1086/302099</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/9792861/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1086/302099" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=PN+Tonin&amp;author=A-M+Mes-Masson&amp;author=PA+Futreal&amp;author=K+Morgan&amp;author=M+Mahon&amp;author=WD+Foulkes&amp;publication_year=1998&amp;title=Founder%20BRCA1%20and%20BRCA2%20mutations%20in%20French%20Canadian%20breast%20and%20ovarian%20cancer%20families&amp;journal=Am+J+Hum+Genet&amp;volume=63&amp;pages=1341-51" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B41" id="B41"></a> 41. Oros KK, Ghadirian P, Greenwood CMT, Perret C, Shen Z, Paredes Y, et al. Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations. <i>Int J Cancer</i> (2004) 112(3):411&#x2013;9. doi:&#xa0;10.1002/ijc.20406</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/15382066/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/ijc.20406" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=KK+Oros&amp;author=P+Ghadirian&amp;author=CMT+Greenwood&amp;author=C+Perret&amp;author=Z+Shen&amp;author=Y+Paredes&amp;publication_year=2004&amp;title=Significant%20proportion%20of%20breast%20and%2For%20ovarian%20cancer%20families%20of%20French%20Canadian%20descent%20harbor%201%20of%205%20BRCA1%20and%20BRCA2%20mutations&amp;journal=Int+J+Cancer&amp;volume=112&amp;pages=411-9" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B42" id="B42"></a> 42. Foulkes WD, Ghadirian P, Akbari MR, Hamel N, Giroux S, Sabbaghian N, et al. Identification of a novel truncating PALB2mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. <i>Breast Cancer Res</i> (2007) 9(6):R83. doi:&#xa0;10.1186/bcr1828</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/18053174/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/bcr1828" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=WD+Foulkes&amp;author=P+Ghadirian&amp;author=MR+Akbari&amp;author=N+Hamel&amp;author=S+Giroux&amp;author=N+Sabbaghian&amp;publication_year=2007&amp;title=Identification%20of%20a%20novel%20truncating%20PALB2mutation%20and%20analysis%20of%20its%20contribution%20to%20early-onset%20breast%20cancer%20in%20French-Canadian%20women&amp;journal=Breast+Cancer+Res&amp;volume=9&amp;pages=R83" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B43" id="B43"></a> 43. Alenezi WM, Milano L, Fierheller CT, Serruya C, Revil T, Oros KK, et al. The genetic and molecular analyses of RAD51C and RAD51D identifies rare variants implicated in hereditary ovarian cancer from a genetically unique population. <i>Cancers 2022</i> (2022) 14:2251. doi:&#xa0;10.3390/CANCERS14092251</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.3390/CANCERS14092251" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=WM+Alenezi&amp;author=L+Milano&amp;author=CT+Fierheller&amp;author=C+Serruya&amp;author=T+Revil&amp;author=KK+Oros&amp;publication_year=2022&amp;title=The%20genetic%20and%20molecular%20analyses%20of%20RAD51C%20and%20RAD51D%20identifies%20rare%20variants%20implicated%20in%20hereditary%20ovarian%20cancer%20from%20a%20genetically%20unique%20population&amp;journal=Cancers+2022&amp;volume=14&amp;pages=2251" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B44" id="B44"></a> 44. Rivera B, Iorio M, Frankum J, Nadaf J, Fahiminiya S, Arcand SL, et al. Functionally null RAD51D missense mutation associates strongly with ovarian carcinoma. <i>Cancer Res</i> (2017) 77:4517&#x2013;29. doi:&#xa0;10.1158/0008-5472.CAN-17-0190</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/28646019/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1158/0008-5472.CAN-17-0190" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=B+Rivera&amp;author=M+Iorio&amp;author=J+Frankum&amp;author=J+Nadaf&amp;author=S+Fahiminiya&amp;author=SL+Arcand&amp;publication_year=2017&amp;title=Functionally%20null%20RAD51D%20missense%20mutation%20associates%20strongly%20with%20ovarian%20carcinoma&amp;journal=Cancer+Res&amp;volume=77&amp;pages=4517-29" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B45" id="B45"></a> 45. Chong G, Jarry J, Marcus V, Thiffault I, Winocour S, Monczak Y, et al. High frequency of exon deletions and putative founder effects in French Canadian lynch syndrome families. <i>Hum Mutat</i> (2009) 30:E797&#x2013;812. doi:&#xa0;10.1002/humu.21056</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/19459153/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.21056" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=G+Chong&amp;author=J+Jarry&amp;author=V+Marcus&amp;author=I+Thiffault&amp;author=S+Winocour&amp;author=Y+Monczak&amp;publication_year=2009&amp;title=High%20frequency%20of%20exon%20deletions%20and%20putative%20founder%20effects%20in%20French%20Canadian%20lynch%20syndrome%20families&amp;journal=Hum+Mutat&amp;volume=30&amp;pages=E797-812" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B46" id="B46"></a> 46. Castellsagu&#xe9; E, Liu J, Volenik A, Giroux S, Gagn&#xe9; R, Maranda B, et al. Characterization of a novel founder MSH6 mutation causing lynch syndrome in the French Canadian population. <i>Clin Genet</i> (2015) 87:536&#x2013;42. doi:&#xa0;10.1111/CGE.12526</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25318681/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/CGE.12526" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=E+Castellsagu%C3%A9&amp;author=J+Liu&amp;author=A+Volenik&amp;author=S+Giroux&amp;author=R+Gagn%C3%A9&amp;author=B+Maranda&amp;publication_year=2015&amp;title=Characterization%20of%20a%20novel%20founder%20MSH6%20mutation%20causing%20lynch%20syndrome%20in%20the%20French%20Canadian%20population&amp;journal=Clin+Genet&amp;volume=87&amp;pages=536-42" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B47" id="B47"></a> 47. Alenezi WM, Fierheller CT, Revil T, Serruya C, Mes-Masson A-M, Foulkes WD, et al. Case review: Whole-exome sequencing analyses identify carriers of a known likely pathogenic intronic BRCA1 variant in ovarian cancer cases clinically negative for pathogenic BRCA1 and BRCA2 variants. <i>Genes 2022 Vol. 13 Page 697</i> (2022) 13:697. doi:&#xa0;10.3390/GENES13040697</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.3390/GENES13040697" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=WM+Alenezi&amp;author=CT+Fierheller&amp;author=T+Revil&amp;author=C+Serruya&amp;author=A-M+Mes-Masson&amp;author=WD+Foulkes&amp;publication_year=2022&amp;title=Case%20review%3A%20Whole-exome%20sequencing%20analyses%20identify%20carriers%20of%20a%20known%20likely%20pathogenic%20intronic%20BRCA1%20variant%20in%20ovarian%20cancer%20cases%20clinically%20negative%20for%20pathogenic%20BRCA1%20and%20BRCA2%20variants&amp;journal=Genes+2022+Vol.+13+Page+697&amp;volume=13&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B48" id="B48"></a> 48. Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. <i>Int J Gynecology Obstetrics</i> (2021) 155:61&#x2013;85. doi:&#xa0;10.1002/IJGO.13878</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1002/IJGO.13878" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=JS+Berek&amp;author=M+Renz&amp;author=S+Kehoe&amp;author=L+Kumar&amp;author=M+Friedlander&amp;publication_year=2021&amp;title=Cancer%20of%20the%20ovary%2C%20fallopian%20tube%2C%20and%20peritoneum%3A%202021%20update&amp;journal=Int+J+Gynecology+Obstetrics&amp;volume=155&amp;pages=61" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B49" id="B49"></a> 49. K&#xf6;bel M, Kang EY. The evolution of ovarian carcinoma subclassification. <i>Cancers</i> (2022) 14:416. doi:&#xa0;10.3390/CANCERS14020416</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/35053578/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3390/CANCERS14020416" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+K%C3%B6bel&amp;author=EY+Kang&amp;publication_year=2022&amp;title=The%20evolution%20of%20ovarian%20carcinoma%20subclassification&amp;journal=Cancers&amp;volume=14&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B50" id="B50"></a> 50. Oros KK, Ghadirian P, Maugard CM, Perret C, Paredes Y, Mes-Masson AM, et al. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent. <i>Clin Genet</i> (2006) 70(4):320&#x2013;9. doi:&#xa0;10.1111/j.1399-0004.2006.00673.x</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/16965326/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/j.1399-0004.2006.00673.x" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=KK+Oros&amp;author=P+Ghadirian&amp;author=CM+Maugard&amp;author=C+Perret&amp;author=Y+Paredes&amp;author=AM+Mes-Masson&amp;publication_year=2006&amp;title=Application%20of%20BRCA1%20and%20BRCA2%20mutation%20carrier%20prediction%20models%20in%20breast%20and%2For%20ovarian%20cancer%20families%20of%20French%20Canadian%20descent&amp;journal=Clin+Genet&amp;volume=70&amp;pages=320-9" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B51" id="B51"></a> 51. Oros KK, Leblanc G, Arcand SL, Shen Z, Perret C, Mes-Masson AM, et al. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families. <i>BMC Med Genet</i> (2006) 7:23. doi:&#xa0;10.1186/1471-2350-7-23</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/16539696/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/1471-2350-7-23" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=KK+Oros&amp;author=G+Leblanc&amp;author=SL+Arcand&amp;author=Z+Shen&amp;author=C+Perret&amp;author=AM+Mes-Masson&amp;publication_year=2006&amp;title=Haplotype%20analysis%20suggest%20common%20founders%20in%20carriers%20of%20the%20recurrent%20BRCA2%20mutation%203398delAAAAG%2C%20in%20French%20Canadian%20hereditary%20breast%20and%2Fovarian%20cancer%20families&amp;journal=BMC+Med+Genet&amp;volume=7&amp;pages=23" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B52" id="B52"></a> 52. Arcand SL, Maugard CM, Ghadirian P, Robidoux A, Perret C, Zhang P, et al. Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families. <i>Breast Cancer Res Treat</i> (2008) 108(3):399&#x2013;408. doi:&#xa0;10.1007/s10549-007-9608-6</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/17541742/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10549-007-9608-6" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SL+Arcand&amp;author=CM+Maugard&amp;author=P+Ghadirian&amp;author=A+Robidoux&amp;author=C+Perret&amp;author=P+Zhang&amp;publication_year=2008&amp;title=Germline%20TP53%20mutations%20in%20BRCA1%20and%20BRCA2%20mutation-negative%20French%20Canadian%20breast%20cancer%20families&amp;journal=Breast+Cancer+Res+Treat&amp;volume=108&amp;pages=399-408" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B53" id="B53"></a> 53. Arcand SL, Akbari MR, Mes-Masson AM, Provencher D, Foulkes WD, Narod SA, et al. Germline TP53 mutational spectrum in French canadians with breast cancer. <i>BMC Med Genet</i> (2015) 16:24. doi:&#xa0;10.1186/s12881-015-0169-y</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25925845/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s12881-015-0169-y" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SL+Arcand&amp;author=MR+Akbari&amp;author=AM+Mes-Masson&amp;author=D+Provencher&amp;author=WD+Foulkes&amp;author=SA+Narod&amp;publication_year=2015&amp;title=Germline%20TP53%20mutational%20spectrum%20in%20French%20canadians%20with%20breast%20cancer&amp;journal=BMC+Med+Genet&amp;volume=16&amp;pages=24" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B54" id="B54"></a> 54. Osher DJ, De Leeneer K, Michils G, Hamel N, Tomiak E, Poppe B, et al. Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families. <i>Br J Cancer</i> (2012) 106(8):1460&#x2013;3. doi:&#xa0;10.1038/bjc.2012.87</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/22415235/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/bjc.2012.87" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=DJ+Osher&amp;author=K+De%20Leeneer&amp;author=G+Michils&amp;author=N+Hamel&amp;author=E+Tomiak&amp;author=B+Poppe&amp;publication_year=2012&amp;title=Mutation%20analysis%20of%20RAD51D%20in%20non-BRCA1%2F2%20ovarian%20and%20breast%20cancer%20families&amp;journal=Br+J+Cancer&amp;volume=106&amp;pages=1460-3" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B55" id="B55"></a> 55. Ancot F, Arcand SL, Mes-Masson AM, Provencher DM, Tonin PN. Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population. <i>Oncol Letters.</i> (2015) 9(6):2787&#x2013;90. doi:&#xa0;10.3892/ol.2015.3123</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.3892/ol.2015.3123" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=F+Ancot&amp;author=SL+Arcand&amp;author=AM+Mes-Masson&amp;author=DM+Provencher&amp;author=PN+Tonin&amp;publication_year=2015&amp;title=Double%20PALB2%20and%20BRCA1%2FBRCA2%20mutation%20carriers%20are%20rare%20in%20breast%20cancer%20and%20breast-ovarian%20cancer%20syndrome%20families%20from%20the%20French%20Canadian%20founder%20population&amp;journal=Oncol+Letters.&amp;volume=9&amp;pages=2787-90" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B56" id="B56"></a> 56. Belanger MH, Dolman L, Arcand SL, Shen Z, Chong G, Mes-Masson AM, et al. A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population. <i>J Ovarian Res</i> (2015) 8:1. doi:&#xa0;10.1186/s13048-015-0124-8</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25884701/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s13048-015-0124-8" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MH+Belanger&amp;author=L+Dolman&amp;author=SL+Arcand&amp;author=Z+Shen&amp;author=G+Chong&amp;author=AM+Mes-Masson&amp;publication_year=2015&amp;title=A%20targeted%20analysis%20identifies%20a%20high%20frequency%20of%20BRCA1%20and%20BRCA2%20mutation%20carriers%20in%20women%20with%20ovarian%20cancer%20from%20a%20founder%20population&amp;journal=J+Ovarian+Res&amp;volume=8&amp;pages=1" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B57" id="B57"></a> 57. Guillemette L, Allard C, Lacroix M, Patenaude J, Battista MC, Doyon M, et al. Genetics of glucose regulation in gestation and growth (Gen3G): A prospective prebirth cohort of mother-child pairs in sherbrooke, Canada. <i>BMJ Open</i> (2016) 6(2):e010031. doi:&#xa0;10.1136/bmjopen-2015-010031</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/26842272/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1136/bmjopen-2015-010031" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L+Guillemette&amp;author=C+Allard&amp;author=M+Lacroix&amp;author=J+Patenaude&amp;author=MC+Battista&amp;author=M+Doyon&amp;publication_year=2016&amp;title=Genetics%20of%20glucose%20regulation%20in%20gestation%20and%20growth%20%28Gen3G%29%3A%20A%20prospective%20prebirth%20cohort%20of%20mother-child%20pairs%20in%20sherbrooke%2C%20Canada&amp;journal=BMJ+Open&amp;volume=6&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B58" id="B58"></a> 58. Gan-Or Z, Zhou S, Ambalavanan A, Leblond CS, Xie P, Johnson A, et al. Analysis of functional GLO1 variants in the BTBD9 locus and restless legs syndrome. <i>Sleep Med</i> (2015) 16:1151&#x2013;5. doi:&#xa0;10.1016/J.SLEEP.2015.06.002</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/26298793/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/J.SLEEP.2015.06.002" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=Z+Gan-Or&amp;author=S+Zhou&amp;author=A+Ambalavanan&amp;author=CS+Leblond&amp;author=P+Xie&amp;author=A+Johnson&amp;publication_year=2015&amp;title=Analysis%20of%20functional%20GLO1%20variants%20in%20the%20BTBD9%20locus%20and%20restless%20legs%20syndrome&amp;journal=Sleep+Med&amp;volume=16&amp;pages=1151-5" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B59" id="B59"></a> 59. Awadalla P, Boileau C, Payette Y, Idaghdour Y, Goulet JP, Knoppers B, et al. Cohort profile of the CARTaGENE study: Quebec&#x2019;s population-based biobank for public health and personalized genomics. <i>Int J Epidemiol</i> (2013) 42(5):1285&#x2013;99. doi:&#xa0;10.1093/ije/dys160</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/23071140/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/ije/dys160" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=P+Awadalla&amp;author=C+Boileau&amp;author=Y+Payette&amp;author=Y+Idaghdour&amp;author=JP+Goulet&amp;author=B+Knoppers&amp;publication_year=2013&amp;title=Cohort%20profile%20of%20the%20CARTaGENE%20study%3A%20Quebec%E2%80%99s%20population-based%20biobank%20for%20public%20health%20and%20personalized%20genomics&amp;journal=Int+J+Epidemiol&amp;volume=42&amp;pages=1285-99" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B60" id="B60"></a> 60. Huang K, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, et al. Pathogenic germline variants in 10,389 adult cancers. <i>Cell</i> (2018) 173(2):355&#x2013;370.e14. doi:&#xa0;10.1016/j.cell.2018.03.039</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/29625052/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.cell.2018.03.039" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=K+Huang&amp;author=RJ+Mashl&amp;author=Y+Wu&amp;author=DI+Ritter&amp;author=J+Wang&amp;author=C+Oh&amp;publication_year=2018&amp;title=Pathogenic%20germline%20variants%20in%2010%2C389%20adult%20cancers&amp;journal=Cell&amp;volume=173&amp;pages=355-370.e14" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B61" id="B61"></a> 61. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alf&#xf6;ldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. <i>Nat 2020 581:7809</i> (2020) 581:434&#x2013;43. doi:&#xa0;10.1038/s41586-020-2308-7</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1038/s41586-020-2308-7" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=KJ+Karczewski&amp;author=LC+Francioli&amp;author=G+Tiao&amp;author=BB+Cummings&amp;author=J+Alf%C3%B6ldi&amp;author=Q+Wang&amp;publication_year=2020&amp;title=The%20mutational%20constraint%20spectrum%20quantified%20from%20variation%20in%20141%2C456%20humans&amp;journal=Nat+2020+581:7809&amp;volume=581&amp;pages=434-43" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B62" id="B62"></a> 62. Koch L. Exploring human genomic diversity with gnomAD. <i>Nat Rev Genet</i> (2020) 21(8):448. doi:&#xa0;10.1038/s41576-020-0255-7</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/32488197/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41576-020-0255-7" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L+Koch&amp;publication_year=2020&amp;title=Exploring%20human%20genomic%20diversity%20with%20gnomAD&amp;journal=Nat+Rev+Genet&amp;volume=21&amp;pages=448" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B63" id="B63"></a> 63. Pedersen BS, Brown JM, Dashnow H, Wallace AD, Velinder M, Tristani-Firouzi M, et al. Effective variant filtering and expected candidate variant yield in studies of rare human disease. <i>NPJ Genomic Med 2021 6:1</i> (2021) 6:1&#x2013;8. doi:&#xa0;10.1038/s41525-021-00227-3</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1038/s41525-021-00227-3" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=BS+Pedersen&amp;author=JM+Brown&amp;author=H+Dashnow&amp;author=AD+Wallace&amp;author=M+Velinder&amp;author=M+Tristani-Firouzi&amp;publication_year=2021&amp;title=Effective%20variant%20filtering%20and%20expected%20candidate%20variant%20yield%20in%20studies%20of%20rare%20human%20disease&amp;journal=NPJ+Genomic+Med+2021+6:1&amp;volume=6&amp;pages=1" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B64" id="B64"></a> 64. Thorvaldsd&#xf3;ttir H, Robinson JT, Mesirov JP. Integrative genomics viewer (IGV): High-performance genomics data visualization and exploration. <i>Briefings Bioinf</i> (2013) 14(2):178&#x2013;92. doi:&#xa0;10.1093/bib/bbs017</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1093/bib/bbs017" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H+Thorvaldsd%C3%B3ttir&amp;author=JT+Robinson&amp;author=JP+Mesirov&amp;publication_year=2013&amp;title=Integrative%20genomics%20viewer%20%28IGV%29%3A%20High-performance%20genomics%20data%20visualization%20and%20exploration&amp;journal=Briefings+Bioinf&amp;volume=14&amp;pages=178-92" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B65" id="B65"></a> 65. Davydov EV, Goode DL, Sirota M, Cooper GM, Sidow A, Batzoglou S. Identifying a high fraction of the human genome to be under selective constraint using GERP++. <i>PloS Comput Biol</i> (2010) 6(12):e1001025. doi:&#xa0;10.1371/journal.pcbi.1001025</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/21152010/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1371/journal.pcbi.1001025" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=EV+Davydov&amp;author=DL+Goode&amp;author=M+Sirota&amp;author=GM+Cooper&amp;author=A+Sidow&amp;author=S+Batzoglou&amp;publication_year=2010&amp;title=Identifying%20a%20high%20fraction%20of%20the%20human%20genome%20to%20be%20under%20selective%20constraint%20using%20GERP%2B%2B&amp;journal=PloS+Comput+Biol&amp;volume=6&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B66" id="B66"></a> 66. Pollard KS, Hubisz MJ, Rosenbloom KR, Siepel A. Detection of nonneutral substitution rates on mammalian phylogenies. <i>Genome Res</i> (2010) 20:110&#x2013;21. doi:&#xa0;10.1101/GR.097857.109</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/19858363/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1101/GR.097857.109" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=KS+Pollard&amp;author=MJ+Hubisz&amp;author=KR+Rosenbloom&amp;author=A+Siepel&amp;publication_year=2010&amp;title=Detection%20of%20nonneutral%20substitution%20rates%20on%20mammalian%20phylogenies&amp;journal=Genome+Res&amp;volume=20&amp;pages=110-21" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B67" id="B67"></a> 67. Siepel A, Bejerano G, Pedersen JS, Hinrichs AS, Hou M, Rosenbloom K, et al. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. <i>Genome Res</i> (2005) 15(8):1034&#x2013;50. doi:&#xa0;10.1101/gr.3715005</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/16024819/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1101/gr.3715005" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Siepel&amp;author=G+Bejerano&amp;author=JS+Pedersen&amp;author=AS+Hinrichs&amp;author=M+Hou&amp;author=K+Rosenbloom&amp;publication_year=2005&amp;title=Evolutionarily%20conserved%20elements%20in%20vertebrate%2C%20insect%2C%20worm%2C%20and%20yeast%20genomes&amp;journal=Genome+Res&amp;volume=15&amp;pages=1034-50" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B68" id="B68"></a> 68. Shamsani J, Kazakoff SH, Armean IM, McLaren W, Parsons MT, Thompson BA, et al. A plugin for the ensembl variant effect predictor that uses MaxEntScan to predict variant spliceogenicity. <i>Bioinformatics</i> (2019) 35(13):2315&#x2013;7. doi:&#xa0;10.1093/bioinformatics/bty960</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/30475984/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/bioinformatics/bty960" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Shamsani&amp;author=SH+Kazakoff&amp;author=IM+Armean&amp;author=W+McLaren&amp;author=MT+Parsons&amp;author=BA+Thompson&amp;publication_year=2019&amp;title=A%20plugin%20for%20the%20ensembl%20variant%20effect%20predictor%20that%20uses%20MaxEntScan%20to%20predict%20variant%20spliceogenicity&amp;journal=Bioinformatics&amp;volume=35&amp;pages=2315-7" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B69" id="B69"></a> 69. Liu X, Wu C, Li C, Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice-site SNVs. <i>Hum Mutation.</i> (2016) 37(3):235&#x2013;41. doi:&#xa0;10.1002/humu.22932</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1002/humu.22932" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=X+Liu&amp;author=C+Wu&amp;author=C+Li&amp;author=E+Boerwinkle&amp;publication_year=2016&amp;title=dbNSFP%20v3.0%3A%20A%20one-stop%20database%20of%20functional%20predictions%20and%20annotations%20for%20human%20nonsynonymous%20and%20splice-site%20SNVs&amp;journal=Hum+Mutation.&amp;volume=37&amp;pages=235-41" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B70" id="B70"></a> 70. Ha C, Kim JW, Jang JH. Performance evaluation of SpliceAI for the prediction of splicing of NF1 variants. <i>Genes</i> (2021) 12:1308. doi:&#xa0;10.3390/GENES12091308</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/34573290/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3390/GENES12091308" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C+Ha&amp;author=JW+Kim&amp;author=JH+Jang&amp;publication_year=2021&amp;title=Performance%20evaluation%20of%20SpliceAI%20for%20the%20prediction%20of%20splicing%20of%20NF1%20variants&amp;journal=Genes&amp;volume=12&amp;pages=1308" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B71" id="B71"></a> 71. Ghosh R, Oak N, Plon S. Evaluation of in silico algorithms for use with ACMG/AMP clinical variant interpretation guidelines. <i>Genome Biol</i> (2017) 12(9):1308. doi:&#xa0;10.1186/s13059-017-1353-5</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1186/s13059-017-1353-5" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R+Ghosh&amp;author=N+Oak&amp;author=S+Plon&amp;publication_year=2017&amp;title=Evaluation%20of%20in%20silico%20algorithms%20for%20use%20with%20ACMG%2FAMP%20clinical%20variant%20interpretation%20guidelines&amp;journal=Genome+Biol&amp;volume=12&amp;pages=1308" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B72" id="B72"></a> 72. Niroula A, Vihinen M. How good are pathogenicity predictors in detecting benign variants? <i>PloS Comput Biol</i> (2019) 15(2):e1006481. doi:&#xa0;10.1371/JOURNAL.PCBI.1006481</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/30742610/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1371/JOURNAL.PCBI.1006481" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Niroula&amp;author=M+Vihinen&amp;publication_year=2019&amp;title=How%20good%20are%20pathogenicity%20predictors%20in%20detecting%20benign%20variants&amp;journal=PloS+Comput+Biol&amp;volume=15&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B73" id="B73"></a> 73. Cubuk C, Garrett A, Choi S, King L, Loveday C, Torr B, et al. Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes. <i>Genet medicine : Off J Am Coll Med Genet</i> (2021) 23:2096&#x2013;104. doi:&#xa0;10.1038/S41436-021-01265-Z</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1038/S41436-021-01265-Z" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C+Cubuk&amp;author=A+Garrett&amp;author=S+Choi&amp;author=L+King&amp;author=C+Loveday&amp;author=B+Torr&amp;publication_year=2021&amp;title=Clinical%20likelihood%20ratios%20and%20balanced%20accuracy%20for%2044%20in%20silico%20tools%20against%20multiple%20large-scale%20functional%20assays%20of%20cancer%20susceptibility%20genes&amp;journal=Genet+medicine+:+Off+J+Am+Coll+Med+Genet&amp;volume=23&amp;pages=2096-104" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B74" id="B74"></a> 74. Gunning AC, Fryer V, Fasham J, Crosby AH, Ellard S, Baple EL, et al. Assessing performance of pathogenicity predictors using clinically relevant variant datasets. <i>J Med Genet</i> (2021) 58:547&#x2013;55. doi:&#xa0;10.1136/JMEDGENET-2020-107003</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/32843488/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1136/JMEDGENET-2020-107003" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=AC+Gunning&amp;author=V+Fryer&amp;author=J+Fasham&amp;author=AH+Crosby&amp;author=S+Ellard&amp;author=EL+Baple&amp;publication_year=2021&amp;title=Assessing%20performance%20of%20pathogenicity%20predictors%20using%20clinically%20relevant%20variant%20datasets&amp;journal=J+Med+Genet&amp;volume=58&amp;pages=547-55" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B75" id="B75"></a> 75. Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: Predicting the deleteriousness of variants throughout the human genome. <i>Nucleic Acids Res</i> (2019) 47:D886&#x2013;94. doi:&#xa0;10.1093/nar/gky1016</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/30371827/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/nar/gky1016" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=P+Rentzsch&amp;author=D+Witten&amp;author=GM+Cooper&amp;author=J+Shendure&amp;author=M+Kircher&amp;publication_year=2019&amp;title=CADD%3A%20Predicting%20the%20deleteriousness%20of%20variants%20throughout%20the%20human%20genome&amp;journal=Nucleic+Acids+Res&amp;volume=47&amp;pages=D886-94" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B76" id="B76"></a> 76. Ionita-Laza I, Mccallum K, Xu B, Buxbaum JD. A spectral approach integrating functional genomic annotations for coding and noncoding variants. <i>Nat Genet</i> (2016) 48:214&#x2013;20. doi:&#xa0;10.1038/NG.3477</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/26727659/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/NG.3477" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=I+Ionita-Laza&amp;author=K+Mccallum&amp;author=B+Xu&amp;author=JD+Buxbaum&amp;publication_year=2016&amp;title=A%20spectral%20approach%20integrating%20functional%20genomic%20annotations%20for%20coding%20and%20noncoding%20variants&amp;journal=Nat+Genet&amp;volume=48&amp;pages=214-20" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B77" id="B77"></a> 77. Dong C, Wei P, Jian X, Gibbs R, Boerwinkle E, Wang K, et al. Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. <i>Hum Mol Genet</i> (2015) 24(8):2125&#x2013;37. doi:&#xa0;10.1093/hmg/ddu733</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25552646/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/hmg/ddu733" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C+Dong&amp;author=P+Wei&amp;author=X+Jian&amp;author=R+Gibbs&amp;author=E+Boerwinkle&amp;author=K+Wang&amp;publication_year=2015&amp;title=Comparison%20and%20integration%20of%20deleteriousness%20prediction%20methods%20for%20nonsynonymous%20SNVs%20in%20whole%20exome%20sequencing%20studies&amp;journal=Hum+Mol+Genet&amp;volume=24&amp;pages=2125-37" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B78" id="B78"></a> 78. Li C, Zhi D, Wang K, Liu X. MetaRNN: Differentiating rare pathogenic and rare benign missense SNVs and InDels using deep learning. <i>bioRxiv</i> (2021) 2021:4.09.438706. doi:&#xa0;10.1101/2021.04.09.438706</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1101/2021.04.09.438706" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C+Li&amp;author=D+Zhi&amp;author=K+Wang&amp;author=X+Liu&amp;publication_year=2021&amp;title=MetaRNN%3A%20Differentiating%20rare%20pathogenic%20and%20rare%20benign%20missense%20SNVs%20and%20InDels%20using%20deep%20learning&amp;journal=bioRxiv&amp;volume=2021&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B79" id="B79"></a> 79. Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, et al. REVEL: An ensemble method for predicting the pathogenicity of rare missense variants. <i>Am J Hum Genet</i> (2016) 99(4):877&#x2013;85. doi:&#xa0;10.1016/j.ajhg.2016.08.016</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/27666373/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.ajhg.2016.08.016" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=NM+Ioannidis&amp;author=JH+Rothstein&amp;author=V+Pejaver&amp;author=S+Middha&amp;author=SK+McDonnell&amp;author=S+Baheti&amp;publication_year=2016&amp;title=REVEL%3A%20An%20ensemble%20method%20for%20predicting%20the%20pathogenicity%20of%20rare%20missense%20variants&amp;journal=Am+J+Hum+Genet&amp;volume=99&amp;pages=877-85" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B80" id="B80"></a> 80. Douville C, Masica DL, Stenson PD, Cooper DN, Gygax DM, Kim R, et al. Assessing the pathogenicity of insertion and deletion variants with the variant effect scoring tool (VEST-indel). <i>Hum Mutat</i> (2016) 37:28&#x2013;35. doi:&#xa0;10.1002/HUMU.22911</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/26442818/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/HUMU.22911" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C+Douville&amp;author=DL+Masica&amp;author=PD+Stenson&amp;author=DN+Cooper&amp;author=DM+Gygax&amp;author=R+Kim&amp;publication_year=2016&amp;title=Assessing%20the%20pathogenicity%20of%20insertion%20and%20deletion%20variants%20with%20the%20variant%20effect%20scoring%20tool%20%28VEST-indel%29&amp;journal=Hum+Mutat&amp;volume=37&amp;pages=28" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B81" id="B81"></a> 81. Choi Y, Chan AP. PROVEAN web server: A tool to predict the functional effect of amino acid substitutions and indels. <i>Bioinformatics</i> (2015) 31(16):2745&#x2013;7. doi:&#xa0;10.1093/bioinformatics/btv195</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25851949/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/bioinformatics/btv195" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=Y+Choi&amp;author=AP+Chan&amp;publication_year=2015&amp;title=PROVEAN%20web%20server%3A%20A%20tool%20to%20predict%20the%20functional%20effect%20of%20amino%20acid%20substitutions%20and%20indels&amp;journal=Bioinformatics&amp;volume=31&amp;pages=2745-7" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B82" id="B82"></a> 82. Landrum MJ, Lee JM, Benson M, Brown G, Chao C, Chitipiralla S, et al. ClinVar: Public archive of interpretations of clinically relevant variants. <i>Nucleic Acids Res</i> (2016) 44(D1):D862&#x2013;8. doi:&#xa0;10.1093/nar/gkv1222</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/26582918/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/nar/gkv1222" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MJ+Landrum&amp;author=JM+Lee&amp;author=M+Benson&amp;author=G+Brown&amp;author=C+Chao&amp;author=S+Chitipiralla&amp;publication_year=2016&amp;title=ClinVar%3A%20Public%20archive%20of%20interpretations%20of%20clinically%20relevant%20variants&amp;journal=Nucleic+Acids+Res&amp;volume=44&amp;pages=D862-8" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B83" id="B83"></a> 83. Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: Improving access to variant interpretations and supporting evidence. <i>Nucleic Acids Res</i> (2018) 46:1062&#x2013;7. doi:&#xa0;10.1093/nar/gkx1153</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1093/nar/gkx1153" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MJ+Landrum&amp;author=JM+Lee&amp;author=M+Benson&amp;author=GR+Brown&amp;author=C+Chao&amp;author=S+Chitipiralla&amp;publication_year=2018&amp;title=ClinVar%3A%20Improving%20access%20to%20variant%20interpretations%20and%20supporting%20evidence&amp;journal=Nucleic+Acids+Res&amp;volume=46&amp;pages=1062-7" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B84" id="B84"></a> 84. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. <i>Genet Med</i> (2015) 17(5):405&#x2013;24. doi:&#xa0;10.1038/gim.2015.30</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25741868/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/gim.2015.30" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Richards&amp;author=N+Aziz&amp;author=S+Bale&amp;author=D+Bick&amp;author=S+Das&amp;author=J+Gastier-Foster&amp;publication_year=2015&amp;title=Standards%20and%20guidelines%20for%20the%20interpretation%20of%20sequence%20variants%3A%20A%20joint%20consensus%20recommendation%20of%20the%20American%20college%20of%20medical%20genetics%20and%20genomics%20and%20the%20association%20for%20molecular%20pathology&amp;journal=Genet+Med&amp;volume=17&amp;pages=405-24" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B85" id="B85"></a> 85. Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, et al. Sherloc: A comprehensive refinement of the ACMG-AMP variant classification criteria. <i>Genet Med</i> (2017) 19(10):1105&#x2013;17. doi:&#xa0;10.1038/gim.2017.37</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/28492532/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/gim.2017.37" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=K+Nykamp&amp;author=M+Anderson&amp;author=M+Powers&amp;author=J+Garcia&amp;author=B+Herrera&amp;author=YY+Ho&amp;publication_year=2017&amp;title=Sherloc%3A%20A%20comprehensive%20refinement%20of%20the%20ACMG-AMP%20variant%20classification%20criteria&amp;journal=Genet+Med&amp;volume=19&amp;pages=1105-17" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B86" id="B86"></a> 86. Alenezi WM, Fierheller CT, Recio N, Tonin PN. Literature review of BARD1 as a cancer predisposing gene with a focus on breast and ovarian cancers. <i>Genes</i> (2020) 11:1&#x2013;24. doi:&#xa0;10.3390/GENES11080856</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.3390/GENES11080856" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=WM+Alenezi&amp;author=CT+Fierheller&amp;author=N+Recio&amp;author=PN+Tonin&amp;publication_year=2020&amp;title=Literature%20review%20of%20BARD1%20as%20a%20cancer%20predisposing%20gene%20with%20a%20focus%20on%20breast%20and%20ovarian%20cancers&amp;journal=Genes&amp;volume=11&amp;pages=1" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B87" id="B87"></a> 87. Fedick A, Su J, Jalas C, Northrop L, Devkota B, Ekstein J, et al. High-throughput carrier screening using TaqMan allelic discrimination. <i>PloS One</i> (2013) 8(3):e59722. doi:&#xa0;10.1371/journal.pone.0059722</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/23555759/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1371/journal.pone.0059722" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Fedick&amp;author=J+Su&amp;author=C+Jalas&amp;author=L+Northrop&amp;author=B+Devkota&amp;author=J+Ekstein&amp;publication_year=2013&amp;title=High-throughput%20carrier%20screening%20using%20TaqMan%20allelic%20discrimination&amp;journal=PloS+One&amp;volume=8&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B88" id="B88"></a> 88. Gabriel S, Ziaugra L, Tabbaa D. SNP genotyping using the sequenom massARRAY iPLEX platform. <i>Curr Protoc Hum Genet</i> (2009) Chapter 2:Unit 2.12. doi:&#xa0;10.1002/0471142905.hg0212s60</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/19170031/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/0471142905.hg0212s60" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Gabriel&amp;author=L+Ziaugra&amp;author=D+Tabbaa&amp;publication_year=2009&amp;title=SNP%20genotyping%20using%20the%20sequenom%20massARRAY%20iPLEX%20platform&amp;journal=Curr+Protoc+Hum+Genet&amp;volume=Chapter 2&amp;pages=Unit 2.12" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B89" id="B89"></a> 89. De Wever J, Everaert H, Coppieters F, Rottiers H, Dewettinck K, Lefever S, et al. The development of a novel SNP genotyping assay to differentiate cacao clones. <i>Sci Rep</i> (2019) 9(1):9512. doi:&#xa0;10.1038/S41598-019-45884-8</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/31267023/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/S41598-019-45884-8" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+De%20Wever&amp;author=H+Everaert&amp;author=F+Coppieters&amp;author=H+Rottiers&amp;author=K+Dewettinck&amp;author=S+Lefever&amp;publication_year=2019&amp;title=The%20development%20of%20a%20novel%20SNP%20genotyping%20assay%20to%20differentiate%20cacao%20clones&amp;journal=Sci+Rep&amp;volume=9&amp;pages=9512" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B90" id="B90"></a> 90. Behl S, Hamel N, de Ladurantaye M, Lepage S, Lapointe R, Mes-Masson A-M, et al. Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls. <i>Sci Rep</i> (2020) 10(1):6491. doi:&#xa0;10.1038/s41598-020-63100-w</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/32300229/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41598-020-63100-w" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Behl&amp;author=N+Hamel&amp;author=M+de%20Ladurantaye&amp;author=S+Lepage&amp;author=R+Lapointe&amp;author=A-M+Mes-Masson&amp;publication_year=2020&amp;title=Founder%20BRCA1%2FBRCA2%2FPALB2%20pathogenic%20variants%20in%20French-Canadian%20breast%20cancer%20cases%20and%20controls&amp;journal=Sci+Rep&amp;volume=10&amp;pages=6491" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B91" id="B91"></a> 91. Sousa SB, Abdul-Rahman OA, Bottani A, Cormier-Daire V, Fryer A, Gillessen-Kaesbach G, et al. Nicolaides&#x2013;baraitser syndrome: Delineation of the phenotype. <i>Am J Med Genet</i> (2009) Part A 149A:1628&#x2013;40. doi:&#xa0;10.1002/AJMG.A.32956</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1002/AJMG.A.32956" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SB+Sousa&amp;author=OA+Abdul-Rahman&amp;author=A+Bottani&amp;author=V+Cormier-Daire&amp;author=A+Fryer&amp;author=G+Gillessen-Kaesbach&amp;publication_year=2009&amp;title=Nicolaides%E2%80%93baraitser%20syndrome%3A%20Delineation%20of%20the%20phenotype&amp;journal=Am+J+Med+Genet&amp;volume=Part A 149A&amp;pages=1628-40" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B92" id="B92"></a> 92. Sousa SB, Hennekam RC, Abdul-Rahman O, Alders M, Azzarello-Burri S, Bottani A, et al. Phenotype and genotype in nicolaides-baraitser syndrome. <i>Am J Med Genetics Part C: Semin Med Genet</i> (2014) 166:302&#x2013;14. doi:&#xa0;10.1002/ajmg.c.31409</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1002/ajmg.c.31409" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SB+Sousa&amp;author=RC+Hennekam&amp;author=O+Abdul-Rahman&amp;author=M+Alders&amp;author=S+Azzarello-Burri&amp;author=A+Bottani&amp;publication_year=2014&amp;title=Phenotype%20and%20genotype%20in%20nicolaides-baraitser%20syndrome&amp;journal=Am+J+Med+Genetics+Part+C:+Semin+Med+Genet&amp;volume=166&amp;pages=302-14" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B93" id="B93"></a> 93. Gana S, Panizzon M, Fongaro D, Selicorni A, Memo L, Scandurra V, et al. Nicolaides-baraitser syndrome: Two new cases with autism spectrum disorder. <i>Clin dysmorphology</i> (2011) 20:38&#x2013;41. doi:&#xa0;10.1097/MCD.0B013E32833EDAA9</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1097/MCD.0B013E32833EDAA9" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Gana&amp;author=M+Panizzon&amp;author=D+Fongaro&amp;author=A+Selicorni&amp;author=L+Memo&amp;author=V+Scandurra&amp;publication_year=2011&amp;title=Nicolaides-baraitser%20syndrome%3A%20Two%20new%20cases%20with%20autism%20spectrum%20disorder&amp;journal=Clin+dysmorphology&amp;volume=20&amp;pages=38" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B94" id="B94"></a> 94. Ejaz R, Babul-Hirji R, Chitayat D. The evolving features of nicolaides&#x2013;baraitser syndrome &#x2013; a clinical report of a 20-year follow-up. <i>Clin Case Rep</i> (2016) 4:351. doi:&#xa0;10.1002/CCR3.425</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/27099726/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/CCR3.425" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R+Ejaz&amp;author=R+Babul-Hirji&amp;author=D+Chitayat&amp;publication_year=2016&amp;title=The%20evolving%20features%20of%20nicolaides%E2%80%93baraitser%20syndrome%20%E2%80%93%20a%20clinical%20report%20of%20a%2020-year%20follow-up&amp;journal=Clin+Case+Rep&amp;volume=4&amp;pages=351" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B95" id="B95"></a> 95. Cappuccio G, Sayou C, Tanno P, Tisserant E, Bruel AL, Kennani S, et al. <i>De novo</i> SMARCA2 variants clustered outside the helicase domain cause a new recognizable syndrome with intellectual disability and blepharophimosis distinct from nicolaides&#x2013;baraitser syndrome. <i>Genet Med</i> (2020) 22:1838&#x2013;50. doi:&#xa0;10.1038/s41436-020-0898-y</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/32694869/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41436-020-0898-y" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=G+Cappuccio&amp;author=C+Sayou&amp;author=P+Tanno&amp;author=E+Tisserant&amp;author=AL+Bruel&amp;author=S+Kennani&amp;publication_year=2020&amp;title=De%20novo%20SMARCA2%20variants%20clustered%20outside%20the%20helicase%20domain%20cause%20a%20new%20recognizable%20syndrome%20with%20intellectual%20disability%20and%20blepharophimosis%20distinct%20from%20nicolaides%E2%80%93baraitser%20syndrome&amp;journal=Genet+Med&amp;volume=22&amp;pages=1838-50" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B96" id="B96"></a> 96. Cenik BK, Shilatifard A. COMPASS and SWI/SNF complexes in development and disease. <i>Nat Rev Genet 2020 22:1</i> (2020) 22:38&#x2013;58. doi:&#xa0;10.1038/s41576-020-0278-0</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1038/s41576-020-0278-0" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=BK+Cenik&amp;author=A+Shilatifard&amp;publication_year=2020&amp;title=COMPASS%20and%20SWI%2FSNF%20complexes%20in%20development%20and%20disease&amp;journal=Nat+Rev+Genet+2020+22:1&amp;volume=22&amp;pages=38" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B97" id="B97"></a> 97. Zhang X, Chen H, Song Y, Chen Z, Liu X, Rong P, et al. Ten-year follow-up of nicolaides-baraitser syndrome with a <i>de novo</i> mutation and analysis of 58 gene loci of SMARCA2-associated NCBRS. <i>Mol Genet genomic Med</i> (2022) 10(9):e2009. doi:&#xa0;10.1002/MGG3.2009</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/35811451/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/MGG3.2009" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=X+Zhang&amp;author=H+Chen&amp;author=Y+Song&amp;author=Z+Chen&amp;author=X+Liu&amp;author=P+Rong&amp;publication_year=2022&amp;title=Ten-year%20follow-up%20of%20nicolaides-baraitser%20syndrome%20with%20a%20de%20novo%20mutation%20and%20analysis%20of%2058%20gene%20loci%20of%20SMARCA2-associated%20NCBRS&amp;journal=Mol+Genet+genomic+Med&amp;volume=10&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B98" id="B98"></a> 98. Koemans TS, Kleefstra T, Chubak MC, Stone MH, Reijnders MRF, de Munnik S, et al. Functional convergence of histone methyltransferases EHMT1 and KMT2C involved in intellectual disability and autism spectrum disorder. <i>PloS Genet</i> (2017) 13(10):e1006864. doi:&#xa0;10.1371/JOURNAL.PGEN.1006864</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/29069077/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1371/JOURNAL.PGEN.1006864" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=TS+Koemans&amp;author=T+Kleefstra&amp;author=MC+Chubak&amp;author=MH+Stone&amp;author=MRF+Reijnders&amp;author=S+de%20Munnik&amp;publication_year=2017&amp;title=Functional%20convergence%20of%20histone%20methyltransferases%20EHMT1%20and%20KMT2C%20involved%20in%20intellectual%20disability%20and%20autism%20spectrum%20disorder&amp;journal=PloS+Genet&amp;volume=13&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B99" id="B99"></a> 99. McRae JF, Clayton S, Fitzgerald TW, Kaplanis J, Prigmore E, Rajan D, et al. Prevalence and architecture of <i>de novo</i> mutations in developmental disorders. <i>Nat 2017 542:7642</i> (2017) 542:433&#x2013;8. doi:&#xa0;10.1038/nature21062</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1038/nature21062" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=JF+McRae&amp;author=S+Clayton&amp;author=TW+Fitzgerald&amp;author=J+Kaplanis&amp;author=E+Prigmore&amp;author=D+Rajan&amp;publication_year=2017&amp;title=Prevalence%20and%20architecture%20of%20de%20novo%20mutations%20in%20developmental%20disorders&amp;journal=Nat+2017+542:7642&amp;volume=542&amp;pages=433-8" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B100" id="B100"></a> 100. Faundes V, Newman WG, Bernardini L, Canham N, Clayton-Smith J, Dallapiccola B, et al. Histone lysine methylases and demethylases in the landscape of human developmental disorders. <i>Am J Hum Genet</i> (2018) 102:175&#x2013;87. doi:&#xa0;10.1016/J.AJHG.2017.11.013</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/29276005/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/J.AJHG.2017.11.013" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=V+Faundes&amp;author=WG+Newman&amp;author=L+Bernardini&amp;author=N+Canham&amp;author=J+Clayton-Smith&amp;author=B+Dallapiccola&amp;publication_year=2018&amp;title=Histone%20lysine%20methylases%20and%20demethylases%20in%20the%20landscape%20of%20human%20developmental%20disorders&amp;journal=Am+J+Hum+Genet&amp;volume=102&amp;pages=175-87" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B101" id="B101"></a> 101. Lavery WJ, Barski A, Wiley S, Schorry EK, Lindsley AW. KMT2C/D COMPASS complex-associated diseases [KCDCOM-ADs]: An emerging class of congenital regulopathies. <i>Clin Epigenet 2020 12:1</i> (2020) 12:1&#x2013;20. doi:&#xa0;10.1186/S13148-019-0802-2</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1186/S13148-019-0802-2" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=WJ+Lavery&amp;author=A+Barski&amp;author=S+Wiley&amp;author=EK+Schorry&amp;author=AW+Lindsley&amp;publication_year=2020&amp;title=KMT2C%2FD%20COMPASS%20complex-associated%20diseases%20%5BKCDCOM-ADs%5D%3A%20An%20emerging%20class%20of%20congenital%20regulopathies&amp;journal=Clin+Epigenet+2020+12:1&amp;volume=12&amp;pages=1" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B102" id="B102"></a> 102. Thompson ER, Doyle MA, Ryland GL, Rowley SM, Choong DYH, Tothill RW, et al. Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles. <i>PloS Genet</i> (2012) 8(9):e1002894. doi:&#xa0;10.1371/journal.pgen.1002894</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/23028338/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1371/journal.pgen.1002894" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=ER+Thompson&amp;author=MA+Doyle&amp;author=GL+Ryland&amp;author=SM+Rowley&amp;author=DYH+Choong&amp;author=RW+Tothill&amp;publication_year=2012&amp;title=Exome%20sequencing%20identifies%20rare%20deleterious%20mutations%20in%20DNA%20repair%20genes%20FANCC%20and%20BLM%20as%20potential%20breast%20cancer%20susceptibility%20alleles&amp;journal=PloS+Genet&amp;volume=8&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B103" id="B103"></a> 103. Morales J, Pujar S, Loveland JE, Astashyn A, Bennett R, Berry A, et al. A joint NCBI and EMBL-EBI transcript set for clinical genomics and research. <i>Nat 2022</i> (2022) 604(7905):310&#x2013;315. doi:&#xa0;10.1038/s41586-022-04558-8</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1038/s41586-022-04558-8" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Morales&amp;author=S+Pujar&amp;author=JE+Loveland&amp;author=A+Astashyn&amp;author=R+Bennett&amp;author=A+Berry&amp;publication_year=2022&amp;title=A%20joint%20NCBI%20and%20EMBL-EBI%20transcript%20set%20for%20clinical%20genomics%20and%20research&amp;journal=Nat+2022&amp;volume=604&amp;pages=310-315" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B104" id="B104"></a> 104. Richards CS, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Response to biesecker and Harrison. <i>Genet Med</i> (2018) 20:1689&#x2013;90. doi:&#xa0;10.1038/gim.2018.43</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/29543230/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/gim.2018.43" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=CS+Richards&amp;author=N+Aziz&amp;author=S+Bale&amp;author=D+Bick&amp;author=S+Das&amp;author=J+Gastier-Foster&amp;publication_year=2018&amp;title=Response%20to%20biesecker%20and%20Harrison&amp;journal=Genet+Med&amp;volume=20&amp;pages=1689-90" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B105" id="B105"></a> 105. Abou Tayoun AN, Pesaran T, DiStefano MT, Oza A, Rehm HL, Biesecker LG, et al. Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion. <i>Hum Mutat</i> (2018) 39:1517&#x2013;24. doi:&#xa0;10.1002/humu.23626</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/30192042/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.23626" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=AN+Abou%20Tayoun&amp;author=T+Pesaran&amp;author=MT+DiStefano&amp;author=A+Oza&amp;author=HL+Rehm&amp;author=LG+Biesecker&amp;publication_year=2018&amp;title=Recommendations%20for%20interpreting%20the%20loss%20of%20function%20PVS1%20ACMG%2FAMP%20variant%20criterion&amp;journal=Hum+Mutat&amp;volume=39&amp;pages=1517-24" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B106" id="B106"></a> 106. Jian X, Boerwinkle E, Liu X. In silico prediction of splice-altering single nucleotide variants in the human genome. <i>Nucleic Acids Res</i> (2014) 42(22):13534&#x2013;44. doi:&#xa0;10.1093/nar/gku1206</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25416802/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/nar/gku1206" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=X+Jian&amp;author=E+Boerwinkle&amp;author=X+Liu&amp;publication_year=2014&amp;title=In%20silico%20prediction%20of%20splice-altering%20single%20nucleotide%20variants%20in%20the%20human%20genome&amp;journal=Nucleic+Acids+Res&amp;volume=42&amp;pages=13534-44" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B107" id="B107"></a> 107. Pirim D, Kaya N, Y&#x131;ld&#x131;r&#x131;m EU, Sag &#x15e;O, Temel SG. Characterization and in silico analyses of the BRCA1/2 variants identified in individuals with personal and/or family history of BRCA-related cancers. <i>Int J Biol Macromolecules</i> (2020) 162:1166&#x2013;77. doi:&#xa0;10.1016/J.IJBIOMAC.2020.06.222</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1016/J.IJBIOMAC.2020.06.222" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=D+Pirim&amp;author=N+Kaya&amp;author=EU+Y%C4%B1ld%C4%B1r%C4%B1m&amp;author=%C5%9EO+Sag&amp;author=SG+Temel&amp;publication_year=2020&amp;title=Characterization%20and%20in%20silico%20analyses%20of%20the%20BRCA1%2F2%20variants%20identified%20in%20individuals%20with%20personal%20and%2For%20family%20history%20of%20BRCA-related%20cancers&amp;journal=Int+J+Biol+Macromolecules&amp;volume=162&amp;pages=1166-77" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B108" id="B108"></a> 108. Trego KS, Groesser T, Davalos AR, Parplys AC, Zhao W, Nelson MR, et al. Non-catalytic roles for XPG with BRCA1 and BRCA2 in homologous recombination and genome stability. <i>Mol Cell</i> (2016) 61:535. doi:&#xa0;10.1016/J.MOLCEL.2015.12.026</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/26833090/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/J.MOLCEL.2015.12.026" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=KS+Trego&amp;author=T+Groesser&amp;author=AR+Davalos&amp;author=AC+Parplys&amp;author=W+Zhao&amp;author=MR+Nelson&amp;publication_year=2016&amp;title=Non-catalytic%20roles%20for%20XPG%20with%20BRCA1%20and%20BRCA2%20in%20homologous%20recombination%20and%20genome%20stability&amp;journal=Mol+Cell&amp;volume=61&amp;pages=535" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B109" id="B109"></a> 109. Galick HA, Marsden CG, Kathe S, Dragon JA, Volk L, Nemec AA, et al. The NEIL1 G83D germline DNA glycosylase variant induces genomic instability and cellular transformation. <i>Oncotarget</i> (2017) 8:85883&#x2013;95. doi:&#xa0;10.18632/ONCOTARGET.20716</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/29156764/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.18632/ONCOTARGET.20716" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=HA+Galick&amp;author=CG+Marsden&amp;author=S+Kathe&amp;author=JA+Dragon&amp;author=L+Volk&amp;author=AA+Nemec&amp;publication_year=2017&amp;title=The%20NEIL1%20G83D%20germline%20DNA%20glycosylase%20variant%20induces%20genomic%20instability%20and%20cellular%20transformation&amp;journal=Oncotarget&amp;volume=8&amp;pages=85883-95" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B110" id="B110"></a> 110. Li N, Lim BWX, Thompson ER, McInerny S, Zethoven M, Cheasley D, et al. Investigation of monogenic causes of familial breast cancer: Data from the BEACCON case-control study. <i>NPJ Breast Cancer</i> (2021) 7(1):76. doi:&#xa0;10.1038/S41523-021-00279-9</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/34117267/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/S41523-021-00279-9" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=N+Li&amp;author=BWX+Lim&amp;author=ER+Thompson&amp;author=S+McInerny&amp;author=M+Zethoven&amp;author=D+Cheasley&amp;publication_year=2021&amp;title=Investigation%20of%20monogenic%20causes%20of%20familial%20breast%20cancer%3A%20Data%20from%20the%20BEACCON%20case-control%20study&amp;journal=NPJ+Breast+Cancer&amp;volume=7&amp;pages=76" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B111" id="B111"></a> 111. Li N, Zethoven M, McInerny S, Devereux L, Huang YK, Thio N, et al. Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: An international multi-center study of 47,180 subjects. <i>NPJ Breast Cancer</i> (2021) 7(1):52. doi:&#xa0;10.1038/S41523-021-00255-3</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/33980861/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/S41523-021-00255-3" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=N+Li&amp;author=M+Zethoven&amp;author=S+McInerny&amp;author=L+Devereux&amp;author=YK+Huang&amp;author=N+Thio&amp;publication_year=2021&amp;title=Evaluation%20of%20the%20association%20of%20heterozygous%20germline%20variants%20in%20NTHL1%20with%20breast%20cancer%20predisposition%3A%20An%20international%20multi-center%20study%20of%2047%2C180%20subjects&amp;journal=NPJ+Breast+Cancer&amp;volume=7&amp;pages=52" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B112" id="B112"></a> 112. Brenner D, Poirier A, Smith L, Aziz LS, Ellison L, Fitzgerald N, et al. Members of the Canadian cancer statistics advisory committee analytic leads additional analysis project management. (2021).</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="http://scholar.google.com/scholar_lookup?author=D+Brenner&amp;author=A+Poirier&amp;author=L+Smith&amp;author=LS+Aziz&amp;author=L+Ellison&amp;author=N+Fitzgerald&amp;publication_year=2021&amp;title=Members%20of%20the%20Canadian%20cancer%20statistics%20advisory%20committee%20analytic%20leads%20additional%20analysis%20project%20management&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B113" id="B113"></a> 113. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <i>CA: A Cancer J Clin</i> (2021) 71:209&#x2013;49. doi:&#xa0;10.3322/CAAC.21660</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.3322/CAAC.21660" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H+Sung&amp;author=J+Ferlay&amp;author=RL+Siegel&amp;author=M+Laversanne&amp;author=I+Soerjomataram&amp;author=A+Jemal&amp;publication_year=2021&amp;title=Global%20cancer%20statistics%202020%3A%20GLOBOCAN%20estimates%20of%20incidence%20and%20mortality%20worldwide%20for%2036%20cancers%20in%20185%20countries&amp;journal=CA:+A+Cancer+J+Clin&amp;volume=71&amp;pages=209-49" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B114" id="B114"></a> 114. Foulkes WD. Inherited susceptibility to common cancers. <i>New Engl J Med</i> (2008) 359:2143&#x2013;53. doi:&#xa0;10.1056/nejmra0802968</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/19005198/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1056/nejmra0802968" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=WD+Foulkes&amp;publication_year=2008&amp;title=Inherited%20susceptibility%20to%20common%20cancers&amp;journal=New+Engl+J+Med&amp;volume=359&amp;pages=2143-53" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B115" id="B115"></a> 115. Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, Darbandi SF, Knowles D, Li YI, et al. Predicting splicing from primary sequence with deep learning. <i>Cell</i> (2019) 176:535&#x2013;548.e24. doi:&#xa0;10.1016/J.CELL.2018.12.015</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/30661751/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/J.CELL.2018.12.015" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=K+Jaganathan&amp;author=S+Kyriazopoulou%20Panagiotopoulou&amp;author=JF+McRae&amp;author=SF+Darbandi&amp;author=D+Knowles&amp;author=YI+Li&amp;publication_year=2019&amp;title=Predicting%20splicing%20from%20primary%20sequence%20with%20deep%20learning&amp;journal=Cell&amp;volume=176&amp;pages=535" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B116" id="B116"></a> 116. Metcalfe KA, Poll A, Royer R, Llacuachaqui M, Tulman A, Sun P, et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. <i>J Clin Oncol</i> (2010) 28:387&#x2013;91. doi:&#xa0;10.1200/JCO.2009.25.0712</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/20008623/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1200/JCO.2009.25.0712" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=KA+Metcalfe&amp;author=A+Poll&amp;author=R+Royer&amp;author=M+Llacuachaqui&amp;author=A+Tulman&amp;author=P+Sun&amp;publication_year=2010&amp;title=Screening%20for%20founder%20mutations%20in%20BRCA1%20and%20BRCA2%20in%20unselected%20Jewish%20women&amp;journal=J+Clin+Oncol&amp;volume=28&amp;pages=387-91" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B117" id="B117"></a> 117. Klungland A, H&#xf6;ss M, Gunz D, Constantinou A, Clarkson SG, Doetsch PW, et al. Base excision repair of oxidative DNA damage activated by XPG protein. <i>Mol Cell</i> (1999) 3:33&#x2013;42. doi:&#xa0;10.1016/S1097-2765(00)80172-0</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/10024877/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/S1097-2765(00)80172-0" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Klungland&amp;author=M+H%C3%B6ss&amp;author=D+Gunz&amp;author=A+Constantinou&amp;author=SG+Clarkson&amp;author=PW+Doetsch&amp;publication_year=1999&amp;title=Base%20excision%20repair%20of%20oxidative%20DNA%20damage%20activated%20by%20XPG%20protein&amp;journal=Mol+Cell&amp;volume=3&amp;pages=33" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B118" id="B118"></a> 118. Sertic S, Quadri R, Lazzaro F, Muzi-Falconi M. EXO1: A tightly regulated nuclease. <i>DNA Repair</i> (2020) 93:102929. doi:&#xa0;10.1016/J.DNAREP.2020.102929</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/33087266/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/J.DNAREP.2020.102929" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Sertic&amp;author=R+Quadri&amp;author=F+Lazzaro&amp;author=M+Muzi-Falconi&amp;publication_year=2020&amp;title=EXO1%3A%20A%20tightly%20regulated%20nuclease&amp;journal=DNA+Repair&amp;volume=93&amp;pages=102929" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B119" id="B119"></a> 119. Vali-Pour M, Lehner B, Supek F. The impact of rare germline variants on human somatic mutation processes. <i>Nat Commun</i> (2022) 13:1&#x2013;21. doi:&#xa0;10.1038/s41467-022-31483-1</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/34983933/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41467-022-31483-1" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Vali-Pour&amp;author=B+Lehner&amp;author=F+Supek&amp;publication_year=2022&amp;title=The%20impact%20of%20rare%20germline%20variants%20on%20human%20somatic%20mutation%20processes&amp;journal=Nat+Commun&amp;volume=13&amp;pages=1" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B120" id="B120"></a> 120. Nalepa G, Clapp DW. Fanconi anaemia and cancer: An intricate relationship. <i>Nat Rev Cancer</i> (2018) 18:168&#x2013;85. doi:&#xa0;10.1038/NRC.2017.116</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/29376519/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/NRC.2017.116" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=G+Nalepa&amp;author=DW+Clapp&amp;publication_year=2018&amp;title=Fanconi%20anaemia%20and%20cancer%3A%20An%20intricate%20relationship&amp;journal=Nat+Rev+Cancer&amp;volume=18&amp;pages=168-85" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B121" id="B121"></a> 121. David SS, O&#x2019;Shea VL, Kundu S. Base-excision repair of oxidative DNA damage. <i>Nat 2007 447:7147</i> (2007) 447:941&#x2013;50. doi:&#xa0;10.1038/nature05978</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1038/nature05978" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SS+David&amp;author=VL+O%E2%80%99Shea&amp;author=S+Kundu&amp;publication_year=2007&amp;title=Base-excision%20repair%20of%20oxidative%20DNA%20damage&amp;journal=Nat+2007+447:7147&amp;volume=447&amp;pages=941-50" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B122" id="B122"></a> 122. Weren RDA, Ligtenberg MJL, Kets CM, De Voer RM, Verwiel ETP, Spruijt L, et al. A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. <i>Nat Genet</i> (2015) 47(6):668&#x2013;71. doi:&#xa0;10.1038/ng.3287</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25938944/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/ng.3287" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=RDA+Weren&amp;author=MJL+Ligtenberg&amp;author=CM+Kets&amp;author=RM+De%20Voer&amp;author=ETP+Verwiel&amp;author=L+Spruijt&amp;publication_year=2015&amp;title=A%20germline%20homozygous%20mutation%20in%20the%20base-excision%20repair%20gene%20NTHL1%20causes%20adenomatous%20polyposis%20and%20colorectal%20cancer&amp;journal=Nat+Genet&amp;volume=47&amp;pages=668-71" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B123" id="B123"></a> 123. Grolleman JE, de Voer RM, Elsayed FA, Nielsen M, Weren RDA, Palles C, et al. Mutational signature analysis reveals NTHL1 deficiency to cause a multi-tumor phenotype. <i>Cancer Cell</i> (2019) 35(2):256&#x2013;266.e5. doi:&#xa0;10.1016/j.ccell.2018.12.011</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/30753826/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.ccell.2018.12.011" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=JE+Grolleman&amp;author=RM+de%20Voer&amp;author=FA+Elsayed&amp;author=M+Nielsen&amp;author=RDA+Weren&amp;author=C+Palles&amp;publication_year=2019&amp;title=Mutational%20signature%20analysis%20reveals%20NTHL1%20deficiency%20to%20cause%20a%20multi-tumor%20phenotype&amp;journal=Cancer+Cell&amp;volume=35&amp;pages=256-266.e5" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B124" id="B124"></a> 124. Loong L, Garrett A, Allen S, Choi S, Durkie M, Callaway A, et al. Reclassification of clinically-detected sequence variants: Framework for genetic clinicians and clinical scientists by CanVIG-UK (Cancer variant interpretation group UK). <i>Genet medicine : Off J Am Coll Med Genet</i> (2022) 24(9):1867&#x2013;77. doi:&#xa0;10.1016/J.GIM.2022.05.002</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1016/J.GIM.2022.05.002" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L+Loong&amp;author=A+Garrett&amp;author=S+Allen&amp;author=S+Choi&amp;author=M+Durkie&amp;author=A+Callaway&amp;publication_year=2022&amp;title=Reclassification%20of%20clinically-detected%20sequence%20variants%3A%20Framework%20for%20genetic%20clinicians%20and%20clinical%20scientists%20by%20CanVIG-UK%20%28Cancer%20variant%20interpretation%20group%20UK%29&amp;journal=Genet+medicine+:+Off+J+Am+Coll+Med+Genet&amp;volume=24&amp;pages=1867-77" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B125" id="B125"></a> 125. Tung N, Domchek SM, Stadler Z, Nathanson KL, Couch F, Garber JE, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. <i>Nat Rev Clin Oncol</i> (2016) 13:581&#x2013;8. doi:&#xa0;10.1038/NRCLINONC.2016.90</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/27296296/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/NRCLINONC.2016.90" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=N+Tung&amp;author=SM+Domchek&amp;author=Z+Stadler&amp;author=KL+Nathanson&amp;author=F+Couch&amp;author=JE+Garber&amp;publication_year=2016&amp;title=Counselling%20framework%20for%20moderate-penetrance%20cancer-susceptibility%20mutations&amp;journal=Nat+Rev+Clin+Oncol&amp;volume=13&amp;pages=581-8" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B126" id="B126"></a> 126. Liu YL, Breen K, Catchings A, Ranganathan M, Latham A, Goldfrank DJ, et al. Risk-reducing bilateral salpingo-oophorectomy for ovarian cancer: A review and clinical guide for hereditary predisposition genes. <i>JCO Oncol Pract</i> (2021) 18(3):201&#x2013;9. doi:&#xa0;10.1200/OP.21.00382</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/34582274/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1200/OP.21.00382" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=YL+Liu&amp;author=K+Breen&amp;author=A+Catchings&amp;author=M+Ranganathan&amp;author=A+Latham&amp;author=DJ+Goldfrank&amp;publication_year=2021&amp;title=Risk-reducing%20bilateral%20salpingo-oophorectomy%20for%20ovarian%20cancer%3A%20A%20review%20and%20clinical%20guide%20for%20hereditary%20predisposition%20genes&amp;journal=JCO+Oncol+Pract&amp;volume=18&amp;pages=201-9" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B127" id="B127"></a> 127. Hsiao YW, Lu TP. Race-specific genetic profiles of homologous recombination deficiency in multiple cancers. <i>J personalized Med</i> (2021) 11(12):1287. doi:&#xa0;10.3390/JPM11121287</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.3390/JPM11121287" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=YW+Hsiao&amp;author=TP+Lu&amp;publication_year=2021&amp;title=Race-specific%20genetic%20profiles%20of%20homologous%20recombination%20deficiency%20in%20multiple%20cancers&amp;journal=J+personalized+Med&amp;volume=11&amp;pages=1287" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B128" id="B128"></a> 128. Bonache S, Esteban I, Moles-Fern&#xe1;ndez A, Ten&#xe9;s A, Duran-Lozano L, Montalban G, et al. Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings. <i>J Cancer Res Clin Oncol</i> (2018) 144:2495&#x2013;513. doi:&#xa0;10.1007/S00432-018-2763-9</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/30306255/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/S00432-018-2763-9" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Bonache&amp;author=I+Esteban&amp;author=A+Moles-Fern%C3%A1ndez&amp;author=A+Ten%C3%A9s&amp;author=L+Duran-Lozano&amp;author=G+Montalban&amp;publication_year=2018&amp;title=Multigene%20panel%20testing%20beyond%20BRCA1%2F2%20in%20breast%2Fovarian%20cancer%20Spanish%20families%20and%20clinical%20actionability%20of%20findings&amp;journal=J+Cancer+Res+Clin+Oncol&amp;volume=144&amp;pages=2495-513" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B129" id="B129"></a> 129. Jarhelle E, Riise Stensland HMF, Hansen G&#xc5;M, Skarsfjord S, Jonsrud C, Ingebrigtsen M, et al. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients. <i>Sci Rep</i> (2019) 9(1):19986. doi:&#xa0;10.1038/s41598-019-55515-x</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/31882575/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41598-019-55515-x" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=E+Jarhelle&amp;author=HMF+Riise%20Stensland&amp;author=G%C3%85M+Hansen&amp;author=S+Skarsfjord&amp;author=C+Jonsrud&amp;author=M+Ingebrigtsen&amp;publication_year=2019&amp;title=Identifying%20sequence%20variants%20contributing%20to%20hereditary%20breast%20and%20ovarian%20cancer%20in%20BRCA1%20and%20BRCA2%20negative%20breast%20and%20ovarian%20cancer%20patients&amp;journal=Sci+Rep&amp;volume=9&amp;pages=19986" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B130" id="B130"></a> 130. Hirasawa A, Imoto I, Naruto T, Akahane T, Yamagami W, Nomura H, et al. Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer. <i>Oncotarget</i> (2017) 8:112258&#x2013;67. doi:&#xa0;10.18632/ONCOTARGET.22733</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/29348823/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.18632/ONCOTARGET.22733" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Hirasawa&amp;author=I+Imoto&amp;author=T+Naruto&amp;author=T+Akahane&amp;author=W+Yamagami&amp;author=H+Nomura&amp;publication_year=2017&amp;title=Prevalence%20of%20pathogenic%20germline%20variants%20detected%20by%20multigene%20sequencing%20in%20unselected%20Japanese%20patients%20with%20ovarian%20cancer&amp;journal=Oncotarget&amp;volume=8&amp;pages=112258-67" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B131" id="B131"></a> 131. Pan ZW, Wang XJ, Chen T, DIng XW, Jiang X, Gao Y, et al. Deleterious mutations in DNA repair gene FANCC exist in BRCA1/2-negative Chinese familial breast and/or ovarian cancer patients. <i>Front Oncol</i> (2019) 9:169. doi:&#xa0;10.3389/FONC.2019.00169</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/30967997/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3389/FONC.2019.00169" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=ZW+Pan&amp;author=XJ+Wang&amp;author=T+Chen&amp;author=XW+DIng&amp;author=X+Jiang&amp;author=Y+Gao&amp;publication_year=2019&amp;title=Deleterious%20mutations%20in%20DNA%20repair%20gene%20FANCC%20exist%20in%20BRCA1%2F2-negative%20Chinese%20familial%20breast%20and%2For%20ovarian%20cancer%20patients&amp;journal=Front+Oncol&amp;volume=9&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B132" id="B132"></a> 132. del Valle J, Rofes P, Moreno-Cabrera JM, L&#xf3;pez-D&#xf3;riga A, Belhadj S, Vargas-Parra G, et al. Exploring the role of mutations in fanconi anemia genes in hereditary cancer patients. <i>Cancers</i> (2020) 12(4):829. doi:&#xa0;10.3390/CANCERS12040829</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/32235514/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3390/CANCERS12040829" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+del%20Valle&amp;author=P+Rofes&amp;author=JM+Moreno-Cabrera&amp;author=A+L%C3%B3pez-D%C3%B3riga&amp;author=S+Belhadj&amp;author=G+Vargas-Parra&amp;publication_year=2020&amp;title=Exploring%20the%20role%20of%20mutations%20in%20fanconi%20anemia%20genes%20in%20hereditary%20cancer%20patients&amp;journal=Cancers&amp;volume=12&amp;pages=829" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B133" id="B133"></a> 133. Westphalen CB, Fine AD, Andr&#xe9; F, Ganesan S, Heinemann V, Rouleau E, et al. Pan-cancer analysis of homologous recombination repair-associated gene alterations and genome-wide loss-of-Heterozygosity score. <i>Clin Cancer research : an Off J Am Assoc Cancer Res</i> (2022) 28:1412&#x2013;21. doi:&#xa0;10.1158/1078-0432.CCR-21-2096</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1158/1078-0432.CCR-21-2096" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=CB+Westphalen&amp;author=AD+Fine&amp;author=F+Andr%C3%A9&amp;author=S+Ganesan&amp;author=V+Heinemann&amp;author=E+Rouleau&amp;publication_year=2022&amp;title=Pan-cancer%20analysis%20of%20homologous%20recombination%20repair-associated%20gene%20alterations%20and%20genome-wide%20loss-of-Heterozygosity%20score&amp;journal=Clin+Cancer+research+:+an+Off+J+Am+Assoc+Cancer+Res&amp;volume=28&amp;pages=1412-21" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B134" id="B134"></a> 134. Doddato G, Valentino F, Giliberti A, Papa FT, Tita R, Bruno LP, et al. Exome sequencing in BRCA1-2 candidate familias: The contribution of other cancer susceptibility genes. <i>Front Oncol</i> (2021) 11:649435. doi:&#xa0;10.3389/FONC.2021.649435</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/34026625/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3389/FONC.2021.649435" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=G+Doddato&amp;author=F+Valentino&amp;author=A+Giliberti&amp;author=FT+Papa&amp;author=R+Tita&amp;author=LP+Bruno&amp;publication_year=2021&amp;title=Exome%20sequencing%20in%20BRCA1-2%20candidate%20familias%3A%20The%20contribution%20of%20other%20cancer%20susceptibility%20genes&amp;journal=Front+Oncol&amp;volume=11&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B135" id="B135"></a> 135. Salo-Mullen EE, Maio A, Mukherjee S, Bandlamudi C, Shia J, Kemel Y, et al. Prevalence and characterization of biallelic and monoallelic NTHL1 and MSH3 variant carriers from a pan-cancer patient population. <i>JCO Precis Oncol</i> (2021) 5:455&#x2013;65. doi:&#xa0;10.1200/PO.20.00443</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1200/PO.20.00443" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=EE+Salo-Mullen&amp;author=A+Maio&amp;author=S+Mukherjee&amp;author=C+Bandlamudi&amp;author=J+Shia&amp;author=Y+Kemel&amp;publication_year=2021&amp;title=Prevalence%20and%20characterization%20of%20biallelic%20and%20monoallelic%20NTHL1%20and%20MSH3%20variant%20carriers%20from%20a%20pan-cancer%20patient%20population&amp;journal=JCO+Precis+Oncol&amp;volume=5&amp;pages=455-65" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B136" id="B136"></a> 136. Broderick P, Bagratuni T, Vijayakrishnan J, Lubbe S, Chandler I, Houlston RS. Evaluation of NTHL1, NEIL1, NEIL2MPG, TDG, UNG and SMUG1 genes in familial colorectal cancer predisposition. <i>BMC Cancer</i> (2006) 6:243. doi:&#xa0;10.1186/1471-2407-6-243</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/17029639/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/1471-2407-6-243" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=P+Broderick&amp;author=T+Bagratuni&amp;author=J+Vijayakrishnan&amp;author=S+Lubbe&amp;author=I+Chandler&amp;author=RS+Houlston&amp;publication_year=2006&amp;title=Evaluation%20of%20NTHL1%2C%20NEIL1%2C%20NEIL2MPG%2C%20TDG%2C%20UNG%20and%20SMUG1%20genes%20in%20familial%20colorectal%20cancer%20predisposition&amp;journal=BMC+Cancer&amp;volume=6&amp;pages=243" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B137" id="B137"></a> 137. Ciavarella M, Miccoli S, Prossomariti A, Pippucci T, Bonora E, Buscherini F, et al. Somatic APC mosaicism and oligogenic inheritance in genetically unsolved colorectal adenomatous polyposis patients. <i>Eur J Hum genetics : EJHG</i> (2018) 26:387&#x2013;95. doi:&#xa0;10.1038/S41431-017-0086-Y</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1038/S41431-017-0086-Y" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Ciavarella&amp;author=S+Miccoli&amp;author=A+Prossomariti&amp;author=T+Pippucci&amp;author=E+Bonora&amp;author=F+Buscherini&amp;publication_year=2018&amp;title=Somatic%20APC%20mosaicism%20and%20oligogenic%20inheritance%20in%20genetically%20unsolved%20colorectal%20adenomatous%20polyposis%20patients&amp;journal=Eur+J+Hum+genetics+:+EJHG&amp;volume=26&amp;pages=387-95" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B138" id="B138"></a> 138. Das R, Kundu S, Laskar S, Choudhury Y, Ghosh SK. Assessment of DNA repair susceptibility genes identified by whole exome sequencing in head and neck cancer. <i>DNA Repair</i> (2018) 66&#x2013;67:50&#x2013;63. doi:&#xa0;10.1016/J.DNAREP.2018.04.005</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/29747023/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/J.DNAREP.2018.04.005" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R+Das&amp;author=S+Kundu&amp;author=S+Laskar&amp;author=Y+Choudhury&amp;author=SK+Ghosh&amp;publication_year=2018&amp;title=Assessment%20of%20DNA%20repair%20susceptibility%20genes%20identified%20by%20whole%20exome%20sequencing%20in%20head%20and%20neck%20cancer&amp;journal=DNA+Repair&amp;volume=66&#x2013;67&amp;pages=50" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B139" id="B139"></a> 139. Lawrenson K, Iversen ES, Tyrer J, Weber RP, Concannon P, Hazelett DJ, et al. Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. <i>Carcinogenesis</i> (2015) 36:1341&#x2013;53. doi:&#xa0;10.1093/CARCIN/BGV138</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/26424751/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/CARCIN/BGV138" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=K+Lawrenson&amp;author=ES+Iversen&amp;author=J+Tyrer&amp;author=RP+Weber&amp;author=P+Concannon&amp;author=DJ+Hazelett&amp;publication_year=2015&amp;title=Common%20variants%20at%20the%20CHEK2%20gene%20locus%20and%20risk%20of%20epithelial%20ovarian%20cancer&amp;journal=Carcinogenesis&amp;volume=36&amp;pages=1341-53" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B140" id="B140"></a> 140. Kurman RJ, Shih IM. The dualistic model of ovarian carcinogenesis: Revisited, revised, and expanded. <i>Am J Pathol</i> (2016) 186:733&#x2013;47. doi:&#xa0;10.1016/J.AJPATH.2015.11.011</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/27012190/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/J.AJPATH.2015.11.011" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=RJ+Kurman&amp;author=IM+Shih&amp;publication_year=2016&amp;title=The%20dualistic%20model%20of%20ovarian%20carcinogenesis%3A%20Revisited%2C%20revised%2C%20and%20expanded&amp;journal=Am+J+Pathol&amp;volume=186&amp;pages=733-47" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B141" id="B141"></a> 141. Srinivasan P, Bandlamudi C, Jonsson P, Kemel Y, Chavan SS, Richards AL, et al. The context-specific role of germline pathogenicity in tumorigenesis. <i>Nat Genet</i> (2021) 53:1577&#x2013;85. doi:&#xa0;10.1038/s41588-021-00949-1</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/34741162/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41588-021-00949-1" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=P+Srinivasan&amp;author=C+Bandlamudi&amp;author=P+Jonsson&amp;author=Y+Kemel&amp;author=SS+Chavan&amp;author=AL+Richards&amp;publication_year=2021&amp;title=The%20context-specific%20role%20of%20germline%20pathogenicity%20in%20tumorigenesis&amp;journal=Nat+Genet&amp;volume=53&amp;pages=1577-85" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B142" id="B142"></a> 142. Damia G, Broggini M. Platinum resistance in ovarian cancer: Role of DNA repair. <i>Cancers</i> (2019) 11(1):119. doi:&#xa0;10.3390/CANCERS11010119</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/30669514/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3390/CANCERS11010119" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=G+Damia&amp;author=M+Broggini&amp;publication_year=2019&amp;title=Platinum%20resistance%20in%20ovarian%20cancer%3A%20Role%20of%20DNA%20repair&amp;journal=Cancers&amp;volume=11&amp;pages=119" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B143" id="B143"></a> 143. Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J. PARP inhibitor resistance: the underlying mechanisms and clinical implications. <i>Mol Cancer 2020 19:1</i> (2020) 19:1&#x2013;16. doi:&#xa0;10.1186/S12943-020-01227-0</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1186/S12943-020-01227-0" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H+Li&amp;author=ZY+Liu&amp;author=N+Wu&amp;author=YC+Chen&amp;author=Q+Cheng&amp;author=J+Wang&amp;publication_year=2020&amp;title=PARP%20inhibitor%20resistance%3A%20the%20underlying%20mechanisms%20and%20clinical%20implications&amp;journal=Mol+Cancer+2020+19:1&amp;volume=19&amp;pages=1" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B144" id="B144"></a> 144. MacArthur DG, Manolio TA, Dimmock DP, Rehm HL, Shendure J, Abecasis GR, et al. Guidelines for investigating causality of sequence variants in human disease. <i>Nat 2014 508:7497</i> (2014) 508:469&#x2013;76. doi:&#xa0;10.1038/nature13127</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1038/nature13127" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=DG+MacArthur&amp;author=TA+Manolio&amp;author=DP+Dimmock&amp;author=HL+Rehm&amp;author=J+Shendure&amp;author=GR+Abecasis&amp;publication_year=2014&amp;title=Guidelines%20for%20investigating%20causality%20of%20sequence%20variants%20in%20human%20disease&amp;journal=Nat+2014+508:7497&amp;volume=508&amp;pages=469-76" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B145" id="B145"></a> 145. Ramsey SD, Yoon P, Moonesinghe R, Khoury MJ. Population-based study of the prevalence of family history of cancer: Implications for cancer screening and prevention. <i>Genet Med</i> (2006) 8:571&#x2013;5. doi:&#xa0;10.1097/01.gim.0000237867.34011.12</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/16980813/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1097/01.gim.0000237867.34011.12" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SD+Ramsey&amp;author=P+Yoon&amp;author=R+Moonesinghe&amp;author=MJ+Khoury&amp;publication_year=2006&amp;title=Population-based%20study%20of%20the%20prevalence%20of%20family%20history%20of%20cancer%3A%20Implications%20for%20cancer%20screening%20and%20prevention&amp;journal=Genet+Med&amp;volume=8&amp;pages=571-5" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B146" id="B146"></a> 146. Zheng G, Yu H, Hemminki A, F&#xf6;rsti A, Sundquist K, Hemminki K. Familial associations of female breast cancer with other cancers. <i>Int J Cancer</i> (2017) 141:2253&#x2013;9. doi:&#xa0;10.1002/ijc.30927</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/28801919/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/ijc.30927" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=G+Zheng&amp;author=H+Yu&amp;author=A+Hemminki&amp;author=A+F%C3%B6rsti&amp;author=K+Sundquist&amp;author=K+Hemminki&amp;publication_year=2017&amp;title=Familial%20associations%20of%20female%20breast%20cancer%20with%20other%20cancers&amp;journal=Int+J+Cancer&amp;volume=141&amp;pages=2253-9" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B147" id="B147"></a> 147. Momozawa Y, Sasai R, Usui Y, Shiraishi K, Iwasaki Y, Taniyama Y, et al. Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants. <i>JAMA Oncol</i> (2022) 8:871&#x2013;8. doi:&#xa0;10.1001/JAMAONCOL.2022.0476</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/35420638/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1001/JAMAONCOL.2022.0476" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=Y+Momozawa&amp;author=R+Sasai&amp;author=Y+Usui&amp;author=K+Shiraishi&amp;author=Y+Iwasaki&amp;author=Y+Taniyama&amp;publication_year=2022&amp;title=Expansion%20of%20cancer%20risk%20profile%20for%20BRCA1%20and%20BRCA2%20pathogenic%20variants&amp;journal=JAMA+Oncol&amp;volume=8&amp;pages=871-8" target="_blank">Google Scholar</a></p></div></div><div class="thinLineM20"></div><div class="AbstractSummary"><p><span>Keywords:</span> germline variants, familial ovarian cancer, cancer predisposing genes, whole exome sequencing, DNA repair pathways, Genetic drift</p><p><span>Citation:</span> Alenezi WM, Fierheller CT, Serruya C, Revil T, Oros KK, Subramanian DN, Bruce J, Spiegelman D, Pugh T, Campbell IG, Mes-Masson A-M, Provencher D, Foulkes WD, Haffaf ZE, Rouleau G, Bouchard L, Greenwood CMT, Ragoussis J and Tonin PN (2023) Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases. <i>Front. Oncol.</i> 13:1111191. doi: 10.3389/fonc.2023.1111191</p><p id="timestamps"><span>Received:</span> 29 November 2022; <span>Accepted:</span> 06 February 2023;<br><span>Published:</span> 08 March 2023.</p><div><p>Edited by:</p><a href="https://loop.frontiersin.org/people/489555">Paolo Peterlongo</a>, IFOM - The FIRC Institute of Molecular Oncology, Italy</div><div><p>Reviewed by:</p><a href="https://loop.frontiersin.org/people/310601">Miguel De La Hoya</a>, San Carlos University Clinical Hospital, Spain<br><a href="https://loop.frontiersin.org/people/952778">Yiyang Wu</a>, Vanderbilt University Medical Center, United States</div><p><span>Copyright</span> &#xa9; 2023 Alenezi, Fierheller, Serruya, Revil, Oros, Subramanian, Bruce, Spiegelman, Pugh, Campbell, Mes-Masson, Provencher, Foulkes, Haffaf, Rouleau, Bouchard, Greenwood, Ragoussis and Tonin. This is an open-access article distributed under the terms of the <a rel="license" href="http://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License (CC BY)</a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p><p><span>*Correspondence:</span> Patricia N. Tonin, <a id="encmail">cGF0cmljaWEudG9uaW5AbWNnaWxsLmNh</a></p><div class="clear"></div></div></div></div><p class="AbstractSummary__disclaimer"><span>Disclaimer: </span> All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. </p></div></div><!----></main><aside class="Layout__aside"><div class="ArticleDetails__wrapper"><div class="ArticleDetails__aside"><div class="ArticleDetails__aside__responsiveButtons"><div class="ActionsDropDown" id="FloatingButtonsEl"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--icon ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fonc.2023.1111191" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="ArticleDetails__aside__responsiveButtons__items"><span></span><div class="ArticleDetailsShare__responsive"><button class="ArticleDetailsShare__trigger" aria-label="Open share options"></button><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div></div><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeIconButton ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><!----></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Export citation</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div></div></div><div class="TotalViews"><div class="TotalViews__data"><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">3,5K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Total views</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">3K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Downloads</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">11</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Citations</div></div></div><div class="ImpactMetricsInfoPopover"><button aria-label="Open impact metrics info" class="ImpactMetricsInfoPopover__button"></button><div class="ImpactMetricsInfoPopover__tooltip"><button aria-label="Close impact metrics info" class="ImpactMetricsInfoPopover__tooltip__closeButton"></button><div class="ImpactMetricsInfoPopover__tooltip__text"> Citation numbers are available from Dimensions </div></div></div></div><div class="TotalViews__viewImpactLink"><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View article impact" href="http://loop-impact.frontiersin.org/impact/article/1111191#totalviews/views" target="_blank" data-event="customLink-link-a_viewArticleImpact"><span>View article impact</span></a></span></div><div class="TotalViews__altmetric"><div data-badge-popover="bottom" data-badge-type="donut" data-doi="10.3389/fonc.2023.1111191" data-condensed="true" data-link-target="new" class="altmetric-embed"></div><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View altmetric score" href="https://www.altmetric.com/details/doi/10.3389/fonc.2023.1111191" target="_blank" data-event="customLink-link-a_viewAltmetricScore"><span>View altmetric score</span></a></span></div></div><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Edited by</div><!--[--><a href="https://loop.frontiersin.org/people/489555/overview" data-event="editorInfo-a-paoloPeterlongo" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">P</span><span class="notranslate">P</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Paolo  Peterlongo</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">European Institute of Oncology (IEO), Italy</div></div></a><!--]--></div></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Reviewed by</div><!--[--><a href="https://loop.frontiersin.org/people/310601/overview" data-event="editorInfo-a-miguelDeLaHoya" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">M</span><span class="notranslate">D</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Miguel  De La Hoya</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">San Carlos University Clinical Hospital, Spain</div></div></a><a href="https://loop.frontiersin.org/people/952778/overview" data-event="editorInfo-a-yiyangWu" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">Y</span><span class="notranslate">W</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Yiyang  Wu</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Vanderbilt University Medical Center, United States</div></div></a><!--]--></div></div><div class="ArticleDetailsGlossary ArticleDetailsGlossary--open"><button class="ArticleDetailsGlossary__header"><div class="ArticleDetailsGlossary__header__title">Table of contents</div><div class="ArticleDetailsGlossary__header__arrow"></div></button><div class="ArticleDetailsGlossary__content"><ul class="flyoutJournal"><li><a href="#h1">Abstract</a></li><li><a href="#h2">Introduction</a></li><li><a href="#h3">Materials and methods</a></li><li><a href="#h4">Results</a></li><li><a href="#h5">Discussion</a></li><li><a href="#h6">Data availability statement</a></li><li><a href="#h7">Ethics statement</a></li><li><a href="#h8">Author contributions</a></li><li><a href="#h9">Funding</a></li><li><a href="#h10">Acknowledgments</a></li><li><a href="#h11">Conflict of interest</a></li><li><a href="#h12">Publisher&#x2019;s note</a></li><li><a href="#h13">Supplementary material</a></li><li><a href="#h14">References</a></li></ul></div></div><span></span><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeOutline ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Export citation</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="CheckForUpdates"><button data-target="crossmark" class="CheckForUpdates__link" data-event="checkForUpdates-btn-openModal"><img class="CheckForUpdates__link__img" src="/ap-2024/images/crossmark.svg" alt="Crossmark icon"><div class="CheckForUpdates__link__text">Check for updates</div></button></div><div class="AnnouncementCard"><p class="AnnouncementCard__title">Frontiers&#39; impact</p><article class="CardA"><div class="CardA__wrapper CardA__wrapper--vertical"><figure class="FrontiersImage CardA__img"><picture class="FrontiersImage"><!--[--><source srcset="https://images-provider.frontiersin.org/api/ipx/w=440&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 563px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=320x400&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1024px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=268x280&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1441px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><!--]--><img src="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" class="is-inside-mask" alt loading="eager"></picture><!----></figure><div class="CardA__info"><!--[--><h2 class="CardA__title">Articles published with Frontiers have received 12 million total citations</h2><p class="CardA__text">Your research is the real superpower - learn how we maximise its impact through our leading community journals</p><br><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--small Link--icon Link--chevronRight Link--right" aria-label="Explore our impact metrics" href="https://www.frontiersin.org/about/impact" target="_self" data-event="customLink-linkType-a_exploreOurImpactMe"><span>Explore our impact metrics</span></a></span><!--]--></div></div></article></div><!----><!----></div><div><div class="Modal Modal--noFooter"><button aria-label="Close modal" class="Modal__overlay" data-event="modal-overlay-close"></button><div class="Modal__container"><div class="Modal__header"><p class="Modal__title">Supplementary Material</p><button aria-label="Close modal" class="Modal__close" data-event="modal-button-close"></button></div><div class="Modal__body"><!--[--><div class="SupplementalData"><ul class="SupplementalData__list"><!--[--><!--]--></ul></div><!--]--><!----></div><!----><!----></div></div></div><div><div class="FloatingButtons"><!----><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--iconDownload ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Download</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fonc.2023.1111191" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><!----></div></div></div></aside></div><div class=""><!----></div><!--]--></div><!----><footer class="Footer"><div class="Footer__wrapper"><div class="Footer__sections"><ul class="Accordion"><!--[--><!--[--><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Guidelines</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/guidelines/author-guidelines" target="_self" data-event="footer-block_0-a_authorGuidelines">Author guidelines</a></li><li><a href="https://www.frontiersin.org/for-authors/author-services" target="_self" data-event="footer-block_0-a_servicesForAuthors">Services for authors</a></li><li><a href="https://www.frontiersin.org/guidelines/policies-and-publication-ethics" target="_self" data-event="footer-block_0-a_policiesAndPublicationE">Policies and publication ethics</a></li><li><a href="https://www.frontiersin.org/guidelines/editor-guidelines" target="_self" data-event="footer-block_0-a_editorGuidelines">Editor guidelines</a></li><li><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="footer-block_0-a_feePolicy">Fee policy</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Explore</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/articles" target="_self" data-event="footer-block_1-a_articles">Articles</a></li><li><a href="https://www.frontiersin.org/research-topics" target="_self" data-event="footer-block_1-a_researchTopics">Research Topics </a></li><li><a href="https://www.frontiersin.org/journals" target="_self" data-event="footer-block_1-a_journals">Journals</a></li><li><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="footer-block_1-a_howWePublish">How we publish</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Outreach</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://forum.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForum">Frontiers Forum </a></li><li><a href="https://policylabs.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersPolicyLabs">Frontiers Policy Labs </a></li><li><a href="https://kids.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForYoungMinds">Frontiers for Young Minds</a></li><li><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="footer-block_2-a_frontiersPlanetPrize">Frontiers Planet Prize</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Connect</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://helpcenter.frontiersin.org" target="_blank" data-event="footer-block_3-a_helpCenter">Help center</a></li><li><a href="https://subscription-management.frontiersin.org/emails/preferences#block0" target="_blank" data-event="footer-block_3-a_emailsAndAlerts">Emails and alerts </a></li><li><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="footer-block_3-a_contactUs">Contact us </a></li><li><a href="https://www.frontiersin.org/submission/submit" target="_self" data-event="footer-block_3-a_submit">Submit</a></li><li><a href="https://careers.frontiersin.org/" target="_blank" data-event="footer-block_3-a_careerOpportunities">Career opportunities</a></li><!--]--></ul><!--]--></div></li><!--]--><!--]--></ul><div class="Footer__socialLinks"><div class="Footer__socialLinks__title">Follow us</div><!--[--><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--facebook Link--right" aria-label="Frontiers Facebook" href="https://www.facebook.com/Frontiersin" target="_blank" data-event="footer-facebook-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--twitter Link--right" aria-label="Frontiers Twitter" href="https://twitter.com/frontiersin" target="_blank" data-event="footer-twitter-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--linkedin Link--right" aria-label="Frontiers LinkedIn" href="https://www.linkedin.com/company/frontiers" target="_blank" data-event="footer-linkedIn-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--instagram Link--right" aria-label="Frontiers Instagram" href="https://www.instagram.com/frontiersin_" target="_blank" data-event="footer-instagram-a_true"><span></span></a></span><!--]--></div></div><div class="Footer__copyright"><div><span> 2025 Frontiers Media SA. All rights reserved.</span></div><div><a href="https://www.frontiersin.org/legal/privacy-policy" target="_blank">Privacy policy</a><span>|</span><a href="https://www.frontiersin.org/legal/terms-and-conditions" target="_blank">Terms and conditions</a></div></div></div></footer><div class="SnackbarWrapper"><div class="SnackbarManager"><!--[--><!--]--></div></div></div><noscript><iframe
            src="https://tag-manager.frontiersin.org/ns.html?id=GTM-M322FV2&gtm_auth=owVbWxfaJr21yQv1fe1cAQ&gtm_preview=env-1&gtm_cookies_win=x"
            height="0"
            width="0"
            style="display: none; visibility: hidden">
          </iframe></noscript><!--]--></div><div id="teleports"></div><script type="application/json" id="__NUXT_DATA__" data-ssr="true">[["ShallowReactive",1],{"data":2,"state":4,"once":10,"_errors":11,"serverRendered":13,"path":14,"pinia":15},["ShallowReactive",3],{},["Reactive",5],{"$ssite-config":6},{"env":7,"name":8,"url":9},"production","Frontiers articles","https://article-pages-2024.frontiersin.org/",["Set"],["ShallowReactive",12],{},true,"/journals/oncology/articles/10.3389/fonc.2023.1111191/full",["Reactive",16],{"main":17,"user":532,"article":533,"articleHub":1008,"mainHeader":1012},{"ibar":18,"footer":284,"newsletterComponent":-1,"snackbarItem":366,"toggleShowSnackbar":367,"contentfulJournal":368,"graphJournal":433,"settingsFeaturesSwitchers":437,"templateToggleBanner":438,"tenantConfig":497},{"tenantLogo":19,"journalLogo":19,"aboutUs":20,"submitUrl":113,"showSubmitButton":13,"journal":114,"sectionTerm":215,"aboutJournal":216,"mainLinks":265,"journalLinks":272,"helpCenterLink":281},"",[21,38,47,71,87],{"title":22,"links":23},"Who we are",[24,29,32,35],{"text":25,"url":26,"target":27,"ariaLabel":28},"Mission and values","https://www.frontiersin.org/about/mission","_self",null,{"text":30,"url":31,"target":27,"ariaLabel":28},"History","https://www.frontiersin.org/about/history",{"text":33,"url":34,"target":27,"ariaLabel":28},"Leadership","https://www.frontiersin.org/about/leadership",{"text":36,"url":37,"target":27,"ariaLabel":28},"Awards","https://www.frontiersin.org/about/awards",{"title":39,"links":40},"Impact and progress",[41,44],{"text":42,"url":43,"target":27,"ariaLabel":28},"Frontiers' impact","https://www.frontiersin.org/about/impact",{"text":45,"url":46,"target":27,"ariaLabel":28},"Our annual reports","https://www.frontiersin.org/about/annual-reports",{"title":48,"links":49},"Publishing model",[50,53,56,59,62,65,68],{"text":51,"url":52,"target":27,"ariaLabel":28},"How we publish","https://www.frontiersin.org/about/how-we-publish",{"text":54,"url":55,"target":27,"ariaLabel":28},"Open access","https://www.frontiersin.org/about/open-access",{"text":57,"url":58,"target":27,"ariaLabel":28},"Peer review","https://www.frontiersin.org/about/peer-review",{"text":60,"url":61,"target":27,"ariaLabel":28},"Research integrity","https://www.frontiersin.org/about/research-integrity",{"text":63,"url":64,"target":27,"ariaLabel":28},"Research Topics","https://www.frontiersin.org/about/research-topics",{"text":66,"url":67,"target":27,"ariaLabel":28},"FAIR Data Management","https://www.frontiersin.org/about/fair-data-management",{"text":69,"url":70,"target":27,"ariaLabel":28},"Fee policy","https://www.frontiersin.org/about/fee-policy",{"title":72,"links":73},"Services",[74,78,81,84],{"text":75,"url":76,"target":77,"ariaLabel":28},"Societies","https://publishingpartnerships.frontiersin.org/","_blank",{"text":79,"url":80,"target":27,"ariaLabel":28},"National consortia","https://www.frontiersin.org/open-access-agreements/consortia",{"text":82,"url":83,"target":27,"ariaLabel":28},"Institutional partnerships","https://www.frontiersin.org/about/open-access-agreements",{"text":85,"url":86,"target":27,"ariaLabel":28},"Collaborators","https://www.frontiersin.org/about/collaborators",{"title":88,"links":89},"More from Frontiers",[90,94,97,101,105,109],{"text":91,"url":92,"target":77,"ariaLabel":93},"Frontiers Forum","https://forum.frontiersin.org/","this link will take you to the Frontiers Forum website",{"text":95,"url":96,"target":27,"ariaLabel":28},"Frontiers Planet Prize","https://www.frontiersin.org/about/frontiers-planet-prize",{"text":98,"url":99,"target":77,"ariaLabel":100},"Press office","https://pressoffice.frontiersin.org/","this link will take you to the Frontiers press office website",{"text":102,"url":103,"target":27,"ariaLabel":104},"Sustainability","https://www.frontiersin.org/about/sustainability","link to information about Frontiers' sustainability",{"text":106,"url":107,"target":77,"ariaLabel":108},"Career opportunities","https://careers.frontiersin.org/","this link will take you to the Frontiers careers website",{"text":110,"url":111,"target":27,"ariaLabel":112},"Contact us","https://www.frontiersin.org/about/contact","this link will take you to the help pages to contact our support team","https://www.frontiersin.org/submission/submit?domainid=2&fieldid=57&specialtyid=0&entitytype=2&entityid=451",{"id":115,"name":116,"slug":117,"sections":118},451,"Frontiers in Oncology","oncology",[119,123,127,131,135,139,143,147,151,155,159,163,167,171,175,179,183,187,191,195,199,203,207,211],{"id":120,"name":121,"slug":122},500,"Breast Cancer","breast-cancer",{"id":124,"name":125,"slug":126},2606,"Cancer Cell Signaling","cancer-cell-signaling",{"id":128,"name":129,"slug":130},513,"Cancer Epidemiology and Prevention","cancer-epidemiology-and-prevention",{"id":132,"name":133,"slug":134},506,"Cancer Genetics","cancer-genetics",{"id":136,"name":137,"slug":138},515,"Cancer Imaging and Image-directed Interventions","cancer-imaging-and-image-directed-interventions",{"id":140,"name":141,"slug":142},527,"Cancer Immunity and Immunotherapy","cancer-immunity-and-immunotherapy",{"id":144,"name":145,"slug":146},1510,"Cancer Metabolism","cancer-metabolism",{"id":148,"name":149,"slug":150},507,"Cancer Molecular Targets and Therapeutics","cancer-molecular-targets-and-therapeutics",{"id":152,"name":153,"slug":154},1513,"Cardio-Oncology","cardio-oncology",{"id":156,"name":157,"slug":158},2413,"Gastrointestinal Cancers: Colorectal Cancer","gastrointestinal-cancers-colorectal-cancer",{"id":160,"name":161,"slug":162},2415,"Gastrointestinal Cancers: Gastric and Esophageal Cancers","gastrointestinal-cancers-gastric-and-esophageal-cancers",{"id":164,"name":165,"slug":166},2414,"Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers","gastrointestinal-cancers-hepato-pancreatic-biliary-cancers",{"id":168,"name":169,"slug":170},503,"Genitourinary Oncology","genitourinary-oncology",{"id":172,"name":173,"slug":174},2079,"Gynecological Oncology","gynecological-oncology",{"id":176,"name":177,"slug":178},517,"Head and Neck Cancer","head-and-neck-cancer",{"id":180,"name":181,"slug":182},505,"Hematologic Malignancies","hematologic-malignancies",{"id":184,"name":185,"slug":186},508,"Molecular and Cellular Oncology","molecular-and-cellular-oncology",{"id":188,"name":189,"slug":190},150,"Neuro-Oncology and Neurosurgical Oncology","neuro-oncology-and-neurosurgical-oncology",{"id":192,"name":193,"slug":194},509,"Pediatric Oncology","pediatric-oncology",{"id":196,"name":197,"slug":198},192,"Pharmacology of Anti-Cancer Drugs","pharmacology-of-anti-cancer-drugs",{"id":200,"name":201,"slug":202},511,"Radiation Oncology","radiation-oncology",{"id":204,"name":205,"slug":206},1630,"Skin Cancer","skin-cancer",{"id":208,"name":209,"slug":210},512,"Surgical Oncology","surgical-oncology",{"id":212,"name":213,"slug":214},502,"Thoracic Oncology","thoracic-oncology","Sections",[217,241],{"title":218,"links":219},"Scope",[220,223,226,229,232,235,238],{"text":221,"url":222,"target":27,"ariaLabel":28},"Field chief editors","https://www.frontiersin.org/journals/oncology/about#about-editors",{"text":224,"url":225,"target":27,"ariaLabel":28},"Mission & scope","https://www.frontiersin.org/journals/oncology/about#about-scope",{"text":227,"url":228,"target":27,"ariaLabel":28},"Facts","https://www.frontiersin.org/journals/oncology/about#about-facts",{"text":230,"url":231,"target":27,"ariaLabel":28},"Journal sections","https://www.frontiersin.org/journals/oncology/about#about-submission",{"text":233,"url":234,"target":27,"ariaLabel":28},"Open access statement","https://www.frontiersin.org/journals/oncology/about#about-open",{"text":236,"url":237,"target":27,"ariaLabel":28},"Copyright statement","https://www.frontiersin.org/journals/oncology/about#copyright-statement",{"text":239,"url":240,"target":27,"ariaLabel":28},"Quality","https://www.frontiersin.org/journals/oncology/about#about-quality",{"title":242,"links":243},"For authors",[244,247,250,253,256,259,262],{"text":245,"url":246,"target":27,"ariaLabel":28},"Why submit?","https://www.frontiersin.org/journals/oncology/for-authors/why-submit",{"text":248,"url":249,"target":27,"ariaLabel":28},"Article types","https://www.frontiersin.org/journals/oncology/for-authors/article-types",{"text":251,"url":252,"target":27,"ariaLabel":28},"Author guidelines","https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines",{"text":254,"url":255,"target":27,"ariaLabel":28},"Editor guidelines","https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines",{"text":257,"url":258,"target":27,"ariaLabel":28},"Publishing fees","https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees",{"text":260,"url":261,"target":27,"ariaLabel":28},"Submission checklist","https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist",{"text":263,"url":264,"target":27,"ariaLabel":28},"Contact editorial office","https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office",[266,269],{"text":267,"url":268,"target":27,"ariaLabel":28},"All journals","https://www.frontiersin.org/journals",{"text":270,"url":271,"target":27,"ariaLabel":28},"All articles","https://www.frontiersin.org/articles",[273,276,278],{"text":274,"url":275,"target":27,"ariaLabel":28},"Articles","articles",{"text":63,"url":277,"target":27,"ariaLabel":28},"research-topics",{"text":279,"url":280,"target":27,"ariaLabel":28},"Editorial board","editors",{"text":282,"url":283,"target":77,"ariaLabel":282},"Help center","https://helpcenter.frontiersin.org",{"blocks":285,"socialLinks":339,"copyright":363,"termsAndConditionsUrl":364,"privacyPolicyUrl":365},[286,300,310,324],{"title":287,"links":288},"Guidelines",[289,291,294,297,299],{"text":251,"url":290,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/author-guidelines",{"text":292,"url":293,"target":27,"ariaLabel":28},"Services for authors","https://www.frontiersin.org/for-authors/author-services",{"text":295,"url":296,"target":27,"ariaLabel":28},"Policies and publication ethics","https://www.frontiersin.org/guidelines/policies-and-publication-ethics",{"text":254,"url":298,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/editor-guidelines",{"text":69,"url":70,"target":27,"ariaLabel":28},{"title":301,"links":302},"Explore",[303,304,307,309],{"text":274,"url":271,"target":27,"ariaLabel":28},{"text":305,"url":306,"target":27,"ariaLabel":28},"Research Topics ","https://www.frontiersin.org/research-topics",{"text":308,"url":268,"target":27,"ariaLabel":28},"Journals",{"text":51,"url":52,"target":27,"ariaLabel":28},{"title":311,"links":312},"Outreach",[313,316,319,323],{"text":314,"url":92,"target":77,"ariaLabel":315},"Frontiers Forum ","Frontiers Forum website",{"text":317,"url":318,"target":77,"ariaLabel":28},"Frontiers Policy Labs ","https://policylabs.frontiersin.org/",{"text":320,"url":321,"target":77,"ariaLabel":322},"Frontiers for Young Minds","https://kids.frontiersin.org/","Frontiers for Young Minds journal",{"text":95,"url":96,"target":27,"ariaLabel":28},{"title":325,"links":326},"Connect",[327,328,332,335,338],{"text":282,"url":283,"target":77,"ariaLabel":282},{"text":329,"url":330,"target":77,"ariaLabel":331},"Emails and alerts ","https://subscription-management.frontiersin.org/emails/preferences#block0","Subscribe to Frontiers emails",{"text":333,"url":111,"target":27,"ariaLabel":334},"Contact us ","Subscribe to newsletter",{"text":336,"url":337,"target":27,"ariaLabel":28},"Submit","https://www.frontiersin.org/submission/submit",{"text":106,"url":107,"target":77,"ariaLabel":28},[340,348,353,358],{"link":341,"type":344,"color":345,"icon":346,"size":347,"hiddenText":13},{"text":342,"url":343,"target":77,"ariaLabel":342},"Frontiers Facebook","https://www.facebook.com/Frontiersin","Link","Grey","Facebook","Medium",{"link":349,"type":344,"color":345,"icon":352,"size":347,"hiddenText":13},{"text":350,"url":351,"target":77,"ariaLabel":28},"Frontiers Twitter","https://twitter.com/frontiersin","Twitter",{"link":354,"type":344,"color":345,"icon":357,"size":347,"hiddenText":13},{"text":355,"url":356,"target":77,"ariaLabel":28},"Frontiers LinkedIn","https://www.linkedin.com/company/frontiers","LinkedIn",{"link":359,"type":344,"color":345,"icon":362,"size":347,"hiddenText":13},{"text":360,"url":361,"target":77,"ariaLabel":28},"Frontiers Instagram","https://www.instagram.com/frontiersin_","Instagram","Frontiers Media SA. All rights reserved.","https://www.frontiersin.org/legal/terms-and-conditions","https://www.frontiersin.org/legal/privacy-policy",{},false,{"__typename":369,"identifier":115,"name":116,"slug":117,"banner":370,"description":426,"mission":427,"palette":428,"impactFactor":429,"citeScore":430,"citations":431,"showTagline":28,"twitter":432},"Journal",[371],{"id":372,"src":373,"name":374,"tags":375,"type":384,"width":385,"height":386,"idHash":387,"archive":388,"brandId":389,"limited":388,"fileSize":390,"isPublic":391,"original":392,"copyright":393,"extension":394,"thumbnails":396,"dateCreated":404,"description":405,"orientation":406,"userCreated":407,"watermarked":388,"dateModified":404,"datePublished":408,"ecsArchiveFiles":409,"propertyOptions":410,"property_Channel":415,"property_Sub-Type":417,"property_Asset_Type":419,"activeOriginalFocusPoint":421,"property_Office_Department":424},"A08FCA58-05EE-4283-A13E51F93BB73C97","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/webimage-6A59331A-8816-4B2C-BC3F6EF168F6183E.jpg","FONC_Main Visual_Purple_Website",[376,377,378,379,380,381,382,383],"body part","dead","anatomy","defending","protection","skin","treatment","cell","image",7200,4050,"7f2922f165e2e1ba",0,"22C10171-81B3-4DA6-99342F272A32E8BB",9449881,1,"https://brand.frontiersin.org/m/7f2922f165e2e1ba/original/FONC_Main-Visual_Purple_Website.jpeg","Copyright (c) 2021 Design_Cells/Shutterstock.  No use without permission.",[395],"jpeg",{"mini":397,"thul":398,"webimage":373,"Guidelines":399,"WebsiteJpg_XL":400,"WebsiteWebP_L":401,"WebsiteWebP_M":402,"WebsiteWebP_XL":403},"https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/mini-5795EAF1-94A7-4623-B52EAC7FC8A5098F.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/thul-301BCB38-FCF6-4517-9359D5382707B640.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/Guidelines-FONC_Main Visual_Purple_Website.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteJpg_XL-FONC_Main Visual_Purple_Website.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteWebP_L-FONC_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteWebP_M-FONC_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteWebP_XL-FONC_Main Visual_Purple_Website.webp","2022-06-27T10:00:39Z","Cancer cell, cell grow out of control and become invasive. 3d illustration","landscape","Caroline Sutter","2022-06-27T09:27:09Z",[],[411,412,413,414],"414FB2D4-2283-43FD-BE14E534ECA67928","6C18119B-14BD-4951-B437696F4357BD33","7C692885-DB25-4858-B1FB4FF47B241E9B","D88C0047-EC30-4506-A7DF28A4D765E1CF",[416],"frontiersin_org",[418],"Main_Visual",[420],"Photography",{"x":422,"y":423},3600,2025,[425],"Publishing","Explore global oncology research advancing cancer diagnosis, treatment, and management across diverse populations and healthcare systems.","\u003Cp>Frontiers in Oncology is a broad-scope, multidisciplinary journal covering all areas of cancer research to advance our knowledge of cancer epidemiology to improve diagnosis, therapeutics, and management strategies.\u003C/p>\n\n\u003Cp>The journal is led by Field Chief Editor Prof Giuseppe Giaccone (Cornell University and Amgen, USA), and Assistant Field Chief Editor Prof Sharon Pine (University of Colorado, USA). Indexed in PubMed Central (PMC), Scopus, Web of Science (SCIE), and the DOAJ, Frontiers in Oncology welcomes clinical and experimental research contributions in the various domains of cancer research, which bridge the gap between basic research and clinical applications. Topics include, but are not limited to:\u003C/p>\n\u003Cul>\n  \u003Cli>breast cancer\u003C/li>\n  \u003Cli>cancer cell signaling\u003C/li>\n  \u003Cli>cancer epidemiology and prevention\u003C/li>\n  \u003Cli>cancer genetics\u003C/li>\n  \u003Cli>cancer imaging and image-directed interventions\u003C/li>\n  \u003Cli>cancer immunity and immunotherapy\u003C/li>\n  \u003Cli>cancer metabolism\u003C/li>\n  \u003Cli>cancer molecular targets and therapeutics\u003C/li>\n  \u003Cli>cardio-oncology\u003C/li>\n  \u003Cli>gastrointestinal cancers\u003C/li>\n  \u003Cli>genitourinary oncology\u003C/li>\n  \u003Cli>gynecological oncology\u003C/li>\n  \u003Cli>head and neck cancer\u003C/li>\n  \u003Cli>hematologic malignancies\u003C/li>\n  \u003Cli>molecular and cellular oncology\u003C/li>\n  \u003Cli>neuro-oncology and neurosurgical oncology\u003C/li>\n  \u003Cli>pediatric oncology\u003C/li>\n  \u003Cli>pharmacology of anti-cancer drugs\u003C/li>\n  \u003Cli>radiation oncology\u003C/li>\n  \u003Cli>skin cancer\u003C/li>\n  \u003Cli>surgical oncology\u003C/li>\n  \u003Cli>thoracic oncology.\u003C/li>\n\u003C/ul>\n\n\u003Cp>In particular, the journal welcomes submissions which support and advance the UNs Sustainable Development Goals (SDGs), notable SDG 3: ensure healthy lives and promote well-being for all at all ages.\u003C/p>\n\n\u003Cp>Frontiers' journals require that manuscripts primarily comprising solely of bioinformatics analyses, computational studies of public data, or findings from Mendelian Randomisation studies must include appropriate validation. Acceptable forms of validation include:\u003Cp>\n\u003Cul>\n  \u003Cli>independent clinical or patient cohorts that are not publicly available\u003C/li>\n  \u003Cli>biological validation of the main conclusions, either \u003Cem>in vitro\u003C/em> or \u003Cem>in vivo\u003C/em>\u003C/li>\n  \u003Cli>multi-database queries (bibliometric studies only)\u003C/li>\n\u003C/ul>\n\n\u003Cp>Manuscripts lacking robust validation will be considered unsuitable for publication, as they do not meet the required evidence standards necessary for scientific conclusions. Please refer to the \u003Ca href=\"https://www.frontiersin.org/guidelines/policies-and-publication-ethics#standards-for-research-methodology\">Frontiers Standards for research methodology policy\u003C/a>, for more information.\u003C/p>\n\n\u003Cp>Frontiers in Oncology is committed to advancing developments in the field of cancer research by allowing unrestricted access to articles, and communicating scientific knowledge to researchers and the public alike, to enable the scientific breakthroughs of the future.\u003C/p>","purple","4.7","5.2","464146","@FrontOncology",{"id":115,"name":116,"slug":117,"abbreviation":434,"isOnline":13,"isOpenForSubmissions":13,"citeScore":435,"impactFactor":436},"fonc",6.9,3.3,{"displayTitlePillLabels":13,"displayRelatedArticlesBox":13,"showEditors":13,"showReviewers":13,"showLoopImpactLink":13,"enableFigshare":367},{"isPublic":13,"allowCompanyUsers":367,"whiteListEmails":439,"enableAllJournals":13,"whiteListJournals":461},[440,441,442,443,444,445,446,447,448,445,449,450,451,452,453,454,455,456,457,458,459,460],"Y2FybG9zLmxvcmNhQGZyb250aWVyc2luLm9yZw==","ZGFuaWVsLmx1ekBmcm9udGllcnNpbi5vcmc=","bGF1cmEudGVuYUBmcm9udGllcnNpbi5vcmc=","cmFmYWVsLnJpYW5jaG9AZnJvbnRpZXJzaW4ub3Jn","amFtZXMuc21hbGxib25lQGZyb250aWVyc2luLm9yZw==","ZnJhbi5tb3Jlbm9AZnJvbnRpZXJzaW4ub3Jn","c2FtdWVsLmZlcm5hbmRlekBmcm9udGllcnNpbi5vcmc=","YmFyYmFyYS5jYXJjYW5naXVAZnJvbnRpZXJzaW4ub3Jn","aXZhbi5zYW50YW1hcmlhQGZyb250aWVyc2luLm9yZw==","aHVlLnRyYW5AZnJvbnRpZXJzaW4ub3Jn","Z29uY2Fsby52YXJnYXNAZnJvbnRpZXJzaW4ub3Jn","bHVjaWUuc2VubkBmcm9udGllcnNpbi5vcmc=","bG9ybi5mcmFzZXJAZnJvbnRpZXJzaW4ub3Jn","ZWxzYS5jYXJyb25AZnJvbnRpZXJzaW4ub3Jn","bWFhcnRlbi52YW5kaWpja0Bmcm9udGllcnNpbi5vcmc=","YmluZGh1LmtyaXNobmFuQGZyb250aWVyc2luLm9yZw==","bWF0dGhldy5hdHR3YXRlcnNAZnJvbnRpZXJzaW4ub3Jn","Z2l1bGlhLnZhbHNlY2NoaUBmcm9udGllcnNpbi5vcmc=","ZmFiaWFuLmRlbGxhbW9ydGVAZnJvbnRpZXJzaW4ub3Jn","dmlqYXlhbi5wcEBwaXRzb2x1dGlvbnMuY29t","Z3VpbGxhdW1lLnNldXJhdEBmcm9udGllcnNpbi5vcmc=",[462,463,464,465,466,467,391,468,469,470,471,472,473,474,475,476,477,478,479,480,481,115,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496],2232,1729,2357,2456,2176,2333,1843,602,106,616,310,657,3123,1468,2137,628,1566,2726,2086,1490,141,1335,2655,1238,604,698,1547,176,1440,403,1239,755,2136,609,1534,{"spaceId":391,"name":391,"availableJournalPages":498,"announcement":502},[275,280,277,499,500,501],"volumes","about","community-reviewers",{"__typename":503,"sys":504,"preHeader":42,"title":506,"description":507,"image":508,"link":530},"Announcement",{"id":505},"5ITtnTtQgAzPPGH6rX0AlM","Articles published with Frontiers have received 12 million total citations","Your research is the real superpower - learn how we maximise its impact through our leading community journals",[509],{"archive":388,"brandId":389,"copyright":28,"dateCreated":510,"dateModified":511,"datePublished":512,"description":28,"extension":513,"fileSize":515,"height":516,"id":517,"isPublic":388,"limited":388,"name":518,"orientation":406,"original":28,"thumbnails":519,"type":384,"watermarked":388,"width":526,"videoPreviewURLs":527,"tags":528,"textMetaproperties":529,"src":520},"2025-06-18T12:58:01Z","2025-06-18T14:15:34Z","2025-06-18T12:57:32Z",[514],"png",1365026,920,"7C5269C4-3C83-4591-951A74D15B95DAEA","Impact metrics banner for article pages",{"webimage":520,"thul":521,"mini":522,"WebsiteWebP_L":523,"WebsiteWebP_M":524,"Guidelines":525},"https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/thul-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/mini-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_L/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_M/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/Guidelines/Impact-metrics-banner-for-article-pages.png",1600,[],[],[],{"text":531,"url":43,"target":27,"ariaLabel":28},"Explore our impact metrics",{"loggedUserInfo":-1},{"currentArticle":534,"isPreviewPage":367,"hasSupplementalData":367,"showCrossmarkWidget":13,"articleTemplate":810,"currentArticlePageMetaInfo":811,"xmlParsedArticleContent":-1,"xmlParsingError":-1},{"id":535,"doi":536,"title":537,"acceptanceDate":538,"receptionDate":539,"publicationDate":540,"lastModifiedDate":541,"isPublished":13,"abstract":542,"researchTopic":543,"articleType":549,"stage":552,"keywords":554,"authors":562,"editors":738,"reviewers":748,"journal":767,"section":775,"impactMetrics":777,"volume":781,"articleVolume":782,"relatedArticles":783,"isPublishedV2":367,"contents":784,"files":787},1111191,"10.3389/fonc.2023.1111191","Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases",["Date","2023-02-06T14:05:22.000Z"],["Date","2022-11-29T12:51:26.000Z"],["Date","2023-03-08T00:00:00.000Z"],["Date","2025-11-25T03:28:33.086Z"],"Not all familial ovarian cancer (OC) cases are explained by pathogenic germline variants in known risk genes. A candidate gene approach involving DNA repair pathway genes was applied to identify rare recurring pathogenic variants in familial OC cases not associated with known OC risk genes from a population exhibiting genetic drift. Whole exome sequencing (WES) data of 15 OC cases from 13 families tested negative for pathogenic variants in known OC risk genes were investigated for candidate variants in 468 DNA repair pathway genes. Filtering and prioritization criteria were applied to WES data to select top candidates for further analyses. Candidates were genotyped in ancestry defined study groups of 214 familial and 998 sporadic OC or breast cancer (BC) cases and 1025 population-matched controls and screened for additional carriers in 605 population-matched OC cases. The candidate genes were also analyzed in WES data from 937 familial or sporadic OC cases of diverse ancestries. Top candidate variants in ERCC5, EXO1, FANCC, NEIL1 and NTHL1 were identified in 5/13 (39%) OC families. Collectively, candidate variants were identified in 7/435 (1.6%) sporadic OC cases and 1/566 (0.2%) sporadic BC cases versus 1/1025 (0.1%) controls. Additional carriers were identified in 6/605 (0.9%) OC cases. Tumour DNA from ERCC5, NEIL1 and NTHL1 variant carriers exhibited loss of the wild-type allele. Carriers of various candidate variants in these genes were identified in 31/937 (3.3%) OC cases of diverse ancestries versus 0-0.004% in cancer-free controls. The strategy of applying a candidate gene approach in a population exhibiting genetic drift identified new candidate OC predisposition variants in DNA repair pathway genes.",{"id":544,"title":545,"articlesCount":546,"isMagazinePage":13,"slug":547,"isOpenForSubmission":367,"views":548},49571,"Bioinformatics and computational approaches for precision medicine implementation",5,"bioinformatics-and-computational-approaches-for-precision-medicine-implementation",22553,{"id":550,"name":551},24,"Original Research",{"id":553,"name":19},18,[555,556,557,558,559,560,561],"Germline variants","Familial ovarian cancer","Cancer predisposing genes","whole exome sequencing","DNA repair pathways","single-stranded DNA repair genes","double-stranded DNA repair genes",[563,576,583,589,598,606,614,621,629,639,648,658,666,681,689,697,709,720,728],{"id":388,"firstName":564,"middleName":19,"lastName":565,"givenNames":566,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":567},"Wejdan M.","Alenezi","Wejdan M. ",[568,571,573],{"organizationName":569,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Department of Human Genetics, McGill University","Canada",{"organizationName":572,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Cancer Research Program, Centre for Translational Biology, The Research Institute of McGill University Health Centre",{"organizationName":574,"countryName":575,"cityName":19,"stateName":19,"zipCode":19},"Department of Medical Laboratory Technology, Taibah University","Saudi Arabia",{"id":388,"firstName":577,"middleName":19,"lastName":578,"givenNames":579,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":580},"Caitlin T.","Fierheller","Caitlin T. ",[581,582],{"organizationName":569,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":572,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"id":388,"firstName":584,"middleName":19,"lastName":585,"givenNames":586,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":587},"Corinne","Serruya","Corinne ",[588],{"organizationName":572,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"id":590,"firstName":591,"middleName":19,"lastName":592,"givenNames":593,"isCorresponding":367,"isProfilePublic":13,"userId":590,"email":-1,"affiliations":594},608170,"Timothe","Revil","Timothe ",[595,596],{"organizationName":569,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":597,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"McGill Genome Centre, McGill University",{"id":599,"firstName":600,"middleName":19,"lastName":601,"givenNames":602,"isCorresponding":367,"isProfilePublic":13,"userId":599,"email":-1,"affiliations":603},341820,"Kathleen K.","Oros","Kathleen K. ",[604],{"organizationName":605,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Lady Davis Institute for Medical Research of the Jewish General Hospital",{"id":388,"firstName":607,"middleName":19,"lastName":608,"givenNames":609,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":610},"Deepak N.","Subramanian","Deepak N. ",[611],{"organizationName":612,"countryName":613,"cityName":19,"stateName":19,"zipCode":19},"Cancer Genetics Laboratory, Peter MacCallum Cancer Centre","Australia",{"id":388,"firstName":615,"middleName":19,"lastName":616,"givenNames":617,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":618},"Jeffrey","Bruce","Jeffrey ",[619],{"organizationName":620,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Princess Margaret Cancer Centre, University Health Network",{"id":388,"firstName":622,"middleName":19,"lastName":623,"givenNames":624,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":625},"Dan","Spiegelman","Dan ",[626,627],{"organizationName":569,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":628,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Montreal Neurological Institute, McGill University",{"id":388,"firstName":630,"middleName":19,"lastName":631,"givenNames":632,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":633},"Trevor","Pugh","Trevor ",[634,635,637],{"organizationName":620,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":636,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Department of Medical Biophysics, University of Toronto",{"organizationName":638,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Ontario Institute for Cancer Research",{"id":640,"firstName":641,"middleName":19,"lastName":642,"givenNames":643,"isCorresponding":367,"isProfilePublic":13,"userId":640,"email":-1,"affiliations":644},43010,"Ian G.","Campbell","Ian G. ",[645,646],{"organizationName":612,"countryName":613,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":647,"countryName":613,"cityName":19,"stateName":19,"zipCode":19},"Sir Peter MacCallum Department of Oncology, University of Melbourne",{"id":649,"firstName":650,"middleName":19,"lastName":651,"givenNames":652,"isCorresponding":367,"isProfilePublic":13,"userId":649,"email":-1,"affiliations":653},866336,"Anne-Marie","Mes-Masson","Anne-Marie ",[654,656],{"organizationName":655,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Centre de recherche du Centre hospitalier de lUniversit de Montral and Institut du cancer de Montral",{"organizationName":657,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Departement of Medicine, Universit de Montral",{"id":388,"firstName":659,"middleName":19,"lastName":660,"givenNames":661,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":662},"Diane","Provencher","Diane ",[663,664],{"organizationName":655,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":665,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Division of Gynecologic Oncology, Universit de Montral",{"id":667,"firstName":668,"middleName":19,"lastName":669,"givenNames":670,"isCorresponding":367,"isProfilePublic":13,"userId":667,"email":-1,"affiliations":671},1785849,"William D.","Foulkes","William D. ",[672,673,674,675,677,679],{"organizationName":569,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":572,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":605,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":676,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Department of Medical Genetics, McGill University Health Centre",{"organizationName":678,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Department of Medicine, McGill University",{"organizationName":680,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Gerald Bronfman Department of Oncology, McGill University",{"id":388,"firstName":682,"middleName":19,"lastName":683,"givenNames":684,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":685},"Zaki El","Haffaf","Zaki El ",[686,687],{"organizationName":655,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":688,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Service de Mdecine Gnique, Centre Hospitalier de lUniversit de Montral",{"id":690,"firstName":691,"middleName":19,"lastName":692,"givenNames":693,"isCorresponding":367,"isProfilePublic":13,"userId":690,"email":-1,"affiliations":694},530157,"Guy","Rouleau","Guy ",[695,696],{"organizationName":569,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":628,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"id":698,"firstName":699,"middleName":19,"lastName":700,"givenNames":701,"isCorresponding":367,"isProfilePublic":13,"userId":698,"email":-1,"affiliations":702},48062,"Luigi","Bouchard","Luigi ",[703,705,707],{"organizationName":704,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Department of Biochemistry and Functional Genomics, Universit de Sherbrooke",{"organizationName":706,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Department of Medical Biology, Centres intgrs universitaires de sant et de services sociaux du Saguenay-Lac-Saint-Jean hpital Universitaire de Chicoutimi",{"organizationName":708,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Centre de Recherche du Centre hospitalier lUniversit de Sherbrooke",{"id":710,"firstName":711,"middleName":19,"lastName":712,"givenNames":713,"isCorresponding":367,"isProfilePublic":13,"userId":710,"email":-1,"affiliations":714},29786,"Celia M. T.","Greenwood","Celia M. T. ",[715,716,717,718],{"organizationName":569,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":605,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":680,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":719,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Department of Epidemiology, Biostatistics and Occupational Health, McGill University",{"id":721,"firstName":722,"middleName":19,"lastName":723,"givenNames":724,"isCorresponding":367,"isProfilePublic":13,"userId":721,"email":-1,"affiliations":725},350612,"Jiannis","Ragoussis","Jiannis ",[726,727],{"organizationName":569,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":597,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"id":729,"firstName":730,"middleName":19,"lastName":731,"givenNames":732,"isCorresponding":13,"isProfilePublic":13,"userId":729,"email":733,"affiliations":734},363949,"Patricia N.","Tonin","Patricia N. ","patricia.tonin@mcgill.ca",[735,736,737],{"organizationName":569,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":572,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":678,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},[739],{"id":740,"firstName":741,"middleName":19,"lastName":742,"givenNames":743,"isCorresponding":367,"isProfilePublic":13,"userId":740,"email":-1,"affiliations":744},489555,"Paolo","Peterlongo","Paolo ",[745],{"organizationName":746,"countryName":747,"cityName":19,"stateName":19,"zipCode":19},"European Institute of Oncology (IEO)","Italy",[749,758],{"id":750,"firstName":751,"middleName":19,"lastName":752,"givenNames":753,"isCorresponding":367,"isProfilePublic":13,"userId":750,"email":-1,"affiliations":754},310601,"Miguel","De La Hoya","Miguel ",[755],{"organizationName":756,"countryName":757,"cityName":19,"stateName":19,"zipCode":19},"San Carlos University Clinical Hospital","Spain",{"id":759,"firstName":760,"middleName":19,"lastName":761,"givenNames":762,"isCorresponding":367,"isProfilePublic":13,"userId":759,"email":-1,"affiliations":763},952778,"Yiyang","Wu","Yiyang ",[764],{"organizationName":765,"countryName":766,"cityName":19,"stateName":19,"zipCode":19},"Vanderbilt University Medical Center","United States",{"id":115,"slug":117,"name":116,"shortName":768,"electronicISSN":769,"field":770,"specialtyId":28,"journalSectionPaths":773},"Front. Oncol.","2234-943X",{"id":771,"domainId":772},57,2,[774],{"section":775},{"id":132,"name":133,"slug":134,"specialtyId":776},129,{"views":778,"downloads":779,"citations":780},3450,2969,11,13,"Volume 13 - 2023",[],{"titleHtml":537,"fullTextHtml":785,"menuHtml":786},"\u003Cdiv class=\"JournalAbstract\">\u003Ca id=\"h1\" name=\"h1\">\u003C/a>\u003Cdiv class=\"authors\">\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Wejdan M. Alenezi,,\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Wejdan M. Alenezi\u003Csup>1,2,3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Caitlin T. Fierheller,\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Caitlin T. Fierheller\u003Csup>1,2\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Corinne Serruya\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Corinne Serruya\u003Csup>2\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/608170\" class=\"user-id-608170\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/608170/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Timoth&#xe;e Revil,\">Timoth&#xe9;e Revil\u003C/a>\u003Csup>1,4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/341820\" class=\"user-id-341820\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/341820/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Kathleen K. Oros\">Kathleen K. Oros\u003C/a>\u003Csup>5\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Deepak N. Subramanian\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Deepak N. Subramanian\u003Csup>6\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Jeffrey Bruce\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Jeffrey Bruce\u003Csup>7\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Dan Spiegelman,\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Dan Spiegelman\u003Csup>1,8\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Trevor Pugh,,\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Trevor Pugh\u003Csup>7,9,10\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/43010\" class=\"user-id-43010\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/43010/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Ian G. Campbell,\">Ian G. Campbell\u003C/a>\u003Csup>6,11\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/866336\" class=\"user-id-866336\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/866336/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Anne-Marie Mes-Masson,\">Anne-Marie Mes-Masson\u003C/a>\u003Csup>12,13\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Diane Provencher,\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Diane Provencher\u003Csup>12,14\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1785849\" class=\"user-id-1785849\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1785849/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"William D. Foulkes,,,,,\">William D. Foulkes\u003C/a>\u003Csup>1,2,5,15,16,17\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Zaki El Haffaf,\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Zaki El Haffaf\u003Csup>12,18\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/530157\" class=\"user-id-530157\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/530157/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Guy Rouleau,\">Guy Rouleau\u003C/a>\u003Csup>1,8\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/48062\" class=\"user-id-48062\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/48062/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Luigi Bouchard,,\">Luigi Bouchard\u003C/a>\u003Csup>19,20,21\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/29786\" class=\"user-id-29786\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/29786/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Celia M. T. Greenwood,,,\">Celia M. T. Greenwood\u003C/a>\u003Csup>1,5,17,22\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/350612\" class=\"user-id-350612\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/350612/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Jiannis Ragoussis,\">Jiannis Ragoussis\u003C/a>\u003Csup>1,4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/363949\" class=\"user-id-363949\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/363949/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Patricia N. Tonin,,*\">Patricia N. Tonin\u003C/a>\u003Csup>1,2,16*\u003C/sup>\u003C/span>\u003C/div>\u003Cul class=\"notes\">\u003Cli>\u003Cspan>\u003Csup>1\u003C/sup>\u003C/span>Department of Human Genetics, McGill University, Montreal, QC, Canada\u003C/li>\u003Cli>\u003Cspan>\u003Csup>2\u003C/sup>\u003C/span>Cancer Research Program, Centre for Translational Biology, The Research Institute of McGill University Health Centre, Montreal, QC, Canada\u003C/li>\u003Cli>\u003Cspan>\u003Csup>3\u003C/sup>\u003C/span>Department of Medical Laboratory Technology, Taibah University, Medina, Saudi Arabia\u003C/li>\u003Cli>\u003Cspan>\u003Csup>4\u003C/sup>\u003C/span>McGill Genome Centre, McGill University, Montreal, QC, Canada\u003C/li>\u003Cli>\u003Cspan>\u003Csup>5\u003C/sup>\u003C/span>Lady Davis Institute for Medical Research of the Jewish General Hospital, Montreal, QC, Canada\u003C/li>\u003Cli>\u003Cspan>\u003Csup>6\u003C/sup>\u003C/span>Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia\u003C/li>\u003Cli>\u003Cspan>\u003Csup>7\u003C/sup>\u003C/span>Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada\u003C/li>\u003Cli>\u003Cspan>\u003Csup>8\u003C/sup>\u003C/span>Montreal Neurological Institute, McGill University, Montreal, QC, Canada\u003C/li>\u003Cli>\u003Cspan>\u003Csup>9\u003C/sup>\u003C/span>Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada\u003C/li>\u003Cli>\u003Cspan>\u003Csup>10\u003C/sup>\u003C/span>Ontario Institute for Cancer Research, Toronto, ON, Canada\u003C/li>\u003Cli>\u003Cspan>\u003Csup>11\u003C/sup>\u003C/span>Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia\u003C/li>\u003Cli>\u003Cspan>\u003Csup>12\u003C/sup>\u003C/span>Centre de recherche du Centre hospitalier de l&#x2019;Universit&#xe9; de Montr&#xe9;al and Institut du cancer de Montr&#xe9;al, Montreal, QC, Canada\u003C/li>\u003Cli>\u003Cspan>\u003Csup>13\u003C/sup>\u003C/span>Departement of Medicine, Universit&#xe9; de Montr&#xe9;al, Montreal, QC, Canada\u003C/li>\u003Cli>\u003Cspan>\u003Csup>14\u003C/sup>\u003C/span>Division of Gynecologic Oncology, Universit&#xe9; de Montr&#xe9;al, Montreal, QC, Canada\u003C/li>\u003Cli>\u003Cspan>\u003Csup>15\u003C/sup>\u003C/span>Department of Medical Genetics, McGill University Health Centre, Montreal, QC, Canada\u003C/li>\u003Cli>\u003Cspan>\u003Csup>16\u003C/sup>\u003C/span>Department of Medicine, McGill University, Montreal, QC, Canada\u003C/li>\u003Cli>\u003Cspan>\u003Csup>17\u003C/sup>\u003C/span>Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada\u003C/li>\u003Cli>\u003Cspan>\u003Csup>18\u003C/sup>\u003C/span>Service de M&#xe9;decine G&#xe9;nique, Centre Hospitalier de l&#x2019;Universit&#xe9; de Montr&#xe9;al, Montreal, QC, Canada\u003C/li>\u003Cli>\u003Cspan>\u003Csup>19\u003C/sup>\u003C/span>Department of Biochemistry and Functional Genomics, Universit&#xe9; de Sherbrooke, Sherbrooke, QC, Canada\u003C/li>\u003Cli>\u003Cspan>\u003Csup>20\u003C/sup>\u003C/span>Department of Medical Biology, Centres int&#xe9;gr&#xe9;s universitaires de sant&#xe9; et de services sociaux du Saguenay-Lac-Saint-Jean h&#xf4;pital Universitaire de Chicoutimi, Saguenay, QC, Canada\u003C/li>\u003Cli>\u003Cspan>\u003Csup>21\u003C/sup>\u003C/span>Centre de Recherche du Centre hospitalier l&#x2019;Universit&#xe9; de Sherbrooke, Sherbrooke, QC, Canada\u003C/li>\u003Cli>\u003Cspan>\u003Csup>22\u003C/sup>\u003C/span>Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada\u003C/li>\u003C/ul>\u003Cp>Not all familial ovarian cancer (OC) cases are explained by pathogenic germline variants in known risk genes. A candidate gene approach involving DNA repair pathway genes was applied to identify rare recurring pathogenic variants in familial OC cases not associated with known OC risk genes from a population exhibiting genetic drift. Whole exome sequencing (WES) data of 15 OC cases from 13 families tested negative for pathogenic variants in known OC risk genes were investigated for candidate variants in 468 DNA repair pathway genes. Filtering and prioritization criteria were applied to WES data to select top candidates for further analyses. Candidates were genotyped in ancestry defined study groups of 214 familial and 998 sporadic OC or breast cancer (BC) cases and 1025 population-matched controls and screened for additional carriers in 605 population-matched OC cases. The candidate genes were also analyzed in WES data from 937 familial or sporadic OC cases of diverse ancestries. Top candidate variants in \u003Ci>ERCC5\u003C/i>, \u003Ci>EXO1\u003C/i>, \u003Ci>FANCC, NEIL1\u003C/i> and \u003Ci>NTHL1\u003C/i> were identified in 5/13 (39%) OC families. Collectively, candidate variants were identified in 7/435 (1.6%) sporadic OC cases and 1/566 (0.2%) sporadic BC cases versus 1/1025 (0.1%) controls. Additional carriers were identified in 6/605 (0.9%) OC cases. Tumour DNA from \u003Ci>ERCC5, NEIL1\u003C/i> and \u003Ci>NTHL1\u003C/i> variant carriers exhibited loss of the wild-type allele. Carriers of various candidate variants in these genes were identified in 31/937 (3.3%) OC cases of diverse ancestries versus 0-0.004% in cancer-free controls. The strategy of applying a candidate gene approach in a population exhibiting genetic drift identified new candidate OC predisposition variants in DNA repair pathway genes.\u003C/p>\u003Cdiv class=\"clear\">\u003C/div>\u003C/div>\u003Cdiv class=\"JournalFullText\">\u003Ca id=\"h2\" name=\"h2\">\u003C/a>\u003Ch2>Introduction\u003C/h2>\u003Cp class=\"mb15\">Since the identification of \u003Ci>BRCA1\u003C/i> (\u003Ca href=\"#B1\">1\u003C/a>) and \u003Ci>BRCA2\u003C/i> (\u003Ca href=\"#B2\">2\u003C/a>) as breast cancer (BC) and ovarian cancer (OC) predisposing genes, which are involved in the homologous recombination (HR) DNA repair pathway (\u003Ca href=\"#B3\">3\u003C/a>), no other major high risk gene has been reported to account for the remaining familial cancer cases found to be negative for germline pathogenic variants (PVs) in these genes (\u003Ca href=\"#B4\">4\u003C/a>). Carriers of PVs in \u003Ci>MLH1, MSH2\u003C/i>, \u003Ci>MSH6\u003C/i> or \u003Ci>PMS2\u003C/i>, genes involved in the mismatch repair (MMR) pathway (\u003Ca href=\"#B3\">3\u003C/a>), have also been shown to have a significantly increased lifetime risk of developing OC (\u003Ca href=\"#B5\">5\u003C/a>, \u003Ca href=\"#B6\">6\u003C/a>) often associated with hereditary non-polyposis colorectal cancer syndrome families (\u003Ca href=\"#B7\">7\u003C/a>). However, carriers of PVs in MMR genes are very rare accounting for fewer than 1% of sporadic OC cases, which is significantly lower than the 5-15% carrier frequency of PVs in \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i>, depending on the population studied (\u003Ca href=\"#B8\">8\u003C/a>). Carriers of PVs in relatively new OC predisposing genes have been reported such as \u003Ci>RAD51C\u003C/i> (\u003Ca href=\"#B9\">9\u003C/a>), \u003Ci>RAD51D\u003C/i> (\u003Ca href=\"#B10\">10\u003C/a>) and \u003Ci>BRIP1\u003C/i> (\u003Ca href=\"#B11\">11\u003C/a>), genes also involved in the HR DNA repair pathway (\u003Ca href=\"#B3\">3\u003C/a>). The carrier frequency of PVs in each of these genes combined is estimated to be less than 2% of sporadic OC cases (\u003Ca href=\"#B8\">8\u003C/a>, \u003Ca href=\"#B12\">12\u003C/a>&#x2013;\u003Ca href=\"#B14\">14\u003C/a>). PVs in other DNA repair genes such as \u003Ci>PALB2\u003C/i> (\u003Ca href=\"#B15\">15\u003C/a>&#x2013;\u003Ca href=\"#B19\">19\u003C/a>), \u003Ci>CHEK2\u003C/i> (\u003Ca href=\"#B16\">16\u003C/a>, \u003Ca href=\"#B20\">20\u003C/a>) and \u003Ci>ATM\u003C/i> (\u003Ca href=\"#B16\">16\u003C/a>, \u003Ca href=\"#B17\">17\u003C/a>), all associated with BC risk, were recently associated with OC, though risk has yet to be established. Other genes also playing a role in various DNA repair pathways have been proposed as candidate OC risk genes such as \u003Ci>FANCM\u003C/i> (\u003Ca href=\"#B15\">15\u003C/a>, \u003Ca href=\"#B21\">21\u003C/a>), \u003Ci>POLE\u003C/i> (\u003Ca href=\"#B22\">22\u003C/a>), \u003Ci>MRE11\u003C/i> (\u003Ca href=\"#B17\">17\u003C/a>, \u003Ca href=\"#B23\">23\u003C/a>), \u003Ci>RAD1\u003C/i> (\u003Ca href=\"#B17\">17\u003C/a>) and \u003Ci>FANCI\u003C/i> (\u003Ca href=\"#B24\">24\u003C/a>), and collectively, the frequency of carriers of PVs in these genes are also low relative to \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> carriers. Thus, research has consistently shown that a candidate gene approach investigating DNA pathway genes has successfully identified new and candidate OC predisposing genes (\u003Ca href=\"#B25\">25\u003C/a>, \u003Ca href=\"#B26\">26\u003C/a>), though it is expected that the carrier frequency is significantly lower relative to carriers harbouring PVs in \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i>.\u003C/p>\u003Cp class=\"mb15\">Defining the contribution of moderate- to high-risk genes in OC remains a challenge as it is not clear that all monogenic cancer predisposing genes have been identified for this genetically heterogeneous disease (\u003Ca href=\"#B4\">4\u003C/a>). Based on the family history of cancer and the population investigated, the proportion of OC families known to be negative for \u003Ci>BRCA1\u003C/i> or \u003Ci>BRCA2\u003C/i> PVs has a wide range of approximately 15-65% (\u003Ca href=\"#B8\">8\u003C/a>, \u003Ca href=\"#B27\">27\u003C/a>). Indeed, a recent whole exome sequencing (WES) study of familial and sporadic OC cases revealed significant heterogeneity of candidate OC risk genes, representing diverse functional pathways with relatively few involved in the approximately 200 investigated DNA repair genes (\u003Ca href=\"#B17\">17\u003C/a>). However, this study focused only on investigating rare, protein-coding loss-of-function (LoF) variants (\u003Ca href=\"#B17\">17\u003C/a>). As there are at least 400 known or putative genes that are directly or indirectly involved in repairing DNA (\u003Ca href=\"#B3\">3\u003C/a>, \u003Ca href=\"#B28\">28\u003C/a>&#x2013;\u003Ca href=\"#B32\">32\u003C/a>), it is plausible that PVs (LoF or missense) in genes not previously investigated in OC could be associated with OC risk that have yet to be identified. As carriers of new candidate variants are likely to be rare, identifying them will be challenging.\u003C/p>\u003Cp class=\"mb15\">We have proposed a strategy for identifying candidate variants in new cancer predisposing genes that involves the investigation of cancer families from populations exhibiting genetic drift (\u003Ca href=\"#B33\">33\u003C/a>). Over time, rare PVs in such populations could attain disproportionally high carrier frequencies of rare risk variants relative to the general population (\u003Ca href=\"#B34\">34\u003C/a>, \u003Ca href=\"#B35\">35\u003C/a>). For example, \u003Ci>PALB2\u003C/i> (\u003Ca href=\"#B36\">36\u003C/a>) and \u003Ci>BRIP1\u003C/i> (\u003Ca href=\"#B11\">11\u003C/a>) were discovered as BC and OC predisposing genes by investigating cancer families and cases from the Finnish and Icelandic populations, respectively, both populations exhibiting genetic drift. Our research of French Canadians (FC) from the Quebec population of Canada, identified \u003Ci>RECQL\u003C/i> (\u003Ca href=\"#B37\">37\u003C/a>) and \u003Ci>FANCI\u003C/i> (\u003Ca href=\"#B24\">24\u003C/a>) as new candidate BC or OC predisposing genes, respectively. Genetic drift in the FCs of Quebec has been attributed to common ancestors as a result of the geographic isolation and multiple waves of expansion of European settlers from France since 1608 (\u003Ca href=\"#B33\">33\u003C/a>&#x2013;\u003Ca href=\"#B35\">35\u003C/a>, \u003Ca href=\"#B38\">38\u003C/a>, \u003Ca href=\"#B39\">39\u003C/a>). Investigating these populations facilitates the characterization of deleterious variants in known or candidate cancer predisposing genes as all types of variants could be investigated and not only LoF variants (\u003Ca href=\"#B33\">33\u003C/a>). A small number of PVs in \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> (\u003Ca href=\"#B40\">40\u003C/a>, \u003Ca href=\"#B41\">41\u003C/a>) and one in each of \u003Ci>PALB2\u003C/i> (\u003Ca href=\"#B42\">42\u003C/a>), \u003Ci>RAD51C\u003C/i> (\u003Ca href=\"#B43\">43\u003C/a>) and \u003Ci>RAD51D\u003C/i> (\u003Ca href=\"#B43\">43\u003C/a>, \u003Ca href=\"#B44\">44\u003C/a>) have been shown to be frequently occurring in FC OC and/or BC cases versus population-matched controls. Specific PVs in \u003Ci>MLH1\u003C/i> (\u003Ca href=\"#B45\">45\u003C/a>)\u003Ci>, MSH2\u003C/i> (\u003Ca href=\"#B45\">45\u003C/a>) and \u003Ci>MSH6\u003C/i> (\u003Ca href=\"#B46\">46\u003C/a>) have also been reported in FCs in the context of hereditary non-polyposis colorectal cancer.\u003C/p>\u003Cp class=\"mb0\">We recently reported that not all remaining \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> negative families with at least two close relatives with OC from the FC population of Quebec by WES analysis were due to PVs in \u003Ci>RAD51C\u003C/i>, \u003Ci>RAD51D\u003C/i> or \u003Ci>BRIP1\u003C/i> approximating that 40% of such cases are unaccounted for by known or emerging OC predisposing genes (\u003Ca href=\"#B33\">33\u003C/a>, \u003Ca href=\"#B43\">43\u003C/a>, \u003Ca href=\"#B47\">47\u003C/a>). Also, we reported that likely pathogenic variants (LPV) in \u003Ci>FANCI\u003C/i>, a proposed new OC predisposing gene from the Fanconi anemia (FA) pathway, were rarely implicated in familial and sporadic OC cases in this population (\u003Ca href=\"#B24\">24\u003C/a>). We posit that DNA repair pathways genes have not been fully explored as candidate OC risk genes. In this study, we report the identification of candidate LPVs in DNA repair pathway genes that were identified by applying a candidate gene approach focusing on an extensive list of 468 DNA repair pathway genes in available WES data derived from the germline of FC familial OC cases. Candidate variants prioritized based on our bioinformatic analyses were selected for targeted genotyping in larger groups of defined FC cases to determine carrier frequencies in 1212 FC and 937 non-FC familial and sporadic OC cases and 1025 population-matched controls. Available tumour DNA from our FC carriers also was investigated for loss of the wild-type allele of candidate loci.\u003C/p>\u003Ca id=\"h3\" name=\"h3\">\u003C/a>\u003Ch2>Materials and methods\u003C/h2>\u003Ch3>Study participants\u003C/h3>\u003Cp class=\"mb0\">FC cancer cases and controls are described in \u003Ca href=\"#f1\">Figure&#xa0;1\u003C/a> and \u003Ca href=\"#h10\">Table S1\u003C/a>. For clarity, cases diagnosed with primary fallopian tubes or peritoneal cancers were included as cases in recognition of common aetiology with OC, which are associated with hereditary cancer risk factors (\u003Ca href=\"#B48\">48\u003C/a>, \u003Ca href=\"#B49\">49\u003C/a>). For the discovery of new candidate OC risk variants (study phase I; \u003Ca href=\"#f1\">Figure&#xa0;1A\u003C/a>), WES data from peripheral blood lymphocytes (PBL) DNA was available from 15 OC cases from 13 families, each family having at least two first-, second- or third-degree relatives with OC. These cases were confirmed negative for PVs in the known OC risk genes: \u003Ci>BRCA1\u003C/i>, \u003Ci>BRCA2, BRIP1, RAD51C\u003C/i> or \u003Ci>RAD51D\u003C/i> as previously reported (\u003Ca href=\"#B47\">47\u003C/a>, \u003Ca href=\"#B43\">43\u003C/a>). This group includes three index cases harbouring a LPV in \u003Ci>FANCI\u003C/i> c.1813C&gt;T; p.Leu605Phe (\u003Ca href=\"#B24\">24\u003C/a>). As \u003Ci>FANCI\u003C/i> remains a candidate OC predisposing gene requiring further independent studies, we did not exclude \u003Ci>FANCI\u003C/i> variant carriers from any of our study groups for our investigation.\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE&#xa0;1\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g001.jpg\" name=\"\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g001.jpg\" alt=\"www.frontiersin.org\" id=\"f1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cb>Figure&#xa0;1\u003C/b> Scheme describing different phases of this study in identifying and evaluating candidate variants in genes involved in various DNA repair pathways. The diagram illustrates: \u003Cb>(A)\u003C/b> study phase I for identifying candidate variants by applying a candidate gene approach of known or putative DNA repair genes (see \u003Ca href=\"#h10\">Table S2\u003C/a>) on peripheral blood lymphocytes (PBL) DNA from familial ovarian cancer (OC) cases of French Canadians (FC) of Quebec by whole exome sequencing (WES) and bioinformatic analyses (see \u003Ca href=\"#h10\">Table S1\u003C/a>); \u003Cb>(B)\u003C/b> study phase II for determining the carrier frequencies of the topprioritized candidate variants in FC familial and sporadic OC and BC cases, including hereditary breast and ovarian cancer (HBOC) syndrome and hereditary breast cancer (HBC) syndrome families, and population-matched controls by targeted genetic analyses (see \u003Ca href=\"#h10\">Table S1\u003C/a>); \u003Cb>(C)\u003C/b> study phase III for identifying additional carriers in FC OC cases by targeted genetic analyses (see \u003Ca href=\"#h10\">Table S1\u003C/a>); and \u003Cb>(D)\u003C/b> study phase IV for identifying candidate variants in the identified candidate DNA repair genes from phase I in non-FC OC cases, mainly of European origin, by targeted genetic analyses: (MIX, mixed ethnicity; AUS, Australian; and TCGA, The Cancer Genome Atlas) (see \u003Ca href=\"#h10\">Table S1\u003C/a>). Teal ribbon signifies women with OC and pink ribbon signifies women with BC, and diagrams contain the provincial flag of Quebec, Canada denoting the geographic ascertainment of cases and controls. MAF, Minor allele frequency; and VAF, Variant allele frequency.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cp class=\"mb15 w100pc float_left mt15\">Targeted analyses of the candidate variants was performed to determine their carrier frequencies (study phase II; \u003Ca href=\"#f1\">Figure&#xa0;1B\u003C/a>) on the PBL DNA from FC OC cases, regardless of their carrier status for \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> PVs, from 42 hereditary breast and ovarian cancer (HBOC) syndrome families having one OC and at least two BC cases in the same familial branch and 435 sporadic OC cases not selected for age at diagnosis with the disease or for family history of any cancers. Genetic data was available from 1025 population-matched controls provided by three independent biobanks as previously described (\u003Ca href=\"#B43\">43\u003C/a>). As known OC predisposing genes are also involved in BC risk (nccn.org/guidelines/category_2), targeted analyses of the candidate variants was also performed on the PBL DNA from FC BC cases, regardless of their \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> PV carrier status, from 33 HBOC families, 139 hereditary breast cancer (HBC) syndrome families having at least three close relatives with BC within first-, second- or third-degree of relationship from the same familial branch and 563 sporadic BC cases not selected for age at diagnosis with the disease or for family history of any cancers.\u003C/p>\u003Cp class=\"mb15\">Targeted analyses of PBL DNA from additional OC cases was performed to identify more OC carriers of our candidate variants (study phase III; \u003Ca href=\"#f1\">Figure&#xa0;1C\u003C/a>). These groups were comprised of: 52 sporadic early-onset cases diagnosed with high-grade serous ovarian carcinoma (HGSC) before the age of 50 years who tested negative for PVs in \u003Ci>BRCA1\u003C/i> or \u003Ci>BRCA2\u003C/i>; and 553 OC cases, regardless of their \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> PV carrier status and not defined by any criteria as previously described in this study (\u003Ca href=\"#B43\">43\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">The majority of FC cancer cases self-reported FC ancestry of Quebec as described previously (\u003Ca href=\"#B24\">24\u003C/a>, \u003Ca href=\"#B40\">40\u003C/a>, \u003Ca href=\"#B41\">41\u003C/a>, \u003Ca href=\"#B43\">43\u003C/a>, \u003Ca href=\"#B47\">47\u003C/a>, \u003Ca href=\"#B50\">50\u003C/a>&#x2013;\u003Ca href=\"#B56\">56\u003C/a>). FC controls from Universit&#xe9; de Sherbrooke-The Genetics of Glucose Regulation in Gestation and Growth (Gen3G) (\u003Ca href=\"#B57\">57\u003C/a>) and McGill University-Montreal Neurological Institute (MNI) (\u003Ca href=\"#B58\">58\u003C/a>) biobanks self-reported FC ancestry as described previously (\u003Ca href=\"#B43\">43\u003C/a>). FC controls from CARTaGENE biobank (cartagene.qc.ca) were born in the province of Quebec, reported being FC ancestry, having parents and all four grandparents born in Canada and French as first language learned as described previously (\u003Ca href=\"#B43\">43\u003C/a>, \u003Ca href=\"#B59\">59\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">The cancer cases and controls not selected for being of FC ancestry of Quebec, mainly of European ancestry are referred to as non-FC groups in this study, were available from different resources. Genetic analyses to determine the spectrum and prevalence of candidate variants in genes that were identified in the study phase I were performed (study phase IV; \u003Ca href=\"#f1\">Figure&#xa0;1D\u003C/a>) on available genetic data derived from PBL DNA from three independent groups with OC: 9 OC cases from 7 families with at least two close relatives with OC (MIX familial OC cases) (\u003Ca href=\"#B47\">47\u003C/a>); 516 OC familial or sporadic cases from the Australian population (AUS OC cases) (\u003Ca href=\"#B17\">17\u003C/a>) and 412 OC cases as part of The Cancer Genome Atlas (TCGA) Pan-Cancer Atlas project (not selected for ethnicity) (\u003Ca href=\"#B60\">60\u003C/a>) and cancer-free controls as part of the Genome Aggregation Database (gnomAD) v2.1.1. (\u003Ca href=\"#B61\">61\u003C/a>). The gnomAD v2.1.1. controls were also used to filter common variants as part of study phase I (\u003Ca href=\"#f1\">Figure&#xa0;1A\u003C/a> and \u003Ca href=\"#h10\">Table S1\u003C/a>) which is described in the following section.\u003C/p>\u003Cp class=\"mb0\">All biological samples, clinico-pathological, pedigree and relevant medical genetic information from the cancer cases and control groups that were investigated in this study are from biobanks where participants had been recruited in accordance with ethical guidelines of the biobanks respective Institutions Research Ethics Boards as described in \u003Ca href=\"#h10\">Table S1\u003C/a>. Where applicable, samples were anonymized at source by the providers and were assigned a unique identifier (PT followed by four digits) to further protect their identity. This project was conducted with approval and in accordance with the guidelines of The McGill University Health Centre Research Ethics Board (MP-37-2019-4783).\u003C/p>\u003Ch3>Identifying and selecting for top candidate variants in FC cancer cases\u003C/h3>\u003Cp class=\"mb15\">For phase I of the study (\u003Ca href=\"#f1\">Figure&#xa0;1A\u003C/a>), WES data was available from PBL DNA from 15 OC index cases from 13 cancer families that had at least one first-, second- or third-degree relative from the same familial branch with OC, and were confirmed being negative for PVs in \u003Ci>BRCA1\u003C/i>, \u003Ci>BRCA2, BRIP1, RAD51C\u003C/i> or \u003Ci>RAD51D\u003C/i> by WES analyses (\u003Ca href=\"#B43\">43\u003C/a>, \u003Ca href=\"#B47\">47\u003C/a>). WES had been subjected to a customized bioinformatics pipeline for germline variant calling at the McGill Genome Center as previously reported by our group (\u003Ca href=\"#B24\">24\u003C/a>, \u003Ca href=\"#B43\">43\u003C/a>). In brief, NimbleGen SeqCap\u003Csup>&#xae;\u003C/sup> EZ Exome v3.0 library kit (Roche, US), followed by paired-end sequencing on different Illumina HiSeq platforms was performed. Reads were aligned to the human reference genome assembly GRCh37/hg19 using Burrows-Wheeler aligner v0.7.17, followed by PCR deduplication using Picard v2.9.0. Realignment around small insertions and deletions was performed, and germline variants were called using HaplotypeCaller using Genome Analysis Toolkit (GATK) v3.5. Variants were then filtered for base sequencing quality score &#x2265;30 and annotated using Ensembl Variant Effect Predictor (VEP) and GEMINI v0.19.1.\u003C/p>\u003Cp class=\"mb15\">Using a candidate gene approach, a curated list of 468 known or putative DNA repair genes (\u003Ca href=\"#B28\">28\u003C/a>&#x2013;\u003Ca href=\"#B32\">32\u003C/a>) (ebi.ac.uk/QuickGO/term/GO:0006281) (\u003Ca href=\"#h10\">Table S2\u003C/a>) were investigated for candidate PVs in WES data from selected index OC cases (\u003Ca href=\"#f1\">Figure&#xa0;1A\u003C/a>). Variants identified in these DNA repair genes were extracted from the annotated variant call format (VCF) files from the index OC cases (\u003Ca href=\"#f1\">Figure&#xa0;1A\u003C/a>\u003Cb>)\u003C/b>. Variants with minor allele frequency (MAF) &gt;0.005 in gnomAD v2.1.1. (\u003Ca href=\"#B61\">61\u003C/a>, \u003Ca href=\"#B62\">62\u003C/a>), with total low coverage &lt;10 reads and/or those with variant allele frequency (VAF) &lt;0.2 and &gt;0.8 were filtered out and retained variants were subjected for further prioritization and selection. These thresholds have been tested previously under the assumption that new variants follow an autosomal dominant mode of inheritance (\u003Ca href=\"#B63\">63\u003C/a>). These variants were then verified by manual inspection in the aligned sequences in compressed binary alignment map (BAM) files by Integrative Genomics Viewer (IGV) v2.4.10. (\u003Ca href=\"#B64\">64\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">Top candidate variants were selected from this master list of variants for further analyses based on various prioritization criteria as shown in \u003Ca href=\"#f1\">Figure&#xa0;1A\u003C/a>. First, we prioritized LoF variants (nonsense, frameshift and alternative splicing variants), inframe, missense and intronic variants, which were predicted to be conserved and damaging at the RNA or protein level by 15 selected in silico tools: (1) by at least one out of three prediction tools for conservation Genomic Evolutionary Rate Profiling v1.0 (GERP++ [score&#x2265;2.0]) (\u003Ca href=\"#B65\">65\u003C/a>), Phylogenetic P value of 100 vertebrates v4.2 (PhyloP 100 way [score &#x2265;0.2]) (\u003Ca href=\"#B66\">66\u003C/a>) and PHAST Conservation of 100 vertebrates v4.2 (PhastCons 100 way [score &#x2265;0.9]) (\u003Ca href=\"#B67\">67\u003C/a>); (2) by at least one out of four prediction tools for splicing Maximum Entropy Estimates of Splice Junction v2.0 (MaxEntScan) (\u003Ca href=\"#B68\">68\u003C/a>), two different Database Splicing Consensus Single Nucleotide Variant (dbscSNV) in silico tools: AdaBoost v4.0 (ADA [score &#x2265;0.4]) and Random Forest v4.0 (RF [score&#x2265;0.4]) (\u003Ca href=\"#B69\">69\u003C/a>) and SpliceAI (score &#x2265;0.4) (\u003Ca href=\"#B70\">70\u003C/a>); and (3) at least six out of eight prediction tools for damaging of protein function based on their best performance (\u003Ca href=\"#B71\">71\u003C/a>&#x2013;\u003Ca href=\"#B74\">74\u003C/a>): Combined Annotation Dependent Depletion v1.4 (CADD [Phred score &#x2265;20]) (\u003Ca href=\"#B75\">75\u003C/a>), Eigen (score &#x2265;0.0) (\u003Ca href=\"#B76\">76\u003C/a>), Meta-analytic Logistic Regression v4.2 (MetaLR [score &#x2265;0.5]) (\u003Ca href=\"#B77\">77\u003C/a>), Meta-analytic support Vector Machine v4.2 (MetaSVM [score &#x2265;0.0]) (\u003Ca href=\"#B77\">77\u003C/a>), MetaRNN 4.2 (score &#x2265;0.5) (\u003Ca href=\"#B78\">78\u003C/a>), Rare Exome Variant Ensemble Learner v4.2 (REVEL [score &#x2265;0.5)) (\u003Ca href=\"#B79\">79\u003C/a>), Variant Effect Scoring Test v4.2 (VEST [score &#x2265;0.5]) (\u003Ca href=\"#B80\">80\u003C/a>) and Protein Variation Effect Analyzer v4.0 (PROVEAN v4.0 [score &#x2264;&#x2212;2.5]) (\u003Ca href=\"#B81\">81\u003C/a>). Then, the variants having a clinical classification as benign or likely benign in the context of hereditary cancer syndromes in ClinVar (\u003Ca href=\"#B82\">82\u003C/a>, \u003Ca href=\"#B83\">83\u003C/a>) and/or American College of Medical Genetics and Genomics (ACMG) guidelines (\u003Ca href=\"#B84\">84\u003C/a>, \u003Ca href=\"#B85\">85\u003C/a>) were given a lower priority for further investigation.\u003C/p>\u003Cp class=\"mb15\">The remaining prioritized variants were then subjected to further prioritization. Variants were surveyed in available genetic data generated from the germline of three FC study groups (\u003Ca href=\"#h10\">Table S1\u003C/a>): (1) WES data from the germline of 52 sporadic early-onset OC cases negative for PVs in \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> (\u003Ca href=\"#B43\">43\u003C/a>, \u003Ca href=\"#B47\">47\u003C/a>); and (2) sequencing-based (WES or whole genome sequencing [WGS]) data and/or genotyping-based data from 1025 FC controls (\u003Ca href=\"#B43\">43\u003C/a>). Then, the variants were subjected for further selection and characterization for genetic analyses.\u003C/p>\u003Cp class=\"mb0\">Selected top candidate variants were verified in the PBL DNA by bidirectional Sanger sequencing using customized primers (available upon request) performed at the McGill Genome Center as described previously (\u003Ca href=\"#B86\">86\u003C/a>, \u003Ca href=\"#B43\">43\u003C/a>, \u003Ca href=\"#B47\">47\u003C/a>; \u003Ca href=\"#B24\">24\u003C/a>, \u003Ca href=\"#B33\">33\u003C/a>). Sequencing chromatograms were visually inspected for variant heterozygosity using 4Peaks v1.8. (nucleobytes.com/4peaks/) (The Netherlands Cancer institute, Amsterdam, The Netherlands).\u003C/p>\u003Ch3>Determining carrier frequencies of selected candidate variants in FC cancer cases and controls\u003C/h3>\u003Cp class=\"mb15\">Selected top candidate variants were investigated for carrier frequencies in defined FC study groups (study phase II) comprised of 42 index OC and 33 index BC cases from 75 HBOC families, 139 index BC cases from 139 HBC families, 435 sporadic OC cases and 563 sporadic BC cases (\u003Ca href=\"#f1\">Figure&#xa0;1B\u003C/a> and \u003Ca href=\"#h10\">Table S1\u003C/a>). PBL DNA from index cases were genotyped using customized TaqMan\u003Csup>&#xae;\u003C/sup> (\u003Ca href=\"#B87\">87\u003C/a>), Sequenom iPLEX\u003Csup>&#xae;\u003C/sup> Gold (\u003Ca href=\"#B88\">88\u003C/a>) or Fluidigm\u003Csup>&#xae;\u003C/sup> SNP Type\u003Csup>&#x2122;\u003C/sup>(\u003Ca href=\"#B89\">89\u003C/a>) genotyping assays (primers available upon request) as described previously (\u003Ca href=\"#B24\">24\u003C/a>, \u003Ca href=\"#B43\">43\u003C/a>, \u003Ca href=\"#B90\">90\u003C/a>). Tumour DNA samples from the index case were genotyped where PBL DNA was no longer available from the biobank. Carriers of candidate variants were verified by bidirectional Sanger sequencing of PBL DNA as described above. Selected candidate variants were also investigated for carrier frequency in population-matched controls by surveying 1025 available sequencing-based data sets (\u003Ca href=\"#h10\">Table S1\u003C/a>) and/or 8493 single nucleotide polymorphism (SNP) genotyping-based data sets as previously described (\u003Ca href=\"#B43\">43\u003C/a>). For probes of variants not presented on the SNP array, pre-phasing and imputation were performed as described previously (\u003Ca href=\"#B24\">24\u003C/a>, \u003Ca href=\"#B43\">43\u003C/a>).\u003C/p>\u003Cp class=\"mb0\">Pair-wise comparisons were performed of carrier frequencies of candidate variants in different FC cancer groups versus sequencing-based controls. Two-tailed Fisher&#x2019;s exact test was used to compare carrier frequencies in the cancer versus control groups where un-adjusted \u003Ci>P\u003C/i> values &lt;0.05 for multiple testing was considered significant.\u003C/p>\u003Ch3>Targeted genetic analyses of selected candidate variants or genes in FC cancer cases\u003C/h3>\u003Cp class=\"mb0\">To further characterize our candidate variants and genes in a population exhibiting genetic drift, we investigated carrier status in additional OC cases from the FC population. Selected top candidate variants were investigated (study phase III) in 52 sporadic early-onset FC HGSC cases and in an additional 553 FC OC cases by surveying available genetic data or targeted genotyping of PBL DNA (\u003Ca href=\"#f1\">Figure&#xa0;1C\u003C/a> and \u003Ca href=\"#h10\">Table S1\u003C/a>). We also investigated other variants in our gene candidates that met our filtering and prioritizing criteria in the available WES data from the sporadic early-onset OC cases (\u003Ca href=\"#f1\">Figure&#xa0;1C\u003C/a>).\u003C/p>\u003Ch3>Loss of heterozygosity analyses of candidate genes loci in OC tumour DNA from FC candidate variant carriers\u003C/h3>\u003Cp class=\"mb0\">To investigate evidence for inactivation of candidate genes in cancer cells, we performed loss of heterozygosity (LOH) analysis of tumour DNA from variant carriers. Bi-directional Sanger sequencing of available tumour DNA was performed using customized primers (available upon request) as described above. Extracted DNA from fresh-frozen (FF) or histopathological sections from formalin-fixed paraffin-embedded (FFPE) tumour tissues were provided by the RRCancer biobank for DNA extraction and LOH analysis (Promega, Canada). Sequencing chromatograms were inspected for loss of the wild-type allele using 4Peaks v1.8. (nucleobytes.com/4peaks/) (The Netherlands Cancer Institute, Amsterdam, The Netherlands).\u003C/p>\u003Ch3>Genetic analyses of candidate genes in non-FC cancer cases and controls\u003C/h3>\u003Cp class=\"mb0\">To further characterize the candidate variants and genes identified in our FC cancer cases, we investigated available genetic data from other populations that were not specifically selected for FC ancestry. The spectrum and prevalence of our candidate variants were investigated in genetic data from non-FC OC cases being predominantly of European ancestry and cancer-free controls were investigated for new variants in our candidate genes that met our filtering and prioritizing criteria (\u003Ca href=\"#f1\">Figure&#xa0;1D\u003C/a> and \u003Ca href=\"#h10\">Table S1\u003C/a>). Variants were extracted from the annotated VCF files generated by WES data from the germline of: (1) 9 MIX familial OC cases; (2) 516 AUS OC cases; and (3) 412 OC cases from the Pan-Cancer TCGA project. Variants were extracted from the comma separated value (CSV) files downloaded directly from (\u003Ca href=\"https://gnomad.broadinstitute.org\">https://gnomad.broadinstitute.org\u003C/a>). All variants were annotated and subjected to our filtering and prioritizing criteria to identify candidate variants as described above (see \u003Ca href=\"#f1\">Figure&#xa0;1A\u003C/a>).\u003C/p>\u003Ch3>Genetic analyses for co-occurring rare pathogenic variants in known OC risk genes in FC and non-FC candidate variant carriers\u003C/h3>\u003Cp class=\"mb0\">We investigated available WES data from OC cases, to determine whether the identified carriers of candidate variants (regardless of the ethnicity and study phase in which they were identified) also harbour rare PVs or LPVs in known OC risk genes (n=11): \u003Ci>BRCA1\u003C/i> (NM_007294.4), \u003Ci>BRCA2\u003C/i> (NM_000059.4), \u003Ci>MLH1\u003C/i> (NM_000249.4), \u003Ci>MSH2\u003C/i> (NM_000251.3), \u003Ci>MSH6\u003C/i> (NM_000179.3), \u003Ci>PMS2\u003C/i> (NM_000535.7), \u003Ci>BRIP1\u003C/i> (NM_032043.3), \u003Ci>RAD51C\u003C/i> (NM_058216.3), \u003Ci>RAD51D\u003C/i> (NM_001142571.2), \u003Ci>PALB2\u003C/i> (NM_024675.4) and \u003Ci>ATM\u003C/i> (NM_000051.4) based on the National Comprehensive Cancer Network (NCCN) Clinical Practice in Oncology Guidelines 2022 (Version 2.2022) &#x2014;Genetic/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic (nccn.org/guidelines/category_2). Variants were extracted from the annotated VCF files from carriers and subjected to our filtering and prioritizing criteria as previously described (\u003Ca href=\"#B47\">47\u003C/a>).\u003C/p>\u003Ca id=\"h4\" name=\"h4\">\u003C/a>\u003Ch2>Results\u003C/h2>\u003Ch3>Prioritization and selection of candidate variants: Phase I\u003C/h3>\u003Cp class=\"mb0\">We first extracted variants identified in a curated list of 468 DNA repair genes (\u003Ca href=\"#h10\">Table S2\u003C/a>) from VCF files generated from WES data from the 15 index FC OC cases from 13 families. In these index cases, we identified a total of 3,557 variants in 426 of 468 DNA repair genes (\u003Ca href=\"#f1\">Figure&#xa0;1\u003C/a>). Based on their rarity and variant quality, we retained a total of 201 variants in 137 of 426 DNA repair genes where each index case harboured 3 to 25 (median=15) variants. From this list of 201 variants, we prioritized candidates that were predicted to be conserved or damaging at the level of RNA or protein using our selected in silico tools; and those classified benign or likely benign in the context of hereditary cancers using ClinVar and/or ACMG guidelines were not pursued further. Using these criteria, we retained a total of 15 of the 201 variants, each of which was found in a different gene: 3 nonsense variants, 1 canonical alternative splicing variant, 1 inframe and 10 missense variants (\u003Ca href=\"#h10\">Table S3\u003C/a>). These variants were identified in 10 of the 15 index cases from 8 out of the 13 OC families (\u003Ca href=\"#f2\">Figures&#xa0;2\u003C/a>,  \u003Ca href=\"#h10\">S1\u003C/a>). One of these variants was identified in two OC cases from the same family, two variants were identified in two OC cases from the same family and the remaining 12 variants were identified in one index case from independent OC families (\u003Ca href=\"#h10\">Table S3\u003C/a>). Two cases harboured either three or four variants, while the remaining nine cases harboured one to two variants.\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE&#xa0;2\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g002.jpg\" name=\"\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g002.jpg\" alt=\"www.frontiersin.org\" id=\"f2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cb>Figure&#xa0;2\u003C/b> Pedigrees of index ovarian cancer cases harbouring candidate variants in DNA repair genes identified in phase I of the study. Selected top candidate variants were identified in 5 of 13 families having at least two or more OC cases. Anonymized pedigrees indicate carrier status of tested index case (arrow) and available family members denoted by plus (carrier) or minus (not a carrier) signs. All Index cases (arrow) were subjected to whole exome sequencing analyses (WES). All carriers were found in a heterozygous state. Age in years is shown at cancer diagnosis and death where applicable. Superscript C denotes histological subtypes that were confirmed by pathology reports or death certificates.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cp class=\"mb0\">To select our top candidates for further analyses, we reviewed the individual context wherein the 15 variants were identified as shown in \u003Ca href=\"#h10\">Table S3\u003C/a> and \u003Ca href=\"#f2\">Figures&#xa0;2\u003C/a>, \u003Ca href=\"#h10\">S1\u003C/a>. We estimated the allele frequencies of the 15 candidate variants in population-matched FC controls. Thereby, we did not pursue \u003Ci>ALKBH3\u003C/i> c.677A&gt;G; p.Asn226Ser, which was identified in an index case (PT0136) from family F1506, as it has a MAF &#x2265;0.01 in FC controls. We also excluded the missense variant in \u003Ci>DNA2\u003C/i> c.836C&gt;T; p.Thr279Ile for further analyses as it was identified in the index case (PT0128) and four unaffected members of the family F694, and was not inherited from the affected mother with the family history of OC and other cancers (\u003Ca href=\"#h10\">Figure S1\u003C/a>). We did not pursue \u003Ci>RBBP8\u003C/i> c.1941T&gt;G; p.Asp647Glu as it was not harboured by the other index OC case (PT0056) from the same family F1528 (\u003Ca href=\"#h10\">Figure S1\u003C/a>). Additional variants that were excluded for further analyses included: (1) \u003Ci>RHNO1\u003C/i> c.250C&gt;T; p.Arg84Ter in the index OC case (PT0158) from family F1288; (2) \u003Ci>ATRX\u003C/i> c.4377_4379del; p.Glu1464del in one of the index OC case (PT0057) from family F1528 as they were classified as benign in ClinVar and by ACMG guidelines, and the latter as not being harboured by the other index OC case of the same family F1528 (\u003Ca href=\"#h10\">Figure S1\u003C/a>); (3) \u003Ci>SMARCA2\u003C/i> c.3265C&gt;T in the index OC case (PT0128) from family F694; p.Arg1089Trp; and (4) \u003Ci>KMT2C\u003C/i> c.6916C&gt;T; p.Pro2306Ser in the index OC case (PT0047) from family F1490 as variants in these genes are associated with non-cancer related syndromes (\u003Ca href=\"#h10\">Figure S1\u003C/a>). Heterozygous germline variants in \u003Ci>SMARCA2\u003C/i> are linked with Nicolaides-Baraitser syndrome (MIM: 601358), which is characterized by intellectual disability, seizures, limited to absence of speech ability, short stature, dysmorphic facial features and sparse hair (\u003Ca href=\"#B91\">91\u003C/a>, \u003Ca href=\"#B92\">92\u003C/a>; \u003Ca href=\"#B93\">93\u003C/a>&#x2013;\u003Ca href=\"#B97\">97\u003C/a>); and heterozygous germline variants in \u003Ci>KMT2C\u003C/i> are linked with Kleefstra syndrome, type 2 (MIM: 617768), which is characterized by delayed psychomotor development, variable intellectual disability and mild dysmorphic features (\u003Ca href=\"#B98\">98\u003C/a>&#x2013;\u003Ca href=\"#B101\">101\u003C/a>). A genotype-phenotype of heterozygous variants located within exon 15-25 of \u003Ci>SMARCA2\u003C/i>, which encodes the ATPase domain, have been recently reported that over 80% of these variants were \u003Ci>de novo\u003C/i> based on WES analyses of 80 cases in trios with Nicolaides-Baraitser syndrome that have been documented worldwide so far (\u003Ca href=\"#B92\">92\u003C/a>, \u003Ca href=\"#B95\">95\u003C/a>, \u003Ca href=\"#B97\">97\u003C/a>). Our \u003Ci>SMARCA2\u003C/i> c.3265C&gt;T; p.Arg1089Trp has never been reported in the literature, but it is located in exon 23 that encodes the ATPase domain (\u003Ca href=\"#B97\">97\u003C/a>). Whereas, \u003Ci>KMT2C\u003C/i> c.6916C&gt;T; p.Pro2306Ser was reported in the context of Kleefstra syndrome (\u003Ca href=\"#B100\">100\u003C/a>). Finally, we did not pursue: \u003Ci>RECQL5\u003C/i> c.918G&gt;A; p.Met306Ile, \u003Ci>ASCC3\u003C/i> c.3808C&gt;T; p.Arg1270Ter and \u003Ci>UBB\u003C/i> c.569C&gt;A; p.Pro190His as all were harboured by the same index case (PT0139) from family F1606 that also harbouring \u003Ci>FANCC\u003C/i> c.897G&gt;T; p.Arg299Ser as this variant is a plausible and intriguing candidate where \u003Ci>FANCC\u003C/i> has been reported as a candidate BC predisposing gene (\u003Ca href=\"#B102\">102\u003C/a>). Thus, \u003Ci>FANCC\u003C/i> c.897G&gt;T; p.Arg299Ser and the remaining variants identified in \u003Ci>ERCC5\u003C/i> c.2556A&gt;G; p.Ile852Met\u003Ci>, EXO1\u003C/i> c.1268-1G&gt;T\u003Ci>, NEIL1\u003C/i> c.248G&gt;T; p.Gly83Asp and \u003Ci>NTHL1\u003C/i> c.244C&gt;T; p.Gln82Ter from our list of most promising variants were selected for further analyses as candidates.\u003C/p>\u003Ch3>Characterization of the selected top candidate variants: Phase I\u003C/h3>\u003Cp class=\"mb0\">We selected five variants each identified in an OC family for further characterization and analyses (\u003Ca href=\"#T1\">Table&#xa0;1\u003C/a> and \u003Ca href=\"#f2\">Figure&#xa0;2\u003C/a>): a nonsense variant \u003Ci>NTHL1\u003C/i> c.244C&gt;T; p.Gln82Ter, a canonical splicing variant \u003Ci>EXO1\u003C/i> c.1268-1G&gt;T, an exonic splicing variant \u003Ci>FANCC\u003C/i> c.897G&gt;T; p.Arg299Ser and two missense variants \u003Ci>ERCC5\u003C/i> c.2556A&gt;G; p.Ile852Met and \u003Ci>NEIL1\u003C/i> c.248G&gt;T; p.Gly83Asp. Both missense variants were predicted to affect amino acid residues that are located in catalytic domains of their respective proteins that are critical to the biological function of ERCC5 (\u003Ca href=\"#B108\">108\u003C/a>) and NEIL1 (\u003Ca href=\"#B109\">109\u003C/a>) in the HR, nucleotide excision repair (NER) and base excision repair (BER) pathways.\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">TABLE&#xa0;1\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t001.jpg\" name=\"table&#xa0;1\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t001.jpg\" alt=\"www.frontiersin.org\" id=\"T1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cb>Table&#xa0;1\u003C/b> Characteristics of top-prioritized candidate variants identified in familial French Canadian cases with ovarian cancer.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cp class=\"mb15 w100pc float_left mt15\">Except for \u003Ci>EXO1\u003C/i> c.1268-1G&gt;T, which was not found in the gnomAD v2.1.1. database, all other candidate variants were found to have MAFs between 0.002 and 0.00001 in the non-cancer non-Finnish European populations with variation in these frequencies across populations of different ancestry groups (\u003Ca href=\"#h10\">Table S4\u003C/a>). The loci of all five candidate variants were predicted to be conserved by at least one of the selected in silico tools. The variants in \u003Ci>EXO1\u003C/i> and \u003Ci>FANCC\u003C/i> were predicted to affect splicing by all four selected in silico tools. The missense variants in \u003Ci>ERCC5\u003C/i> and \u003Ci>NEIL1\u003C/i> were predicted to be damaging by at least six selected in silico tools, including REVEL and VEST, which are two of the recently validated as top performing prediction in silico tools (\u003Ca href=\"#B73\">73\u003C/a>) (\u003Ca href=\"#h10\">Table S3\u003C/a>). Only \u003Ci>NTHL1\u003C/i> c.244C&gt;T; p.Gln82Ter is classified as PV in ClinVar and by ACMG guidelines in the context of hereditary multi-cancer syndrome in an autosomal recessive mode of inheritance, and has recently been associated with BC risk in an autosomal dominant mode of inheritance (\u003Ca href=\"#B110\">110\u003C/a>, \u003Ca href=\"#B111\">111\u003C/a>). Whereas, \u003Ci>FANCC\u003C/i> c.897G&gt;T; p.Arg299Ser was classified as being of uncertain significance (VUS) in ClinVar in the context of FA, an autosomal recessive disorder (MIM: 227645) and as LPV by ACMG guidelines. As noted above, \u003Ci>FANCC\u003C/i> has been associated with BC predisposition in an autosomal dominant mode of inheritance (\u003Ca href=\"#B102\">102\u003C/a>). The remaining candidate variants have not been reported in ClinVar, but classified by ACMG guidelines as LPV for \u003Ci>EXO1\u003C/i> c.1268-1G&gt;T, VUS for \u003Ci>ERCC5\u003C/i> c.2556A&gt;G; p.Ile852Met and likely benign for \u003Ci>NEIL1\u003C/i> c.248G&gt;T; p.Gly83Asp.\u003C/p>\u003Cp class=\"mb0\">We genotyped PBL DNA samples from family members of the index carriers where possible to determine if the candidate allele segregated with disease (\u003Ca href=\"#f2\">Figure&#xa0;2\u003C/a>). For family F1085, both the unaffected mother (PT0178) and sister (PT0177) of the index carrier cases did not carry \u003Ci>NTHL1\u003C/i> c.244C&gt;T; p.Gln82Ter, suggesting that the variant allele may have been transmitted paternally. This observation is interesting as the paternal side of the family had numerous cancer cases including BC, OC, colorectal and pancreatic cancers. In family F1288, though the mother of the index \u003Ci>EXO1\u003C/i> c.1268-1G&gt;T carrier case (PT0158) with BC and melanoma also carried the \u003Ci>EXO1\u003C/i> variant, her sibling (PT0180) and maternal female cousin (PT0181) both with BC were not carriers of the \u003Ci>EXO1\u003C/i> variant. These observations are interesting given the number of different types of cancer cases on the maternal side of the family. In family F1506, the index carrier harbouring \u003Ci>ERCC5\u003C/i> c.2556 A&gt;G also had a remarkable family history of diverse cancer types, whereas the index carrier of \u003Ci>NEIL1\u003C/i> c.248G&gt;T; c.1268-1G&gt;T from family F1601 had a cancer family history consistent with HBOC syndrome. The index carrier of \u003Ci>FANCC\u003C/i> c.897G&gt;T; p.Arg299Ser from family F1606 reported a mother with OC and a father with lung cancer.\u003C/p>\u003Ch3>Identification of carriers of selected candidate variants in defined FC cancer study groups: Phase II\u003C/h3>\u003Cp class=\"mb15\">We genotyped or surveyed available genetic data of our candidate variants: \u003Ci>NTHL1\u003C/i> c.244C&gt;T; p.Gln82Ter, \u003Ci>EXO1\u003C/i> c.1268-1G&gt;T\u003Ci>, FANCC\u003C/i> c.897G&gt;T; p.Arg299Ser, \u003Ci>ERCC5\u003C/i> c.2556A&gt;G; p.Ile852Met and \u003Ci>NEIL1\u003C/i> c.248G&gt;T; p.Gly83Asp in different FC OC and BC study groups and population-matched controls, regardless of their carrier status for \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> PVs (\u003Ca href=\"#f1\">Figure&#xa0;1B\u003C/a> and \u003Ca href=\"#h10\">Table S1\u003C/a>). Carriers were identified in the sporadic OC study group with frequencies of 0.2% (1/435) for \u003Ci>EXO1\u003C/i> variant carriers and 0.5% (2/435) for carriers of each \u003Ci>NTHL1\u003C/i>, \u003Ci>ERCC5\u003C/i> or \u003Ci>NEIL1\u003C/i> variants, and one \u003Ci>NTHL1\u003C/i> carrier among sporadic BC cases (0.2%, 1/563). Carriers were not identified among index cases from HBOC and HBC families. \u003Ci>FANCC\u003C/i> variant carriers were not identified in any of these FC cancer study groups.\u003C/p>\u003Cp class=\"mb0\">Carriers of all candidate variants in the FC controls are likely very rare as indicated by the observation that only one carrier was identified among 1025 FC sequencing-based controls (\u003Ca href=\"#T2\">Table&#xa0;2\u003C/a>). Identifying a carrier of \u003Ci>NTHL1\u003C/i> c.224C&gt;T; p.Gln82Ter was not surprising given the frequency of carriers of this variant = 0.002 in the non-cancer non-Finnish European population in gnomAD v2.1.1 (\u003Ca href=\"#h10\">Table S4\u003C/a>). Overall, the carrier frequencies of our candidates are higher in cancer groups relative to our population-matched controls though the results were not significant (\u003Ca href=\"#T2\">Table&#xa0;2\u003C/a>).\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">TABLE&#xa0;2\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t002.jpg\" name=\"table&#xa0;2\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-t002.jpg\" alt=\"www.frontiersin.org\" id=\"T2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cb>Table&#xa0;2\u003C/b> Carrier frequency of candidate variants in French Canadian cancer cases and controls.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cp class=\"mb0\">We investigated our variants in 8493 non-cancer SNP array genotyping-based controls from cancer-free FC population (see \u003Ca href=\"#h10\">Table S1\u003C/a>). None of the probes for variants in \u003Ci>EXO1, FANCC\u003C/i> and \u003Ci>ERCC5\u003C/i> were represented on any of the SNP arrays, nor was imputation possible as they were not represented in the Haplotype Reference Consortium (HRC.r1) release panel (\u003Ca href=\"#B43\">43\u003C/a>). However, we were able to determine the carrier frequency of the \u003Ci>NTHL1\u003C/i> (0.2%, 19/8493) and \u003Ci>NEIL1\u003C/i> (0.3%, 24/8493) variants (\u003Ca href=\"#h10\">Table S5\u003C/a>). The frequencies of these variants are consistent with those in the non-cancer non-Finnish European population in gnomAD v2.1.1. (\u003Ca href=\"#h10\">Table S4\u003C/a>), though we did not identify any carriers among the FC controls harbouring both \u003Ci>NTHL1\u003C/i> and \u003Ci>NEIL1\u003C/i> candidate variants.\u003C/p>\u003Ch3>Genetic analyses of other FC OC cases identified additional carriers of candidate variants: Phase III\u003C/h3>\u003Cp class=\"mb0\">Given genetic drift exhibited by the FC population that may result in higher frequency of candidate variant carriers with OC (\u003Ca href=\"#B34\">34\u003C/a>, \u003Ca href=\"#B35\">35\u003C/a>, \u003Ca href=\"#B43\">43\u003C/a>), we genotyped the germline of PBL DNA from additional 553 FC OC cases, which were recruited to the biobank but did not meet our criteria for the abovementioned defined OC study groups, and surveyed WES data available from 52 early-onset OC cases (\u003Ca href=\"#f1\">Figure&#xa0;1C\u003C/a> and \u003Ca href=\"#h10\">Table S1\u003C/a>). We identified a total of six OC cases harbouring \u003Ci>NTHL1\u003C/i> c.244C&gt;T (n=1), \u003Ci>EXO1\u003C/i> c.1268-1G&gt;T (n=1), \u003Ci>FANCC\u003C/i> c.897G&gt;T (n=1) and \u003Ci>NEIL1\u003C/i> c.248G&gt;A (n=3) (\u003Ca href=\"#h10\">Table S6\u003C/a>).\u003C/p>\u003Ch3>Genetic analyses of sporadic early-onset FC OC cases identified other variants in our candidate genes: Phase III\u003C/h3>\u003Cp class=\"mb0\">Given the genetic heterogeneity observed in the FC population for rare PVs identified in \u003Ci>BRCA1, BRCA2\u003C/i>, \u003Ci>RAD51C\u003C/i> and \u003Ci>RAD51D\u003C/i> (\u003Ca href=\"#B33\">33\u003C/a>, \u003Ca href=\"#B43\">43\u003C/a>, \u003Ca href=\"#B44\">44\u003C/a>), we surveyed WES data available from 52 early-onset FC OC cases diagnosed at less than 50 years of age (\u003Ca href=\"#f1\">Figure&#xa0;1C\u003C/a> and \u003Ca href=\"#h10\">Table S1\u003C/a>). The rationale for investigating this group is based on the plausibility that carriers of some of the known OC predisposing genes are more likely to develop OC before age of 60 as it is the median age of diagnosis of this disease in the general population with OC (\u003Ca href=\"#B112\">112\u003C/a>, \u003Ca href=\"#B113\">113\u003C/a>). We identified a carrier of a rare variant in \u003Ci>NEIL1\u003C/i> c.569C&gt;A; p.Pro276His that met our filtering and prioritizing criteria (\u003Ca href=\"#h10\">Table S6\u003C/a>). We genotyped this variant in our defined FC cancer study groups and controls, and we did not identify any other carriers of this \u003Ci>NEIL1\u003C/i> variant or in any of the additional 553 FC OC cases. We could not determine the variant carrier frequency in the 8493 genotyping-based FC cancer-free controls as it was not represented on the SNP array, and we could not impute this variant as it was not available in the HRC.r1 haplotype reference panel.\u003C/p>\u003Ch3>Evidence of loss of the wild-type allele in tumour DNA from carriers of candidate variants\u003C/h3>\u003Cp class=\"mb0\">As known OC risk genes behave as tumour suppressors where there is loss of the gene function in tumours is be expected (\u003Ca href=\"#B114\">114\u003C/a>), we performed LOH analyses to investigate one of the classical mechanisms of inactivation of the loci of our candidate genes: \u003Ci>ERCC5\u003C/i>, \u003Ci>EXO1\u003C/i>, \u003Ci>FANCC\u003C/i>, \u003Ci>NEIL1\u003C/i> or \u003Ci>NTHL1\u003C/i>. We were able to perform LOH analyses on OC tumour DNA from our FC carriers of the candidate variants where possible due to availability from the RRCancer biobank as follows: \u003Ci>NTHL1\u003C/i> c.244C&gt;T; p.Gln82Ter (n=4), \u003Ci>FANCC\u003C/i> c.897G&gt;T; p.Arg299Ser (n=1), \u003Ci>ERCC5\u003C/i> c.2556A&gt;G; p.Ile852Met (n=2) and \u003Ci>NEIL1\u003C/i> c.248G&gt;T; p.Gly83Asp (n=3) (\u003Ca href=\"#h10\">Table S7\u003C/a>). Chromatograms of bidirectional Sanger sequencing of OC tumour DNA and case matched normal were inspected for allelic content. We observed partial or complete loss of the wild-type alleles in the tumour DNA from two \u003Ci>NEIL1\u003C/i> variant carriers, two \u003Ci>NTHL1\u003C/i> variant carriers and one \u003Ci>ERCC5\u003C/i> variant carrier (\u003Ca href=\"#h10\">Table S7\u003C/a>); chromatogram of one example is shown in \u003Ca href=\"#f3\">Figure&#xa0;3\u003C/a>. Moreover, we observed partial or complete loss of the wild-type alleles in the tumour DNA from the left and the right ovaries from both \u003Ci>NTHL1\u003C/i> variant carriers having bilateral OC. There was no clear evidence for loss of the wild-type allele in the remaining samples from tumour DNA from carriers of \u003Ci>FANCC\u003C/i> or \u003Ci>EXO1\u003C/i>. However, loss of the variant allele was observed in the tumour DNA from \u003Ci>FANCC\u003C/i> and \u003Ci>EXO1\u003C/i> variant carriers (\u003Ca href=\"#h10\">Table S7\u003C/a>).\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE&#xa0;3\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g003.jpg\" name=\"\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g003.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g003.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g003.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g003.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g003.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g003.jpg\" alt=\"www.frontiersin.org\" id=\"f3\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cb>Figure&#xa0;3\u003C/b> Loss of heterozygosity analyses of candidate genes loci. Sanger sequencing chromatograms showing loss of heterozygosity (LOH) analyses of the candidate variants (see \u003Ca href=\"#h10\">Table S7\u003C/a>), in genomic peripheral blood lymphocyte (PBL) DNA, ovarian tumour tissue DNA from carriers of \u003Cb>(A)\u003C/b> \u003Ci>NEIL1\u003C/i> c.248G&gt;T; p.Gly83Asp (PT0171); \u003Cb>(B)\u003C/b> \u003Ci>NTHL1\u003C/i> c.244C&gt;T; p.Gln82Ter (PT0160); and \u003Cb>(C)\u003C/b> \u003Ci>ERCC5\u003C/i> c.2556A&gt;G; p.Ile852Met (PT0136). Each variant is indicated by an arrow. One example of such genetic event per candidate variant carrier is shown.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Ch3>Genetic analyses of non-FC cases identified other candidate variants in our gene candidates: Phase IV\u003C/h3>\u003Cp class=\"mb0\">To determine the relevance of our candidate genes to OC in non-FC populations, we investigated the spectrum and prevalence of rare variants in our candidate genes in genetic data from three defined non-FC study groups (\u003Ca href=\"#f1\">Figure&#xa0;1D\u003C/a> and \u003Ca href=\"#h10\">Table S1\u003C/a>). We applied our filtering and prioritizing criteria to WES data that was available from the germline of PBL DNA from: (1) 9 index OC cases from MIX familial OC cases; (2) 516 index AUS OC cases from HBOC and sporadic disease; and (3) 412 OC cases from Pan-Cancer &#x2013; TCGA. In these study groups, we identified: one of the 9 MIX familial OC cases (11.1%) harbouring a \u003Ci>NTHL1\u003C/i> variant; 17 of 516 AUS OC cases (3.3%) harbouring 11 variants in \u003Ci>NTHL1\u003C/i> (n=6), \u003Ci>NEIL1\u003C/i> (n=3), \u003Ci>ERCC5\u003C/i> (n=1) and \u003Ci>EXO1\u003C/i> (n=1); 12 of 412 Pan-Cancer &#x2013; TCGA OC cases (2.9%) harbouring 10 variants in \u003Ci>NEIL1\u003C/i> (n=4), \u003Ci>EXO1\u003C/i> (n=2), \u003Ci>FANCC\u003C/i> (n=2), \u003Ci>NTHL1\u003C/i> (n=1) and \u003Ci>ERCC5\u003C/i> (n=1) (\u003Ca href=\"#h10\">Table S6\u003C/a> and \u003Ca href=\"#f4\">Figure&#xa0;4\u003C/a>). Noteworthy, the frequency of all LoF rare (MAF &#x2264;0.005) variants in these genes in the cancer-free gnomAD v2.1.1 controls as follows: 112/1,563 (0.07) in \u003Ci>ERCC5\u003C/i>; 105/1,207 (0.09) in \u003Ci>EXO1\u003C/i>; 87/943 (0.09) in \u003Ci>FANCC\u003C/i>; 85/811 (0.1) in \u003Ci>NEIL1\u003C/i> and 47/629 (0.07) in \u003Ci>NTHL1\u003C/i>. Collectively, candidate variants we identified in cancer cases are comprised of three nonsense, four frameshift, three alternative splicing and nine missense variants. Variants in and \u003Ci>NEIL1\u003C/i> (n=3), \u003Ci>EXO1\u003C/i> (n=2), \u003Ci>NTHL1\u003C/i> (n=2), \u003Ci>ERCC5\u003C/i> (n=1) and \u003Ci>FANCC\u003C/i> (n=1) were LoF variants and classified as PVs or LPVs in ClinVar and/or by ACMG guidelines. The remaining variants were missense predicted to be PV or LPVs by our set of in silico tools. Some of these variants were those already identified in our FC study groups: three of 516 (0.6%) AUS OC cases and two of 412 (0.5%) Pan-Cancer &#x2013; TCGA OC cases carried \u003Ci>NTHL1\u003C/i> c.244C&gt;T; p.Gln82Ter, while one each of 516 (0.2%) AUS OC cases and 412 (0.2%) Pan-Cancer &#x2013; TCGA OC cases carried \u003Ci>NEIL1\u003C/i> c.248G&gt;A; p.Gly83Asp.\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE&#xa0;4\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g004.jpg\" name=\"\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g004.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g004.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g004.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g004.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g004.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g004.jpg\" alt=\"www.frontiersin.org\" id=\"f4\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cb>Figure&#xa0;4\u003C/b> Location of candidate variants in \u003Ci>NTHL1\u003C/i>, \u003Ci>EXO1\u003C/i>, \u003Ci>FANCC\u003C/i>, \u003Ci>ERCC5\u003C/i> and \u003Ci>NEIL1\u003C/i> identified in all study groups. The coding regions and protein domains of candidate genes \u003Ci>NTHL1\u003C/i> (NM_002528.7), \u003Ci>EXO1\u003C/i> (NM_130398.4), \u003Ci>FANCC\u003C/i> (NM_000136.3), \u003Ci>ERCC5\u003C/i> (NM_000123.4) and \u003Ci>NEIL1\u003C/i> (NM_024608.4), based on NCBI RefSeq transcripts (tark.ensembl.org/web/manelist/) (\u003Ca href=\"#B103\">103\u003C/a>), were annotated for the location of candidate variants. Variants classified as PV or LPV are bolded and those identified in French Canadian ovarian cancer cases each are indicated with an arrow.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cp class=\"mb0\">We identified one Pan-Cancer &#x2013; TCGA OC carrier of a synonymous variant in \u003Ci>NEIL1\u003C/i> c.159C&gt;T; p.Gly53Gly that was predicted to affect splicing using SpliceAI (\u003Ca href=\"#B115\">115\u003C/a>) that may result in gain of a new donor splice site.\u003C/p>\u003Ch3>Most candidate variant carriers do not harbour co-occurring pathogenic variants in known OC predisposing genes\u003C/h3>\u003Cp class=\"mb15\">We investigated whether OC carriers harbouring any of our candidate variants may also harbour PVs in known OC predisposing genes (n=11) (nccn.org/guidelines/category_2) (\u003Ca href=\"#h10\">Tables S8\u003C/a>, \u003Ca href=\"#h10\">S9\u003C/a>). Only one of the 15 FC OC carriers investigated carried both \u003Ci>NEIL1\u003C/i> c.248G&gt;A; p.Gly83Asp (PT0175) and \u003Ci>BRCA1\u003C/i> c.5102_5103del; p.Leu1701GlnfsTer14. This \u003Ci>BRCA1\u003C/i> variant is one of the most frequently occurring PVs in OC and BC cases from the FC population (\u003Ca href=\"#B33\">33\u003C/a>, \u003Ca href=\"#B40\">40\u003C/a>, \u003Ca href=\"#B41\">41\u003C/a>, \u003Ca href=\"#B116\">116\u003C/a>).\u003C/p>\u003Cp class=\"mb0\">Regarding non-FC OC carriers, one of the 17 OC AUS carriers of \u003Ci>NEIL1\u003C/i> c.248G&gt;A; p.Gly83Asp (PT0314) also harboured a variant in a known OC risk gene \u003Ci>RAD51C\u003C/i> c.145+1_145+2insC, which was classified as PV by ACMG guidelines (\u003Ca href=\"#h10\">Table S9\u003C/a>) and was reported previously in an investigation of this study group (\u003Ca href=\"#B17\">17\u003C/a>). Two of the 13 carriers of our candidate variants from OC Pan-Cancer &#x2013; TCGA project cases, harboured variants in known OC risk genes: a carrier of \u003Ci>NTHL1\u003C/i> c.244C&gt;T; p.Gln82Ter (PT0261) also harboured \u003Ci>BRCA2\u003C/i> c.5065_5066insA; p.Ala1689AspfsTer6 and a carrier of \u003Ci>EXO1\u003C/i> c.2152C&gt;T; p.Gln718Ter (PT0263) also harboured \u003Ci>BRCA2\u003C/i> c.1029del; p.Lys343AsnfsTer6. Both \u003Ci>BRCA2\u003C/i> variants have been classified as PVs in the ClinVar database and by ACMG guidelines.\u003C/p>\u003Ca id=\"h5\" name=\"h5\">\u003C/a>\u003Ch2>Discussion\u003C/h2>\u003Cp class=\"mb15\">Our investigation of potentially deleterious variants in 468 genes that play a direct or associated role in various DNA repair pathways in the FC population exhibiting genetic drift identified LoF and potentially deleterious missense variants as candidates for OC predisposition in \u003Ci>ERCC5\u003C/i>, \u003Ci>EXO1\u003C/i>, \u003Ci>FANCC\u003C/i>, \u003Ci>NEIL1\u003C/i> or \u003Ci>NTHL1\u003C/i>. Genotyping analyses of independently ascertained FC cancer study groups identified multiple carriers with OC harbouring the same variant, which is likely due to common ancestors within the FC population of Quebec (\u003Ca href=\"#B33\">33\u003C/a>&#x2013;\u003Ca href=\"#B35\">35\u003C/a>). Overall, carriers of each variant are rare, each accounting for &lt;1%, but collectively 9.6% of 52 familial OC cases with at least two or more OC cases and 1.6% of all 435 sporadic OC cases versus 0.1% of the population-matched controls. It is notable that none of the variants were found in known OC predisposing genes (nccn.org/guidelines/category_2), confirming prior findings from either clinical testing or our WES analyses of this group of cases (\u003Ca href=\"#B24\">24\u003C/a>, \u003Ca href=\"#B43\">43\u003C/a>, \u003Ca href=\"#B47\">47\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">Our candidate variants were identified by investigating a curated list of 468 known or putative genes involved in different DNA repair pathways. \u003Ci>ERCC5\u003C/i> is known to be involved in the NER pathway as an endonuclease, but it has been shown that this gene is also involved in the BER (\u003Ca href=\"#B117\">117\u003C/a>) and HR (\u003Ca href=\"#B108\">108\u003C/a>) pathways. \u003Ci>EXO1\u003C/i> is involved in the HR and MMR pathways as an exonuclease (\u003Ca href=\"#B118\">118\u003C/a>, \u003Ca href=\"#B119\">119\u003C/a>). \u003Ci>FANCC\u003C/i> plays a role in the FA pathway as a member of the core complex (\u003Ca href=\"#B120\">120\u003C/a>). \u003Ci>NTHL1\u003C/i> and \u003Ci>NEIL1\u003C/i> are DNA glycosylases in the BER pathway (\u003Ca href=\"#B121\">121\u003C/a>). Although the role of these genes in conferring risk to hereditary OC requires further investigation with larger cohorts, a recent Australian study of familial and sporadic OC cases reported that there was a statistically significant difference in the frequency of germline LoF variants in the single-stranded DNA repair pathway genes involved in BER, NER and MMR in OC cases versus non-cancer controls (\u003Ca href=\"#B17\">17\u003C/a>). On the other hand, homozygous or compound heterozygous PVs in \u003Ci>NTHL1\u003C/i> have been linked to Familial adenomatous polyposis - 3 (MIM: 616415) (\u003Ca href=\"#B122\">122\u003C/a>) and most recently a multi-tumour phenotype (\u003Ca href=\"#B123\">123\u003C/a>). Homozygous or compound heterozygous PVs in \u003Ci>FANCC\u003C/i> and \u003Ci>ERCC5\u003C/i> are known to be linked to autosomal recessive disorders, Fanconi anemia complementation group C (MIM: 227645) and Xeroderma pigmentosum complementation group G (MIM: 278780), respectively, known to exhibit increased risk to cancer.\u003C/p>\u003Cp class=\"mb15\">Three of our top candidate variants were predicted to be LoF: \u003Ci>NTHL1\u003C/i> c.244C&gt;T; p.Gln82Ter, \u003Ci>EXO1\u003C/i> c.1268-1G&gt;T and \u003Ci>FANCC\u003C/i> c.897G&gt;T; p.Arg299Ser. \u003Ci>NTHL1\u003C/i> c.244C&gt;T; p.Gln82Ter has been independently reported in the literature due to its frequency, while \u003Ci>FANCC\u003C/i> c.897G&gt;T; p.Arg299Ser has been reported only in ClinVar database. The introduction of a termination codon in \u003Ci>NTHL1\u003C/i> p.Gln82Ter is predicted to affect NTHL1 protein production, eliciting its classification as PV in ClinVar and by ACMG guidelines. \u003Ci>EXO1\u003C/i> c.1268-1G&gt;T and \u003Ci>FANCC\u003C/i> c.897G&gt;T; p.Arg299Ser were predicted to affect splicing by all of our selected in silico tools. As RNA was not available from carriers of these variants, we were unable to investigate their effect on the gene transcripts. We applied a stringent criteria for prioritizing missense variants using a selected set of high performance in silico prediction tools (\u003Ca href=\"#B71\">71\u003C/a>&#x2013;\u003Ca href=\"#B74\">74\u003C/a>). \u003Ci>ERCC5\u003C/i> c.2556A&gt;G; p.Ile852Met and \u003Ci>NEIL1\u003C/i> c.248G&gt;T; p.Gly83Asp, which have been independently reported in the literature due to their frequencies, were among our top prioritized missense variants. A recent study assessed the performance of 44 in silico tools with 70 tool-threshold combinations in predicting missense variants using a curated dataset of over 9,000 missense variants in five OC and/or BC risk genes that were classified as deleterious or tolerated based on different functional assays (\u003Ca href=\"#B73\">73\u003C/a>). Two of the in silico tools that were selected in our analysis, REVEL with a threshold of &gt;0.7 and VEST with a threshold of &#x2265;0.5 prediction scores of a missense variant being deleterious, were shown to have the best performance of 79% and 74%, respectively (\u003Ca href=\"#B73\">73\u003C/a>). Moreover, a combination of both tools with these prediction score thresholds boosts the prediction performance up to 81% (\u003Ca href=\"#B73\">73\u003C/a>). \u003Ci>NEIL1\u003C/i> c.248G&gt;A; p.Gly83Asp had REVEL and VEST scores of &gt;0.7, while \u003Ci>ERCC5\u003C/i> c.2556A&gt;G; p.Ile852Met had a REVEL score at the threshold of 0.7 and VEST score of 0.9. The biological impact of ERCC5 p.Ile852Met is unknown, though the variant alters a codon in the highly conserved I-Nuclease domain (see \u003Ca href=\"#f4\">Figure&#xa0;4\u003C/a>), which may impact ERCC5 endonuclease activity. Whereas, cells expressing NEIL1 p.Gly83Asp have been shown to increase levels of stalled replication forks and double-strand breaks as compared to wild-type NEIL1 (\u003Ca href=\"#B109\">109\u003C/a>). For the missense variants identified in the non-FC cases, eight of the nine missense variants were predicted to be deleterious by REVEL (&gt;0.7) and/or VEST (&#x2265;0.5). One variant, \u003Ci>NTHL1\u003C/i> c.349C&gt;T; p.Pro117Ser, was found to have a REVEL score of 0.6 and VEST score of 0.5, which is within the intermediate window of prediction scores (REVEL &lt;0.7-&gt;0.4; VEST&lt;0.5) where the threshold of predicting missense variants being tolerated is &lt;0.4 (\u003Ca href=\"#B73\">73\u003C/a>). It is evident that in silico tools are being developed with increasing improvement in their performance and are useful alternatives to biological modelling of variants for selecting and prioritizing missense candidates for further characterization (\u003Ca href=\"#B73\">73\u003C/a>, \u003Ca href=\"#B124\">124\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">We applied stringent criteria to select top candidates for further analyses as it was not feasible to perform WES on all our FC OC study cases. Though selecting for rare variants with MAF &#x2264;0.005 aligns with our hypothesis for identifying candidate moderate- to high-risk variants with the assumption that new candidate genes are transmitted \u003Ci>via\u003C/i> an autosomal dominant mode of inheritance (\u003Ca href=\"#B63\">63\u003C/a>, \u003Ca href=\"#B114\">114\u003C/a>, \u003Ca href=\"#B125\">125\u003C/a>, \u003Ca href=\"#B126\">126\u003C/a>), we filtered out our recently reported, LPV \u003Ci>FANCI\u003C/i> c.1813C&gt;T; p.Leu605Phe (\u003Ca href=\"#B24\">24\u003C/a>). Notable is that the one family harbouring this \u003Ci>FANCI\u003C/i> variant among the 13 familial cases investigated in this study, did not harbour any of our top candidates. As our strategy selected but not eliminated top candidates, further research is required to determine their relevance to OC risk. Moreover, as we have shown in our studies of predicted missense identified in \u003Ci>RAD51C\u003C/i> and \u003Ci>RAD51D\u003C/i> (\u003Ca href=\"#B43\">43\u003C/a>) and \u003Ci>FANCI\u003C/i> (\u003Ca href=\"#B24\">24\u003C/a>) in OC cases from the FC population, modeling variants by in cellulo assays would provide further evidence for their relevance in OC biology.\u003C/p>\u003Cp class=\"mb15\">Some of our candidate variants or others in these genes that met our selection criteria were identified in 3.3% of 937 non-FC familial or sporadic OC cases of mostly European ancestry 0-0.004% in gnomAD controls, suggesting that our gene candidates may be relevant in other populations. Though this observation was not unexpected, given that approximately 55% of our non-FC OC cases were from the same Australian study group (\u003Ca href=\"#B17\">17\u003C/a>), they are also consistent with our analysis of the Pan-Cancer TCGA OC cases. During the course of this study, a recent report investigated a set of DNA repair genes in 33 different cancers from Pan-Cancer TCGA, and they found that missense variants predicted damaging are statistically enriched in OC cases (\u003Ca href=\"#B127\">127\u003C/a>). Moreover, carriers of LoF variants in some of our candidate genes have been reported in HBOC families such as \u003Ci>ERCC5\u003C/i> (\u003Ca href=\"#B128\">128\u003C/a>, \u003Ca href=\"#B129\">129\u003C/a>)\u003Ci>, FANCC\u003C/i> (\u003Ca href=\"#B130\">130\u003C/a>&#x2013;\u003Ca href=\"#B133\">133\u003C/a>) or \u003Ci>NTHL1\u003C/i> (\u003Ca href=\"#B111\">111\u003C/a>, \u003Ca href=\"#B134\">134\u003C/a>, \u003Ca href=\"#B135\">135\u003C/a>) from different populations. Interestingly, LoF variants in \u003Ci>ERCC5\u003C/i> (\u003Ca href=\"#B110\">110\u003C/a>), \u003Ci>FANCC\u003C/i> (\u003Ca href=\"#B102\">102\u003C/a>) or \u003Ci>NTHL1\u003C/i> (\u003Ca href=\"#B111\">111\u003C/a>, \u003Ca href=\"#B110\">110\u003C/a>) have been associated with hereditary BC cases in the context of HBOC families. On the other hand, our literature search did not identify reports of germline PVs in \u003Ci>EXO1\u003C/i> or \u003Ci>NEIL1\u003C/i> in OC, although variants in these genes have been reported in the context of other hereditary cancers such as colorectal cancer (\u003Ca href=\"#B136\">136\u003C/a>&#x2013;\u003Ca href=\"#B138\">138\u003C/a>). However, common variants (MAF&gt;1%) in \u003Ci>EXO1\u003C/i> have been associated with OC risk (\u003Ca href=\"#B139\">139\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">Although we are limited by sample size, we did not observe any striking clinical characteristics regarding age at diagnosis or histopathology of OC disease in carriers of our candidate variants. The average age at diagnosis with OC in FC variant carriers (average=58; median=60 years) is comparable to that of AUS variant carriers as well as Pan-Cancer &#x2013; TCGA variant carriers (average=59; median=59 years), which in turn is comparable with that of carriers of \u003Ci>BRCA2\u003C/i> PVs (average=58 years) (\u003Ca href=\"#B41\">41\u003C/a>) and the general population (median=63 years) (\u003Ca href=\"#B112\">112\u003C/a>, \u003Ca href=\"#B113\">113\u003C/a>). The majority of OC cases harbouring the candidate variants had HGSC (91.1%, 41/45), which is the most common subtype of OC reported in epithelial ovarian cancer (\u003Ca href=\"#B49\">49\u003C/a>) and thus is overrepresented in our study groups (\u003Ca href=\"#B56\">56\u003C/a>). We did observe three carriers of \u003Ci>EXO1\u003C/i> c.1268-1G&gt;T, \u003Ci>NEIL1\u003C/i> c.248G&gt;A; p.Gly83Asp and \u003Ci>NTHL1\u003C/i> c.244C&gt;T; p.Gln82Ter with mixed histology (serous mixed with endometrioid or unspecified cell type; and endometrioid mixed with mucinous) (see \u003Ca href=\"#h10\">Table S8\u003C/a>). Interestingly, a survey of our candidate variants in the Ovarian Cancer Association Consortium (OCAC) database (ocac.ccge.medschl.cam.ac.uk/data-projects/, accessed on 15 June 2020), showed that \u003Ci>NEIL1\u003C/i> c.248G&gt;T; p.Gly83Asp was significantly associated with OC overall (odds ratio [OR] = 1.5; p = 0.038), and this association was stronger with the endometrioid subtype (OR = 3.75; p= 0.00008) (see \u003Ca href=\"#h10\">Table S10\u003C/a>). \u003Ci>NTHL1\u003C/i> c.244C&gt;T; p.Gln82Ter showed a higher OR = 1.5 in clear cell subtype but was not statistically significant (p = 0.36) (see \u003Ca href=\"#h10\">Table S10\u003C/a>). These observations are interesting as \u003Ci>NTHL1\u003C/i> and \u003Ci>NEIL1\u003C/i> are involved in repairing single stranded-DNA breaks \u003Ci>via\u003C/i> BER pathway. MMR genes as also involved in repairing single stranded-DNA breaks \u003Ci>via\u003C/i> MMR pathway that are associated with conferring an increased risk to the endometrioid and clear cell histological subtypes of OC (\u003Ca href=\"#B7\">7\u003C/a>). We could not investigate the other candidate variants \u003Ci>ERCC5\u003C/i> c.2556A&gt;G; p.Ile852Met, \u003Ci>EXO1\u003C/i> c.1268-1G&gt;T and \u003Ci>FANCC\u003C/i> c.897G&gt;T; p.Arg299Ser from this genotyping-based database as they were not represented in the SNP arrays, which could be due to their rarity in the general population.\u003C/p>\u003Cp class=\"mb15\">The role of our candidate genes in the etiology of OC is unknown, though LOH analyses suggest that loss of function of some of our candidate genes in tumour cells may be important in tumourigenesis of OC as has been demonstrated for known OC risk genes (\u003Ca href=\"#B114\">114\u003C/a>). We showed loss of the wild-type allele in tumours from carriers of \u003Ci>ERCC5\u003C/i> c.2556A&gt;G, \u003Ci>NEIL1\u003C/i> c.248G&gt;T; p.Gly83Asp or \u003Ci>NTHL1\u003C/i> c.244C&gt;T; p.Gln82Ter. We also showed loss of the wild-type allele in the tumour DNA from the left and the right ovaries from two \u003Ci>NTHL1\u003C/i> c.244C&gt;T carriers with bilateral OC. This suggests the possibility that loss of wild-type allele occurred at an early stage in tumourigenesis (\u003Ca href=\"#B140\">140\u003C/a>). However, we observed no LOH in tumour DNA from one carrier each of \u003Ci>ERCC5\u003C/i> or \u003Ci>NEIL1\u003C/i> variants and two carriers of \u003Ci>NTHL1\u003C/i> variant (see \u003Ca href=\"#h10\">Table S7\u003C/a>). In previous studies we have also demonstrated complete or partial loss of wild-type alleles in tumour DNA from FC carriers of \u003Ci>RAD51C\u003C/i> c.705G&gt;T; p.Lys235Asn (\u003Ca href=\"#B43\">43\u003C/a>), \u003Ci>RAD51D\u003C/i> c.620C&gt;T; p.Ser207Leu (\u003Ca href=\"#B43\">43\u003C/a>, \u003Ca href=\"#B44\">44\u003C/a>) and \u003Ci>FANCI\u003C/i> c.1813C&gt;T; p.Leu605Phe (\u003Ca href=\"#B24\">24\u003C/a>) also from the analyses of RRCancer biobank materials. We also observed no LOH in some of the tumour DNA from OC carriers of our \u003Ci>RAD51C\u003C/i> c.705G&gt;T; p.Lys235AsnAs and \u003Ci>RAD51D\u003C/i> c.620C&gt;T; p.Ser207Leu, as the DNA was extracted post-chemotherapy treatment, suggesting the possibility of stromal cell contamination (\u003Ca href=\"#B43\">43\u003C/a>, \u003Ca href=\"#B44\">44\u003C/a>). Indeed, all of the DNA tumours from the four cases analysed in this study were confirmed to be extracted after chemotherapy. Interestingly, our LOH analyses in this study provided evidence for loss of variant allele from other candidate variants \u003Ci>EXO1\u003C/i> c.1268-1G&gt;T and \u003Ci>FANCC\u003C/i> c.897G&gt;T carriers. It is not clear if this is due to contaminating normal tissues as our analyses were not performed on selected tumour cells as HGSC samples are often enriched in tumour cells (\u003Ca href=\"#B24\">24\u003C/a>). Srinivasan et&#xa0;al. (\u003Ca href=\"#B141\">141\u003C/a>) recently reported that approximately 20% of the 55 investigated cancers, including OC, showed a retention of the wild-type alleles in the high-penetrant genes such as \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> (\u003Ca href=\"#B141\">141\u003C/a>). A retention of the \u003Ci>RAD51D\u003C/i> c.620C&gt;T; p.Ser207Leu was also observed in tumour DNA from an OC carrier (\u003Ca href=\"#B44\">44\u003C/a>). It is not clear if such cases reflect a reversion of variant to wild type allele as has been shown with \u003Ci>BRCA1\u003C/i> or \u003Ci>BRCA2\u003C/i> carriers in the context of developing resistance to cisplatin or the targeted therapy poly (ADP-ribose) polymerase (PARP) inhibitors (\u003Ca href=\"#B142\">142\u003C/a>, \u003Ca href=\"#B143\">143\u003C/a>). Further research is required at the tumour cell level to determine biological impact of variants in the context of wild-type alleles in carriers.\u003C/p>\u003Cp class=\"mb15\">There are several limitations in this original study that should be acknowledged. This study was limited in the sample size of the FC OC families, sporadic cases and cancer-free controls (study phase I and II). The small sample size in our cases and controls did not allow us to estimate the associated risk with OC of any of the candidate variants to support their candidacy as OC predisposing variants/genes (\u003Ca href=\"#B144\">144\u003C/a>) as such risk assessment requires thousands of cases and controls (\u003Ca href=\"#B12\">12\u003C/a>, \u003Ca href=\"#B13\">13\u003C/a>, 1, \u003Ca href=\"#B19\">19\u003C/a>). However, our highly selected OC families regardless of their status of PVs in \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> are very rare. The proportion of families with two first-degree relatives with OC is estimated to be less than 5%, and less than 1% for those with more than two first-degree relatives with OC (\u003Ca href=\"#B145\">145\u003C/a>&#x2013;\u003Ca href=\"#B147\">147\u003C/a>). This study was also limited in lacking of biological samples that were required to confirm the predicted effect on RNA splicing of two of the candidate variants \u003Ci>EXO1\u003C/i> c.1268-1G&gt;T and \u003Ci>FANCC\u003C/i> c.897G&gt;T; p.Arg299Ser. Likewise, we were not able to perform LOH analysis on all OC carriers of the candidate variants as well as genotyping PBL DNA of the other family members to further support the candidacy of our variants. This was due to the fact that the extracted DNA from only PBL and/or tumour specimens were biobanked for almost all of the OC cases. Moreover, histopathological blocks for DNA and/or RNA extraction of these carriers were not available from the respective biobanks as some of the cancer families and cases date back to the early 2000s (see \u003Ca href=\"#h10\">Table S1\u003C/a>).\u003C/p>\u003Cp class=\"mb0\">In conclusion, our WES and genetic analyses of 468 genes directly or associated with DNA repair pathways in study groups from a genetically defined population identified candidate variants in \u003Ci>ERCC5\u003C/i>, \u003Ci>EXO1\u003C/i>, \u003Ci>FANCC\u003C/i>, \u003Ci>NEIL1\u003C/i> or \u003Ci>NTHL1\u003C/i>. The genetic analyses of these variants and genes in non-FC OC study groups implicate these genes in other populations. Genetic epidemiology of variant carriers and functional assays to assess the biological impact of variant proteins could elucidate the effect of candidate variants to OC risk.\u003C/p>\u003Ca id=\"h6\" name=\"h6\">\u003C/a>\u003Ch2>Data availability statement\u003C/h2>\u003Cp class=\"mb0\">The datasets presented in this article are not readily available because sequencing data for familial and sporadic ovarian cancer (OC) cases, CARTaGENE, McGill University-Montreal Neurological Institute (MNI) and Universit&#xe9; de Sherbrooke-The Genetics of Glucose Regulation in Gestation and Growth (Gen3G) will be returned to their respective biobanks at the conclusion of our study of OC predisposing genes which is still ongoing. For more information concerning these data contact Patricia N. Tonin at \u003Ca id=\"encmail\">cGF0cmljaWEudG9uaW5AbWNnaWxsLmNh\u003C/a>. The data from the analyses of investigation of The Ovarian Cancer Association Consortium (OCAC) and The Genome Aggregation Database (gnomAD) are available from each of these data resource banks.\u003C/p>\u003Ca id=\"h7\" name=\"h7\">\u003C/a>\u003Ch2>Ethics statement\u003C/h2>\u003Cp class=\"mb0\">This project has received approval from The McGill University Health Centre (MUHC) REB (MP-37-2019-4783). The patients/participants provided their written informed consent to participate in this study.\u003C/p>\u003Ca id=\"h8\" name=\"h8\">\u003C/a>\u003Ch2>Author contributions\u003C/h2>\u003Cp class=\"mb15\">WA and PT conceived and designed the study. WA performed whole exome sequencing and bioinformatics analyses, conducted, and interpreted the genotyping and Sanger sequencing and wrote the initial drafts of this manuscript. TR performed the bioinformatics pipelines. CF aided in bioinformatics analysis. CS aided in collecting and reviewing all clinical pedigrees with associated information. KO performed imputation and provided required information from CARTaGENE genotyping-based data. DS and IC provided required information from in-house sequencing-based Australian ovarian cancer cases. JB and TP provided required information from The Cancer Genomic Atlas (TCGA) sequencing-based breast and ovarian cancer cases. DS, GR and LB provided required information from in-house sequencing-based control data. A-MM-M, DP, WF and ZH provided the study samples and clinical information. CG oversaw the statistical analyses. JR oversaw the WES analysis and bioinformatics pipeline. PT designed and oversaw all aspects of the study. All authors contributed to the article and approved the submitted version.\u003C/p>\u003Ca id=\"h9\" name=\"h9\">\u003C/a>\u003Ch2>Funding\u003C/h2>\u003Cp class=\"mb15\">The work was supported in part by the Department of Medicine, McGill University to PT; Saudi Arabian Cultural Bureau to PT and WA; The Canadian Institute for Health Research (CIHR) operating grants (PCC-156736 to PT, CG and JR) and (PJT-156124 to PT and JR); Cancer Research Society and Ovarian Cancer Canada partnership grant (21123 to PT); Department of Medicine, McGill University Grant to PT; the Fond de la recherche du Qu&#xe9;bec en sant&#xe9; (FRQS) and Quebec Breast Cancer Foundation network grants to PT; Compute Canada resource allocation project wst-164 and Genome Canada Genome Technology Platform award to JR; Institut du cancer de Montr&#xe9;al Fonds D&#xe9;fi Spyder and Anne-Marie Chagnon which covers funds from platform to DP and A-MM-M; Gen3G has been supported over the time by FRQS grant (20697 to Marie-France Hivert); CIHR grant (MOP-115071 to Dr. Marie-France Hivert) and (PJT-152989 to LB); American Diabetes Association (ADA) accelerator award (1-15-ACE-26 to Marie-France Hivert). LB is a senior research scholar from FRQS. The sequencing of the Gen3G offspring has been sponsored by Fonds de recherche du Qu&#xe9;bec, McGill University and Universit&#xe9; de Sherbrooke. Ovarian tumour banking was supported by the Banque de tissus et de donn&#xe9;es of the R&#xe9;seau de recherche sur le cancer of the FRQS affiliated with the Canadian Tumour Repository Network (CTRNet). WA was supported by a Scholarship Award by Ministry of Education in Saudi Arabia and CF was supported in part by RI-MUHC Scholarship Award and James O and Maria Meadows Award.\u003C/p>\u003Ca id=\"h10\" name=\"h10\">\u003C/a>\u003Ch2>Acknowledgments\u003C/h2>\u003Cp class=\"mb0\">We acknowledge the Banque de tissus et de donn&#xe9;es of the RRCancer of the Fonds recherche Qu&#xe9;bec - Sant&#xe9; (FRQS), which is affiliated with the Canadian Tissue Repository Network (CTRNet) for providing the DNA samples from cancer families. We also acknowledge CARTaGENE biobank; and Drs. Patrice Peron, Luigi Bouchard, and Marie-France Hivert who established the Gen3G cohort and sequencing. Pierre-&#xc9;tienne Jacques and Simon Gravel contributed to the generation and analysis of sequencing data in Gen3G. The authors acknowledge Manon De Ladurantaye and Lise Portelance for providing all clinical data and DNA from the RRCancer biobank; Liliane Meunier for providing the sections from histopathological blocks; Supriya Behl, Nancy Hamel and Celine Domecq for providing genetic data for sporadic breast cancer cases; and Suzanna Arcand for organizing samples for whole exome sequencing (WES). The authors acknowledge Mary Fujiwara for reviewing the final draft of the manuscript.\u003C/p>\u003Ca id=\"h11\" name=\"h11\">\u003C/a>\u003Ch2>Conflict of interest\u003C/h2>\u003Cp class=\"mb0\">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\u003C/p>\u003Ca id=\"h12\" name=\"h12\">\u003C/a>\u003Ch2>Publisher&#x2019;s note\u003C/h2>\u003Cp class=\"mb0\">All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.\u003C/p>\u003Ca id=\"h13\" name=\"h13\">\u003C/a>\u003Ch2>Supplementary material\u003C/h2>\u003Cp class=\"mb15\">The Supplementary Material for this article can be found online at: \u003Ca href=\"https://www.frontiersin.org/articles/10.3389/fonc.2023.1111191/full#supplementary-material\">https://www.frontiersin.org/articles/10.3389/fonc.2023.1111191/full#supplementary-material\u003C/a>\u003C/p>\u003Ca id=\"h14\" name=\"h14\">\u003C/a>\u003Ch2>References\u003C/h2>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B1\" id=\"B1\">\u003C/a> 1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. \u003Ci>Science\u003C/i> (1994) 266(5182):66&#x2013;71. doi:&#xa0;10.1126/science.7545954\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/7545954/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1126/science.7545954\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=Y+Miki&amp;author=J+Swensen&amp;author=D+Shattuck-Eidens&amp;author=PA+Futreal&amp;author=K+Harshman&amp;author=S+Tavtigian&amp;publication_year=1994&amp;title=A%20strong%20candidate%20for%20the%20breast%20and%20ovarian%20cancer%20susceptibility%20gene%20BRCA1&amp;journal=Science&amp;volume=266&amp;pages=66-71\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B2\" id=\"B2\">\u003C/a> 2. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. \u003Ci>Nature\u003C/i> (1995) 378(6559):789&#x2013;92. doi:&#xa0;10.1038/378789a0\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/8524414/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/378789a0\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R+Wooster&amp;author=G+Bignell&amp;author=J+Lancaster&amp;author=S+Swift&amp;author=S+Seal&amp;author=J+Mangion&amp;publication_year=1995&amp;title=Identification%20of%20the%20breast%20cancer%20susceptibility%20gene%20BRCA2&amp;journal=Nature&amp;volume=378&amp;pages=789-92\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B3\" id=\"B3\">\u003C/a> 3. Nielsen FC, van Overeem Hansen T, S&#xf8;rensen CS. Hereditary breast and ovarian cancer: new genes in confined pathways. \u003Ci>Nat Rev Cancer 2016 16:9\u003C/i> (2016) 16:599&#x2013;612. doi:&#xa0;10.1038/nrc.2016.72\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1038/nrc.2016.72\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=FC+Nielsen&amp;author=T+van%20Overeem%20Hansen&amp;author=CS+S%C3%B8rensen&amp;publication_year=2016&amp;title=Hereditary%20breast%20and%20ovarian%20cancer%3A%20new%20genes%20in%20confined%20pathways&amp;journal=Nat+Rev+Cancer+2016+16:9&amp;volume=16&amp;pages=599\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B4\" id=\"B4\">\u003C/a> 4. Turnbull C, Sud A, Houlston RS. Cancer genetics, precision prevention and a call to action. \u003Ci>Nat Genet\u003C/i> (2018) 50(9):1212&#x2013;8. doi:&#xa0;10.1038/s41588-018-0202-0\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30158684/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41588-018-0202-0\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=C+Turnbull&amp;author=A+Sud&amp;author=RS+Houlston&amp;publication_year=2018&amp;title=Cancer%20genetics%2C%20precision%20prevention%20and%20a%20call%20to%20action&amp;journal=Nat+Genet&amp;volume=50&amp;pages=1212-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B5\" id=\"B5\">\u003C/a> 5. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, De A, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. \u003Ci>Wiley Online Library\u003C/i> (1999) 81:214&#x2013;8. doi: 10.1002/(SICI)1097-0215(19990412)81:2&lt;214::AID-IJC8&gt;3.0.CO;2-L\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1002/(SICI)1097-0215(19990412)81:2&lt;214::AID-IJC8&gt;3.0.CO;2-L\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Aarnio&amp;author=R+Sankila&amp;author=E+Pukkala&amp;author=R+Salovaara&amp;author=LA+Aaltonen&amp;author=A+De&amp;publication_year=1999&amp;title=Cancer%20risk%20in%20mutation%20carriers%20of%20DNA-mismatch-repair%20genes&amp;journal=Wiley+Online+Library&amp;volume=81&amp;pages=214-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B6\" id=\"B6\">\u003C/a> 6. Stoll J, Rosenthal E, Cummings S, Willmott J, Bernhisel R, Kupferl SS. No evidence of increased risk of breast cancer in women with lynch syndrome identified by multigene panel testing. \u003Ci>JCO Precis Oncol\u003C/i> (2020) 4:51&#x2013;60. doi:&#xa0;10.1200/PO.19.00271\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/35050728/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1200/PO.19.00271\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+Stoll&amp;author=E+Rosenthal&amp;author=S+Cummings&amp;author=J+Willmott&amp;author=R+Bernhisel&amp;author=SS+Kupferl&amp;publication_year=2020&amp;title=No%20evidence%20of%20increased%20risk%20of%20breast%20cancer%20in%20women%20with%20lynch%20syndrome%20identified%20by%20multigene%20panel%20testing&amp;journal=JCO+Precis+Oncol&amp;volume=4&amp;pages=51\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B7\" id=\"B7\">\u003C/a> 7. Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M, et al. Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management. \u003Ci>Mol Oncol\u003C/i> (2009) 3(2):97&#x2013;137. doi:&#xa0;10.1016/j.molonc.2009.02.004\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/19383374/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.molonc.2009.02.004\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=HT+Lynch&amp;author=MJ+Casey&amp;author=CL+Snyder&amp;author=C+Bewtra&amp;author=JF+Lynch&amp;author=M+Butts&amp;publication_year=2009&amp;title=Hereditary%20ovarian%20carcinoma%3A%20Heterogeneity%2C%20molecular%20genetics%2C%20pathology%2C%20and%20management&amp;journal=Mol+Oncol&amp;volume=3&amp;pages=97-137\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B8\" id=\"B8\">\u003C/a> 8. Pavanello M, Chan IH, Ariff A, Pharoah PD, Gayther SA, Ramus SJ. Rare germline genetic variants and the risks of epithelial ovarian cancer. \u003Ci>Cancers 2020 Vol. 12 Page 3046\u003C/i> (2020) 12:3046. doi:&#xa0;10.3390/CANCERS12103046\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.3390/CANCERS12103046\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Pavanello&amp;author=IH+Chan&amp;author=A+Ariff&amp;author=PD+Pharoah&amp;author=SA+Gayther&amp;author=SJ+Ramus&amp;publication_year=2020&amp;title=Rare%20germline%20genetic%20variants%20and%20the%20risks%20of%20epithelial%20ovarian%20cancer&amp;journal=Cancers+2020+Vol.+12+Page+3046&amp;volume=12&amp;pages=3046\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B9\" id=\"B9\">\u003C/a> 9. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. \u003Ci>Nat Genet\u003C/i> (2010) 42(5):410&#x2013;4. doi:&#xa0;10.1038/ng.569\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/20400964/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/ng.569\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Meindl&amp;author=H+Hellebrand&amp;author=C+Wiek&amp;author=V+Erven&amp;author=B+Wappenschmidt&amp;author=D+Niederacher&amp;publication_year=2010&amp;title=Germline%20mutations%20in%20breast%20and%20ovarian%20cancer%20pedigrees%20establish%20RAD51C%20as%20a%20human%20cancer%20susceptibility%20gene&amp;journal=Nat+Genet&amp;volume=42&amp;pages=410-4\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B10\" id=\"B10\">\u003C/a> 10. Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. \u003Ci>Nat Genet\u003C/i> (2011) 43(9):879&#x2013;82. doi:&#xa0;10.1038/ng.893\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/21822267/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/ng.893\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=C+Loveday&amp;author=C+Turnbull&amp;author=E+Ramsay&amp;author=D+Hughes&amp;author=E+Ruark&amp;author=JR+Frankum&amp;publication_year=2011&amp;title=Germline%20mutations%20in%20RAD51D%20confer%20susceptibility%20to%20ovarian%20cancer&amp;journal=Nat+Genet&amp;volume=43&amp;pages=879-82\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B11\" id=\"B11\">\u003C/a> 11. Rafnar T, Gudbjartsson DF, Sulem P, Jonasdottir A, Sigurdsson A, Jonasdottir A, et al. Mutations in BRIP1 confer high risk of ovarian cancer. \u003Ci>Nat Genet\u003C/i> (2011) 43(11):1104&#x2013;7. doi:&#xa0;10.1038/ng.955\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/21964575/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/ng.955\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=T+Rafnar&amp;author=DF+Gudbjartsson&amp;author=P+Sulem&amp;author=A+Jonasdottir&amp;author=A+Sigurdsson&amp;author=A+Jonasdottir&amp;publication_year=2011&amp;title=Mutations%20in%20BRIP1%20confer%20high%20risk%20of%20ovarian%20cancer&amp;journal=Nat+Genet&amp;volume=43&amp;pages=1104-7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B12\" id=\"B12\">\u003C/a> 12. Ramus SJ, Song H, Dicks E, Tyrer JP, Rosenthal AN, Intermaggio MP, et al. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. \u003Ci>J Natl Cancer Institute\u003C/i> (2015) 107(11):djv214. doi:&#xa0;10.1093/jnci/djv214\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1093/jnci/djv214\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=SJ+Ramus&amp;author=H+Song&amp;author=E+Dicks&amp;author=JP+Tyrer&amp;author=AN+Rosenthal&amp;author=MP+Intermaggio&amp;publication_year=2015&amp;title=Germline%20mutations%20in%20the%20BRIP1%2C%20BARD1%2C%20PALB2%2C%20and%20NBN%20genes%20in%20women%20with%20ovarian%20cancer&amp;journal=J+Natl+Cancer+Institute&amp;volume=107&amp;pages=djv214\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B13\" id=\"B13\">\u003C/a> 13. Song H, Dicks E, Ramus SJ, Tyrer JP, Intermaggio MP, Hayward J, et al. Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. \u003Ci>J Clin Oncol\u003C/i> (2015) 33:2901&#x2013;7. doi:&#xa0;10.1200/JCO.2015.61.2408\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26261251/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1200/JCO.2015.61.2408\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H+Song&amp;author=E+Dicks&amp;author=SJ+Ramus&amp;author=JP+Tyrer&amp;author=MP+Intermaggio&amp;author=J+Hayward&amp;publication_year=2015&amp;title=Contribution%20of%20germline%20mutations%20in%20the%20RAD51B%2C%20RAD51C%2C%20and%20RAD51D%20genes%20to%20ovarian%20cancer%20in%20the%20population&amp;journal=J+Clin+Oncol&amp;volume=33&amp;pages=2901-7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B14\" id=\"B14\">\u003C/a> 14. Suszynska M, Ratajska M, Kozlowski P. BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: Mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases. \u003Ci>J Ovarian Res\u003C/i> (2020) 13(1):50. doi:&#xa0;10.1186/s13048-020-00654-3\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32359370/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s13048-020-00654-3\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Suszynska&amp;author=M+Ratajska&amp;author=P+Kozlowski&amp;publication_year=2020&amp;title=BRIP1%2C%20RAD51C%2C%20and%20RAD51D%20mutations%20are%20associated%20with%20high%20susceptibility%20to%20ovarian%20cancer%3A%20Mutation%20prevalence%20and%20precise%20risk%20estimates%20based%20on%20a%20pooled%20analysis%20of%20~30%2C000%20cases&amp;journal=J+Ovarian+Res&amp;volume=13&amp;pages=50\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B15\" id=\"B15\">\u003C/a> 15. Kanchi KL, Johnson KJ, Lu C, McLellan MD, Leiserson MDM, Wendl MC, et al. Integrated analysis of germline and somatic variants in ovarian cancer. \u003Ci>Nat Commun\u003C/i> (2014) 5:3156. doi:&#xa0;10.1038/ncomms4156\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24448499/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/ncomms4156\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=KL+Kanchi&amp;author=KJ+Johnson&amp;author=C+Lu&amp;author=MD+McLellan&amp;author=MDM+Leiserson&amp;author=MC+Wendl&amp;publication_year=2014&amp;title=Integrated%20analysis%20of%20germline%20and%20somatic%20variants%20in%20ovarian%20cancer&amp;journal=Nat+Commun&amp;volume=5&amp;pages=3156\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B16\" id=\"B16\">\u003C/a> 16. Lu HM, Li S, Black MH, Lee S, Hoiness R, Wu S, et al. Association of breast and ovarian cancers with predisposition genes identified by Large-scale sequencing. \u003Ci>JAMA Oncol\u003C/i> (2019) 5:51&#x2013;7. doi:&#xa0;10.1001/JAMAONCOL.2018.2956\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30128536/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1001/JAMAONCOL.2018.2956\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=HM+Lu&amp;author=S+Li&amp;author=MH+Black&amp;author=S+Lee&amp;author=R+Hoiness&amp;author=S+Wu&amp;publication_year=2019&amp;title=Association%20of%20breast%20and%20ovarian%20cancers%20with%20predisposition%20genes%20identified%20by%20Large-scale%20sequencing&amp;journal=JAMA+Oncol&amp;volume=5&amp;pages=51-7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B17\" id=\"B17\">\u003C/a> 17. Subramanian DN, Zethoven M, McInerny S, Morgan JA, Rowley SM, Lee JEA, et al. Exome sequencing of familial high-grade serous ovarian carcinoma reveals heterogeneity for rare candidate susceptibility genes. \u003Ci>Nat Commun\u003C/i> (2020) 11:1&#x2013;11. doi:&#xa0;10.1038/s41467-020-15461-z\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31911652/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41467-020-15461-z\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=DN+Subramanian&amp;author=M+Zethoven&amp;author=S+McInerny&amp;author=JA+Morgan&amp;author=SM+Rowley&amp;author=JEA+Lee&amp;publication_year=2020&amp;title=Exome%20sequencing%20of%20familial%20high-grade%20serous%20ovarian%20carcinoma%20reveals%20heterogeneity%20for%20rare%20candidate%20susceptibility%20genes&amp;journal=Nat+Commun&amp;volume=11&amp;pages=1\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B18\" id=\"B18\">\u003C/a> 18. Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, et al. Cancer risks associated with germline PALB2 pathogenic variants: An international study of 524 families. \u003Ci>J Clin Oncol\u003C/i> (2020) 38:674&#x2013;85. doi:&#xa0;10.1200/JCO.19.01907\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31841383/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1200/JCO.19.01907\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=X+Yang&amp;author=G+Leslie&amp;author=A+Doroszuk&amp;author=S+Schneider&amp;author=J+Allen&amp;author=B+Decker&amp;publication_year=2020&amp;title=Cancer%20risks%20associated%20with%20germline%20PALB2%20pathogenic%20variants%3A%20An%20international%20study%20of%20524%20families&amp;journal=J+Clin+Oncol&amp;volume=38&amp;pages=674-85\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B19\" id=\"B19\">\u003C/a> 19. Song H, Dicks EM, Tyrer J, Intermaggio M, Chenevix-Trench G, Bowtell DD, et al. Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer. \u003Ci>J Med Genet\u003C/i> (2021) 58:305&#x2013;13. doi:&#xa0;10.1136/JMEDGENET-2019-106739\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32546565/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1136/JMEDGENET-2019-106739\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H+Song&amp;author=EM+Dicks&amp;author=J+Tyrer&amp;author=M+Intermaggio&amp;author=G+Chenevix-Trench&amp;author=DD+Bowtell&amp;publication_year=2021&amp;title=Population-based%20targeted%20sequencing%20of%2054%20candidate%20genes%20identifies%20PALB2%20as%20a%20susceptibility%20gene%20for%20high-grade%20serous%20ovarian%20cancer&amp;journal=J+Med+Genet&amp;volume=58&amp;pages=305-13\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B20\" id=\"B20\">\u003C/a> 20. Szymanska-Pasternak J, Szymanska A, Medrek K, Imyanitov EN, Cybulski C, Gorski B, et al. CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors. \u003Ci>Gynecologic Oncol\u003C/i> (2006) 102:429&#x2013;31. doi:&#xa0;10.1016/J.YGYNO.2006.05.040\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1016/J.YGYNO.2006.05.040\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+Szymanska-Pasternak&amp;author=A+Szymanska&amp;author=K+Medrek&amp;author=EN+Imyanitov&amp;author=C+Cybulski&amp;author=B+Gorski&amp;publication_year=2006&amp;title=CHEK2%20variants%20predispose%20to%20benign%2C%20borderline%20and%20low-grade%20invasive%20ovarian%20tumors&amp;journal=Gynecologic+Oncol&amp;volume=102&amp;pages=429-31\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B21\" id=\"B21\">\u003C/a> 21. Dicks E, Song H, Ramus SJ, Van Oudenhove E, Tyrer JP, Intermaggio MP, et al. Germline whole exome sequencing and large-scale replication identifies &amp;lt;i&lt;FANCM&amp;lt;/i&lt; as a likely high grade serous ovarian cancer susceptibility gene. \u003Ci>Oncotarget\u003C/i> (2017) 8(31):50930&#x2013;40. doi:&#xa0;10.18632/oncotarget.15871\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28881617/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.18632/oncotarget.15871\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=E+Dicks&amp;author=H+Song&amp;author=SJ+Ramus&amp;author=E+Van%20Oudenhove&amp;author=JP+Tyrer&amp;author=MP+Intermaggio&amp;publication_year=2017&amp;title=Germline%20whole%20exome%20sequencing%20and%20large-scale%20replication%20identifies%20%26lt%3Bi%3CFANCM%26lt%3B%2Fi%3C%20as%20a%20likely%20high%20grade%20serous%20ovarian%20cancer%20susceptibility%20gene&amp;journal=Oncotarget&amp;volume=8&amp;pages=50930-40\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B22\" id=\"B22\">\u003C/a> 22. Zhu Q, Zhang J, Chen Y, Hu Q, Shen H, Huang RY, et al. Whole-exome sequencing of ovarian cancer families uncovers putative predisposition genes. \u003Ci>Int J Cancer\u003C/i> (2019) 146(8):2147&#x2013;55. doi:&#xa0;10.1002/ijc.32545\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31265121/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/ijc.32545\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=Q+Zhu&amp;author=J+Zhang&amp;author=Y+Chen&amp;author=Q+Hu&amp;author=H+Shen&amp;author=RY+Huang&amp;publication_year=2019&amp;title=Whole-exome%20sequencing%20of%20ovarian%20cancer%20families%20uncovers%20putative%20predisposition%20genes&amp;journal=Int+J+Cancer&amp;volume=146&amp;pages=2147-55\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B23\" id=\"B23\">\u003C/a> 23. Heikkinen K, Karppinen SM, Soini Y, M&#xe4;kinen M, Winqvist R. Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility. \u003Ci>J Med Genet\u003C/i> (2003) 40(12):e131. doi:&#xa0;10.1136/JMG.40.12.E131\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/14684699/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1136/JMG.40.12.E131\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=K+Heikkinen&amp;author=SM+Karppinen&amp;author=Y+Soini&amp;author=M+M%C3%A4kinen&amp;author=R+Winqvist&amp;publication_year=2003&amp;title=Mutation%20screening%20of%20Mre11%20complex%20genes%3A%20indication%20of%20RAD50%20involvement%20in%20breast%20and%20ovarian%20cancer%20susceptibility&amp;journal=J+Med+Genet&amp;volume=40&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B24\" id=\"B24\">\u003C/a> 24. Fierheller CT, Guitton-Sert L, Alenezi WM, Revil T, Oros KK, Gao Y, et al. A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene. \u003Ci>Genome Med\u003C/i> (2021) 13(1):186. doi:&#xa0;10.1186/S13073-021-00998-5\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/34861889/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/S13073-021-00998-5\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=CT+Fierheller&amp;author=L+Guitton-Sert&amp;author=WM+Alenezi&amp;author=T+Revil&amp;author=KK+Oros&amp;author=Y+Gao&amp;publication_year=2021&amp;title=A%20functionally%20impaired%20missense%20variant%20identified%20in%20French%20Canadian%20families%20implicates%20FANCI%20as%20a%20candidate%20ovarian%20cancer-predisposing%20gene&amp;journal=Genome+Med&amp;volume=13&amp;pages=186\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B25\" id=\"B25\">\u003C/a> 25. Pharoah PDP, Dunning AM, Ponder BAJ, Easton DF. Association studies for finding cancer-susceptibility genetic variants. \u003Ci>Nat Rev Cancer\u003C/i> (2004) 4:850&#x2013;60. doi:&#xa0;10.1038/nrc1476\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/15516958/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nrc1476\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=PDP+Pharoah&amp;author=AM+Dunning&amp;author=BAJ+Ponder&amp;author=DF+Easton&amp;publication_year=2004&amp;title=Association%20studies%20for%20finding%20cancer-susceptibility%20genetic%20variants&amp;journal=Nat+Rev+Cancer&amp;volume=4&amp;pages=850-60\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B26\" id=\"B26\">\u003C/a> 26. Rahman N. Realizing the promise of cancer predisposition genes. \u003Ci>Nature\u003C/i> (2014) 505(7483):302&#x2013;8. doi:&#xa0;10.1038/nature12981\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24429628/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nature12981\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=N+Rahman&amp;publication_year=2014&amp;title=Realizing%20the%20promise%20of%20cancer%20predisposition%20genes&amp;journal=Nature&amp;volume=505&amp;pages=302-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B27\" id=\"B27\">\u003C/a> 27. Ramus SJ, Gayther SA. The contribution of BRCA1 and BRCA2 to ovarian cancer. \u003Ci>Mol Oncol\u003C/i> (2009) 3(2):138&#x2013;50. doi:&#xa0;10.1016/j.molonc.2009.02.001\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/19383375/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.molonc.2009.02.001\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=SJ+Ramus&amp;author=SA+Gayther&amp;publication_year=2009&amp;title=The%20contribution%20of%20BRCA1%20and%20BRCA2%20to%20ovarian%20cancer&amp;journal=Mol+Oncol&amp;volume=3&amp;pages=138-50\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B28\" id=\"B28\">\u003C/a> 28. Milanowska K, Krwawicz J, Papaj G, Kosi&#x144;ski J, Poleszak K, Lesiak J, et al. REPAIRtoire&#x2013;a database of DNA repair pathways. \u003Ci>Nucleic Acids Res\u003C/i> (2011) 39(Database issue):D788&#x2013;92. doi:&#xa0;10.1093/NAR/GKQ1087\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/21051355/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/NAR/GKQ1087\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=K+Milanowska&amp;author=J+Krwawicz&amp;author=G+Papaj&amp;author=J+Kosi%C5%84ski&amp;author=K+Poleszak&amp;author=J+Lesiak&amp;publication_year=2011&amp;title=REPAIRtoire%E2%80%93a%20database%20of%20DNA%20repair%20pathways&amp;journal=Nucleic+Acids+Res&amp;volume=39&amp;pages=D788-92\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B29\" id=\"B29\">\u003C/a> 29. Chae YK, Anker JF, Carneiro BA, Chandra S, Kaplan J, Kalyan A, et al. Genomic landscape of DNA repair genes in cancer. \u003Ci>Oncotarget\u003C/i> (2016). doi:&#xa0;10.18632/oncotarget.8196\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.18632/oncotarget.8196\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=YK+Chae&amp;author=JF+Anker&amp;author=BA+Carneiro&amp;author=S+Chandra&amp;author=J+Kaplan&amp;author=A+Kalyan&amp;publication_year=2016&amp;title=Genomic%20landscape%20of%20DNA%20repair%20genes%20in%20cancer&amp;journal=Oncotarget&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B30\" id=\"B30\">\u003C/a> 30. Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, et al. Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas. \u003Ci>Cell Rep\u003C/i> (2018) 23(1):239&#x2013;254.e6. doi:&#xa0;10.1016/j.celrep.2018.03.076\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29617664/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.celrep.2018.03.076\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=TA+Knijnenburg&amp;author=L+Wang&amp;author=MT+Zimmermann&amp;author=N+Chambwe&amp;author=GF+Gao&amp;author=AD+Cherniack&amp;publication_year=2018&amp;title=Genomic%20and%20molecular%20landscape%20of%20DNA%20damage%20repair%20deficiency%20across%20the%20cancer%20genome%20atlas&amp;journal=Cell+Rep&amp;volume=23&amp;pages=239-254.e6\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B31\" id=\"B31\">\u003C/a> 31. Glentis S, Dimopoulos AC, Rouskas K, Ntritsos G, Evangelou E, Narod SA, et al. Exome sequencing in BRCA1- and BRCA2-negative Greek families identifies MDM1 and NBEAL1 as candidate risk genes for hereditary breast cancer. \u003Ci>Front Genet\u003C/i> (2019) 10:1005. doi:&#xa0;10.3389/FGENE.2019.01005\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31681433/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3389/FGENE.2019.01005\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+Glentis&amp;author=AC+Dimopoulos&amp;author=K+Rouskas&amp;author=G+Ntritsos&amp;author=E+Evangelou&amp;author=SA+Narod&amp;publication_year=2019&amp;title=Exome%20sequencing%20in%20BRCA1-%20and%20BRCA2-negative%20Greek%20families%20identifies%20MDM1%20and%20NBEAL1%20as%20candidate%20risk%20genes%20for%20hereditary%20breast%20cancer&amp;journal=Front+Genet&amp;volume=10&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B32\" id=\"B32\">\u003C/a> 32. Sherill-Rofe D, Rahat D, Findlay S, Mellul A, Guberman I, Braun M, et al. Mapping global and local coevolution across 600 species to identify novel homologous recombination repair genes. \u003Ci>Genome Res\u003C/i> (2019) 29:439&#x2013;48. doi:&#xa0;10.1101/gr.241414.118\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30718334/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1101/gr.241414.118\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=D+Sherill-Rofe&amp;author=D+Rahat&amp;author=S+Findlay&amp;author=A+Mellul&amp;author=I+Guberman&amp;author=M+Braun&amp;publication_year=2019&amp;title=Mapping%20global%20and%20local%20coevolution%20across%20600%20species%20to%20identify%20novel%20homologous%20recombination%20repair%20genes&amp;journal=Genome+Res&amp;volume=29&amp;pages=439-48\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B33\" id=\"B33\">\u003C/a> 33. Fierheller CT, Alenezi WM, Tonin PN. The genetic analyses of French canadians of Quebec facilitate the characterization of new cancer predisposing genes implicated in hereditary breast and/or ovarian cancer syndrome families. \u003Ci>Cancers\u003C/i> (2021) 13(14):3406. doi:&#xa0;10.3390/CANCERS13143406\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/34298626/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3390/CANCERS13143406\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=CT+Fierheller&amp;author=WM+Alenezi&amp;author=PN+Tonin&amp;publication_year=2021&amp;title=The%20genetic%20analyses%20of%20French%20canadians%20of%20Quebec%20facilitate%20the%20characterization%20of%20new%20cancer%20predisposing%20genes%20implicated%20in%20hereditary%20breast%20and%2For%20ovarian%20cancer%20syndrome%20families&amp;journal=Cancers&amp;volume=13&amp;pages=3406\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B34\" id=\"B34\">\u003C/a> 34. Scriver CR. Human genetics: lessons from Quebec populations. \u003Ci>Annual review of genomics and human genetics\u003C/i>. \u003Ci>Annu Rev Genomics Hum Genet\u003C/i> (2001) 2:69&#x2013;101. doi:&#xa0;10.1146/annurev.genom.6.080604.162340\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/11701644/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1146/annurev.genom.6.080604.162340\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=CR+Scriver&amp;publication_year=2001&amp;title=Human%20genetics%3A%20lessons%20from%20Quebec%20populations.%20Annual%20review%20of%20genomics%20and%20human%20genetics&amp;journal=Annu+Rev+Genomics+Hum+Genet&amp;volume=2&amp;pages=69-101\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B35\" id=\"B35\">\u003C/a> 35. Laberge AM, Michaud J, Richter A, Lemyre E, Lambert M, Brais B, et al. Population history and its impact on medical genetics in Quebec. \u003Ci>Clin Genet\u003C/i> (2005) 68(4):287&#x2013;301. doi:&#xa0;10.1111/j.1399-0004.2005.00497.x\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16143014/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/j.1399-0004.2005.00497.x\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=AM+Laberge&amp;author=J+Michaud&amp;author=A+Richter&amp;author=E+Lemyre&amp;author=M+Lambert&amp;author=B+Brais&amp;publication_year=2005&amp;title=Population%20history%20and%20its%20impact%20on%20medical%20genetics%20in%20Quebec&amp;journal=Clin+Genet&amp;volume=68&amp;pages=287-301\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B36\" id=\"B36\">\u003C/a> 36. Erkko H, Xia B, Nikkil&#xe4; J, Schleutker J, Syrj&#xe4;koski K, Mannermaa A, et al. LETTERS a recurrent mutation in PALB2 in Finnish cancer families. \u003Ci>Nature\u003C/i> (2007) 446(7133):316&#x2013;9. doi:&#xa0;10.1038/nature05609\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/17287723/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nature05609\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H+Erkko&amp;author=B+Xia&amp;author=J+Nikkil%C3%A4&amp;author=J+Schleutker&amp;author=K+Syrj%C3%A4koski&amp;author=A+Mannermaa&amp;publication_year=2007&amp;title=LETTERS%20a%20recurrent%20mutation%20in%20PALB2%20in%20Finnish%20cancer%20families&amp;journal=Nature&amp;volume=446&amp;pages=316-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B37\" id=\"B37\">\u003C/a> 37. Cybulski C, Carrot-Zhang J, Klulniak W, Rivera B, Kashyap A, Wokolorczyk D, et al. Germline RECQL mutations are associated with breast cancer susceptibility. \u003Ci>Nat Genet\u003C/i> (2015) 47:643&#x2013;6. doi:&#xa0;10.1038/NG.3284\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25915596/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/NG.3284\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=C+Cybulski&amp;author=J+Carrot-Zhang&amp;author=W+Klulniak&amp;author=B+Rivera&amp;author=A+Kashyap&amp;author=D+Wokolorczyk&amp;publication_year=2015&amp;title=Germline%20RECQL%20mutations%20are%20associated%20with%20breast%20cancer%20susceptibility&amp;journal=Nat+Genet&amp;volume=47&amp;pages=643-6\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B38\" id=\"B38\">\u003C/a> 38. Charbonneau H, Desjardins B, L&#xe9;gar&#xe9; J, Denis H. &#x201c;The population of the st. Lawrence Valley 1608-1760 | bibliographie sur l&#x2019;histoire de montr&#xe9;al,&#x201d;. In: Haines MR, Steckel RH, editors. \u003Ci>A population history of north America\u003C/i>. Cambridge University Press (2000). p. 99&#x2013;142.\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H+Charbonneau&amp;author=B+Desjardins&amp;author=J+L%C3%A9gar%C3%A9&amp;author=H+Denis&amp;publication_year=2000&amp;title=%E2%80%9CThe%20population%20of%20the%20st.%20Lawrence%20Valley%201608-1760%20%7C%20bibliographie%20sur%20l%E2%80%99histoire%20de%20montr%C3%A9al%2C%E2%80%9D&amp;book=A+population+history+of+north+America&amp;pages=99\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B39\" id=\"B39\">\u003C/a> 39. Gagnon A, Heyer E. Fragmentation of the qu&#xe9;bec population genetic pool (Canada): Evidence from the genetic contribution of founders per region in the 17th and 18th centuries. \u003Ci>Am J Phys Anthropology\u003C/i> (2001) 114:30&#x2013;41. doi:&#xa0;10.1002/1096-8644(200101)114:1&lt;30::AID-AJPA1003&gt;3.0.CO;2-L\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1002/1096-8644(200101)114:1&lt;30::AID-AJPA1003&gt;3.0.CO;2-L\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Gagnon&amp;author=E+Heyer&amp;publication_year=2001&amp;title=Fragmentation%20of%20the%20qu%C3%A9bec%20population%20genetic%20pool%20%28Canada%29%3A%20Evidence%20from%20the%20genetic%20contribution%20of%20founders%20per%20region%20in%20the%2017th%20and%2018th%20centuries&amp;journal=Am+J+Phys+Anthropology&amp;volume=114&amp;pages=30\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B40\" id=\"B40\">\u003C/a> 40. Tonin PN, Mes-Masson A-M, Futreal PA, Morgan K, Mahon M, Foulkes WD, et al. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. \u003Ci>Am J Hum Genet\u003C/i> (1998) 63(5):1341&#x2013;51. doi:&#xa0;10.1086/302099\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/9792861/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1086/302099\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=PN+Tonin&amp;author=A-M+Mes-Masson&amp;author=PA+Futreal&amp;author=K+Morgan&amp;author=M+Mahon&amp;author=WD+Foulkes&amp;publication_year=1998&amp;title=Founder%20BRCA1%20and%20BRCA2%20mutations%20in%20French%20Canadian%20breast%20and%20ovarian%20cancer%20families&amp;journal=Am+J+Hum+Genet&amp;volume=63&amp;pages=1341-51\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B41\" id=\"B41\">\u003C/a> 41. Oros KK, Ghadirian P, Greenwood CMT, Perret C, Shen Z, Paredes Y, et al. Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations. \u003Ci>Int J Cancer\u003C/i> (2004) 112(3):411&#x2013;9. doi:&#xa0;10.1002/ijc.20406\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/15382066/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/ijc.20406\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=KK+Oros&amp;author=P+Ghadirian&amp;author=CMT+Greenwood&amp;author=C+Perret&amp;author=Z+Shen&amp;author=Y+Paredes&amp;publication_year=2004&amp;title=Significant%20proportion%20of%20breast%20and%2For%20ovarian%20cancer%20families%20of%20French%20Canadian%20descent%20harbor%201%20of%205%20BRCA1%20and%20BRCA2%20mutations&amp;journal=Int+J+Cancer&amp;volume=112&amp;pages=411-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B42\" id=\"B42\">\u003C/a> 42. Foulkes WD, Ghadirian P, Akbari MR, Hamel N, Giroux S, Sabbaghian N, et al. Identification of a novel truncating PALB2mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. \u003Ci>Breast Cancer Res\u003C/i> (2007) 9(6):R83. doi:&#xa0;10.1186/bcr1828\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/18053174/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/bcr1828\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=WD+Foulkes&amp;author=P+Ghadirian&amp;author=MR+Akbari&amp;author=N+Hamel&amp;author=S+Giroux&amp;author=N+Sabbaghian&amp;publication_year=2007&amp;title=Identification%20of%20a%20novel%20truncating%20PALB2mutation%20and%20analysis%20of%20its%20contribution%20to%20early-onset%20breast%20cancer%20in%20French-Canadian%20women&amp;journal=Breast+Cancer+Res&amp;volume=9&amp;pages=R83\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B43\" id=\"B43\">\u003C/a> 43. Alenezi WM, Milano L, Fierheller CT, Serruya C, Revil T, Oros KK, et al. The genetic and molecular analyses of RAD51C and RAD51D identifies rare variants implicated in hereditary ovarian cancer from a genetically unique population. \u003Ci>Cancers 2022\u003C/i> (2022) 14:2251. doi:&#xa0;10.3390/CANCERS14092251\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.3390/CANCERS14092251\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=WM+Alenezi&amp;author=L+Milano&amp;author=CT+Fierheller&amp;author=C+Serruya&amp;author=T+Revil&amp;author=KK+Oros&amp;publication_year=2022&amp;title=The%20genetic%20and%20molecular%20analyses%20of%20RAD51C%20and%20RAD51D%20identifies%20rare%20variants%20implicated%20in%20hereditary%20ovarian%20cancer%20from%20a%20genetically%20unique%20population&amp;journal=Cancers+2022&amp;volume=14&amp;pages=2251\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B44\" id=\"B44\">\u003C/a> 44. Rivera B, Iorio M, Frankum J, Nadaf J, Fahiminiya S, Arcand SL, et al. Functionally null RAD51D missense mutation associates strongly with ovarian carcinoma. \u003Ci>Cancer Res\u003C/i> (2017) 77:4517&#x2013;29. doi:&#xa0;10.1158/0008-5472.CAN-17-0190\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28646019/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1158/0008-5472.CAN-17-0190\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=B+Rivera&amp;author=M+Iorio&amp;author=J+Frankum&amp;author=J+Nadaf&amp;author=S+Fahiminiya&amp;author=SL+Arcand&amp;publication_year=2017&amp;title=Functionally%20null%20RAD51D%20missense%20mutation%20associates%20strongly%20with%20ovarian%20carcinoma&amp;journal=Cancer+Res&amp;volume=77&amp;pages=4517-29\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B45\" id=\"B45\">\u003C/a> 45. Chong G, Jarry J, Marcus V, Thiffault I, Winocour S, Monczak Y, et al. High frequency of exon deletions and putative founder effects in French Canadian lynch syndrome families. \u003Ci>Hum Mutat\u003C/i> (2009) 30:E797&#x2013;812. doi:&#xa0;10.1002/humu.21056\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/19459153/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.21056\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=G+Chong&amp;author=J+Jarry&amp;author=V+Marcus&amp;author=I+Thiffault&amp;author=S+Winocour&amp;author=Y+Monczak&amp;publication_year=2009&amp;title=High%20frequency%20of%20exon%20deletions%20and%20putative%20founder%20effects%20in%20French%20Canadian%20lynch%20syndrome%20families&amp;journal=Hum+Mutat&amp;volume=30&amp;pages=E797-812\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B46\" id=\"B46\">\u003C/a> 46. Castellsagu&#xe9; E, Liu J, Volenik A, Giroux S, Gagn&#xe9; R, Maranda B, et al. Characterization of a novel founder MSH6 mutation causing lynch syndrome in the French Canadian population. \u003Ci>Clin Genet\u003C/i> (2015) 87:536&#x2013;42. doi:&#xa0;10.1111/CGE.12526\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25318681/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/CGE.12526\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=E+Castellsagu%C3%A9&amp;author=J+Liu&amp;author=A+Volenik&amp;author=S+Giroux&amp;author=R+Gagn%C3%A9&amp;author=B+Maranda&amp;publication_year=2015&amp;title=Characterization%20of%20a%20novel%20founder%20MSH6%20mutation%20causing%20lynch%20syndrome%20in%20the%20French%20Canadian%20population&amp;journal=Clin+Genet&amp;volume=87&amp;pages=536-42\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B47\" id=\"B47\">\u003C/a> 47. Alenezi WM, Fierheller CT, Revil T, Serruya C, Mes-Masson A-M, Foulkes WD, et al. Case review: Whole-exome sequencing analyses identify carriers of a known likely pathogenic intronic BRCA1 variant in ovarian cancer cases clinically negative for pathogenic BRCA1 and BRCA2 variants. \u003Ci>Genes 2022 Vol. 13 Page 697\u003C/i> (2022) 13:697. doi:&#xa0;10.3390/GENES13040697\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.3390/GENES13040697\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=WM+Alenezi&amp;author=CT+Fierheller&amp;author=T+Revil&amp;author=C+Serruya&amp;author=A-M+Mes-Masson&amp;author=WD+Foulkes&amp;publication_year=2022&amp;title=Case%20review%3A%20Whole-exome%20sequencing%20analyses%20identify%20carriers%20of%20a%20known%20likely%20pathogenic%20intronic%20BRCA1%20variant%20in%20ovarian%20cancer%20cases%20clinically%20negative%20for%20pathogenic%20BRCA1%20and%20BRCA2%20variants&amp;journal=Genes+2022+Vol.+13+Page+697&amp;volume=13&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B48\" id=\"B48\">\u003C/a> 48. Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. \u003Ci>Int J Gynecology Obstetrics\u003C/i> (2021) 155:61&#x2013;85. doi:&#xa0;10.1002/IJGO.13878\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1002/IJGO.13878\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=JS+Berek&amp;author=M+Renz&amp;author=S+Kehoe&amp;author=L+Kumar&amp;author=M+Friedlander&amp;publication_year=2021&amp;title=Cancer%20of%20the%20ovary%2C%20fallopian%20tube%2C%20and%20peritoneum%3A%202021%20update&amp;journal=Int+J+Gynecology+Obstetrics&amp;volume=155&amp;pages=61\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B49\" id=\"B49\">\u003C/a> 49. K&#xf6;bel M, Kang EY. The evolution of ovarian carcinoma subclassification. \u003Ci>Cancers\u003C/i> (2022) 14:416. doi:&#xa0;10.3390/CANCERS14020416\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/35053578/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3390/CANCERS14020416\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+K%C3%B6bel&amp;author=EY+Kang&amp;publication_year=2022&amp;title=The%20evolution%20of%20ovarian%20carcinoma%20subclassification&amp;journal=Cancers&amp;volume=14&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B50\" id=\"B50\">\u003C/a> 50. Oros KK, Ghadirian P, Maugard CM, Perret C, Paredes Y, Mes-Masson AM, et al. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent. \u003Ci>Clin Genet\u003C/i> (2006) 70(4):320&#x2013;9. doi:&#xa0;10.1111/j.1399-0004.2006.00673.x\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16965326/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/j.1399-0004.2006.00673.x\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=KK+Oros&amp;author=P+Ghadirian&amp;author=CM+Maugard&amp;author=C+Perret&amp;author=Y+Paredes&amp;author=AM+Mes-Masson&amp;publication_year=2006&amp;title=Application%20of%20BRCA1%20and%20BRCA2%20mutation%20carrier%20prediction%20models%20in%20breast%20and%2For%20ovarian%20cancer%20families%20of%20French%20Canadian%20descent&amp;journal=Clin+Genet&amp;volume=70&amp;pages=320-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B51\" id=\"B51\">\u003C/a> 51. Oros KK, Leblanc G, Arcand SL, Shen Z, Perret C, Mes-Masson AM, et al. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families. \u003Ci>BMC Med Genet\u003C/i> (2006) 7:23. doi:&#xa0;10.1186/1471-2350-7-23\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16539696/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/1471-2350-7-23\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=KK+Oros&amp;author=G+Leblanc&amp;author=SL+Arcand&amp;author=Z+Shen&amp;author=C+Perret&amp;author=AM+Mes-Masson&amp;publication_year=2006&amp;title=Haplotype%20analysis%20suggest%20common%20founders%20in%20carriers%20of%20the%20recurrent%20BRCA2%20mutation%203398delAAAAG%2C%20in%20French%20Canadian%20hereditary%20breast%20and%2Fovarian%20cancer%20families&amp;journal=BMC+Med+Genet&amp;volume=7&amp;pages=23\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B52\" id=\"B52\">\u003C/a> 52. Arcand SL, Maugard CM, Ghadirian P, Robidoux A, Perret C, Zhang P, et al. Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families. \u003Ci>Breast Cancer Res Treat\u003C/i> (2008) 108(3):399&#x2013;408. doi:&#xa0;10.1007/s10549-007-9608-6\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/17541742/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10549-007-9608-6\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=SL+Arcand&amp;author=CM+Maugard&amp;author=P+Ghadirian&amp;author=A+Robidoux&amp;author=C+Perret&amp;author=P+Zhang&amp;publication_year=2008&amp;title=Germline%20TP53%20mutations%20in%20BRCA1%20and%20BRCA2%20mutation-negative%20French%20Canadian%20breast%20cancer%20families&amp;journal=Breast+Cancer+Res+Treat&amp;volume=108&amp;pages=399-408\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B53\" id=\"B53\">\u003C/a> 53. Arcand SL, Akbari MR, Mes-Masson AM, Provencher D, Foulkes WD, Narod SA, et al. Germline TP53 mutational spectrum in French canadians with breast cancer. \u003Ci>BMC Med Genet\u003C/i> (2015) 16:24. doi:&#xa0;10.1186/s12881-015-0169-y\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25925845/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s12881-015-0169-y\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=SL+Arcand&amp;author=MR+Akbari&amp;author=AM+Mes-Masson&amp;author=D+Provencher&amp;author=WD+Foulkes&amp;author=SA+Narod&amp;publication_year=2015&amp;title=Germline%20TP53%20mutational%20spectrum%20in%20French%20canadians%20with%20breast%20cancer&amp;journal=BMC+Med+Genet&amp;volume=16&amp;pages=24\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B54\" id=\"B54\">\u003C/a> 54. Osher DJ, De Leeneer K, Michils G, Hamel N, Tomiak E, Poppe B, et al. Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families. \u003Ci>Br J Cancer\u003C/i> (2012) 106(8):1460&#x2013;3. doi:&#xa0;10.1038/bjc.2012.87\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/22415235/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/bjc.2012.87\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=DJ+Osher&amp;author=K+De%20Leeneer&amp;author=G+Michils&amp;author=N+Hamel&amp;author=E+Tomiak&amp;author=B+Poppe&amp;publication_year=2012&amp;title=Mutation%20analysis%20of%20RAD51D%20in%20non-BRCA1%2F2%20ovarian%20and%20breast%20cancer%20families&amp;journal=Br+J+Cancer&amp;volume=106&amp;pages=1460-3\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B55\" id=\"B55\">\u003C/a> 55. Ancot F, Arcand SL, Mes-Masson AM, Provencher DM, Tonin PN. Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population. \u003Ci>Oncol Letters.\u003C/i> (2015) 9(6):2787&#x2013;90. doi:&#xa0;10.3892/ol.2015.3123\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.3892/ol.2015.3123\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=F+Ancot&amp;author=SL+Arcand&amp;author=AM+Mes-Masson&amp;author=DM+Provencher&amp;author=PN+Tonin&amp;publication_year=2015&amp;title=Double%20PALB2%20and%20BRCA1%2FBRCA2%20mutation%20carriers%20are%20rare%20in%20breast%20cancer%20and%20breast-ovarian%20cancer%20syndrome%20families%20from%20the%20French%20Canadian%20founder%20population&amp;journal=Oncol+Letters.&amp;volume=9&amp;pages=2787-90\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B56\" id=\"B56\">\u003C/a> 56. Belanger MH, Dolman L, Arcand SL, Shen Z, Chong G, Mes-Masson AM, et al. A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population. \u003Ci>J Ovarian Res\u003C/i> (2015) 8:1. doi:&#xa0;10.1186/s13048-015-0124-8\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25884701/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s13048-015-0124-8\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MH+Belanger&amp;author=L+Dolman&amp;author=SL+Arcand&amp;author=Z+Shen&amp;author=G+Chong&amp;author=AM+Mes-Masson&amp;publication_year=2015&amp;title=A%20targeted%20analysis%20identifies%20a%20high%20frequency%20of%20BRCA1%20and%20BRCA2%20mutation%20carriers%20in%20women%20with%20ovarian%20cancer%20from%20a%20founder%20population&amp;journal=J+Ovarian+Res&amp;volume=8&amp;pages=1\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B57\" id=\"B57\">\u003C/a> 57. Guillemette L, Allard C, Lacroix M, Patenaude J, Battista MC, Doyon M, et al. Genetics of glucose regulation in gestation and growth (Gen3G): A prospective prebirth cohort of mother-child pairs in sherbrooke, Canada. \u003Ci>BMJ Open\u003C/i> (2016) 6(2):e010031. doi:&#xa0;10.1136/bmjopen-2015-010031\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26842272/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1136/bmjopen-2015-010031\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=L+Guillemette&amp;author=C+Allard&amp;author=M+Lacroix&amp;author=J+Patenaude&amp;author=MC+Battista&amp;author=M+Doyon&amp;publication_year=2016&amp;title=Genetics%20of%20glucose%20regulation%20in%20gestation%20and%20growth%20%28Gen3G%29%3A%20A%20prospective%20prebirth%20cohort%20of%20mother-child%20pairs%20in%20sherbrooke%2C%20Canada&amp;journal=BMJ+Open&amp;volume=6&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B58\" id=\"B58\">\u003C/a> 58. Gan-Or Z, Zhou S, Ambalavanan A, Leblond CS, Xie P, Johnson A, et al. Analysis of functional GLO1 variants in the BTBD9 locus and restless legs syndrome. \u003Ci>Sleep Med\u003C/i> (2015) 16:1151&#x2013;5. doi:&#xa0;10.1016/J.SLEEP.2015.06.002\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26298793/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/J.SLEEP.2015.06.002\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=Z+Gan-Or&amp;author=S+Zhou&amp;author=A+Ambalavanan&amp;author=CS+Leblond&amp;author=P+Xie&amp;author=A+Johnson&amp;publication_year=2015&amp;title=Analysis%20of%20functional%20GLO1%20variants%20in%20the%20BTBD9%20locus%20and%20restless%20legs%20syndrome&amp;journal=Sleep+Med&amp;volume=16&amp;pages=1151-5\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B59\" id=\"B59\">\u003C/a> 59. Awadalla P, Boileau C, Payette Y, Idaghdour Y, Goulet JP, Knoppers B, et al. Cohort profile of the CARTaGENE study: Quebec&#x2019;s population-based biobank for public health and personalized genomics. \u003Ci>Int J Epidemiol\u003C/i> (2013) 42(5):1285&#x2013;99. doi:&#xa0;10.1093/ije/dys160\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23071140/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/ije/dys160\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=P+Awadalla&amp;author=C+Boileau&amp;author=Y+Payette&amp;author=Y+Idaghdour&amp;author=JP+Goulet&amp;author=B+Knoppers&amp;publication_year=2013&amp;title=Cohort%20profile%20of%20the%20CARTaGENE%20study%3A%20Quebec%E2%80%99s%20population-based%20biobank%20for%20public%20health%20and%20personalized%20genomics&amp;journal=Int+J+Epidemiol&amp;volume=42&amp;pages=1285-99\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B60\" id=\"B60\">\u003C/a> 60. Huang K, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, et al. Pathogenic germline variants in 10,389 adult cancers. \u003Ci>Cell\u003C/i> (2018) 173(2):355&#x2013;370.e14. doi:&#xa0;10.1016/j.cell.2018.03.039\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29625052/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.cell.2018.03.039\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=K+Huang&amp;author=RJ+Mashl&amp;author=Y+Wu&amp;author=DI+Ritter&amp;author=J+Wang&amp;author=C+Oh&amp;publication_year=2018&amp;title=Pathogenic%20germline%20variants%20in%2010%2C389%20adult%20cancers&amp;journal=Cell&amp;volume=173&amp;pages=355-370.e14\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B61\" id=\"B61\">\u003C/a> 61. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alf&#xf6;ldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. \u003Ci>Nat 2020 581:7809\u003C/i> (2020) 581:434&#x2013;43. doi:&#xa0;10.1038/s41586-020-2308-7\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1038/s41586-020-2308-7\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=KJ+Karczewski&amp;author=LC+Francioli&amp;author=G+Tiao&amp;author=BB+Cummings&amp;author=J+Alf%C3%B6ldi&amp;author=Q+Wang&amp;publication_year=2020&amp;title=The%20mutational%20constraint%20spectrum%20quantified%20from%20variation%20in%20141%2C456%20humans&amp;journal=Nat+2020+581:7809&amp;volume=581&amp;pages=434-43\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B62\" id=\"B62\">\u003C/a> 62. Koch L. Exploring human genomic diversity with gnomAD. \u003Ci>Nat Rev Genet\u003C/i> (2020) 21(8):448. doi:&#xa0;10.1038/s41576-020-0255-7\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32488197/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41576-020-0255-7\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=L+Koch&amp;publication_year=2020&amp;title=Exploring%20human%20genomic%20diversity%20with%20gnomAD&amp;journal=Nat+Rev+Genet&amp;volume=21&amp;pages=448\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B63\" id=\"B63\">\u003C/a> 63. Pedersen BS, Brown JM, Dashnow H, Wallace AD, Velinder M, Tristani-Firouzi M, et al. Effective variant filtering and expected candidate variant yield in studies of rare human disease. \u003Ci>NPJ Genomic Med 2021 6:1\u003C/i> (2021) 6:1&#x2013;8. doi:&#xa0;10.1038/s41525-021-00227-3\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1038/s41525-021-00227-3\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=BS+Pedersen&amp;author=JM+Brown&amp;author=H+Dashnow&amp;author=AD+Wallace&amp;author=M+Velinder&amp;author=M+Tristani-Firouzi&amp;publication_year=2021&amp;title=Effective%20variant%20filtering%20and%20expected%20candidate%20variant%20yield%20in%20studies%20of%20rare%20human%20disease&amp;journal=NPJ+Genomic+Med+2021+6:1&amp;volume=6&amp;pages=1\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B64\" id=\"B64\">\u003C/a> 64. Thorvaldsd&#xf3;ttir H, Robinson JT, Mesirov JP. Integrative genomics viewer (IGV): High-performance genomics data visualization and exploration. \u003Ci>Briefings Bioinf\u003C/i> (2013) 14(2):178&#x2013;92. doi:&#xa0;10.1093/bib/bbs017\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1093/bib/bbs017\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H+Thorvaldsd%C3%B3ttir&amp;author=JT+Robinson&amp;author=JP+Mesirov&amp;publication_year=2013&amp;title=Integrative%20genomics%20viewer%20%28IGV%29%3A%20High-performance%20genomics%20data%20visualization%20and%20exploration&amp;journal=Briefings+Bioinf&amp;volume=14&amp;pages=178-92\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B65\" id=\"B65\">\u003C/a> 65. Davydov EV, Goode DL, Sirota M, Cooper GM, Sidow A, Batzoglou S. Identifying a high fraction of the human genome to be under selective constraint using GERP++. \u003Ci>PloS Comput Biol\u003C/i> (2010) 6(12):e1001025. doi:&#xa0;10.1371/journal.pcbi.1001025\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/21152010/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1371/journal.pcbi.1001025\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=EV+Davydov&amp;author=DL+Goode&amp;author=M+Sirota&amp;author=GM+Cooper&amp;author=A+Sidow&amp;author=S+Batzoglou&amp;publication_year=2010&amp;title=Identifying%20a%20high%20fraction%20of%20the%20human%20genome%20to%20be%20under%20selective%20constraint%20using%20GERP%2B%2B&amp;journal=PloS+Comput+Biol&amp;volume=6&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B66\" id=\"B66\">\u003C/a> 66. Pollard KS, Hubisz MJ, Rosenbloom KR, Siepel A. Detection of nonneutral substitution rates on mammalian phylogenies. \u003Ci>Genome Res\u003C/i> (2010) 20:110&#x2013;21. doi:&#xa0;10.1101/GR.097857.109\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/19858363/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1101/GR.097857.109\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=KS+Pollard&amp;author=MJ+Hubisz&amp;author=KR+Rosenbloom&amp;author=A+Siepel&amp;publication_year=2010&amp;title=Detection%20of%20nonneutral%20substitution%20rates%20on%20mammalian%20phylogenies&amp;journal=Genome+Res&amp;volume=20&amp;pages=110-21\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B67\" id=\"B67\">\u003C/a> 67. Siepel A, Bejerano G, Pedersen JS, Hinrichs AS, Hou M, Rosenbloom K, et al. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. \u003Ci>Genome Res\u003C/i> (2005) 15(8):1034&#x2013;50. doi:&#xa0;10.1101/gr.3715005\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16024819/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1101/gr.3715005\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Siepel&amp;author=G+Bejerano&amp;author=JS+Pedersen&amp;author=AS+Hinrichs&amp;author=M+Hou&amp;author=K+Rosenbloom&amp;publication_year=2005&amp;title=Evolutionarily%20conserved%20elements%20in%20vertebrate%2C%20insect%2C%20worm%2C%20and%20yeast%20genomes&amp;journal=Genome+Res&amp;volume=15&amp;pages=1034-50\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B68\" id=\"B68\">\u003C/a> 68. Shamsani J, Kazakoff SH, Armean IM, McLaren W, Parsons MT, Thompson BA, et al. A plugin for the ensembl variant effect predictor that uses MaxEntScan to predict variant spliceogenicity. \u003Ci>Bioinformatics\u003C/i> (2019) 35(13):2315&#x2013;7. doi:&#xa0;10.1093/bioinformatics/bty960\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30475984/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/bioinformatics/bty960\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+Shamsani&amp;author=SH+Kazakoff&amp;author=IM+Armean&amp;author=W+McLaren&amp;author=MT+Parsons&amp;author=BA+Thompson&amp;publication_year=2019&amp;title=A%20plugin%20for%20the%20ensembl%20variant%20effect%20predictor%20that%20uses%20MaxEntScan%20to%20predict%20variant%20spliceogenicity&amp;journal=Bioinformatics&amp;volume=35&amp;pages=2315-7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B69\" id=\"B69\">\u003C/a> 69. Liu X, Wu C, Li C, Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice-site SNVs. \u003Ci>Hum Mutation.\u003C/i> (2016) 37(3):235&#x2013;41. doi:&#xa0;10.1002/humu.22932\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1002/humu.22932\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=X+Liu&amp;author=C+Wu&amp;author=C+Li&amp;author=E+Boerwinkle&amp;publication_year=2016&amp;title=dbNSFP%20v3.0%3A%20A%20one-stop%20database%20of%20functional%20predictions%20and%20annotations%20for%20human%20nonsynonymous%20and%20splice-site%20SNVs&amp;journal=Hum+Mutation.&amp;volume=37&amp;pages=235-41\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B70\" id=\"B70\">\u003C/a> 70. Ha C, Kim JW, Jang JH. Performance evaluation of SpliceAI for the prediction of splicing of NF1 variants. \u003Ci>Genes\u003C/i> (2021) 12:1308. doi:&#xa0;10.3390/GENES12091308\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/34573290/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3390/GENES12091308\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=C+Ha&amp;author=JW+Kim&amp;author=JH+Jang&amp;publication_year=2021&amp;title=Performance%20evaluation%20of%20SpliceAI%20for%20the%20prediction%20of%20splicing%20of%20NF1%20variants&amp;journal=Genes&amp;volume=12&amp;pages=1308\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B71\" id=\"B71\">\u003C/a> 71. Ghosh R, Oak N, Plon S. Evaluation of in silico algorithms for use with ACMG/AMP clinical variant interpretation guidelines. \u003Ci>Genome Biol\u003C/i> (2017) 12(9):1308. doi:&#xa0;10.1186/s13059-017-1353-5\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1186/s13059-017-1353-5\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R+Ghosh&amp;author=N+Oak&amp;author=S+Plon&amp;publication_year=2017&amp;title=Evaluation%20of%20in%20silico%20algorithms%20for%20use%20with%20ACMG%2FAMP%20clinical%20variant%20interpretation%20guidelines&amp;journal=Genome+Biol&amp;volume=12&amp;pages=1308\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B72\" id=\"B72\">\u003C/a> 72. Niroula A, Vihinen M. How good are pathogenicity predictors in detecting benign variants? \u003Ci>PloS Comput Biol\u003C/i> (2019) 15(2):e1006481. doi:&#xa0;10.1371/JOURNAL.PCBI.1006481\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30742610/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1371/JOURNAL.PCBI.1006481\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Niroula&amp;author=M+Vihinen&amp;publication_year=2019&amp;title=How%20good%20are%20pathogenicity%20predictors%20in%20detecting%20benign%20variants&amp;journal=PloS+Comput+Biol&amp;volume=15&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B73\" id=\"B73\">\u003C/a> 73. Cubuk C, Garrett A, Choi S, King L, Loveday C, Torr B, et al. Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes. \u003Ci>Genet medicine : Off J Am Coll Med Genet\u003C/i> (2021) 23:2096&#x2013;104. doi:&#xa0;10.1038/S41436-021-01265-Z\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1038/S41436-021-01265-Z\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=C+Cubuk&amp;author=A+Garrett&amp;author=S+Choi&amp;author=L+King&amp;author=C+Loveday&amp;author=B+Torr&amp;publication_year=2021&amp;title=Clinical%20likelihood%20ratios%20and%20balanced%20accuracy%20for%2044%20in%20silico%20tools%20against%20multiple%20large-scale%20functional%20assays%20of%20cancer%20susceptibility%20genes&amp;journal=Genet+medicine+:+Off+J+Am+Coll+Med+Genet&amp;volume=23&amp;pages=2096-104\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B74\" id=\"B74\">\u003C/a> 74. Gunning AC, Fryer V, Fasham J, Crosby AH, Ellard S, Baple EL, et al. Assessing performance of pathogenicity predictors using clinically relevant variant datasets. \u003Ci>J Med Genet\u003C/i> (2021) 58:547&#x2013;55. doi:&#xa0;10.1136/JMEDGENET-2020-107003\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32843488/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1136/JMEDGENET-2020-107003\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=AC+Gunning&amp;author=V+Fryer&amp;author=J+Fasham&amp;author=AH+Crosby&amp;author=S+Ellard&amp;author=EL+Baple&amp;publication_year=2021&amp;title=Assessing%20performance%20of%20pathogenicity%20predictors%20using%20clinically%20relevant%20variant%20datasets&amp;journal=J+Med+Genet&amp;volume=58&amp;pages=547-55\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B75\" id=\"B75\">\u003C/a> 75. Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: Predicting the deleteriousness of variants throughout the human genome. \u003Ci>Nucleic Acids Res\u003C/i> (2019) 47:D886&#x2013;94. doi:&#xa0;10.1093/nar/gky1016\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30371827/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/nar/gky1016\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=P+Rentzsch&amp;author=D+Witten&amp;author=GM+Cooper&amp;author=J+Shendure&amp;author=M+Kircher&amp;publication_year=2019&amp;title=CADD%3A%20Predicting%20the%20deleteriousness%20of%20variants%20throughout%20the%20human%20genome&amp;journal=Nucleic+Acids+Res&amp;volume=47&amp;pages=D886-94\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B76\" id=\"B76\">\u003C/a> 76. Ionita-Laza I, Mccallum K, Xu B, Buxbaum JD. A spectral approach integrating functional genomic annotations for coding and noncoding variants. \u003Ci>Nat Genet\u003C/i> (2016) 48:214&#x2013;20. doi:&#xa0;10.1038/NG.3477\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26727659/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/NG.3477\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=I+Ionita-Laza&amp;author=K+Mccallum&amp;author=B+Xu&amp;author=JD+Buxbaum&amp;publication_year=2016&amp;title=A%20spectral%20approach%20integrating%20functional%20genomic%20annotations%20for%20coding%20and%20noncoding%20variants&amp;journal=Nat+Genet&amp;volume=48&amp;pages=214-20\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B77\" id=\"B77\">\u003C/a> 77. Dong C, Wei P, Jian X, Gibbs R, Boerwinkle E, Wang K, et al. Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. \u003Ci>Hum Mol Genet\u003C/i> (2015) 24(8):2125&#x2013;37. doi:&#xa0;10.1093/hmg/ddu733\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25552646/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/hmg/ddu733\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=C+Dong&amp;author=P+Wei&amp;author=X+Jian&amp;author=R+Gibbs&amp;author=E+Boerwinkle&amp;author=K+Wang&amp;publication_year=2015&amp;title=Comparison%20and%20integration%20of%20deleteriousness%20prediction%20methods%20for%20nonsynonymous%20SNVs%20in%20whole%20exome%20sequencing%20studies&amp;journal=Hum+Mol+Genet&amp;volume=24&amp;pages=2125-37\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B78\" id=\"B78\">\u003C/a> 78. Li C, Zhi D, Wang K, Liu X. MetaRNN: Differentiating rare pathogenic and rare benign missense SNVs and InDels using deep learning. \u003Ci>bioRxiv\u003C/i> (2021) 2021:4.09.438706. doi:&#xa0;10.1101/2021.04.09.438706\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1101/2021.04.09.438706\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=C+Li&amp;author=D+Zhi&amp;author=K+Wang&amp;author=X+Liu&amp;publication_year=2021&amp;title=MetaRNN%3A%20Differentiating%20rare%20pathogenic%20and%20rare%20benign%20missense%20SNVs%20and%20InDels%20using%20deep%20learning&amp;journal=bioRxiv&amp;volume=2021&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B79\" id=\"B79\">\u003C/a> 79. Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, et al. REVEL: An ensemble method for predicting the pathogenicity of rare missense variants. \u003Ci>Am J Hum Genet\u003C/i> (2016) 99(4):877&#x2013;85. doi:&#xa0;10.1016/j.ajhg.2016.08.016\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27666373/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.ajhg.2016.08.016\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=NM+Ioannidis&amp;author=JH+Rothstein&amp;author=V+Pejaver&amp;author=S+Middha&amp;author=SK+McDonnell&amp;author=S+Baheti&amp;publication_year=2016&amp;title=REVEL%3A%20An%20ensemble%20method%20for%20predicting%20the%20pathogenicity%20of%20rare%20missense%20variants&amp;journal=Am+J+Hum+Genet&amp;volume=99&amp;pages=877-85\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B80\" id=\"B80\">\u003C/a> 80. Douville C, Masica DL, Stenson PD, Cooper DN, Gygax DM, Kim R, et al. Assessing the pathogenicity of insertion and deletion variants with the variant effect scoring tool (VEST-indel). \u003Ci>Hum Mutat\u003C/i> (2016) 37:28&#x2013;35. doi:&#xa0;10.1002/HUMU.22911\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26442818/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/HUMU.22911\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=C+Douville&amp;author=DL+Masica&amp;author=PD+Stenson&amp;author=DN+Cooper&amp;author=DM+Gygax&amp;author=R+Kim&amp;publication_year=2016&amp;title=Assessing%20the%20pathogenicity%20of%20insertion%20and%20deletion%20variants%20with%20the%20variant%20effect%20scoring%20tool%20%28VEST-indel%29&amp;journal=Hum+Mutat&amp;volume=37&amp;pages=28\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B81\" id=\"B81\">\u003C/a> 81. Choi Y, Chan AP. PROVEAN web server: A tool to predict the functional effect of amino acid substitutions and indels. \u003Ci>Bioinformatics\u003C/i> (2015) 31(16):2745&#x2013;7. doi:&#xa0;10.1093/bioinformatics/btv195\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25851949/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/bioinformatics/btv195\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=Y+Choi&amp;author=AP+Chan&amp;publication_year=2015&amp;title=PROVEAN%20web%20server%3A%20A%20tool%20to%20predict%20the%20functional%20effect%20of%20amino%20acid%20substitutions%20and%20indels&amp;journal=Bioinformatics&amp;volume=31&amp;pages=2745-7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B82\" id=\"B82\">\u003C/a> 82. Landrum MJ, Lee JM, Benson M, Brown G, Chao C, Chitipiralla S, et al. ClinVar: Public archive of interpretations of clinically relevant variants. \u003Ci>Nucleic Acids Res\u003C/i> (2016) 44(D1):D862&#x2013;8. doi:&#xa0;10.1093/nar/gkv1222\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26582918/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/nar/gkv1222\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MJ+Landrum&amp;author=JM+Lee&amp;author=M+Benson&amp;author=G+Brown&amp;author=C+Chao&amp;author=S+Chitipiralla&amp;publication_year=2016&amp;title=ClinVar%3A%20Public%20archive%20of%20interpretations%20of%20clinically%20relevant%20variants&amp;journal=Nucleic+Acids+Res&amp;volume=44&amp;pages=D862-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B83\" id=\"B83\">\u003C/a> 83. Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: Improving access to variant interpretations and supporting evidence. \u003Ci>Nucleic Acids Res\u003C/i> (2018) 46:1062&#x2013;7. doi:&#xa0;10.1093/nar/gkx1153\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1093/nar/gkx1153\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MJ+Landrum&amp;author=JM+Lee&amp;author=M+Benson&amp;author=GR+Brown&amp;author=C+Chao&amp;author=S+Chitipiralla&amp;publication_year=2018&amp;title=ClinVar%3A%20Improving%20access%20to%20variant%20interpretations%20and%20supporting%20evidence&amp;journal=Nucleic+Acids+Res&amp;volume=46&amp;pages=1062-7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B84\" id=\"B84\">\u003C/a> 84. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. \u003Ci>Genet Med\u003C/i> (2015) 17(5):405&#x2013;24. doi:&#xa0;10.1038/gim.2015.30\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25741868/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/gim.2015.30\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+Richards&amp;author=N+Aziz&amp;author=S+Bale&amp;author=D+Bick&amp;author=S+Das&amp;author=J+Gastier-Foster&amp;publication_year=2015&amp;title=Standards%20and%20guidelines%20for%20the%20interpretation%20of%20sequence%20variants%3A%20A%20joint%20consensus%20recommendation%20of%20the%20American%20college%20of%20medical%20genetics%20and%20genomics%20and%20the%20association%20for%20molecular%20pathology&amp;journal=Genet+Med&amp;volume=17&amp;pages=405-24\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B85\" id=\"B85\">\u003C/a> 85. Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, et al. Sherloc: A comprehensive refinement of the ACMG-AMP variant classification criteria. \u003Ci>Genet Med\u003C/i> (2017) 19(10):1105&#x2013;17. doi:&#xa0;10.1038/gim.2017.37\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28492532/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/gim.2017.37\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=K+Nykamp&amp;author=M+Anderson&amp;author=M+Powers&amp;author=J+Garcia&amp;author=B+Herrera&amp;author=YY+Ho&amp;publication_year=2017&amp;title=Sherloc%3A%20A%20comprehensive%20refinement%20of%20the%20ACMG-AMP%20variant%20classification%20criteria&amp;journal=Genet+Med&amp;volume=19&amp;pages=1105-17\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B86\" id=\"B86\">\u003C/a> 86. Alenezi WM, Fierheller CT, Recio N, Tonin PN. Literature review of BARD1 as a cancer predisposing gene with a focus on breast and ovarian cancers. \u003Ci>Genes\u003C/i> (2020) 11:1&#x2013;24. doi:&#xa0;10.3390/GENES11080856\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.3390/GENES11080856\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=WM+Alenezi&amp;author=CT+Fierheller&amp;author=N+Recio&amp;author=PN+Tonin&amp;publication_year=2020&amp;title=Literature%20review%20of%20BARD1%20as%20a%20cancer%20predisposing%20gene%20with%20a%20focus%20on%20breast%20and%20ovarian%20cancers&amp;journal=Genes&amp;volume=11&amp;pages=1\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B87\" id=\"B87\">\u003C/a> 87. Fedick A, Su J, Jalas C, Northrop L, Devkota B, Ekstein J, et al. High-throughput carrier screening using TaqMan allelic discrimination. \u003Ci>PloS One\u003C/i> (2013) 8(3):e59722. doi:&#xa0;10.1371/journal.pone.0059722\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23555759/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1371/journal.pone.0059722\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Fedick&amp;author=J+Su&amp;author=C+Jalas&amp;author=L+Northrop&amp;author=B+Devkota&amp;author=J+Ekstein&amp;publication_year=2013&amp;title=High-throughput%20carrier%20screening%20using%20TaqMan%20allelic%20discrimination&amp;journal=PloS+One&amp;volume=8&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B88\" id=\"B88\">\u003C/a> 88. Gabriel S, Ziaugra L, Tabbaa D. SNP genotyping using the sequenom massARRAY iPLEX platform. \u003Ci>Curr Protoc Hum Genet\u003C/i> (2009) Chapter 2:Unit 2.12. doi:&#xa0;10.1002/0471142905.hg0212s60\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/19170031/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/0471142905.hg0212s60\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+Gabriel&amp;author=L+Ziaugra&amp;author=D+Tabbaa&amp;publication_year=2009&amp;title=SNP%20genotyping%20using%20the%20sequenom%20massARRAY%20iPLEX%20platform&amp;journal=Curr+Protoc+Hum+Genet&amp;volume=Chapter 2&amp;pages=Unit 2.12\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B89\" id=\"B89\">\u003C/a> 89. De Wever J, Everaert H, Coppieters F, Rottiers H, Dewettinck K, Lefever S, et al. The development of a novel SNP genotyping assay to differentiate cacao clones. \u003Ci>Sci Rep\u003C/i> (2019) 9(1):9512. doi:&#xa0;10.1038/S41598-019-45884-8\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31267023/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/S41598-019-45884-8\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+De%20Wever&amp;author=H+Everaert&amp;author=F+Coppieters&amp;author=H+Rottiers&amp;author=K+Dewettinck&amp;author=S+Lefever&amp;publication_year=2019&amp;title=The%20development%20of%20a%20novel%20SNP%20genotyping%20assay%20to%20differentiate%20cacao%20clones&amp;journal=Sci+Rep&amp;volume=9&amp;pages=9512\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B90\" id=\"B90\">\u003C/a> 90. Behl S, Hamel N, de Ladurantaye M, Lepage S, Lapointe R, Mes-Masson A-M, et al. Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls. \u003Ci>Sci Rep\u003C/i> (2020) 10(1):6491. doi:&#xa0;10.1038/s41598-020-63100-w\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32300229/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41598-020-63100-w\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+Behl&amp;author=N+Hamel&amp;author=M+de%20Ladurantaye&amp;author=S+Lepage&amp;author=R+Lapointe&amp;author=A-M+Mes-Masson&amp;publication_year=2020&amp;title=Founder%20BRCA1%2FBRCA2%2FPALB2%20pathogenic%20variants%20in%20French-Canadian%20breast%20cancer%20cases%20and%20controls&amp;journal=Sci+Rep&amp;volume=10&amp;pages=6491\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B91\" id=\"B91\">\u003C/a> 91. Sousa SB, Abdul-Rahman OA, Bottani A, Cormier-Daire V, Fryer A, Gillessen-Kaesbach G, et al. Nicolaides&#x2013;baraitser syndrome: Delineation of the phenotype. \u003Ci>Am J Med Genet\u003C/i> (2009) Part A 149A:1628&#x2013;40. doi:&#xa0;10.1002/AJMG.A.32956\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1002/AJMG.A.32956\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=SB+Sousa&amp;author=OA+Abdul-Rahman&amp;author=A+Bottani&amp;author=V+Cormier-Daire&amp;author=A+Fryer&amp;author=G+Gillessen-Kaesbach&amp;publication_year=2009&amp;title=Nicolaides%E2%80%93baraitser%20syndrome%3A%20Delineation%20of%20the%20phenotype&amp;journal=Am+J+Med+Genet&amp;volume=Part A 149A&amp;pages=1628-40\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B92\" id=\"B92\">\u003C/a> 92. Sousa SB, Hennekam RC, Abdul-Rahman O, Alders M, Azzarello-Burri S, Bottani A, et al. Phenotype and genotype in nicolaides-baraitser syndrome. \u003Ci>Am J Med Genetics Part C: Semin Med Genet\u003C/i> (2014) 166:302&#x2013;14. doi:&#xa0;10.1002/ajmg.c.31409\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1002/ajmg.c.31409\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=SB+Sousa&amp;author=RC+Hennekam&amp;author=O+Abdul-Rahman&amp;author=M+Alders&amp;author=S+Azzarello-Burri&amp;author=A+Bottani&amp;publication_year=2014&amp;title=Phenotype%20and%20genotype%20in%20nicolaides-baraitser%20syndrome&amp;journal=Am+J+Med+Genetics+Part+C:+Semin+Med+Genet&amp;volume=166&amp;pages=302-14\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B93\" id=\"B93\">\u003C/a> 93. Gana S, Panizzon M, Fongaro D, Selicorni A, Memo L, Scandurra V, et al. Nicolaides-baraitser syndrome: Two new cases with autism spectrum disorder. \u003Ci>Clin dysmorphology\u003C/i> (2011) 20:38&#x2013;41. doi:&#xa0;10.1097/MCD.0B013E32833EDAA9\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1097/MCD.0B013E32833EDAA9\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+Gana&amp;author=M+Panizzon&amp;author=D+Fongaro&amp;author=A+Selicorni&amp;author=L+Memo&amp;author=V+Scandurra&amp;publication_year=2011&amp;title=Nicolaides-baraitser%20syndrome%3A%20Two%20new%20cases%20with%20autism%20spectrum%20disorder&amp;journal=Clin+dysmorphology&amp;volume=20&amp;pages=38\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B94\" id=\"B94\">\u003C/a> 94. Ejaz R, Babul-Hirji R, Chitayat D. The evolving features of nicolaides&#x2013;baraitser syndrome &#x2013; a clinical report of a 20-year follow-up. \u003Ci>Clin Case Rep\u003C/i> (2016) 4:351. doi:&#xa0;10.1002/CCR3.425\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27099726/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/CCR3.425\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R+Ejaz&amp;author=R+Babul-Hirji&amp;author=D+Chitayat&amp;publication_year=2016&amp;title=The%20evolving%20features%20of%20nicolaides%E2%80%93baraitser%20syndrome%20%E2%80%93%20a%20clinical%20report%20of%20a%2020-year%20follow-up&amp;journal=Clin+Case+Rep&amp;volume=4&amp;pages=351\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B95\" id=\"B95\">\u003C/a> 95. Cappuccio G, Sayou C, Tanno P, Tisserant E, Bruel AL, Kennani S, et al. \u003Ci>De novo\u003C/i> SMARCA2 variants clustered outside the helicase domain cause a new recognizable syndrome with intellectual disability and blepharophimosis distinct from nicolaides&#x2013;baraitser syndrome. \u003Ci>Genet Med\u003C/i> (2020) 22:1838&#x2013;50. doi:&#xa0;10.1038/s41436-020-0898-y\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32694869/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41436-020-0898-y\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=G+Cappuccio&amp;author=C+Sayou&amp;author=P+Tanno&amp;author=E+Tisserant&amp;author=AL+Bruel&amp;author=S+Kennani&amp;publication_year=2020&amp;title=De%20novo%20SMARCA2%20variants%20clustered%20outside%20the%20helicase%20domain%20cause%20a%20new%20recognizable%20syndrome%20with%20intellectual%20disability%20and%20blepharophimosis%20distinct%20from%20nicolaides%E2%80%93baraitser%20syndrome&amp;journal=Genet+Med&amp;volume=22&amp;pages=1838-50\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B96\" id=\"B96\">\u003C/a> 96. Cenik BK, Shilatifard A. COMPASS and SWI/SNF complexes in development and disease. \u003Ci>Nat Rev Genet 2020 22:1\u003C/i> (2020) 22:38&#x2013;58. doi:&#xa0;10.1038/s41576-020-0278-0\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1038/s41576-020-0278-0\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=BK+Cenik&amp;author=A+Shilatifard&amp;publication_year=2020&amp;title=COMPASS%20and%20SWI%2FSNF%20complexes%20in%20development%20and%20disease&amp;journal=Nat+Rev+Genet+2020+22:1&amp;volume=22&amp;pages=38\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B97\" id=\"B97\">\u003C/a> 97. Zhang X, Chen H, Song Y, Chen Z, Liu X, Rong P, et al. Ten-year follow-up of nicolaides-baraitser syndrome with a \u003Ci>de novo\u003C/i> mutation and analysis of 58 gene loci of SMARCA2-associated NCBRS. \u003Ci>Mol Genet genomic Med\u003C/i> (2022) 10(9):e2009. doi:&#xa0;10.1002/MGG3.2009\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/35811451/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/MGG3.2009\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=X+Zhang&amp;author=H+Chen&amp;author=Y+Song&amp;author=Z+Chen&amp;author=X+Liu&amp;author=P+Rong&amp;publication_year=2022&amp;title=Ten-year%20follow-up%20of%20nicolaides-baraitser%20syndrome%20with%20a%20de%20novo%20mutation%20and%20analysis%20of%2058%20gene%20loci%20of%20SMARCA2-associated%20NCBRS&amp;journal=Mol+Genet+genomic+Med&amp;volume=10&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B98\" id=\"B98\">\u003C/a> 98. Koemans TS, Kleefstra T, Chubak MC, Stone MH, Reijnders MRF, de Munnik S, et al. Functional convergence of histone methyltransferases EHMT1 and KMT2C involved in intellectual disability and autism spectrum disorder. \u003Ci>PloS Genet\u003C/i> (2017) 13(10):e1006864. doi:&#xa0;10.1371/JOURNAL.PGEN.1006864\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29069077/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1371/JOURNAL.PGEN.1006864\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=TS+Koemans&amp;author=T+Kleefstra&amp;author=MC+Chubak&amp;author=MH+Stone&amp;author=MRF+Reijnders&amp;author=S+de%20Munnik&amp;publication_year=2017&amp;title=Functional%20convergence%20of%20histone%20methyltransferases%20EHMT1%20and%20KMT2C%20involved%20in%20intellectual%20disability%20and%20autism%20spectrum%20disorder&amp;journal=PloS+Genet&amp;volume=13&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B99\" id=\"B99\">\u003C/a> 99. McRae JF, Clayton S, Fitzgerald TW, Kaplanis J, Prigmore E, Rajan D, et al. Prevalence and architecture of \u003Ci>de novo\u003C/i> mutations in developmental disorders. \u003Ci>Nat 2017 542:7642\u003C/i> (2017) 542:433&#x2013;8. doi:&#xa0;10.1038/nature21062\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1038/nature21062\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=JF+McRae&amp;author=S+Clayton&amp;author=TW+Fitzgerald&amp;author=J+Kaplanis&amp;author=E+Prigmore&amp;author=D+Rajan&amp;publication_year=2017&amp;title=Prevalence%20and%20architecture%20of%20de%20novo%20mutations%20in%20developmental%20disorders&amp;journal=Nat+2017+542:7642&amp;volume=542&amp;pages=433-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B100\" id=\"B100\">\u003C/a> 100. Faundes V, Newman WG, Bernardini L, Canham N, Clayton-Smith J, Dallapiccola B, et al. Histone lysine methylases and demethylases in the landscape of human developmental disorders. \u003Ci>Am J Hum Genet\u003C/i> (2018) 102:175&#x2013;87. doi:&#xa0;10.1016/J.AJHG.2017.11.013\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29276005/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/J.AJHG.2017.11.013\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=V+Faundes&amp;author=WG+Newman&amp;author=L+Bernardini&amp;author=N+Canham&amp;author=J+Clayton-Smith&amp;author=B+Dallapiccola&amp;publication_year=2018&amp;title=Histone%20lysine%20methylases%20and%20demethylases%20in%20the%20landscape%20of%20human%20developmental%20disorders&amp;journal=Am+J+Hum+Genet&amp;volume=102&amp;pages=175-87\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B101\" id=\"B101\">\u003C/a> 101. Lavery WJ, Barski A, Wiley S, Schorry EK, Lindsley AW. KMT2C/D COMPASS complex-associated diseases [KCDCOM-ADs]: An emerging class of congenital regulopathies. \u003Ci>Clin Epigenet 2020 12:1\u003C/i> (2020) 12:1&#x2013;20. doi:&#xa0;10.1186/S13148-019-0802-2\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1186/S13148-019-0802-2\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=WJ+Lavery&amp;author=A+Barski&amp;author=S+Wiley&amp;author=EK+Schorry&amp;author=AW+Lindsley&amp;publication_year=2020&amp;title=KMT2C%2FD%20COMPASS%20complex-associated%20diseases%20%5BKCDCOM-ADs%5D%3A%20An%20emerging%20class%20of%20congenital%20regulopathies&amp;journal=Clin+Epigenet+2020+12:1&amp;volume=12&amp;pages=1\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B102\" id=\"B102\">\u003C/a> 102. Thompson ER, Doyle MA, Ryland GL, Rowley SM, Choong DYH, Tothill RW, et al. Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles. \u003Ci>PloS Genet\u003C/i> (2012) 8(9):e1002894. doi:&#xa0;10.1371/journal.pgen.1002894\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23028338/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1371/journal.pgen.1002894\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=ER+Thompson&amp;author=MA+Doyle&amp;author=GL+Ryland&amp;author=SM+Rowley&amp;author=DYH+Choong&amp;author=RW+Tothill&amp;publication_year=2012&amp;title=Exome%20sequencing%20identifies%20rare%20deleterious%20mutations%20in%20DNA%20repair%20genes%20FANCC%20and%20BLM%20as%20potential%20breast%20cancer%20susceptibility%20alleles&amp;journal=PloS+Genet&amp;volume=8&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B103\" id=\"B103\">\u003C/a> 103. Morales J, Pujar S, Loveland JE, Astashyn A, Bennett R, Berry A, et al. A joint NCBI and EMBL-EBI transcript set for clinical genomics and research. \u003Ci>Nat 2022\u003C/i> (2022) 604(7905):310&#x2013;315. doi:&#xa0;10.1038/s41586-022-04558-8\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1038/s41586-022-04558-8\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+Morales&amp;author=S+Pujar&amp;author=JE+Loveland&amp;author=A+Astashyn&amp;author=R+Bennett&amp;author=A+Berry&amp;publication_year=2022&amp;title=A%20joint%20NCBI%20and%20EMBL-EBI%20transcript%20set%20for%20clinical%20genomics%20and%20research&amp;journal=Nat+2022&amp;volume=604&amp;pages=310-315\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B104\" id=\"B104\">\u003C/a> 104. Richards CS, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Response to biesecker and Harrison. \u003Ci>Genet Med\u003C/i> (2018) 20:1689&#x2013;90. doi:&#xa0;10.1038/gim.2018.43\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29543230/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/gim.2018.43\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=CS+Richards&amp;author=N+Aziz&amp;author=S+Bale&amp;author=D+Bick&amp;author=S+Das&amp;author=J+Gastier-Foster&amp;publication_year=2018&amp;title=Response%20to%20biesecker%20and%20Harrison&amp;journal=Genet+Med&amp;volume=20&amp;pages=1689-90\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B105\" id=\"B105\">\u003C/a> 105. Abou Tayoun AN, Pesaran T, DiStefano MT, Oza A, Rehm HL, Biesecker LG, et al. Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion. \u003Ci>Hum Mutat\u003C/i> (2018) 39:1517&#x2013;24. doi:&#xa0;10.1002/humu.23626\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30192042/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.23626\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=AN+Abou%20Tayoun&amp;author=T+Pesaran&amp;author=MT+DiStefano&amp;author=A+Oza&amp;author=HL+Rehm&amp;author=LG+Biesecker&amp;publication_year=2018&amp;title=Recommendations%20for%20interpreting%20the%20loss%20of%20function%20PVS1%20ACMG%2FAMP%20variant%20criterion&amp;journal=Hum+Mutat&amp;volume=39&amp;pages=1517-24\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B106\" id=\"B106\">\u003C/a> 106. Jian X, Boerwinkle E, Liu X. In silico prediction of splice-altering single nucleotide variants in the human genome. \u003Ci>Nucleic Acids Res\u003C/i> (2014) 42(22):13534&#x2013;44. doi:&#xa0;10.1093/nar/gku1206\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25416802/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/nar/gku1206\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=X+Jian&amp;author=E+Boerwinkle&amp;author=X+Liu&amp;publication_year=2014&amp;title=In%20silico%20prediction%20of%20splice-altering%20single%20nucleotide%20variants%20in%20the%20human%20genome&amp;journal=Nucleic+Acids+Res&amp;volume=42&amp;pages=13534-44\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B107\" id=\"B107\">\u003C/a> 107. Pirim D, Kaya N, Y&#x131;ld&#x131;r&#x131;m EU, Sag &#x15e;O, Temel SG. Characterization and in silico analyses of the BRCA1/2 variants identified in individuals with personal and/or family history of BRCA-related cancers. \u003Ci>Int J Biol Macromolecules\u003C/i> (2020) 162:1166&#x2013;77. doi:&#xa0;10.1016/J.IJBIOMAC.2020.06.222\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1016/J.IJBIOMAC.2020.06.222\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=D+Pirim&amp;author=N+Kaya&amp;author=EU+Y%C4%B1ld%C4%B1r%C4%B1m&amp;author=%C5%9EO+Sag&amp;author=SG+Temel&amp;publication_year=2020&amp;title=Characterization%20and%20in%20silico%20analyses%20of%20the%20BRCA1%2F2%20variants%20identified%20in%20individuals%20with%20personal%20and%2For%20family%20history%20of%20BRCA-related%20cancers&amp;journal=Int+J+Biol+Macromolecules&amp;volume=162&amp;pages=1166-77\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B108\" id=\"B108\">\u003C/a> 108. Trego KS, Groesser T, Davalos AR, Parplys AC, Zhao W, Nelson MR, et al. Non-catalytic roles for XPG with BRCA1 and BRCA2 in homologous recombination and genome stability. \u003Ci>Mol Cell\u003C/i> (2016) 61:535. doi:&#xa0;10.1016/J.MOLCEL.2015.12.026\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26833090/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/J.MOLCEL.2015.12.026\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=KS+Trego&amp;author=T+Groesser&amp;author=AR+Davalos&amp;author=AC+Parplys&amp;author=W+Zhao&amp;author=MR+Nelson&amp;publication_year=2016&amp;title=Non-catalytic%20roles%20for%20XPG%20with%20BRCA1%20and%20BRCA2%20in%20homologous%20recombination%20and%20genome%20stability&amp;journal=Mol+Cell&amp;volume=61&amp;pages=535\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B109\" id=\"B109\">\u003C/a> 109. Galick HA, Marsden CG, Kathe S, Dragon JA, Volk L, Nemec AA, et al. The NEIL1 G83D germline DNA glycosylase variant induces genomic instability and cellular transformation. \u003Ci>Oncotarget\u003C/i> (2017) 8:85883&#x2013;95. doi:&#xa0;10.18632/ONCOTARGET.20716\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29156764/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.18632/ONCOTARGET.20716\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=HA+Galick&amp;author=CG+Marsden&amp;author=S+Kathe&amp;author=JA+Dragon&amp;author=L+Volk&amp;author=AA+Nemec&amp;publication_year=2017&amp;title=The%20NEIL1%20G83D%20germline%20DNA%20glycosylase%20variant%20induces%20genomic%20instability%20and%20cellular%20transformation&amp;journal=Oncotarget&amp;volume=8&amp;pages=85883-95\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B110\" id=\"B110\">\u003C/a> 110. Li N, Lim BWX, Thompson ER, McInerny S, Zethoven M, Cheasley D, et al. Investigation of monogenic causes of familial breast cancer: Data from the BEACCON case-control study. \u003Ci>NPJ Breast Cancer\u003C/i> (2021) 7(1):76. doi:&#xa0;10.1038/S41523-021-00279-9\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/34117267/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/S41523-021-00279-9\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=N+Li&amp;author=BWX+Lim&amp;author=ER+Thompson&amp;author=S+McInerny&amp;author=M+Zethoven&amp;author=D+Cheasley&amp;publication_year=2021&amp;title=Investigation%20of%20monogenic%20causes%20of%20familial%20breast%20cancer%3A%20Data%20from%20the%20BEACCON%20case-control%20study&amp;journal=NPJ+Breast+Cancer&amp;volume=7&amp;pages=76\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B111\" id=\"B111\">\u003C/a> 111. Li N, Zethoven M, McInerny S, Devereux L, Huang YK, Thio N, et al. Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: An international multi-center study of 47,180 subjects. \u003Ci>NPJ Breast Cancer\u003C/i> (2021) 7(1):52. doi:&#xa0;10.1038/S41523-021-00255-3\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33980861/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/S41523-021-00255-3\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=N+Li&amp;author=M+Zethoven&amp;author=S+McInerny&amp;author=L+Devereux&amp;author=YK+Huang&amp;author=N+Thio&amp;publication_year=2021&amp;title=Evaluation%20of%20the%20association%20of%20heterozygous%20germline%20variants%20in%20NTHL1%20with%20breast%20cancer%20predisposition%3A%20An%20international%20multi-center%20study%20of%2047%2C180%20subjects&amp;journal=NPJ+Breast+Cancer&amp;volume=7&amp;pages=52\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B112\" id=\"B112\">\u003C/a> 112. Brenner D, Poirier A, Smith L, Aziz LS, Ellison L, Fitzgerald N, et al. Members of the Canadian cancer statistics advisory committee analytic leads additional analysis project management. (2021).\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?author=D+Brenner&amp;author=A+Poirier&amp;author=L+Smith&amp;author=LS+Aziz&amp;author=L+Ellison&amp;author=N+Fitzgerald&amp;publication_year=2021&amp;title=Members%20of%20the%20Canadian%20cancer%20statistics%20advisory%20committee%20analytic%20leads%20additional%20analysis%20project%20management&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B113\" id=\"B113\">\u003C/a> 113. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. \u003Ci>CA: A Cancer J Clin\u003C/i> (2021) 71:209&#x2013;49. doi:&#xa0;10.3322/CAAC.21660\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.3322/CAAC.21660\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H+Sung&amp;author=J+Ferlay&amp;author=RL+Siegel&amp;author=M+Laversanne&amp;author=I+Soerjomataram&amp;author=A+Jemal&amp;publication_year=2021&amp;title=Global%20cancer%20statistics%202020%3A%20GLOBOCAN%20estimates%20of%20incidence%20and%20mortality%20worldwide%20for%2036%20cancers%20in%20185%20countries&amp;journal=CA:+A+Cancer+J+Clin&amp;volume=71&amp;pages=209-49\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B114\" id=\"B114\">\u003C/a> 114. Foulkes WD. Inherited susceptibility to common cancers. \u003Ci>New Engl J Med\u003C/i> (2008) 359:2143&#x2013;53. doi:&#xa0;10.1056/nejmra0802968\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/19005198/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1056/nejmra0802968\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=WD+Foulkes&amp;publication_year=2008&amp;title=Inherited%20susceptibility%20to%20common%20cancers&amp;journal=New+Engl+J+Med&amp;volume=359&amp;pages=2143-53\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B115\" id=\"B115\">\u003C/a> 115. Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, Darbandi SF, Knowles D, Li YI, et al. Predicting splicing from primary sequence with deep learning. \u003Ci>Cell\u003C/i> (2019) 176:535&#x2013;548.e24. doi:&#xa0;10.1016/J.CELL.2018.12.015\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30661751/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/J.CELL.2018.12.015\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=K+Jaganathan&amp;author=S+Kyriazopoulou%20Panagiotopoulou&amp;author=JF+McRae&amp;author=SF+Darbandi&amp;author=D+Knowles&amp;author=YI+Li&amp;publication_year=2019&amp;title=Predicting%20splicing%20from%20primary%20sequence%20with%20deep%20learning&amp;journal=Cell&amp;volume=176&amp;pages=535\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B116\" id=\"B116\">\u003C/a> 116. Metcalfe KA, Poll A, Royer R, Llacuachaqui M, Tulman A, Sun P, et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. \u003Ci>J Clin Oncol\u003C/i> (2010) 28:387&#x2013;91. doi:&#xa0;10.1200/JCO.2009.25.0712\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/20008623/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1200/JCO.2009.25.0712\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=KA+Metcalfe&amp;author=A+Poll&amp;author=R+Royer&amp;author=M+Llacuachaqui&amp;author=A+Tulman&amp;author=P+Sun&amp;publication_year=2010&amp;title=Screening%20for%20founder%20mutations%20in%20BRCA1%20and%20BRCA2%20in%20unselected%20Jewish%20women&amp;journal=J+Clin+Oncol&amp;volume=28&amp;pages=387-91\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B117\" id=\"B117\">\u003C/a> 117. Klungland A, H&#xf6;ss M, Gunz D, Constantinou A, Clarkson SG, Doetsch PW, et al. Base excision repair of oxidative DNA damage activated by XPG protein. \u003Ci>Mol Cell\u003C/i> (1999) 3:33&#x2013;42. doi:&#xa0;10.1016/S1097-2765(00)80172-0\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/10024877/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/S1097-2765(00)80172-0\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Klungland&amp;author=M+H%C3%B6ss&amp;author=D+Gunz&amp;author=A+Constantinou&amp;author=SG+Clarkson&amp;author=PW+Doetsch&amp;publication_year=1999&amp;title=Base%20excision%20repair%20of%20oxidative%20DNA%20damage%20activated%20by%20XPG%20protein&amp;journal=Mol+Cell&amp;volume=3&amp;pages=33\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B118\" id=\"B118\">\u003C/a> 118. Sertic S, Quadri R, Lazzaro F, Muzi-Falconi M. EXO1: A tightly regulated nuclease. \u003Ci>DNA Repair\u003C/i> (2020) 93:102929. doi:&#xa0;10.1016/J.DNAREP.2020.102929\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33087266/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/J.DNAREP.2020.102929\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+Sertic&amp;author=R+Quadri&amp;author=F+Lazzaro&amp;author=M+Muzi-Falconi&amp;publication_year=2020&amp;title=EXO1%3A%20A%20tightly%20regulated%20nuclease&amp;journal=DNA+Repair&amp;volume=93&amp;pages=102929\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B119\" id=\"B119\">\u003C/a> 119. Vali-Pour M, Lehner B, Supek F. The impact of rare germline variants on human somatic mutation processes. \u003Ci>Nat Commun\u003C/i> (2022) 13:1&#x2013;21. doi:&#xa0;10.1038/s41467-022-31483-1\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/34983933/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41467-022-31483-1\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Vali-Pour&amp;author=B+Lehner&amp;author=F+Supek&amp;publication_year=2022&amp;title=The%20impact%20of%20rare%20germline%20variants%20on%20human%20somatic%20mutation%20processes&amp;journal=Nat+Commun&amp;volume=13&amp;pages=1\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B120\" id=\"B120\">\u003C/a> 120. Nalepa G, Clapp DW. Fanconi anaemia and cancer: An intricate relationship. \u003Ci>Nat Rev Cancer\u003C/i> (2018) 18:168&#x2013;85. doi:&#xa0;10.1038/NRC.2017.116\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29376519/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/NRC.2017.116\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=G+Nalepa&amp;author=DW+Clapp&amp;publication_year=2018&amp;title=Fanconi%20anaemia%20and%20cancer%3A%20An%20intricate%20relationship&amp;journal=Nat+Rev+Cancer&amp;volume=18&amp;pages=168-85\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B121\" id=\"B121\">\u003C/a> 121. David SS, O&#x2019;Shea VL, Kundu S. Base-excision repair of oxidative DNA damage. \u003Ci>Nat 2007 447:7147\u003C/i> (2007) 447:941&#x2013;50. doi:&#xa0;10.1038/nature05978\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1038/nature05978\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=SS+David&amp;author=VL+O%E2%80%99Shea&amp;author=S+Kundu&amp;publication_year=2007&amp;title=Base-excision%20repair%20of%20oxidative%20DNA%20damage&amp;journal=Nat+2007+447:7147&amp;volume=447&amp;pages=941-50\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B122\" id=\"B122\">\u003C/a> 122. Weren RDA, Ligtenberg MJL, Kets CM, De Voer RM, Verwiel ETP, Spruijt L, et al. A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. \u003Ci>Nat Genet\u003C/i> (2015) 47(6):668&#x2013;71. doi:&#xa0;10.1038/ng.3287\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25938944/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/ng.3287\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=RDA+Weren&amp;author=MJL+Ligtenberg&amp;author=CM+Kets&amp;author=RM+De%20Voer&amp;author=ETP+Verwiel&amp;author=L+Spruijt&amp;publication_year=2015&amp;title=A%20germline%20homozygous%20mutation%20in%20the%20base-excision%20repair%20gene%20NTHL1%20causes%20adenomatous%20polyposis%20and%20colorectal%20cancer&amp;journal=Nat+Genet&amp;volume=47&amp;pages=668-71\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B123\" id=\"B123\">\u003C/a> 123. Grolleman JE, de Voer RM, Elsayed FA, Nielsen M, Weren RDA, Palles C, et al. Mutational signature analysis reveals NTHL1 deficiency to cause a multi-tumor phenotype. \u003Ci>Cancer Cell\u003C/i> (2019) 35(2):256&#x2013;266.e5. doi:&#xa0;10.1016/j.ccell.2018.12.011\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30753826/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.ccell.2018.12.011\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=JE+Grolleman&amp;author=RM+de%20Voer&amp;author=FA+Elsayed&amp;author=M+Nielsen&amp;author=RDA+Weren&amp;author=C+Palles&amp;publication_year=2019&amp;title=Mutational%20signature%20analysis%20reveals%20NTHL1%20deficiency%20to%20cause%20a%20multi-tumor%20phenotype&amp;journal=Cancer+Cell&amp;volume=35&amp;pages=256-266.e5\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B124\" id=\"B124\">\u003C/a> 124. Loong L, Garrett A, Allen S, Choi S, Durkie M, Callaway A, et al. Reclassification of clinically-detected sequence variants: Framework for genetic clinicians and clinical scientists by CanVIG-UK (Cancer variant interpretation group UK). \u003Ci>Genet medicine : Off J Am Coll Med Genet\u003C/i> (2022) 24(9):1867&#x2013;77. doi:&#xa0;10.1016/J.GIM.2022.05.002\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1016/J.GIM.2022.05.002\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=L+Loong&amp;author=A+Garrett&amp;author=S+Allen&amp;author=S+Choi&amp;author=M+Durkie&amp;author=A+Callaway&amp;publication_year=2022&amp;title=Reclassification%20of%20clinically-detected%20sequence%20variants%3A%20Framework%20for%20genetic%20clinicians%20and%20clinical%20scientists%20by%20CanVIG-UK%20%28Cancer%20variant%20interpretation%20group%20UK%29&amp;journal=Genet+medicine+:+Off+J+Am+Coll+Med+Genet&amp;volume=24&amp;pages=1867-77\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B125\" id=\"B125\">\u003C/a> 125. Tung N, Domchek SM, Stadler Z, Nathanson KL, Couch F, Garber JE, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. \u003Ci>Nat Rev Clin Oncol\u003C/i> (2016) 13:581&#x2013;8. doi:&#xa0;10.1038/NRCLINONC.2016.90\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27296296/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/NRCLINONC.2016.90\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=N+Tung&amp;author=SM+Domchek&amp;author=Z+Stadler&amp;author=KL+Nathanson&amp;author=F+Couch&amp;author=JE+Garber&amp;publication_year=2016&amp;title=Counselling%20framework%20for%20moderate-penetrance%20cancer-susceptibility%20mutations&amp;journal=Nat+Rev+Clin+Oncol&amp;volume=13&amp;pages=581-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B126\" id=\"B126\">\u003C/a> 126. Liu YL, Breen K, Catchings A, Ranganathan M, Latham A, Goldfrank DJ, et al. Risk-reducing bilateral salpingo-oophorectomy for ovarian cancer: A review and clinical guide for hereditary predisposition genes. \u003Ci>JCO Oncol Pract\u003C/i> (2021) 18(3):201&#x2013;9. doi:&#xa0;10.1200/OP.21.00382\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/34582274/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1200/OP.21.00382\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=YL+Liu&amp;author=K+Breen&amp;author=A+Catchings&amp;author=M+Ranganathan&amp;author=A+Latham&amp;author=DJ+Goldfrank&amp;publication_year=2021&amp;title=Risk-reducing%20bilateral%20salpingo-oophorectomy%20for%20ovarian%20cancer%3A%20A%20review%20and%20clinical%20guide%20for%20hereditary%20predisposition%20genes&amp;journal=JCO+Oncol+Pract&amp;volume=18&amp;pages=201-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B127\" id=\"B127\">\u003C/a> 127. Hsiao YW, Lu TP. Race-specific genetic profiles of homologous recombination deficiency in multiple cancers. \u003Ci>J personalized Med\u003C/i> (2021) 11(12):1287. doi:&#xa0;10.3390/JPM11121287\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.3390/JPM11121287\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=YW+Hsiao&amp;author=TP+Lu&amp;publication_year=2021&amp;title=Race-specific%20genetic%20profiles%20of%20homologous%20recombination%20deficiency%20in%20multiple%20cancers&amp;journal=J+personalized+Med&amp;volume=11&amp;pages=1287\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B128\" id=\"B128\">\u003C/a> 128. Bonache S, Esteban I, Moles-Fern&#xe1;ndez A, Ten&#xe9;s A, Duran-Lozano L, Montalban G, et al. Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings. \u003Ci>J Cancer Res Clin Oncol\u003C/i> (2018) 144:2495&#x2013;513. doi:&#xa0;10.1007/S00432-018-2763-9\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30306255/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/S00432-018-2763-9\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+Bonache&amp;author=I+Esteban&amp;author=A+Moles-Fern%C3%A1ndez&amp;author=A+Ten%C3%A9s&amp;author=L+Duran-Lozano&amp;author=G+Montalban&amp;publication_year=2018&amp;title=Multigene%20panel%20testing%20beyond%20BRCA1%2F2%20in%20breast%2Fovarian%20cancer%20Spanish%20families%20and%20clinical%20actionability%20of%20findings&amp;journal=J+Cancer+Res+Clin+Oncol&amp;volume=144&amp;pages=2495-513\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B129\" id=\"B129\">\u003C/a> 129. Jarhelle E, Riise Stensland HMF, Hansen G&#xc5;M, Skarsfjord S, Jonsrud C, Ingebrigtsen M, et al. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients. \u003Ci>Sci Rep\u003C/i> (2019) 9(1):19986. doi:&#xa0;10.1038/s41598-019-55515-x\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31882575/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41598-019-55515-x\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=E+Jarhelle&amp;author=HMF+Riise%20Stensland&amp;author=G%C3%85M+Hansen&amp;author=S+Skarsfjord&amp;author=C+Jonsrud&amp;author=M+Ingebrigtsen&amp;publication_year=2019&amp;title=Identifying%20sequence%20variants%20contributing%20to%20hereditary%20breast%20and%20ovarian%20cancer%20in%20BRCA1%20and%20BRCA2%20negative%20breast%20and%20ovarian%20cancer%20patients&amp;journal=Sci+Rep&amp;volume=9&amp;pages=19986\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B130\" id=\"B130\">\u003C/a> 130. Hirasawa A, Imoto I, Naruto T, Akahane T, Yamagami W, Nomura H, et al. Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer. \u003Ci>Oncotarget\u003C/i> (2017) 8:112258&#x2013;67. doi:&#xa0;10.18632/ONCOTARGET.22733\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29348823/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.18632/ONCOTARGET.22733\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Hirasawa&amp;author=I+Imoto&amp;author=T+Naruto&amp;author=T+Akahane&amp;author=W+Yamagami&amp;author=H+Nomura&amp;publication_year=2017&amp;title=Prevalence%20of%20pathogenic%20germline%20variants%20detected%20by%20multigene%20sequencing%20in%20unselected%20Japanese%20patients%20with%20ovarian%20cancer&amp;journal=Oncotarget&amp;volume=8&amp;pages=112258-67\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B131\" id=\"B131\">\u003C/a> 131. Pan ZW, Wang XJ, Chen T, DIng XW, Jiang X, Gao Y, et al. Deleterious mutations in DNA repair gene FANCC exist in BRCA1/2-negative Chinese familial breast and/or ovarian cancer patients. \u003Ci>Front Oncol\u003C/i> (2019) 9:169. doi:&#xa0;10.3389/FONC.2019.00169\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30967997/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3389/FONC.2019.00169\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=ZW+Pan&amp;author=XJ+Wang&amp;author=T+Chen&amp;author=XW+DIng&amp;author=X+Jiang&amp;author=Y+Gao&amp;publication_year=2019&amp;title=Deleterious%20mutations%20in%20DNA%20repair%20gene%20FANCC%20exist%20in%20BRCA1%2F2-negative%20Chinese%20familial%20breast%20and%2For%20ovarian%20cancer%20patients&amp;journal=Front+Oncol&amp;volume=9&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B132\" id=\"B132\">\u003C/a> 132. del Valle J, Rofes P, Moreno-Cabrera JM, L&#xf3;pez-D&#xf3;riga A, Belhadj S, Vargas-Parra G, et al. Exploring the role of mutations in fanconi anemia genes in hereditary cancer patients. \u003Ci>Cancers\u003C/i> (2020) 12(4):829. doi:&#xa0;10.3390/CANCERS12040829\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32235514/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3390/CANCERS12040829\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+del%20Valle&amp;author=P+Rofes&amp;author=JM+Moreno-Cabrera&amp;author=A+L%C3%B3pez-D%C3%B3riga&amp;author=S+Belhadj&amp;author=G+Vargas-Parra&amp;publication_year=2020&amp;title=Exploring%20the%20role%20of%20mutations%20in%20fanconi%20anemia%20genes%20in%20hereditary%20cancer%20patients&amp;journal=Cancers&amp;volume=12&amp;pages=829\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B133\" id=\"B133\">\u003C/a> 133. Westphalen CB, Fine AD, Andr&#xe9; F, Ganesan S, Heinemann V, Rouleau E, et al. Pan-cancer analysis of homologous recombination repair-associated gene alterations and genome-wide loss-of-Heterozygosity score. \u003Ci>Clin Cancer research : an Off J Am Assoc Cancer Res\u003C/i> (2022) 28:1412&#x2013;21. doi:&#xa0;10.1158/1078-0432.CCR-21-2096\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1158/1078-0432.CCR-21-2096\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=CB+Westphalen&amp;author=AD+Fine&amp;author=F+Andr%C3%A9&amp;author=S+Ganesan&amp;author=V+Heinemann&amp;author=E+Rouleau&amp;publication_year=2022&amp;title=Pan-cancer%20analysis%20of%20homologous%20recombination%20repair-associated%20gene%20alterations%20and%20genome-wide%20loss-of-Heterozygosity%20score&amp;journal=Clin+Cancer+research+:+an+Off+J+Am+Assoc+Cancer+Res&amp;volume=28&amp;pages=1412-21\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B134\" id=\"B134\">\u003C/a> 134. Doddato G, Valentino F, Giliberti A, Papa FT, Tita R, Bruno LP, et al. Exome sequencing in BRCA1-2 candidate familias: The contribution of other cancer susceptibility genes. \u003Ci>Front Oncol\u003C/i> (2021) 11:649435. doi:&#xa0;10.3389/FONC.2021.649435\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/34026625/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3389/FONC.2021.649435\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=G+Doddato&amp;author=F+Valentino&amp;author=A+Giliberti&amp;author=FT+Papa&amp;author=R+Tita&amp;author=LP+Bruno&amp;publication_year=2021&amp;title=Exome%20sequencing%20in%20BRCA1-2%20candidate%20familias%3A%20The%20contribution%20of%20other%20cancer%20susceptibility%20genes&amp;journal=Front+Oncol&amp;volume=11&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B135\" id=\"B135\">\u003C/a> 135. Salo-Mullen EE, Maio A, Mukherjee S, Bandlamudi C, Shia J, Kemel Y, et al. Prevalence and characterization of biallelic and monoallelic NTHL1 and MSH3 variant carriers from a pan-cancer patient population. \u003Ci>JCO Precis Oncol\u003C/i> (2021) 5:455&#x2013;65. doi:&#xa0;10.1200/PO.20.00443\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1200/PO.20.00443\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=EE+Salo-Mullen&amp;author=A+Maio&amp;author=S+Mukherjee&amp;author=C+Bandlamudi&amp;author=J+Shia&amp;author=Y+Kemel&amp;publication_year=2021&amp;title=Prevalence%20and%20characterization%20of%20biallelic%20and%20monoallelic%20NTHL1%20and%20MSH3%20variant%20carriers%20from%20a%20pan-cancer%20patient%20population&amp;journal=JCO+Precis+Oncol&amp;volume=5&amp;pages=455-65\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B136\" id=\"B136\">\u003C/a> 136. Broderick P, Bagratuni T, Vijayakrishnan J, Lubbe S, Chandler I, Houlston RS. Evaluation of NTHL1, NEIL1, NEIL2MPG, TDG, UNG and SMUG1 genes in familial colorectal cancer predisposition. \u003Ci>BMC Cancer\u003C/i> (2006) 6:243. doi:&#xa0;10.1186/1471-2407-6-243\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/17029639/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/1471-2407-6-243\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=P+Broderick&amp;author=T+Bagratuni&amp;author=J+Vijayakrishnan&amp;author=S+Lubbe&amp;author=I+Chandler&amp;author=RS+Houlston&amp;publication_year=2006&amp;title=Evaluation%20of%20NTHL1%2C%20NEIL1%2C%20NEIL2MPG%2C%20TDG%2C%20UNG%20and%20SMUG1%20genes%20in%20familial%20colorectal%20cancer%20predisposition&amp;journal=BMC+Cancer&amp;volume=6&amp;pages=243\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B137\" id=\"B137\">\u003C/a> 137. Ciavarella M, Miccoli S, Prossomariti A, Pippucci T, Bonora E, Buscherini F, et al. Somatic APC mosaicism and oligogenic inheritance in genetically unsolved colorectal adenomatous polyposis patients. \u003Ci>Eur J Hum genetics : EJHG\u003C/i> (2018) 26:387&#x2013;95. doi:&#xa0;10.1038/S41431-017-0086-Y\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1038/S41431-017-0086-Y\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Ciavarella&amp;author=S+Miccoli&amp;author=A+Prossomariti&amp;author=T+Pippucci&amp;author=E+Bonora&amp;author=F+Buscherini&amp;publication_year=2018&amp;title=Somatic%20APC%20mosaicism%20and%20oligogenic%20inheritance%20in%20genetically%20unsolved%20colorectal%20adenomatous%20polyposis%20patients&amp;journal=Eur+J+Hum+genetics+:+EJHG&amp;volume=26&amp;pages=387-95\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B138\" id=\"B138\">\u003C/a> 138. Das R, Kundu S, Laskar S, Choudhury Y, Ghosh SK. Assessment of DNA repair susceptibility genes identified by whole exome sequencing in head and neck cancer. \u003Ci>DNA Repair\u003C/i> (2018) 66&#x2013;67:50&#x2013;63. doi:&#xa0;10.1016/J.DNAREP.2018.04.005\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29747023/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/J.DNAREP.2018.04.005\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R+Das&amp;author=S+Kundu&amp;author=S+Laskar&amp;author=Y+Choudhury&amp;author=SK+Ghosh&amp;publication_year=2018&amp;title=Assessment%20of%20DNA%20repair%20susceptibility%20genes%20identified%20by%20whole%20exome%20sequencing%20in%20head%20and%20neck%20cancer&amp;journal=DNA+Repair&amp;volume=66&#x2013;67&amp;pages=50\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B139\" id=\"B139\">\u003C/a> 139. Lawrenson K, Iversen ES, Tyrer J, Weber RP, Concannon P, Hazelett DJ, et al. Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. \u003Ci>Carcinogenesis\u003C/i> (2015) 36:1341&#x2013;53. doi:&#xa0;10.1093/CARCIN/BGV138\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26424751/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/CARCIN/BGV138\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=K+Lawrenson&amp;author=ES+Iversen&amp;author=J+Tyrer&amp;author=RP+Weber&amp;author=P+Concannon&amp;author=DJ+Hazelett&amp;publication_year=2015&amp;title=Common%20variants%20at%20the%20CHEK2%20gene%20locus%20and%20risk%20of%20epithelial%20ovarian%20cancer&amp;journal=Carcinogenesis&amp;volume=36&amp;pages=1341-53\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B140\" id=\"B140\">\u003C/a> 140. Kurman RJ, Shih IM. The dualistic model of ovarian carcinogenesis: Revisited, revised, and expanded. \u003Ci>Am J Pathol\u003C/i> (2016) 186:733&#x2013;47. doi:&#xa0;10.1016/J.AJPATH.2015.11.011\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27012190/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/J.AJPATH.2015.11.011\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=RJ+Kurman&amp;author=IM+Shih&amp;publication_year=2016&amp;title=The%20dualistic%20model%20of%20ovarian%20carcinogenesis%3A%20Revisited%2C%20revised%2C%20and%20expanded&amp;journal=Am+J+Pathol&amp;volume=186&amp;pages=733-47\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B141\" id=\"B141\">\u003C/a> 141. Srinivasan P, Bandlamudi C, Jonsson P, Kemel Y, Chavan SS, Richards AL, et al. The context-specific role of germline pathogenicity in tumorigenesis. \u003Ci>Nat Genet\u003C/i> (2021) 53:1577&#x2013;85. doi:&#xa0;10.1038/s41588-021-00949-1\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/34741162/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41588-021-00949-1\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=P+Srinivasan&amp;author=C+Bandlamudi&amp;author=P+Jonsson&amp;author=Y+Kemel&amp;author=SS+Chavan&amp;author=AL+Richards&amp;publication_year=2021&amp;title=The%20context-specific%20role%20of%20germline%20pathogenicity%20in%20tumorigenesis&amp;journal=Nat+Genet&amp;volume=53&amp;pages=1577-85\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B142\" id=\"B142\">\u003C/a> 142. Damia G, Broggini M. Platinum resistance in ovarian cancer: Role of DNA repair. \u003Ci>Cancers\u003C/i> (2019) 11(1):119. doi:&#xa0;10.3390/CANCERS11010119\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30669514/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3390/CANCERS11010119\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=G+Damia&amp;author=M+Broggini&amp;publication_year=2019&amp;title=Platinum%20resistance%20in%20ovarian%20cancer%3A%20Role%20of%20DNA%20repair&amp;journal=Cancers&amp;volume=11&amp;pages=119\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B143\" id=\"B143\">\u003C/a> 143. Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J. PARP inhibitor resistance: the underlying mechanisms and clinical implications. \u003Ci>Mol Cancer 2020 19:1\u003C/i> (2020) 19:1&#x2013;16. doi:&#xa0;10.1186/S12943-020-01227-0\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1186/S12943-020-01227-0\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H+Li&amp;author=ZY+Liu&amp;author=N+Wu&amp;author=YC+Chen&amp;author=Q+Cheng&amp;author=J+Wang&amp;publication_year=2020&amp;title=PARP%20inhibitor%20resistance%3A%20the%20underlying%20mechanisms%20and%20clinical%20implications&amp;journal=Mol+Cancer+2020+19:1&amp;volume=19&amp;pages=1\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B144\" id=\"B144\">\u003C/a> 144. MacArthur DG, Manolio TA, Dimmock DP, Rehm HL, Shendure J, Abecasis GR, et al. Guidelines for investigating causality of sequence variants in human disease. \u003Ci>Nat 2014 508:7497\u003C/i> (2014) 508:469&#x2013;76. doi:&#xa0;10.1038/nature13127\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1038/nature13127\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=DG+MacArthur&amp;author=TA+Manolio&amp;author=DP+Dimmock&amp;author=HL+Rehm&amp;author=J+Shendure&amp;author=GR+Abecasis&amp;publication_year=2014&amp;title=Guidelines%20for%20investigating%20causality%20of%20sequence%20variants%20in%20human%20disease&amp;journal=Nat+2014+508:7497&amp;volume=508&amp;pages=469-76\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B145\" id=\"B145\">\u003C/a> 145. Ramsey SD, Yoon P, Moonesinghe R, Khoury MJ. Population-based study of the prevalence of family history of cancer: Implications for cancer screening and prevention. \u003Ci>Genet Med\u003C/i> (2006) 8:571&#x2013;5. doi:&#xa0;10.1097/01.gim.0000237867.34011.12\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16980813/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1097/01.gim.0000237867.34011.12\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=SD+Ramsey&amp;author=P+Yoon&amp;author=R+Moonesinghe&amp;author=MJ+Khoury&amp;publication_year=2006&amp;title=Population-based%20study%20of%20the%20prevalence%20of%20family%20history%20of%20cancer%3A%20Implications%20for%20cancer%20screening%20and%20prevention&amp;journal=Genet+Med&amp;volume=8&amp;pages=571-5\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B146\" id=\"B146\">\u003C/a> 146. Zheng G, Yu H, Hemminki A, F&#xf6;rsti A, Sundquist K, Hemminki K. Familial associations of female breast cancer with other cancers. \u003Ci>Int J Cancer\u003C/i> (2017) 141:2253&#x2013;9. doi:&#xa0;10.1002/ijc.30927\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28801919/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/ijc.30927\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=G+Zheng&amp;author=H+Yu&amp;author=A+Hemminki&amp;author=A+F%C3%B6rsti&amp;author=K+Sundquist&amp;author=K+Hemminki&amp;publication_year=2017&amp;title=Familial%20associations%20of%20female%20breast%20cancer%20with%20other%20cancers&amp;journal=Int+J+Cancer&amp;volume=141&amp;pages=2253-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B147\" id=\"B147\">\u003C/a> 147. Momozawa Y, Sasai R, Usui Y, Shiraishi K, Iwasaki Y, Taniyama Y, et al. Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants. \u003Ci>JAMA Oncol\u003C/i> (2022) 8:871&#x2013;8. doi:&#xa0;10.1001/JAMAONCOL.2022.0476\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/35420638/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1001/JAMAONCOL.2022.0476\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=Y+Momozawa&amp;author=R+Sasai&amp;author=Y+Usui&amp;author=K+Shiraishi&amp;author=Y+Iwasaki&amp;author=Y+Taniyama&amp;publication_year=2022&amp;title=Expansion%20of%20cancer%20risk%20profile%20for%20BRCA1%20and%20BRCA2%20pathogenic%20variants&amp;journal=JAMA+Oncol&amp;volume=8&amp;pages=871-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003C/div>\u003Cdiv class=\"thinLineM20\">\u003C/div>\u003Cdiv class=\"AbstractSummary\">\u003Cp>\u003Cspan>Keywords:\u003C/span> germline variants, familial ovarian cancer, cancer predisposing genes, whole exome sequencing, DNA repair pathways, Genetic drift\u003C/p>\u003Cp>\u003Cspan>Citation:\u003C/span> Alenezi WM, Fierheller CT, Serruya C, Revil T, Oros KK, Subramanian DN, Bruce J, Spiegelman D, Pugh T, Campbell IG, Mes-Masson A-M, Provencher D, Foulkes WD, Haffaf ZE, Rouleau G, Bouchard L, Greenwood CMT, Ragoussis J and Tonin PN (2023) Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases. \u003Ci>Front. Oncol.\u003C/i> 13:1111191. doi: 10.3389/fonc.2023.1111191\u003C/p>\u003Cp id=\"timestamps\">\u003Cspan>Received:\u003C/span> 29 November 2022; \u003Cspan>Accepted:\u003C/span> 06 February 2023;\u003Cbr>\u003Cspan>Published:\u003C/span> 08 March 2023.\u003C/p>\u003Cdiv>\u003Cp>Edited by:\u003C/p>\u003Ca href=\"https://loop.frontiersin.org/people/489555\">Paolo Peterlongo\u003C/a>, IFOM - The FIRC Institute of Molecular Oncology, Italy\u003C/div>\u003Cdiv>\u003Cp>Reviewed by:\u003C/p>\u003Ca href=\"https://loop.frontiersin.org/people/310601\">Miguel De La Hoya\u003C/a>, San Carlos University Clinical Hospital, Spain\u003Cbr>\u003Ca href=\"https://loop.frontiersin.org/people/952778\">Yiyang Wu\u003C/a>, Vanderbilt University Medical Center, United States\u003C/div>\u003Cp>\u003Cspan>Copyright\u003C/span> &#xa9; 2023 Alenezi, Fierheller, Serruya, Revil, Oros, Subramanian, Bruce, Spiegelman, Pugh, Campbell, Mes-Masson, Provencher, Foulkes, Haffaf, Rouleau, Bouchard, Greenwood, Ragoussis and Tonin. This is an open-access article distributed under the terms of the \u003Ca rel=\"license\" href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License (CC BY)\u003C/a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.\u003C/p>\u003Cp>\u003Cspan>*Correspondence:\u003C/span> Patricia N. Tonin, \u003Ca id=\"encmail\">cGF0cmljaWEudG9uaW5AbWNnaWxsLmNh\u003C/a>\u003C/p>\u003Cdiv class=\"clear\">\u003C/div>\u003C/div>","\u003Cul class=\"flyoutJournal\">\u003Cli>\u003Ca href=\"#h1\">Abstract\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h2\">Introduction\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h3\">Materials and methods\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h4\">Results\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h5\">Discussion\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h6\">Data availability statement\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h7\">Ethics statement\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h8\">Author contributions\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h9\">Funding\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h10\">Acknowledgments\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h11\">Conflict of interest\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h12\">Publisher&#x2019;s note\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h13\">Supplementary material\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h14\">References\u003C/a>\u003C/li>\u003C/ul>",[788,793,798,801,806],{"name":789,"fileServerPackageEntryId":19,"fileServerId":790,"fileServerVersionNumber":391,"type":791},"EPUB.epub","1111191/epub",{"code":792,"name":792},"EPUB",{"name":794,"fileServerPackageEntryId":794,"fileServerId":795,"fileServerVersionNumber":391,"type":796},"fonc-13-1111191.pdf","1111191/pubmed-zip",{"code":797,"name":797},"PDF",{"name":794,"fileServerPackageEntryId":19,"fileServerId":799,"fileServerVersionNumber":391,"type":800},"1111191/publishers-proof/pdf",{"code":797,"name":797},{"name":802,"fileServerPackageEntryId":802,"fileServerId":795,"fileServerVersionNumber":391,"type":803},"fonc-13-1111191.xml",{"code":804,"name":805},"NLM_XML","XML",{"name":807,"fileServerPackageEntryId":19,"fileServerId":808,"fileServerVersionNumber":391,"type":809},"Provisional PDF.pdf","1111191/provisional-pdf",{"code":797,"name":797},"v3",{"title":812,"link":813,"meta":817,"script":996},"Frontiers | Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases",[814],{"rel":815,"href":816},"canonical","https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/full",[818,821,824,826,829,833,836,840,843,846,849,851,853,855,857,859,862,865,867,870,872,874,877,880,883,886,889,893,897,900,902,905,908,911,913,916,919,922,925,928,931,934,936,939,941,944,946,949,952,955,957,960,962,965,967,970,972,975,978,981,983,986,988,991,993],{"hid":819,"property":819,"name":819,"content":820},"description","Not all familial ovarian cancer (OC) cases are explained by pathogenic germline variants in known risk genes. A candidate gene approach involving DNA repair ...",{"hid":822,"property":822,"name":823,"content":812},"og:title","title",{"hid":825,"property":825,"name":819,"content":820},"og:description",{"hid":827,"name":827,"content":828},"keywords","Germline variants,Familial ovarian cancer,Cancer predisposing genes,whole exome sequencing,DNA repair pathways,single-stranded DNA repair genes,double-stranded DNA repair genes",{"hid":830,"property":830,"name":831,"content":832},"og:site_name","site_name","Frontiers",{"hid":834,"property":834,"name":384,"content":835},"og:image","https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/1111191/fonc-13-1111191-HTML/image_m/fonc-13-1111191-g001.jpg",{"hid":837,"property":837,"name":838,"content":839},"og:type","type","article",{"hid":841,"property":841,"name":842,"content":816},"og:url","url",{"hid":844,"name":844,"content":845},"twitter:card","summary_large_image",{"hid":847,"name":847,"content":848},"citation_volume","13",{"hid":850,"name":850,"content":116},"citation_journal_title",{"hid":852,"name":852,"content":832},"citation_publisher",{"hid":854,"name":854,"content":768},"citation_journal_abbrev",{"hid":856,"name":856,"content":769},"citation_issn",{"hid":858,"name":858,"content":536},"citation_doi",{"hid":860,"name":860,"content":861},"citation_firstpage","1111191",{"hid":863,"name":863,"content":864},"citation_language","English",{"hid":866,"name":866,"content":537},"citation_title",{"hid":868,"name":868,"content":869},"citation_keywords","Germline variants; Familial ovarian cancer; Cancer predisposing genes; whole exome sequencing; DNA repair pathways; single-stranded DNA repair genes; double-stranded DNA repair genes",{"hid":871,"name":871,"content":542},"citation_abstract",{"hid":873,"name":873,"content":551},"citation_article_type",{"hid":875,"name":875,"content":876},"citation_pdf_url","https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/pdf",{"hid":878,"name":878,"content":879},"citation_xml_url","https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1111191/xml",{"hid":881,"name":881,"content":882},"citation_fulltext_world_readable","yes",{"hid":884,"name":884,"content":885},"citation_online_date","2023/02/06",{"hid":887,"name":887,"content":888},"citation_publication_date","2023/03/08",{"hid":890,"name":891,"content":892},"citation_author_0","citation_author","Alenezi, Wejdan M. ",{"hid":894,"name":895,"content":896},"citation_author_institution_0","citation_author_institution","Department of Human Genetics, McGill University, Canada",{"hid":898,"name":891,"content":899},"citation_author_1","Fierheller, Caitlin T. ",{"hid":901,"name":895,"content":896},"citation_author_institution_1",{"hid":903,"name":891,"content":904},"citation_author_2","Serruya, Corinne ",{"hid":906,"name":895,"content":907},"citation_author_institution_2","Cancer Research Program, Centre for Translational Biology, The Research Institute of McGill University Health Centre, Canada",{"hid":909,"name":891,"content":910},"citation_author_3","Revil, Timothe ",{"hid":912,"name":895,"content":896},"citation_author_institution_3",{"hid":914,"name":891,"content":915},"citation_author_4","Oros, Kathleen K. ",{"hid":917,"name":895,"content":918},"citation_author_institution_4","Lady Davis Institute for Medical Research of the Jewish General Hospital, Canada",{"hid":920,"name":891,"content":921},"citation_author_5","Subramanian, Deepak N. ",{"hid":923,"name":895,"content":924},"citation_author_institution_5","Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Australia",{"hid":926,"name":891,"content":927},"citation_author_6","Bruce, Jeffrey ",{"hid":929,"name":895,"content":930},"citation_author_institution_6","Princess Margaret Cancer Centre, University Health Network, Canada",{"hid":932,"name":891,"content":933},"citation_author_7","Spiegelman, Dan ",{"hid":935,"name":895,"content":896},"citation_author_institution_7",{"hid":937,"name":891,"content":938},"citation_author_8","Pugh, Trevor ",{"hid":940,"name":895,"content":930},"citation_author_institution_8",{"hid":942,"name":891,"content":943},"citation_author_9","Campbell, Ian G. ",{"hid":945,"name":895,"content":924},"citation_author_institution_9",{"hid":947,"name":891,"content":948},"citation_author_10","Mes-Masson, Anne-Marie ",{"hid":950,"name":895,"content":951},"citation_author_institution_10","Centre de recherche du Centre hospitalier de lUniversit de Montral and Institut du cancer de Montral, Canada",{"hid":953,"name":891,"content":954},"citation_author_11","Provencher, Diane ",{"hid":956,"name":895,"content":951},"citation_author_institution_11",{"hid":958,"name":891,"content":959},"citation_author_12","Foulkes, William D. ",{"hid":961,"name":895,"content":896},"citation_author_institution_12",{"hid":963,"name":891,"content":964},"citation_author_13","Haffaf, Zaki El ",{"hid":966,"name":895,"content":951},"citation_author_institution_13",{"hid":968,"name":891,"content":969},"citation_author_14","Rouleau, Guy ",{"hid":971,"name":895,"content":896},"citation_author_institution_14",{"hid":973,"name":891,"content":974},"citation_author_15","Bouchard, Luigi ",{"hid":976,"name":895,"content":977},"citation_author_institution_15","Department of Biochemistry and Functional Genomics, Universit de Sherbrooke, Canada",{"hid":979,"name":891,"content":980},"citation_author_16","Greenwood, Celia M. T. ",{"hid":982,"name":895,"content":896},"citation_author_institution_16",{"hid":984,"name":891,"content":985},"citation_author_17","Ragoussis, Jiannis ",{"hid":987,"name":895,"content":896},"citation_author_institution_17",{"hid":989,"name":891,"content":990},"citation_author_18","Tonin, Patricia N. ",{"hid":992,"name":895,"content":896},"citation_author_institution_18",{"hid":994,"name":994,"content":995},"dc.identifier","doi:10.3389/fonc.2023.1111191",[997,1000,1002,1004,1006],{"src":998,"body":13,"type":999,"async":13},"https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6","text/javascript",{"src":1001,"body":13,"type":999,"async":13},"https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML",{"src":1003,"body":13,"type":999,"async":13},"https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",{"src":1005,"body":13,"type":999,"async":13},"https://api.altmetric.com/v1/doi/10.3389/fonc.2023.1111191?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",{"src":1007,"body":13,"type":999,"async":13},"https://crossmark-cdn.crossref.org/widget/v2.0/widget.js",{"articleHubSlug":19,"articleHubPage":1009,"articleHubArticlesList":1010,"canJournalHasArticleHub":367,"articleDoiList":1011},{},[],[],{"title":19,"image":-1,"breadcrumbs":1013,"linksCollection":1014,"metricsCollection":1016},[],{"total":388,"items":1015},[],{"total":388,"items":1017},[]]</script>
<script>window.__NUXT__={};window.__NUXT__.config={public:{isDevMode:false,appName:"article-pages-2024",baseUrl:"https://www.frontiersin.org",domain:"frontiersin.org",loopUrl:"https://loop.frontiersin.org",ssMainDomain:"frontiersin.org",contentfulUrl:"https://graphql.contentful.com/content/v1/spaces",spaceId:1,spaceName:"Frontiers",liveSpaceId:1,tenantLogoUrl:"",frontiersGraphUrl:"https://apollo-federation-gateway.frontiersin.org",registrationApiUrl:"https://onboarding-ui.frontiersin.org",emailDigestApiUrl:"https://api-email-digest.frontiersin.org",journalFilesApiUrl:"https://files-journal-api.frontiersin.org",publicPagesFilesUrl:"https://public-pages-files-2025.frontiersin.org",searchApiUrl:"https://search-api.frontiersin.org",productionForumApiUrl:"https://production-forum-api-v2.frontiersin.org",gtmServerUrl:"https://tag-manager.frontiersin.org",gtmId:"GTM-M322FV2",gtmAuth:"owVbWxfaJr21yQv1fe1cAQ",gtmPreview:"env-1",figsharePluginUrl:"https://widgets.figshare.com/static/figshare.js",figshareApiUrl:"https://api.figshare.com/v2/collections/search",figshareTimeout:3000,crossmarkPublishedDate:"2015/08/24",googleRecaptchaSiteKey:"6LdG3i0UAAAAAOC4qUh35ubHgJotEHp_STXHgr_v",googleRecaptchaKeyName:"FrontiersRecaptchaV2",faviconSize16:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png",faviconSize32:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png",faviconSize180:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_180-tenantFavicon-Frontiers.png",faviconSize192:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_192-tenantFavicon-Frontiers.png",faviconSize512:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_512-tenantFavicon-Frontiers.png",socialMediaImg:"https://brand.frontiersin.org/m/1c8bcb536c789e11/Guidelines-Frontiers_Logo_1200x628_1-91to1.png",linkedArticleCopyText:"'{\"articleTypeCopyText\":[{\"articleTypeId\":0,\"originalArticleCopyText\":\"Part of this article's content has been mentioned in:\",\"linkedArticleCopyText\":\"This article mentions parts of:\"},{\"articleTypeId\":122,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an erratum on:\"},{\"articleTypeId\":129,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an addendum to:\"},{\"articleTypeId\":128,\"originalArticleCopyText\":\"A correction has been applied to this article in:\",\"linkedArticleCopyText\":\"This article is a correction to:\"},{\"articleTypeId\":134,\"originalArticleCopyText\":\"A retraction of this article was approved in:\",\"linkedArticleCopyText\":\"This article is a retraction of:\"},{\"articleTypeId\":29,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"},{\"articleTypeId\":30,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"}],\"articleIdCopyText\":[]}'\n",acceptedArticleExcludedJournalIds:"'[2766,979]'\n",articleTypeConfigurableLabel:"\u003C\u003Carticle-type:uppercase>> article",settingsFeaturesSwitchers:"'{\"displayTitlePillLabels\":true,\"displayRelatedArticlesBox\":true,\"showEditors\":true,\"showReviewers\":true,\"showLoopImpactLink\":true,\"enableFigshare\":false}'\n",journalsWithArticleHub:"'{\"strings\":[\"science\"]}'\n",terminologySettings:"'{\"terms\":[{\"sequenceNumber\":1,\"key\":\"frontiers\",\"tenantTerm\":\"Frontiers\",\"frontiersDefaultTerm\":\"Frontiers\",\"category\":\"Customer\"},{\"sequenceNumber\":2,\"key\":\"submission_system\",\"tenantTerm\":\"submission system\",\"frontiersDefaultTerm\":\"submission system\",\"category\":\"Product\"},{\"sequenceNumber\":3,\"key\":\"public_pages\",\"tenantTerm\":\"public pages\",\"frontiersDefaultTerm\":\"public pages\",\"category\":\"Product\"},{\"sequenceNumber\":4,\"key\":\"my_frontiers\",\"tenantTerm\":\"my frontiers\",\"frontiersDefaultTerm\":\"my frontiers\",\"category\":\"Product\"},{\"sequenceNumber\":5,\"key\":\"digital_editorial_office\",\"tenantTerm\":\"digital editorial office\",\"frontiersDefaultTerm\":\"digital editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":6,\"key\":\"deo\",\"tenantTerm\":\"DEO\",\"frontiersDefaultTerm\":\"DEO\",\"category\":\"Product\"},{\"sequenceNumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantTerm\":\"digital editorial office for chiefs\",\"frontiersDefaultTerm\":\"digital editorial office for chiefs\",\"category\":\"Product\"},{\"sequenceNumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantTerm\":\"digital editorial office for eof\",\"frontiersDefaultTerm\":\"digital editorial office for eof\",\"category\":\"Product\"},{\"sequenceNumber\":9,\"key\":\"editorial_office\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":10,\"key\":\"eof\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"Product\"},{\"sequenceNumber\":11,\"key\":\"research_topic_management\",\"tenantTerm\":\"research topic management\",\"frontiersDefaultTerm\":\"research topic management\",\"category\":\"Product\"},{\"sequenceNumber\":12,\"key\":\"review_forum\",\"tenantTerm\":\"review forum\",\"frontiersDefaultTerm\":\"review forum\",\"category\":\"Product\"},{\"sequenceNumber\":13,\"key\":\"accounting_office\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"Product\"},{\"sequenceNumber\":14,\"key\":\"aof\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"Product\"},{\"sequenceNumber\":15,\"key\":\"publishing_office\",\"tenantTerm\":\"publishing office\",\"frontiersDefaultTerm\":\"publishing office\",\"category\":\"Product\"},{\"sequenceNumber\":16,\"key\":\"production_office\",\"tenantTerm\":\"production office forum\",\"frontiersDefaultTerm\":\"production office forum\",\"category\":\"Product\"},{\"sequenceNumber\":17,\"key\":\"pof\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"Product\"},{\"sequenceNumber\":18,\"key\":\"book_office_forum\",\"tenantTerm\":\"book office forum\",\"frontiersDefaultTerm\":\"book office forum\",\"category\":\"Product\"},{\"sequenceNumber\":19,\"key\":\"bof\",\"tenantTerm\":\"BOF\",\"frontiersDefaultTerm\":\"BOF\",\"category\":\"Product\"},{\"sequenceNumber\":20,\"key\":\"aira\",\"tenantTerm\":\"AIRA\",\"frontiersDefaultTerm\":\"AIRA\",\"category\":\"Product\"},{\"sequenceNumber\":21,\"key\":\"editorial_board_management\",\"tenantTerm\":\"editorial board management\",\"frontiersDefaultTerm\":\"editorial board management\",\"category\":\"Product\"},{\"sequenceNumber\":22,\"key\":\"ebm\",\"tenantTerm\":\"EBM\",\"frontiersDefaultTerm\":\"EBM\",\"category\":\"Product\"},{\"sequenceNumber\":23,\"key\":\"domain\",\"tenantTerm\":\"domain\",\"frontiersDefaultTerm\":\"domain\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":24,\"key\":\"journal\",\"tenantTerm\":\"journal\",\"frontiersDefaultTerm\":\"journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":25,\"key\":\"section\",\"tenantTerm\":\"section\",\"frontiersDefaultTerm\":\"section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":26,\"key\":\"domains\",\"tenantTerm\":\"domains\",\"frontiersDefaultTerm\":\"domains\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":27,\"key\":\"specialty_section\",\"tenantTerm\":\"specialty section\",\"frontiersDefaultTerm\":\"specialty section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":28,\"key\":\"specialty_journal\",\"tenantTerm\":\"specialty journal\",\"frontiersDefaultTerm\":\"specialty journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":29,\"key\":\"journals\",\"tenantTerm\":\"journals\",\"frontiersDefaultTerm\":\"journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":30,\"key\":\"sections\",\"tenantTerm\":\"sections\",\"frontiersDefaultTerm\":\"sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":31,\"key\":\"specialty_sections\",\"tenantTerm\":\"specialty sections\",\"frontiersDefaultTerm\":\"specialty sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":32,\"key\":\"specialty_journals\",\"tenantTerm\":\"specialty journals\",\"frontiersDefaultTerm\":\"specialty journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":33,\"key\":\"manuscript\",\"tenantTerm\":\"manuscript\",\"frontiersDefaultTerm\":\"manuscript\",\"category\":\"Core\"},{\"sequenceNumber\":34,\"key\":\"manuscripts\",\"tenantTerm\":\"manuscripts\",\"frontiersDefaultTerm\":\"manuscripts\",\"category\":\"Core\"},{\"sequenceNumber\":35,\"key\":\"article\",\"tenantTerm\":\"article\",\"frontiersDefaultTerm\":\"article\",\"category\":\"Core\"},{\"sequenceNumber\":36,\"key\":\"articles\",\"tenantTerm\":\"articles\",\"frontiersDefaultTerm\":\"articles\",\"category\":\"Core\"},{\"sequenceNumber\":37,\"key\":\"article_type\",\"tenantTerm\":\"article type\",\"frontiersDefaultTerm\":\"article type\",\"category\":\"Core\"},{\"sequenceNumber\":38,\"key\":\"article_types\",\"tenantTerm\":\"article types\",\"frontiersDefaultTerm\":\"article types\",\"category\":\"Core\"},{\"sequenceNumber\":39,\"key\":\"author\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":40,\"key\":\"authors\",\"tenantTerm\":\"authors\",\"frontiersDefaultTerm\":\"authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":41,\"key\":\"authoring\",\"tenantTerm\":\"authoring\",\"frontiersDefaultTerm\":\"authoring\",\"category\":\"Core\"},{\"sequenceNumber\":42,\"key\":\"authored\",\"tenantTerm\":\"authored\",\"frontiersDefaultTerm\":\"authored\",\"category\":\"Core\"},{\"sequenceNumber\":43,\"key\":\"accept\",\"tenantTerm\":\"accept\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":44,\"key\":\"accepted\",\"tenantTerm\":\"accepted\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantTerm\":\"Assistant Field Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editor\",\"description\":\"An editorial role on a Field Journal that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantTerm\":\"Assistant Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantTerm\":\"Assistant Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":48,\"key\":\"associate_editor\",\"tenantTerm\":\"Associate Editor\",\"frontiersDefaultTerm\":\"Associate Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":49,\"key\":\"specialty_chief_editor\",\"tenantTerm\":\"Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":50,\"key\":\"specialty_chief_editors\",\"tenantTerm\":\"Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":51,\"key\":\"chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":52,\"key\":\"chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":53,\"key\":\"call_for_participation\",\"tenantTerm\":\"call for participation\",\"frontiersDefaultTerm\":\"call for participation\",\"category\":\"Process\"},{\"sequenceNumber\":54,\"key\":\"citation\",\"tenantTerm\":\"citation\",\"frontiersDefaultTerm\":\"citation\",\"category\":\"Misc.\"},{\"sequenceNumber\":55,\"key\":\"citations\",\"tenantTerm\":\"citations\",\"frontiersDefaultTerm\":\"citations\",\"category\":\"Misc.\"},{\"sequenceNumber\":56,\"key\":\"contributor\",\"tenantTerm\":\"contributor\",\"frontiersDefaultTerm\":\"contributor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":57,\"key\":\"contributors\",\"tenantTerm\":\"contributors\",\"frontiersDefaultTerm\":\"contributors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":58,\"key\":\"corresponding_author\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":59,\"key\":\"corresponding_authors\",\"tenantTerm\":\"corresponding authors\",\"frontiersDefaultTerm\":\"corresponding authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":60,\"key\":\"decline\",\"tenantTerm\":\"decline\",\"frontiersDefaultTerm\":\"decline\",\"category\":\"Process\"},{\"sequenceNumber\":61,\"key\":\"declined\",\"tenantTerm\":\"declined\",\"frontiersDefaultTerm\":\"declined\",\"category\":\"Process\"},{\"sequenceNumber\":62,\"key\":\"reject\",\"tenantTerm\":\"reject\",\"frontiersDefaultTerm\":\"reject\",\"category\":\"Process\"},{\"sequenceNumber\":63,\"key\":\"rejected\",\"tenantTerm\":\"rejected\",\"frontiersDefaultTerm\":\"rejected\",\"category\":\"Process\"},{\"sequenceNumber\":64,\"key\":\"publish\",\"tenantTerm\":\"publish\",\"frontiersDefaultTerm\":\"publish\",\"category\":\"Core\"},{\"sequenceNumber\":65,\"key\":\"published\",\"tenantTerm\":\"published\",\"frontiersDefaultTerm\":\"published\",\"category\":\"Core\"},{\"sequenceNumber\":66,\"key\":\"publication\",\"tenantTerm\":\"publication\",\"frontiersDefaultTerm\":\"publication\",\"category\":\"Core\"},{\"sequenceNumber\":67,\"key\":\"peer_review\",\"tenantTerm\":\"peer review\",\"frontiersDefaultTerm\":\"peer review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":68,\"key\":\"peer_reviewed\",\"tenantTerm\":\"peer reviewed\",\"frontiersDefaultTerm\":\"peer reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":69,\"key\":\"initial_validation\",\"tenantTerm\":\"initial validation\",\"frontiersDefaultTerm\":\"initial validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":70,\"key\":\"editorial_assignment\",\"tenantTerm\":\"editorial assignment\",\"frontiersDefaultTerm\":\"editorial assignment\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":71,\"key\":\"independent_review\",\"tenantTerm\":\"independent review\",\"frontiersDefaultTerm\":\"independent review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":72,\"key\":\"interactive_review\",\"tenantTerm\":\"interactive review\",\"frontiersDefaultTerm\":\"interactive review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":73,\"key\":\"review\",\"tenantTerm\":\"review\",\"frontiersDefaultTerm\":\"review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":74,\"key\":\"reviewing\",\"tenantTerm\":\"reviewing\",\"frontiersDefaultTerm\":\"reviewing\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":75,\"key\":\"reviewer\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":76,\"key\":\"reviewers\",\"tenantTerm\":\"reviewers\",\"frontiersDefaultTerm\":\"reviewers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":77,\"key\":\"review_finalized\",\"tenantTerm\":\"review finalized\",\"frontiersDefaultTerm\":\"review finalized\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":78,\"key\":\"final_decision\",\"tenantTerm\":\"final decision\",\"frontiersDefaultTerm\":\"final decision\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":79,\"key\":\"final_validation\",\"tenantTerm\":\"final validation\",\"frontiersDefaultTerm\":\"final validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantTerm\":\"recommend to accept manuscript\",\"frontiersDefaultTerm\":\"accept manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":81,\"key\":\"fee\",\"tenantTerm\":\"fee\",\"frontiersDefaultTerm\":\"fee\",\"category\":\"Accounting\"},{\"sequenceNumber\":82,\"key\":\"fees\",\"tenantTerm\":\"fees\",\"frontiersDefaultTerm\":\"fees\",\"category\":\"Accounting\"},{\"sequenceNumber\":83,\"key\":\"guest_associate_editor\",\"tenantTerm\":\"Guest Associate Editor\",\"frontiersDefaultTerm\":\"Guest Associate Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":84,\"key\":\"guest_associate_editors\",\"tenantTerm\":\"Guest Associate Editors\",\"frontiersDefaultTerm\":\"Guest Associate Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":85,\"key\":\"in_review\",\"tenantTerm\":\"in review\",\"frontiersDefaultTerm\":\"in review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":86,\"key\":\"institutional_member\",\"tenantTerm\":\"institutional partner\",\"frontiersDefaultTerm\":\"institutional partner\",\"category\":\"Accounting\"},{\"sequenceNumber\":87,\"key\":\"institutional_membership\",\"tenantTerm\":\"institutional partnership\",\"frontiersDefaultTerm\":\"institutional partnership\",\"category\":\"Accounting\"},{\"sequenceNumber\":88,\"key\":\"article_processing_charge\",\"tenantTerm\":\"article processing charge\",\"frontiersDefaultTerm\":\"article processing charge\",\"category\":\"Accounting\"},{\"sequenceNumber\":89,\"key\":\"article_processing_charges\",\"tenantTerm\":\"article processing charges\",\"frontiersDefaultTerm\":\"article processing charges\",\"category\":\"Accounting\"},{\"sequenceNumber\":90,\"key\":\"apcs\",\"tenantTerm\":\"APCs\",\"frontiersDefaultTerm\":\"APCs\",\"category\":\"Accounting\"},{\"sequenceNumber\":91,\"key\":\"apc\",\"tenantTerm\":\"APC\",\"frontiersDefaultTerm\":\"APC\",\"category\":\"Accounting\"},{\"sequenceNumber\":92,\"key\":\"received\",\"tenantTerm\":\"received\",\"frontiersDefaultTerm\":\"received\",\"description\":\"Date manuscript was received on.\",\"category\":\"Core\"},{\"sequenceNumber\":93,\"key\":\"transferred\",\"tenantTerm\":\"transferred\",\"frontiersDefaultTerm\":\"transferred\",\"category\":\"Core\"},{\"sequenceNumber\":94,\"key\":\"transfer\",\"tenantTerm\":\"transfer\",\"frontiersDefaultTerm\":\"transfer\",\"category\":\"Core\"},{\"sequenceNumber\":95,\"key\":\"research_topic\",\"tenantTerm\":\"research topic\",\"frontiersDefaultTerm\":\"research topic\",\"category\":\"Core\"},{\"sequenceNumber\":96,\"key\":\"research_topics\",\"tenantTerm\":\"research topics\",\"frontiersDefaultTerm\":\"research topics\",\"category\":\"Core\"},{\"sequenceNumber\":97,\"key\":\"topic_editor\",\"tenantTerm\":\"Topic Editor\",\"frontiersDefaultTerm\":\"Topic Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":98,\"key\":\"review_editor\",\"tenantTerm\":\"Community Reviewer\",\"frontiersDefaultTerm\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":99,\"key\":\"title\",\"tenantTerm\":\"title\",\"frontiersDefaultTerm\":\"title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":100,\"key\":\"running_title\",\"tenantTerm\":\"running title\",\"frontiersDefaultTerm\":\"running title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":101,\"key\":\"submit\",\"tenantTerm\":\"submit\",\"frontiersDefaultTerm\":\"submit\",\"category\":\"Process\"},{\"sequenceNumber\":102,\"key\":\"submitted\",\"tenantTerm\":\"submitted\",\"frontiersDefaultTerm\":\"submitted\",\"category\":\"Process\"},{\"sequenceNumber\":103,\"key\":\"submitting\",\"tenantTerm\":\"submitting\",\"frontiersDefaultTerm\":\"submitting\",\"category\":\"Process\"},{\"sequenceNumber\":104,\"key\":\"t_e\",\"tenantTerm\":\"TE\",\"frontiersDefaultTerm\":\"TE\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":105,\"key\":\"topic\",\"tenantTerm\":\"topic\",\"frontiersDefaultTerm\":\"topic\",\"category\":\"Process\"},{\"sequenceNumber\":106,\"key\":\"topic_summary\",\"tenantTerm\":\"topic summary\",\"frontiersDefaultTerm\":\"topic summary\",\"category\":\"Process\"},{\"sequenceNumber\":107,\"key\":\"figure\",\"tenantTerm\":\"figure\",\"frontiersDefaultTerm\":\"figure\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":108,\"key\":\"figures\",\"tenantTerm\":\"figures\",\"frontiersDefaultTerm\":\"figures\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":109,\"key\":\"editorial_file\",\"tenantTerm\":\"editorial file\",\"frontiersDefaultTerm\":\"editorial file\",\"category\":\"Core\"},{\"sequenceNumber\":110,\"key\":\"editorial_files\",\"tenantTerm\":\"editorial files\",\"frontiersDefaultTerm\":\"editorial files\",\"category\":\"Core\"},{\"sequenceNumber\":111,\"key\":\"e_book\",\"tenantTerm\":\"e-book\",\"frontiersDefaultTerm\":\"e-book\",\"category\":\"Core\"},{\"sequenceNumber\":112,\"key\":\"organization\",\"tenantTerm\":\"organization\",\"frontiersDefaultTerm\":\"organization\",\"category\":\"Core\"},{\"sequenceNumber\":113,\"key\":\"institution\",\"tenantTerm\":\"institution\",\"frontiersDefaultTerm\":\"institution\",\"category\":\"Core\"},{\"sequenceNumber\":114,\"key\":\"reference\",\"tenantTerm\":\"reference\",\"frontiersDefaultTerm\":\"reference\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":115,\"key\":\"references\",\"tenantTerm\":\"references\",\"frontiersDefaultTerm\":\"references\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":116,\"key\":\"sce\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"description\":\"Abbreviation for Specialty Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":117,\"key\":\"submission\",\"tenantTerm\":\"submission\",\"frontiersDefaultTerm\":\"submission\",\"category\":\"Process\"},{\"sequenceNumber\":118,\"key\":\"submissions\",\"tenantTerm\":\"submissions\",\"frontiersDefaultTerm\":\"submissions\",\"category\":\"Process\"},{\"sequenceNumber\":119,\"key\":\"editing\",\"tenantTerm\":\"editing\",\"frontiersDefaultTerm\":\"editing\",\"category\":\"Process\"},{\"sequenceNumber\":120,\"key\":\"in_preparation\",\"tenantTerm\":\"in preparation\",\"frontiersDefaultTerm\":\"in preparation\",\"category\":\"Process\"},{\"sequenceNumber\":121,\"key\":\"country_region\",\"tenantTerm\":\"country/region\",\"frontiersDefaultTerm\":\"country/region\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":122,\"key\":\"countries_regions\",\"tenantTerm\":\"countries/regions\",\"frontiersDefaultTerm\":\"countries/regions\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":123,\"key\":\"specialty\",\"tenantTerm\":\"specialty\",\"frontiersDefaultTerm\":\"specialty\",\"category\":\"Core\"},{\"sequenceNumber\":124,\"key\":\"specialties\",\"tenantTerm\":\"specialties\",\"frontiersDefaultTerm\":\"specialties\",\"category\":\"Core\"},{\"sequenceNumber\":125,\"key\":\"associate_editors\",\"tenantTerm\":\"Associate Editors\",\"frontiersDefaultTerm\":\"Associate Editors\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":126,\"key\":\"reviewed\",\"tenantTerm\":\"reviewed\",\"frontiersDefaultTerm\":\"reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":127,\"key\":\"institutional_members\",\"tenantTerm\":\"institutional partners\",\"frontiersDefaultTerm\":\"institutional partners\",\"category\":\"Accounting\"},{\"sequenceNumber\":128,\"key\":\"institutional_memberships\",\"tenantTerm\":\"institutional partnerships\",\"frontiersDefaultTerm\":\"institutional partnerships\",\"category\":\"Accounting\"},{\"sequenceNumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantTerm\":\"Assistant Field Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":130,\"key\":\"publications\",\"tenantTerm\":\"publications\",\"frontiersDefaultTerm\":\"publications\",\"category\":\"Process\"},{\"sequenceNumber\":131,\"key\":\"ae_accepted\",\"tenantTerm\":\"recommended acceptance\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":132,\"key\":\"field_journal\",\"tenantTerm\":\"field journal\",\"frontiersDefaultTerm\":\"field journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":133,\"key\":\"field_journals\",\"tenantTerm\":\"field journals\",\"frontiersDefaultTerm\":\"field journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":134,\"key\":\"program_manager\",\"tenantTerm\":\"program manager\",\"frontiersDefaultTerm\":\"program manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":135,\"key\":\"journal_manager\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":136,\"key\":\"journal_specialist\",\"tenantTerm\":\"journal specialist\",\"frontiersDefaultTerm\":\"journal specialist\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":137,\"key\":\"program_managers\",\"tenantTerm\":\"program managers\",\"frontiersDefaultTerm\":\"program managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":138,\"key\":\"journal_managers\",\"tenantTerm\":\"journal managers\",\"frontiersDefaultTerm\":\"journal managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":139,\"key\":\"journal_specialists\",\"tenantTerm\":\"journal specialists\",\"frontiersDefaultTerm\":\"journal specialists\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":140,\"key\":\"cover_letter\",\"tenantTerm\":\"manuscript contribution to the field\",\"frontiersDefaultTerm\":\"manuscript contribution to the field\",\"category\":\"Process\"},{\"sequenceNumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantTerm\":\"recommended to accept manuscript\",\"frontiersDefaultTerm\":\"accepted manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":142,\"key\":\"recommend_for_rejection\",\"tenantTerm\":\"recommend for rejection\",\"frontiersDefaultTerm\":\"recommend for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":143,\"key\":\"recommended_for_rejection\",\"tenantTerm\":\"recommended for rejection\",\"frontiersDefaultTerm\":\"recommended for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":144,\"key\":\"ae\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"description\":\"Associate Editor - board member\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":145,\"key\":\"re\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"description\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":146,\"key\":\"rev\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"description\":\"Reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":147,\"key\":\"aut\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"description\":\"Author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":148,\"key\":\"coraut\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"description\":\"Corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":149,\"key\":\"saut\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"description\":\"Submitting author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":150,\"key\":\"coaut\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"description\":\"co-author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":151,\"key\":\"tsof\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"description\":\"Typesetter\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":152,\"key\":\"typesetting_office\",\"tenantTerm\":\"typesetting office\",\"frontiersDefaultTerm\":\"typesetting office\",\"category\":\"Product\"},{\"sequenceNumber\":153,\"key\":\"config\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"description\":\"Configuration office role\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":154,\"key\":\"jm\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"description\":\"Journal Manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":155,\"key\":\"rte\",\"tenantTerm\":\"RTE\",\"frontiersDefaultTerm\":\"RTE\",\"description\":\"Research topic editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":156,\"key\":\"organizations\",\"tenantTerm\":\"organizations\",\"frontiersDefaultTerm\":\"organizations\",\"category\":\"Core\"},{\"sequenceNumber\":157,\"key\":\"publishing\",\"tenantTerm\":\"publishing\",\"frontiersDefaultTerm\":\"publishing\",\"category\":\"Core\"},{\"sequenceNumber\":158,\"key\":\"acceptance\",\"tenantTerm\":\"acceptance\",\"frontiersDefaultTerm\":\"acceptance\",\"category\":\"Process\"},{\"sequenceNumber\":159,\"key\":\"preferred_associate_editor\",\"tenantTerm\":\"preferred associate editor\",\"frontiersDefaultTerm\":\"preferred associate editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":160,\"key\":\"topic_editors\",\"tenantTerm\":\"Topic Editors\",\"frontiersDefaultTerm\":\"Topic Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":161,\"key\":\"institutions\",\"tenantTerm\":\"institutions\",\"frontiersDefaultTerm\":\"institutions\",\"category\":\"Core\"},{\"sequenceNumber\":162,\"key\":\"author(s)\",\"tenantTerm\":\"author(s)\",\"frontiersDefaultTerm\":\"author(s)\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":163,\"key\":\"figure(s)\",\"tenantTerm\":\"figure(s)\",\"frontiersDefaultTerm\":\"figure(s)\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":164,\"key\":\"co-authors\",\"tenantTerm\":\"co-authors\",\"frontiersDefaultTerm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":165,\"key\":\"editorial_board_members\",\"tenantTerm\":\"editorial board members\",\"frontiersDefaultTerm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":166,\"key\":\"editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"Product\"},{\"sequenceNumber\":167,\"key\":\"co-authorship\",\"tenantTerm\":\"co-authorship\",\"frontiersDefaultTerm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"Misc.\"},{\"sequenceNumber\":168,\"key\":\"role_id_1\",\"tenantTerm\":\"registration office\",\"frontiersDefaultTerm\":\"registration office\",\"category\":\"User Role\"},{\"sequenceNumber\":169,\"key\":\"role_id_2\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"User Role\"},{\"sequenceNumber\":170,\"key\":\"role_id_7\",\"tenantTerm\":\"field chief editor\",\"frontiersDefaultTerm\":\"field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":171,\"key\":\"role_id_8\",\"tenantTerm\":\"assistant field chief editor\",\"frontiersDefaultTerm\":\"assistant field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":172,\"key\":\"role_id_9\",\"tenantTerm\":\"specialty chief editor\",\"frontiersDefaultTerm\":\"specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":173,\"key\":\"role_id_10\",\"tenantTerm\":\"assistant specialty chief editor\",\"frontiersDefaultTerm\":\"assistant specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":174,\"key\":\"role_id_11\",\"tenantTerm\":\"associate editor\",\"frontiersDefaultTerm\":\"associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":175,\"key\":\"role_id_12\",\"tenantTerm\":\"guest associate editor\",\"frontiersDefaultTerm\":\"guest associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":176,\"key\":\"role_id_13\",\"tenantTerm\":\"review editor\",\"frontiersDefaultTerm\":\"review editor\",\"category\":\"User Role\"},{\"sequenceNumber\":177,\"key\":\"role_id_14\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":178,\"key\":\"role_id_15\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"User Role\"},{\"sequenceNumber\":179,\"key\":\"role_id_16\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"User Role\"},{\"sequenceNumber\":180,\"key\":\"role_id_17\",\"tenantTerm\":\"submitting author\",\"frontiersDefaultTerm\":\"submitting author\",\"category\":\"User Role\"},{\"sequenceNumber\":181,\"key\":\"role_id_18\",\"tenantTerm\":\"co-author\",\"frontiersDefaultTerm\":\"co-author\",\"category\":\"User Role\"},{\"sequenceNumber\":182,\"key\":\"role_id_20\",\"tenantTerm\":\"production office\",\"frontiersDefaultTerm\":\"production office\",\"category\":\"User Role\"},{\"sequenceNumber\":183,\"key\":\"role_id_22\",\"tenantTerm\":\"typesetting office (typesetter)\",\"frontiersDefaultTerm\":\"typesetting office (typesetter)\",\"category\":\"User Role\"},{\"sequenceNumber\":184,\"key\":\"role_id_24\",\"tenantTerm\":\"registered user\",\"frontiersDefaultTerm\":\"registered user\",\"category\":\"User Role\"},{\"sequenceNumber\":185,\"key\":\"role_id_35\",\"tenantTerm\":\"job office\",\"frontiersDefaultTerm\":\"job office\",\"category\":\"User Role\"},{\"sequenceNumber\":186,\"key\":\"role_id_41\",\"tenantTerm\":\"special event administrator\",\"frontiersDefaultTerm\":\"special event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":187,\"key\":\"role_id_42\",\"tenantTerm\":\"special event reviewer\",\"frontiersDefaultTerm\":\"special event reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":188,\"key\":\"role_id_43\",\"tenantTerm\":\"submit abstract\",\"frontiersDefaultTerm\":\"submit abstract\",\"category\":\"User Role\"},{\"sequenceNumber\":189,\"key\":\"role_id_52\",\"tenantTerm\":\"events office\",\"frontiersDefaultTerm\":\"events office\",\"category\":\"User Role\"},{\"sequenceNumber\":190,\"key\":\"role_id_53\",\"tenantTerm\":\"event administrator\",\"frontiersDefaultTerm\":\"event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":191,\"key\":\"role_id_89\",\"tenantTerm\":\"content management office\",\"frontiersDefaultTerm\":\"content management office\",\"category\":\"User Role\"},{\"sequenceNumber\":192,\"key\":\"role_id_98\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"User Role\"},{\"sequenceNumber\":193,\"key\":\"role_id_99\",\"tenantTerm\":\"projects\",\"frontiersDefaultTerm\":\"projects\",\"category\":\"User Role\"},{\"sequenceNumber\":194,\"key\":\"role_id_103\",\"tenantTerm\":\"configuration office\",\"frontiersDefaultTerm\":\"configuration office\",\"category\":\"User Role\"},{\"sequenceNumber\":195,\"key\":\"role_id_104\",\"tenantTerm\":\"beta user\",\"frontiersDefaultTerm\":\"beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":196,\"key\":\"role_id_106\",\"tenantTerm\":\"wfconf\",\"frontiersDefaultTerm\":\"wfconf\",\"category\":\"User Role\"},{\"sequenceNumber\":197,\"key\":\"role_id_107\",\"tenantTerm\":\"rt management beta user\",\"frontiersDefaultTerm\":\"rt management beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":198,\"key\":\"role_id_108\",\"tenantTerm\":\"deo beta user\",\"frontiersDefaultTerm\":\"deo beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":199,\"key\":\"role_id_109\",\"tenantTerm\":\"search beta user\",\"frontiersDefaultTerm\":\"search beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":200,\"key\":\"role_id_110\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"User Role\"},{\"sequenceNumber\":201,\"key\":\"role_id_111\",\"tenantTerm\":\"myfrontiers beta user\",\"frontiersDefaultTerm\":\"myfrontiers beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":202,\"key\":\"role_id_21\",\"tenantTerm\":\"copy editor\",\"frontiersDefaultTerm\":\"copy editor\",\"category\":\"User Role\"},{\"sequenceNumber\":203,\"key\":\"role_id_1_abr\",\"tenantTerm\":\"ROF\",\"frontiersDefaultTerm\":\"ROF\",\"category\":\"User Role\"},{\"sequenceNumber\":204,\"key\":\"role_id_2_abr\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"User Role\"},{\"sequenceNumber\":205,\"key\":\"role_id_7_abr\",\"tenantTerm\":\"FCE\",\"frontiersDefaultTerm\":\"FCE\",\"category\":\"User Role\"},{\"sequenceNumber\":206,\"key\":\"role_id_8_abr\",\"tenantTerm\":\"AFCE\",\"frontiersDefaultTerm\":\"AFCE\",\"category\":\"User Role\"},{\"sequenceNumber\":207,\"key\":\"role_id_9_abr\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"category\":\"User Role\"},{\"sequenceNumber\":208,\"key\":\"role_id_10_abr\",\"tenantTerm\":\"ASCE\",\"frontiersDefaultTerm\":\"ASCE\",\"category\":\"User Role\"},{\"sequenceNumber\":209,\"key\":\"role_id_11_abr\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"category\":\"User Role\"},{\"sequenceNumber\":210,\"key\":\"role_id_12_abr\",\"tenantTerm\":\"GAE\",\"frontiersDefaultTerm\":\"GAE\",\"category\":\"User Role\"},{\"sequenceNumber\":211,\"key\":\"role_id_13_abr\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"category\":\"User Role\"},{\"sequenceNumber\":212,\"key\":\"role_id_14_abr\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"category\":\"User Role\"},{\"sequenceNumber\":213,\"key\":\"role_id_15_abr\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":214,\"key\":\"role_id_16_abr\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":215,\"key\":\"role_id_17_abr\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":216,\"key\":\"role_id_18_abr\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":217,\"key\":\"role_id_20_abr\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"User Role\"},{\"sequenceNumber\":218,\"key\":\"role_id_22_abr\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"category\":\"User Role\"},{\"sequenceNumber\":219,\"key\":\"role_id_24_abr\",\"tenantTerm\":\"RU\",\"frontiersDefaultTerm\":\"RU\",\"category\":\"User Role\"},{\"sequenceNumber\":220,\"key\":\"role_id_35_abr\",\"tenantTerm\":\"JOF\",\"frontiersDefaultTerm\":\"JOF\",\"category\":\"User Role\"},{\"sequenceNumber\":221,\"key\":\"role_id_41_abr\",\"tenantTerm\":\"SE-ADM\",\"frontiersDefaultTerm\":\"SE-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":222,\"key\":\"role_id_42_abr\",\"tenantTerm\":\"SE-REV\",\"frontiersDefaultTerm\":\"SE-REV\",\"category\":\"User Role\"},{\"sequenceNumber\":223,\"key\":\"role_id_43_abr\",\"tenantTerm\":\"SE-AUT\",\"frontiersDefaultTerm\":\"SE-AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":224,\"key\":\"role_id_52_abr\",\"tenantTerm\":\"EVOF\",\"frontiersDefaultTerm\":\"EVOF\",\"category\":\"User Role\"},{\"sequenceNumber\":225,\"key\":\"role_id_53_abr\",\"tenantTerm\":\"EV-ADM\",\"frontiersDefaultTerm\":\"EV-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":226,\"key\":\"role_id_89_abr\",\"tenantTerm\":\"COMOF\",\"frontiersDefaultTerm\":\"COMOF\",\"category\":\"User Role\"},{\"sequenceNumber\":227,\"key\":\"role_id_98_abr\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"User Role\"},{\"sequenceNumber\":228,\"key\":\"role_id_99_abr\",\"tenantTerm\":\"Projects\",\"frontiersDefaultTerm\":\"Projects\",\"category\":\"User Role\"},{\"sequenceNumber\":229,\"key\":\"role_id_103_abr\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"category\":\"User Role\"},{\"sequenceNumber\":230,\"key\":\"role_id_104_abr\",\"tenantTerm\":\"BETA\",\"frontiersDefaultTerm\":\"BETA\",\"category\":\"User Role\"},{\"sequenceNumber\":231,\"key\":\"role_id_106_abr\",\"tenantTerm\":\"WFCONF\",\"frontiersDefaultTerm\":\"WFCONF\",\"category\":\"User Role\"},{\"sequenceNumber\":232,\"key\":\"role_id_107_abr\",\"tenantTerm\":\"RTBETA\",\"frontiersDefaultTerm\":\"RTBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":233,\"key\":\"role_id_108_abr\",\"tenantTerm\":\"DEOBETA\",\"frontiersDefaultTerm\":\"DEOBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":234,\"key\":\"role_id_109_abr\",\"tenantTerm\":\"SEARCHBETA\",\"frontiersDefaultTerm\":\"SEARCHBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":235,\"key\":\"role_id_110_abr\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"category\":\"User Role\"},{\"sequenceNumber\":236,\"key\":\"role_id_111_abr\",\"tenantTerm\":\"MFBETA\",\"frontiersDefaultTerm\":\"MFBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":237,\"key\":\"role_id_21_abr\",\"tenantTerm\":\"COPED\",\"frontiersDefaultTerm\":\"COPED\",\"category\":\"User Role\"},{\"sequenceNumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"This is the label for the review editorial board\",\"category\":\"Label\"},{\"sequenceNumber\":239,\"key\":\"field_chief_editor\",\"tenantTerm\":\"Field Chief Editor\",\"frontiersDefaultTerm\":\"Field Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":240,\"key\":\"field_chief_editors\",\"tenantTerm\":\"Field Chief Editors\",\"frontiersDefaultTerm\":\"Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":241,\"key\":\"editor\",\"tenantTerm\":\"editor\",\"frontiersDefaultTerm\":\"editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":242,\"key\":\"editors\",\"tenantTerm\":\"editors\",\"frontiersDefaultTerm\":\"editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":243,\"key\":\"board\",\"tenantTerm\":\"board\",\"frontiersDefaultTerm\":\"board\",\"category\":\"Label\"},{\"sequenceNumber\":244,\"key\":\"boards\",\"tenantTerm\":\"boards\",\"frontiersDefaultTerm\":\"boards\",\"category\":\"Label\"},{\"sequenceNumber\":245,\"key\":\"article_collection\",\"tenantTerm\":\"article collection\",\"frontiersDefaultTerm\":\"article collection\",\"category\":\"Label\"},{\"sequenceNumber\":246,\"key\":\"article_collections\",\"tenantTerm\":\"article collections\",\"frontiersDefaultTerm\":\"article collections\",\"category\":\"Label\"},{\"sequenceNumber\":247,\"key\":\"handling_editor\",\"tenantTerm\":\"handling editor\",\"frontiersDefaultTerm\":\"associate editor\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":248,\"key\":\"handling_editors\",\"tenantTerm\":\"handling editors\",\"frontiersDefaultTerm\":\"associate editors\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":249,\"key\":\"ae_accept\",\"tenantTerm\":\"recommend acceptance\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":250,\"key\":\"rtm\",\"tenantTerm\":\"RTM\",\"frontiersDefaultTerm\":\"RTM\",\"category\":\"Product\"},{\"sequenceNumber\":251,\"key\":\"frontiers_media_sa\",\"tenantTerm\":\"Frontiers Media S.A\",\"frontiersDefaultTerm\":\"Frontiers Media S.A\",\"category\":\"Customer\"},{\"sequenceNumber\":252,\"key\":\"review_editors\",\"tenantTerm\":\"Community Reviewers\",\"frontiersDefaultTerm\":\"Review Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":255,\"key\":\"call_for_papers\",\"tenantTerm\":\"Call for papers\",\"frontiersDefaultTerm\":\"Call for papers\",\"category\":\"Label\"},{\"sequenceNumber\":256,\"key\":\"calls_for_papers\",\"tenantTerm\":\"Calls for papers\",\"frontiersDefaultTerm\":\"Calls for papers\",\"category\":\"Label\"},{\"sequenceNumber\":257,\"key\":\"supervising_editor\",\"tenantTerm\":\"Supervising Editor\",\"frontiersDefaultTerm\":\"Supervising Editor\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editor\"},{\"sequenceNumber\":258,\"key\":\"supervising_editors\",\"tenantTerm\":\"Supervising Editors\",\"frontiersDefaultTerm\":\"Supervising Editors\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editors\"},{\"sequenceNumber\":259,\"key\":\"reviewer_endorse\",\"tenantTerm\":\"endorse\",\"frontiersDefaultTerm\":\"endorse\",\"category\":\"Label\"},{\"sequenceNumber\":260,\"key\":\"reviewer_endorsed\",\"tenantTerm\":\"endorsed\",\"frontiersDefaultTerm\":\"endorsed\",\"category\":\"Label\"},{\"sequenceNumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantTerm\":\"endorse publication\",\"frontiersDefaultTerm\":\"endorse publication\",\"category\":\"Label\"},{\"sequenceNumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantTerm\":\"endorsed publication\",\"frontiersDefaultTerm\":\"endorsed publication\",\"category\":\"Label\"},{\"sequenceNumber\":263,\"key\":\"editor_role\",\"tenantTerm\":\"editor role\",\"frontiersDefaultTerm\":\"Editor Role\",\"category\":\"Label\"},{\"sequenceNumber\":264,\"key\":\"editor_roles\",\"tenantTerm\":\"editor roles\",\"frontiersDefaultTerm\":\"Editor Roles\",\"category\":\"Label\"},{\"sequenceNumber\":265,\"key\":\"editorial_role\",\"tenantTerm\":\"editorial role\",\"frontiersDefaultTerm\":\"Editorial Role\",\"category\":\"Label\"},{\"sequenceNumber\":266,\"key\":\"editorial_roles\",\"tenantTerm\":\"editorial roles\",\"frontiersDefaultTerm\":\"Editorial Roles\",\"category\":\"Label\"},{\"sequenceNumber\":267,\"key\":\"call_for_paper\",\"tenantTerm\":\"Call for paper\",\"frontiersDefaultTerm\":\"Call for paper\",\"category\":\"Label\"},{\"sequenceNumber\":268,\"key\":\"research_topic_abstract\",\"tenantTerm\":\"manuscript summary\",\"frontiersDefaultTerm\":\"manuscript summary\",\"category\":\"Process\"},{\"sequenceNumber\":269,\"key\":\"research_topic_abstracts\",\"tenantTerm\":\"manuscript summaries\",\"frontiersDefaultTerm\":\"manuscript summaries\",\"category\":\"Process\"},{\"sequenceNumber\":270,\"key\":\"submissions_team_manager\",\"tenantTerm\":\"Journal Manager\",\"frontiersDefaultTerm\":\"Content Manager\",\"category\":\"Process\"},{\"sequenceNumber\":271,\"key\":\"submissions_team\",\"tenantTerm\":\"Journal Team\",\"frontiersDefaultTerm\":\"Content Team\",\"category\":\"Process\"},{\"sequenceNumber\":272,\"key\":\"topic_coordinator\",\"tenantTerm\":\"topic coordinator\",\"frontiersDefaultTerm\":\"topic coordinator\",\"category\":\"Process\"},{\"sequenceNumber\":273,\"key\":\"topic_coordinators\",\"tenantTerm\":\"topic coordinators\",\"frontiersDefaultTerm\":\"topic coordinators\",\"category\":\"Process\"},{\"sequenceNumber\":274,\"key\":\"frontiers_journal_team\",\"tenantTerm\":\"frontiers journal team\",\"frontiersDefaultTerm\":\"frontiers journal team\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":275,\"key\":\"research_topic_ic_submission\",\"tenantTerm\":\"RT:IC Submission\",\"frontiersDefaultTerm\":\"RT:IC Submission\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":276,\"key\":\"research_topic_ic_submission_participant\",\"tenantTerm\":\"RT:IC Submission participant\",\"frontiersDefaultTerm\":\"RT:IC Submission participant\",\"category\":\"Label (Role)\"}]}'\n",impactGtmId:"GTM-NJF2ML9B",impactGtmAuth:"fYo-7NoDm9w37QgFMs03SA",impactGtmPreview:"env-1",impactGoogleMapsApiKey:"AIzaSyCTEhX2EU8PWfi86GW9FI00FTcyKk6Ifr8",qualtricsV4ToV3:"'{\"enabled\":true,\"interceptId\":\"SI_er0E2ze69Oz8Yn4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsUmux:"'{\"enabled\":false,\"interceptId\":\"SI_89fPHY3eTxQBwtU\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsContinuousBrand:"'{\"enabled\":true,\"interceptId\":\"SI_9ZuT94UT81FcRh4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",defaultArticleTemplate:"v3"},app:{baseURL:"/",buildId:"ed555f16-85f7-4f41-8f2f-451827c59120",buildAssetsDir:"ap-2024/_nuxt",cdnURL:""}}</script>
<script src="https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6" type="text/javascript" async></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML" type="text/javascript" async></script>
<script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js" type="text/javascript" async></script>
<script src="https://api.altmetric.com/v1/doi/10.3389/fonc.2023.1111191?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15" type="text/javascript" async></script>
<script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript" async></script></body></html>